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Epilepsy is a chronic neurological disorder which can arise following an initial insult 
that over time, progresses into a condition characterised by recurrent spontaneous seizures. 
During a latent period between the initial insult and the epilepsy condition proper, major 
changes occur within the brain at both a cellular and molecular level, in a process known as 
epileptogenesis. It is postulated that during epileptogenesis, signal transduction pathways are 
perturbed following the initial insult, which may bring about long term changes in gene 
expression profiles. For example, the expression of a host of neuropeptides is known to be 
modulated in response to an initial insult, including the up-regulation of the pro-convulsant 
tachykinins Substance P and Neurokinin B, encoded by the TAC1 and TAC3 genes, 
respectively. In this thesis I have explored the regulation of both of these genes by two 
distinct transcription factor (TF) families; the Neuron Restrictive Silencing Factor (NRSF) 
isoforms, and the Upstream Stimulatory Factor (USF) proteins. I demonstrate that both NRSF 
and USF variants regulate TAC3 promoter activity, and that NRSF isoforms can modulate 
endogenous NKB expression in a human neuroblastoma cell line. Furthermore, these distinct 
TF families are shown to work in cooperation to regulate the activity of the rat TAC1 
promoter. Thus, both NRSF and USF variants are shown to be important in the regulation of 
pro-convulsant neuropeptides and as both NRSF and USF proteins have been shown to be 
induced by pro-convulsant stresses here, they are potential key TFs in epileptogenesis, 
responding to an initial insult, and orchestrating downstream gene expression changes. 
Consistent with such a model, I have also revealed that both NRSF and USF variants 
are modulated by anti-convulsant drug treatment. Here, three distinct anti-convulsant drugs, 
were found to differentially modulate the expression of both the full-length NRSF, and its 
truncated isoform, as well as the USF proteins USF1 and USF2. Furthermore, whilst the 
drugs had limited impact upon the localisation of these TFs in human neuroblastoma cells, 
they did affect the binding of these TFs to target DNA sequences, particularly NRSF binding 
to its recognition DNA sequence, the NRSE, in a number of genes. In addition, due to an 
increasingly appreciation of the role of cocaine and the dopaminergic pathways in seizure 
progression, I explored the impact of cocaine treatment on the expression of these TFs. 
Cocaine was found to modulate both NRSF and USF variant expression, and NRSF binding 
to target DNA sequences. These findings suggest that both NRSF and USF variants are 
important in epileptogenesis and are targets for modulation by the anti-convulsant drugs 
investigated here. To further explore the significance of NRSF expression in seizure 
progression, I explored the impact of over-expression of NRSF isoforms, modelling that 
which occurs in response to seizure in animal models, on global gene expression pathways. I 
reveal that NRSF isoform over-expression significantly modulates the expression of a host of 
genes with known associations with epilepsy, supporting a model that NRSF isoforms are key 
TFs which respond to the initial insult and coordinate long-term changes in gene expression. 
These findings may help our understanding of the molecular mechanisms at work during 
epileptogenesis, and may better our understanding of the progression of epilepsy. 
Acknowledgements
I would like to take this opportunity to thank the many people who have helped and 
supported me throughout my PhD. Firstly I would like to thank my supervisors Professor 
John Quinn and Dr Jill Bubb, for all their support, direction and friendship over the past three 
years, that has not only shaped my project, but also me as a person. I would also like to thank 
my lab colleagues in white block, most notably Dr Kate Haddley, Dr Sylvia Vasiliou and Dr 
Fahad Ali, who I now consider to be life-long friends. Their friendship and support helped 
me overcome all the barriers that a three-year PhD project presented, and for that I am 
extremely grateful. I would also like to thank Dr Helen Burrell, Mr Iain Kirk, Miss Hannah 
Stevens, Dr Moutasem Abo-onq, Dr Gregory Jacobson and Mr Steven Thompson, who have 
all helped me over the past three years. Finally, I would like to thank my PhD course 
organisers and past MRes supervisors who all helped shape me as a scientist, including 
Professor Andrea Varro, Dr David Criddle and Dr Sylvia Urbe. I also wish to thank the MRC 
for funding my PhD Studentship. 
On a more personal note, I am fortunate to have a fantastic family and great number 
of friends who have all provided support for me over the past few years, whether it was 
listening to my moans, or just simply helping me to relieve stress with a few pints. I would 
like to take this opportunity to thank my parents for 27 years love, support and 
encouragement. They have worked hard throughout their lives to provide a platform for me to 
achieve my aspirations, and for that I am eternally thankful. I would also like to thank Bob, 
Nicola, Ste and Joe, who have always been there for me and provided much needed love and 
laughter. Finally I would like to thank my fiancée Catherine, who has lived through all the 
good times and the bad times with me, and has supported me through both. Catherine has 
been both my rock and inspiration throughout my PhD and I will always love her and be 
thankful for all she has done for me. 
iCONTENTS PAGE
ABBREVIATIONS .............................................................................................................................................................VII
CHAPTER 1: GENERAL INTRODUCTION ............................................................................................................... 10
1.1 EPILEPSY....................................................................................................................................................................... 10
1.1.1 SOCIAL CONTEXT .................................................................................................................................10
1.1.2 THE HIPPOCAMPUS AND SEIZURE..............................................................................................................2
1.1.3 MOLECULAR CHANGES ASSOCIATED WITH EPILEPTIC SEIZURE..........................................................................4
1.1.4 NEUROPEPTIDES IN EPILEPSY ...................................................................................................................6
1.1.5 EPILEPTOGENESIS ..................................................................................................................................7
1.1.6 EPIGENETICS AND EPILEPTOGENESIS ..........................................................................................................9
1.1.7 SEIZURE MODELS ................................................................................................................................10
1.2 THE TACHYKININS .................................................................................................................................................... 14
1.2.1 THE TACHYKININ FAMILY ......................................................................................................................14
1.2.2 NEUROKININ B (NKB) .........................................................................................................................15
1.2.3 REGULATION OF NKB ..........................................................................................................................18
1.2.4 SUBSTANCE P (SP)..............................................................................................................................20
1.2.5 REGULATION OF TAC1.........................................................................................................................22
1.3 GENE REGULATION................................................................................................................................................... 26
1.3.1 TRANSCRIPTION ..................................................................................................................................26
1.3.2 CHROMATIN.......................................................................................................................................29
1.3.3 CHROMATIN REMODELLING...................................................................................................................30
1.3.4 HISTONE MODIFICATIONS .....................................................................................................................33
1.3.4.1 Histone acetylation.................................................................................................................34
1.3.4.2 Histone methylation ...............................................................................................................35
1.4 NEURON RESTRICTIVE SILENCER FACTOR (NRSF) ........................................................................................ 37
1.4.1 NRSF MEDIATED GENE REGULATION AND CHROMATIN REMODELLING ...........................................................39
1.4.2 MODULATION OF NRSF ACTIVITY...........................................................................................................41
1.4.3 TRUNCATED ISOFORM SNRSF ...............................................................................................................43
1.4.4 NRSF LOCALISATION ...........................................................................................................................46
1.4.5 NRSF & DISEASE................................................................................................................................48
1.4.5.1 Cancer.....................................................................................................................................48
1.4.5.2 Huntington’s Disease (HD)......................................................................................................49
1.4.5.3 Epilepsy...................................................................................................................................50
1.5 UPSTREAM STIMULATORY FACTORS (USFS) ................................................................................................... 52
1.5.1 THE USF TFS IN DISEASE ......................................................................................................................54
1.6 ANTI-CONVULSANT DRUGS (ACDS) .................................................................................................................... 56
1.6.1 VOLTAGE-GATED SODIUM CHANNELS .....................................................................................................57
1.6.3 CARBAMAZEPINE (CBZ) .......................................................................................................................58
1.6.4 PHENYTOIN (PHY) ..............................................................................................................................60
ii
1.6.5 LAMOTRIGINE (LMT) ..........................................................................................................................60
1.7 COCAINE ....................................................................................................................................................................... 62
1.8 AIMS & OBJECTIVES ................................................................................................................................................. 64
CHAPTER 2: MATERIALS AND METHODS ............................................................................................................ 66
2.1 MATERIALS.................................................................................................................................................................. 66
2.1.1 PLASMIDS AND VECTORS.......................................................................................................................66
2.1.2 COMMONLY USED SOLUTIONS AND REAGENTS ..........................................................................................68
2.1.2.1 Microbiology and Molecular Biology......................................................................................68
2.1.3 TREATMENT SOLUTIONS .......................................................................................................................70
2.1.3.1 Carbamazepine (CBZ) .............................................................................................................70
2.1.3.2 Phenytoin (PHY) ......................................................................................................................70
2.1.3.3 Lamotrigine (LMT) ..................................................................................................................70
2.1.3.4 Kainic Acid (KA).......................................................................................................................70
2.1.3.5 Cocaine ...................................................................................................................................71
2.1.3.6 Vehicle Control C.....................................................................................................................71
2.1.3.7 Vehicle Control P.....................................................................................................................71
2.1.3.8 Vehicle Control L .....................................................................................................................71
2.1.3.9 Vehicle Control KA ..................................................................................................................71
2.1.3.10 Vehicle Control Cocaine ........................................................................................................72
2.1.4 CELL CULTURE MEDIA...........................................................................................................................72
2.1.4.1 Complete Media for human SK-N-AS neuroblastoma cell line................................................72
2.1.4.2 Serum Free Media for human SK-N-AS neuroblastoma cell line.............................................72
2.1.4.3 Complete Media for human SH-SY5Y neuroblastoma cell line ...............................................72
2.1.4.4 Serum Free Media for human SH-SY5Y neuroblastoma cell line.............................................72
2.2 METHODS...................................................................................................................................................................... 73
2.2.1 GENERAL CLONING METHODS ................................................................................................................73
2.2.1.1 Polymerase Chain Reaction (PCR) primer design....................................................................73
2.2.1.2 Standard PCR ..........................................................................................................................73
2.2.1.3 PCR purification ......................................................................................................................74
2.2.1.4 Analysis of DNA using Agarose Gel-Electrophoresis ...............................................................76
2.2.1.5 Recovery of DNA from agarose-gels.......................................................................................76
2.2.1.6 Generation of NKB promoter reporter gene constructs..........................................................77
2.2.1.7 Ligation...................................................................................................................................78
2.2.1.8 Transformation of chemically competent E. Coli cells ............................................................79
2.2.1.9 Isolation of DNA constructs from bacteria .............................................................................79
2.2.1.9.1 Mini-preparation of plasmid DNA......................................................................................................... 79
2.2.1.9.2 Maxi-preparation of plasmid DNA ........................................................................................................ 80
2.2.1.10 Analytical restriction enzyme digests ...................................................................................81
2.2.1.11 Sequencing............................................................................................................................82
2.2.1.12 Measurement of DNA/RNA concentration by spectrophotometry.......................................82
2.2.2 CELL TREATMENT & TRANSFECTION........................................................................................................83
2.2.2.1 Cell Culture..............................................................................................................................83
2.2.2.1.1 Culture of SK-N-AS cells ......................................................................................................................... 83
2.2.2.1.2 Culture of SH-SY5Y cells ......................................................................................................................... 83
iii
2.2.2.2 Cell Treatment ........................................................................................................................83
2.2.2.3 Delivery of luciferase constructs into neuroblastoma cell line................................................84
2.2.2.4 ExGen 500 in vitro Transfection..............................................................................................84
2.2.2.5 Co-transfection experiments ..................................................................................................85
2.2.2.6 Analysis of transgene expression by Reporter gene assay .....................................................85
2.2.3 MRNA ANALYSIS.................................................................................................................................86
2.2.3.1 RNA extraction........................................................................................................................86
2.2.3.2 DNase digestion of total RNA extraction................................................................................87
2.2.3.3 Reverse Transcriptase PCR (RT-PCR).......................................................................................87
2.2.3.4 PCR to analyse mRNA expression ...........................................................................................88
2.2.3.5 Quantitative PCR (qPCR).........................................................................................................89
2.2.3.6 Affymetrix Microarray Analysis ..............................................................................................90
2.2.4 PROTEIN ANALYSIS ..............................................................................................................................91
2.2.4.1 Protein Extraction from Cell Lysates .......................................................................................91
2.2.4.2 Determination of protein concentration.................................................................................91
2.2.4.3 Western Blotting.....................................................................................................................92
2.2.4.4.1 Denaturing SDS-PAGE ............................................................................................................................ 92
2.2.4.4.2 Electrophoretic transfer......................................................................................................................... 92
2.2.4.4.3 Detection of protein............................................................................................................................... 93
2.2.4.4.4 Stripping and re-probing of a Western Blot ......................................................................................... 94
2.2.4.4 Immunofluorescence ..............................................................................................................94
2.2.5 CHROMATIN IMMUNOPRECIPITATION (CHIP) ...........................................................................................95
2.2.5.1 Cell Fixation and Chromatin Isolation.....................................................................................95
2.2.5.2 Chromatin Sonication Shearing ..............................................................................................96
2.2.5.3 Estimate shearing efficiency and Chromatin concentration...................................................97
2.2.5.4 Capture Chromatin on Magnetic Beads .................................................................................98
2.2.5.5 Elute Chromatin, Reverse Cross-links and Treat with Proteinase K ........................................98
2.2.5.6 PCR screening .........................................................................................................................99
2.2.6 STATISTICS .......................................................................................................................................100
CHAPTER 3: REGULATION OF HUMAN NKB (TAC3) GENE AND ITS PROMOTER BY THE 
TRANSCRIPTION FACTORS NRSF AND USF .......................................................................................................101
3.1 INTRODUCTION ........................................................................................................................................................101
3.2 AIMS .............................................................................................................................................................................104
3.3 METHODS....................................................................................................................................................................105
3.3.1 PCR AMPLIFICATION OF NKB PROMOTER AND GENERATION OF PNKB REPORTER GENE CONSTRUCTS. ...............105
3.3.2 CELL CULTURE, TREATMENT, TRANSFECTIONS AND LUCIFERASE ASSAYS.........................................................105
3.3.3 MRNA EXPRESSION ANALYSIS ..............................................................................................................106
3.3.4 TRANSCRIPTION FACTOR BINDING STUDY................................................................................................106
3.4 RESULTS......................................................................................................................................................................107
3.4.1 IDENTIFICATION OF A PUTATIVE NRSE AND E BOX SITE WITHIN THE NKB PROXIMAL PROMOTER.......................107
3.4.2 EXPRESSION OF NKB IN NEUROBLASTOMA CELL LINES SK-N-AS AND SH-SY5Y ............................................107
3.4.3 NKB PROXIMAL PROMOTER SUPPORTS LUCIFERASE REPORTER GENE ACTIVITY ...............................................108
3.4.4 NRSF ISOFORMS ACTIVATE THE NKB PROMOTER AND INDUCES ITS EXPRESSION ............................................111
3.4.5 USF1 AND USF2 REPRESS THE NKB PROMOTER.....................................................................................114
iv
3.4.6 TRANSCRIPTION FACTOR BINDING TO THE NKB PROMOTER REVEALED BY CHIP .............................................115
3.4.7 THE ANTICONVULSANT CBZ IMPAIRS BOTH NRSF ISOFORM AND USF REGULATION OF THE NKB PROMOTER AND 
REPRESSES NKB EXPRESSION........................................................................................................................117
3.5 DISCUSSION ...............................................................................................................................................................122
CHAPTER 4: DIFFERENTIAL REGULATION OF THE RAT TAC1 PROMOTER BY NRSF AND SNRSF, 
IN COOPERATION WITH USF FAMILY MEMBERS...........................................................................................129
4.1 INTRODUCTION ........................................................................................................................................................129
4.2 AIMS .............................................................................................................................................................................132
4.3 METHODS....................................................................................................................................................................133
4.3.1 CELL CULTURE, TRANSFECTIONS AND LUCIFERASE ASSAYS ..........................................................................133
4.3.2 MRNA EXPRESSION ANALYSIS ..............................................................................................................134
4.3.3 TRANSCRIPTION FACTOR BINDING STUDY................................................................................................134
4.4 RESULTS......................................................................................................................................................................136
4.4.1 EXPRESSION OF TAC1, NRSF, USF1 AND USF2 IN HUMAN SK-N-AS NEUROBLASTOMA CELLS.......................136
4.4.2 THE TAC1 PROXIMAL PROMOTER CONTAINS A -60 E BOX MOTIF, WHICH ACTS AS AN ENHANCER IN SK-N-AS CELLS.
..............................................................................................................................................................137
4.4.3 MODULATION OF TAC1 PROMOTER BY UPSTREAM STIMULATORY FACTORS (USF) 1 & 2 ..............................138
4.4.4 REGULATION OF TAC1 PROMOTER BY THE NRSF ISOFORMS IS INDEPENDENT OF THE -60 E BOX. .....................140
4.4.5 NRSF VARIANTS ARE CAPABLE OF ENHANCED ACTIVATION OF THE TAC1 PROMOTER IN CONJUNCTION WITH USF,
BUT VIA DIFFERENT MECHANISMS. .................................................................................................................142
4.4.6 USF BINDING TO THE HUMAN TAC1 PROMOTER IS CELL SPECIFIC. ..............................................................143
4.5 DISCUSSION ...............................................................................................................................................................147
CHAPTER 5: NRSF ISOFORMS ARE MODULATED BY ACD TREATMENT...............................................153
5.1 INTRODUCTION ........................................................................................................................................................153
5.2 AIMS .............................................................................................................................................................................156
5.3 METHODS....................................................................................................................................................................157
5.3.1 CELL CULTURE AND TREATMENT ...........................................................................................................157
5.3.2 MRNA EXPRESSION ANALYSIS ..............................................................................................................157
5.3.3 PROTEIN ANALYSIS.............................................................................................................................158
5.3.3.1 Western Blotting...................................................................................................................158
5.3.3.2 Immunofluorescence ............................................................................................................158
5.3.4 TF BINDING STUDY - CHIP ..................................................................................................................158
5.4 RESULTS......................................................................................................................................................................159
5.4.1 MODULATION OF NRSF ISOFORM MRNA FOLLOWING KA TREATMENT.......................................................159
5.4.2 MODULATION OF NRSF & SNRSF MRNA FOLLOWING ACD TREATMENT. ..................................................161
5.4.2.1 CBZ modulation of NRSF & sNRSF mRNA..............................................................................161
5.4.2.2 PHY modulation of NRSF & sNRSF mRNA .............................................................................163
5.4.2.3 LMT modulation of NRSF & sNRSF mRNA.............................................................................163
5.4.2.4 CBZ modulates TAC1 mRNA..................................................................................................164
5.4.3 MODULATION OF NRSF & SNRSF LOCALISATION IN HUMAN SH-SY5Y CELLS FOLLOWING ACD TREATMENT. ....167
5.4.3.1 Localisation of NRSF & sNRSF in human SH-SY5Y cells. ........................................................167
v5.4.3.2 CBZ treatment and NRSF isoform localisation in SH-SY5Y cells. ...........................................171
5.4.3.3 PHY and LMT treatment and NRSF isoform localisation in SH-SY5Y cells.............................174
5.4.3 MODULATION OF NRSF BINDING TO TARGET NRSE-CONTAINING REGIONS IN HUMAN SH-SY5Y CELLS BY CBZ AND 
PHY........................................................................................................................................................180
5.4.3.1 NRSF binding to target NRSE-containing regions in human SH-SY5Y cells. ..........................180
5.4.3.2 NRSF binding to target NRSE-containing regions is modulated by ACD treatment in human 
SH-SY5Y cells.....................................................................................................................................181
5.5 DISCUSSION ...............................................................................................................................................................186
5.5.1 NRSF ISOFORM EXPRESSION ...............................................................................................................186
5.5.2 NRSF ISOFORM LOCALISATION ............................................................................................................190
5.5.3 NRSF BINDING TO TARGET NRSE-CONTAINING REGIONS ..........................................................................192
CHAPTER 6: USF1 AND USF2 ARE MODULATED BY ACD TREATMENT ..................................................196
6.1 INTRODUCTION ........................................................................................................................................................196
6.2 AIMS .............................................................................................................................................................................198
6.3 METHODS....................................................................................................................................................................199
6.3.1 CELL CULTURE AND TREATMENT ...........................................................................................................199
6.3.2 MRNA EXPRESSION ANALYSIS ..............................................................................................................199
6.3.3 PROTEIN ANALYSIS.............................................................................................................................200
6.3.3.1 Western blotting...................................................................................................................200
6.3.3.2 Immunofluorescence......................................................................................................200
6.3.4 TF BINDING STUDY – CHIP ASSAY .........................................................................................................200
6.4 RESULTS......................................................................................................................................................................201
6.4.1 MODULATION OF USF1 AND USF2 MRNA FOLLOWING KA TREATMENT.....................................................201
6.4.2 MODULATION OF USF1 AND USF2 EXPRESSION FOLLOWING ACD TREATMENT............................................203
6.4.2.1 CBZ modulation of USF1 & USF2 mRNA ...............................................................................203
6.4.2.2 PHY modulation of USF1 & USF2 mRNA ...............................................................................205
6.4.2.3 LMT modulation of USF1 & USF2 mRNA ..............................................................................205
6.4.3 MODULATION OF USF1 & USF2 LOCATION IN HUMAN SH-SY5Y CELLS FOLLOWING ACD TREATMENT. ...........208
6.4.3.1 Localisation of USF1 & USF2 in human SH-SY5Y cells. ..........................................................208
6.4.3.2 CBZ, PHY and LMT has limited impact upon USF1 and USF2 localisation in human SH-SY5Y 
cells. ..................................................................................................................................................212
6.4.3 Modulation of USF2 binding to TAC1 and NKB promoter regions in human SH-SY5Y cells by CBZ 
treatment. ........................................................................................................................................220
6.5 DISCUSSION ...............................................................................................................................................................222
6.5.1 USF GENE EXPRESSION.......................................................................................................................223
6.5.2 USF PROTEIN LOCALISATION ...............................................................................................................225
6.5.3 USF BINDING ...................................................................................................................................227
CHAPTER 7: A DISTINCT ROLE FOR NRSF VARIANTS IN MODULATION OF EPILEPSY 
ASSOCIATED GENE EXPRESSION – REVEALED BY MICROARRAY ANALYSIS ...................................230
7.1 INTRODUCTION ........................................................................................................................................................230
7.2 AIMS .............................................................................................................................................................................234
vi
7.3 METHODS....................................................................................................................................................................235
7.3.1 CELL CULTURE, TRANSFECTIONS AND RNA EXTRACTION ............................................................................235
7.3.2 AFFYMETRIX MICROARRAY ANALYSIS ....................................................................................................235
7.3.3 BIOINFORMATICS – GENEGO METACORETM ANALYSIS .............................................................................235
7.3.4 MRNA EXPRESSION ANALYSIS – VALIDATION OF MICROARRAY FINDINGS .....................................................236
7.4 RESULTS......................................................................................................................................................................237
7.4.1 OVER-EXPRESSION OF REEX1 AND HZ4 MODULATE DIFFERENTIAL CHANGES IN GENE EXPRESSION PROFILES .......237
7.4.2 REEX1 AND HZ4 OVER-EXPRESSION MODULATES DIFFERENTIAL EXPRESSION OF GENES IMPLICATED IN EPILEPSY..240
7.4.2 RT-PCR VALIDATION OF MICROARRAY DATA – HCN2, HCN3 & SCN9A ....................................................248
7.5 DISCUSSION ...............................................................................................................................................................252
CHAPTER 8: MODULATION OF THE NRSF AND USF FAMILIES FOLLOWING COCAINE 
TREATMENT ...................................................................................................................................................................258
8.1 INTRODUCTION ........................................................................................................................................................258
8.2 AIMS .............................................................................................................................................................................260
8.3 METHODS....................................................................................................................................................................261
8.3.1 CELL CULTURE AND TREATMENT ...........................................................................................................261
8.3.2 MRNA EXPRESSION ANALYSIS ..............................................................................................................261
8.3.2.1 RT-PCR ..................................................................................................................................261
8.3.2.2 Q-PCR....................................................................................................................................261
8.3.3 TF BINDING STUDY – CHIP ASSAY .........................................................................................................262
8.4 RESULTS......................................................................................................................................................................263
8.4.1 COCAINE UP-REGULATES CART MRNA EXPRESSION ................................................................................263
8.4.2 NRSF ISOFORM EXPRESSION IS MODULATED FOLLOWING COCAINE TREATMENT.............................................265
8.4.4 COCAINE MAY AFFECT NRSF BINDING TO TARGET NRSE-CONTAINING REGIONS ............................................267
8.4.5 ENDOGENOUS NKB EXPRESSION IS UNAFFECTED FOLLOWING COCAINE TREATMENT .......................................268
8.4.6 COCAINE REPRESSES USF1 AND USF2 MRNA EXPRESSION .......................................................................270
8.5 DISCUSSION ...............................................................................................................................................................272
CHAPTER 9: NRSF AND USF TFS REGULATE PRO-CONVULSANT NEUROPEPTIDES AND ARE 
MODULATED BY ACD TREATMENT......................................................................................................................277
9.1 MODULATION OF NEUROPEPTIDE EXPRESSION ...........................................................................................279
9.2 NRSF AND USF ARE TARGETS OF ACD TREATMENT....................................................................................284
9.3 IS NRSF IMPORTANT IN EPILEPTOGENESIS? ...............................................................................................286
9.4 COCAINE MODULATES NRSF & USF........................................................................................................288
9.5 RELEVANCE TO EPILEPSY ........................................................................................................................289
REFERENCE LIST ............................................................................................................................................................291
APPENDIX SECTION.......................................................................................................................................................325
vii
Abbreviations
 ACD – Anti-convulsant drugs
 AMPA - alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
 AP1/CRE - activation protein 1/cAMP response element
 ATCC - American Type Culture Collection
 AVP - arginine vasopressin
 BD – Bipolar Disorder
 BDNF – Brain Derived Neurotrophic Factor
 bHLH - basic-Helix-Loop-Helix
 CART - cocaine and amphetamine-regulated transcript
 CBZ – carbamazepine
 CDYL - chromodomain on Y-like
 CGRP - calcitonin gene related peptide
 ChIP – Chromatin Immunoprecipitation
 CNS - central nervous system
 CREB - cAMP response element binding protein
 DMEMs - Dulbecco’s modified eagle’s media
 DMSO - Dimethyl sulfoxide
 DRG – Dorsal root ganglion
 ESCs- embryonic stem cells
 FBS - Foetal bovine serum
 GABA - γ-aminobutyric acid
 GPCRs - G protein-coupled receptors
 HAP-1 - Huntingtin-associated protein 1
 HAT - histone acetyltransferase
 HCN2 - Hyperpolarization activated cyclic nucleotide-gated potassium channel 2
 HD – Huntington’s Disease
 HDAC - histone deacetylase
 HK-1 - hemokinin-1
viii
 HMTs - histone methyltransferases
 HP1 - Heterochromatin protein-1
 hTERT - human telomerase reverse transcriptase
 IP – immunoprecipitations
 KA – Kainic Acid
 KCC2 – K-Cl cotransporter 
 LMT – lamotrigine
 MeCP2 - methyl-CpG-binding protein 2
 MSCs - mesenchymal stem cells
 NEAA - non essential amino acids
 NGF – Nerve growth factor
 NK1R – NK1 receptor
 NK2R – NK2 receptor
 NK3R – NK3 receptor
 NKA – Neurokinin A
 NKB – Neurokinin B
 NMDA - N-methyl-D-aspartic acid
 NPK – neuropeptide K
 NPY – neuropeptide Y
 NPγ - neuropeptide γ
 NRSE – neuron restrictive silencing element
 NRSF - neuron restrictive silencing transcription factor
 PCR – polymerase chain reaction
 PHY – phenytoin
 PIC – Pre-Initiation Complex
 PICt – Protease Inhibitor cocktail
 PME - progressive myoclonus epilepsy
 PNS - peripheral nervous system
 Pol II - RNA Polymerase II
 qPCR – quantitative PCR
ix
 RE-1 - Repressor element-1
 REST - Repressor element-1 silencing transcription factor
 RILP - REST/NRSF interacting Lin-11, Isl-1, Mec-3 (LIM) domain protein
 RT – Room Temperature
 RT-PCR - Reverse Transcriptase PCR
 SCLC – small cell lung cancer
 SCN2a - voltage-gated sodium channel, type II alpha
 SP – Substance P
 SSADH - Succinic semialdehyde dehydrogenase
 SVZ – subventricular zone
 TAF – TBP associated factor
 TBP – TATA binding protein
 TF – transcription factor
 TSS - transcription start site
 USF - upstream stimulatory factor
 USF1 - upstream stimulatory factor 1
 USF2 - upstream stimulatory factor 2
 VPA – Valproic Acid
 DG – Dentate Gyrus
 GTC - Generalised Tonic-Clonic
 PPS – Perforant path stimulation
 SE – status epilepticus
 SSSE – self-sustaining status epilepticus
 TLE – temporal Lobe Epilepsy
xCHAPTER 1: General Introduction
1.1 Epilepsy
1.1.1 Social context
Epilepsy is one of the most commonly acquired, chronic, neurological disorders 
suffered worldwide. There are approximately 50 million people suffering with epilepsy, 
with nearly 90% of cases in the developing countries (WHO, January 2009). The 
incidence of epilepsy is quoted as being around 40-70 per 100,000 people, in developed 
countries, rising to 120 per 100,000 in undeveloped countries, whilst the prevalence rate 
is between 0.4-1% (Bell & Sander., 2001; De Boer et al., 2008). Unfortunately, despite 
the availability of a diverse array of anti-convulsant drugs (ACDs), approximately half 
of patients treated with modern ACDs continue to experience seizures (Pitkanen, 2002). 
Epileptic seizures are defined as clinical manifestations of abnormal, excessive or 
synchronous neuronal activity in the brain (Fisher et al., 2005). It should be noted that 
the presence of a single seizure, is not synonymous with having epilepsy, and that 
epilepsy is defined by the occurrence of at least one epileptic seizure, together with an 
enduring alteration of the brain (Fisher et al., 2005). Seizures can be one of two types, 
partial (focal) or generalised. Partial, refers to abnormal discharge in a localised group 
of neurons, resulting in altered senses, facial movements and twitches. Generalised 
seizures in contrast occur when generalised neuronal activity begins simultaneously in 
both brain hemispheres, and can result in the loss of consciousness, falls and involuntary 
muscular contractions known as ‘convulsions’. 
2Epilepsy is not a single condition, but a diverse family of disorders that share an 
increased “propensity to have seizures”. This definition encompasses multiple forms of 
epilepsy including absence epilepsy and temporal lobe epilepsy (TLE). Absence 
epilepsies are defined as non-convulsive epileptic seizures where loss of consciousness 
occurs (Crunelli & Leresche., 2002), whilst TLE is characterised by recurrent 
unprovoked seizures, originating from the medial or lateral temporal lobe, consisting of 
a combination of simple or complex partial and secondarily generalised seizures, which 
may result in memory loss (Abou-Khalil et al., 1993; Briellmann et al., 2002). Some 
epilepsy disorders may be idiopathic, with no known cause (besides a possible genetic 
cause), such as idiopathic generalised epilepsy which can include generalised tonic-
clonic (GTC) or ‘grand-mal’ seizures (seizure involving the entire body, with violent 
convulsions and loss of consciousness). Alternatively, an epilepsy condition may arise 
due to a known cause, known as symptomatic generalised (or partial) epilepsy. 
Symptomatic generalised epilepsy results from widespread damage to the brain, often 
during birth, leading to seizures, in addition to other neurological disorders such as 
mental retardation. Symptomatic partial epilepsy is the most common type of epilepsy 
which develops in adulthood, and is caused by localised damage to the brain, resulting 
from a stroke for example. 
1.1.2 The hippocampus and seizure
Status epilepticus (SE) is a term given to describe when a seizure persists for a 
prolonged period of time, which in the past was considered to be over 20mins, but is 
more recently considered any seizure lasting longer than 5 minutes (reviewed in Chen & 
Wasterlain., 2006). Estimates of the incidence rate of SE, range from 6.8-40 per 100,000 
3people per year, with mortality associated with SE as high as 26% (Feen et al., 2008). 
Animal models of self-sustaining status epilepticus (SSSE), such as the perforant path 
stimulation (PPS) model, have revealed the areas of the brain metabolically up-regulated 
during SE. These areas include the hippocampus, amygdala, the substantia nigra, the 
nucleus accumbens, the caudate putamen and the medial thalamus (Wasterlain et al., 
2002), with the hippocampus a major area of focus in epilepsy research. 
The hippocampus is an important part of the limbic system, playing a major role 
in memory (Bliss & Collingridge., 1993) and spatial navigation (Bilkey & Clearwater., 
2005). The hippocampus consists of six distinct regions: the hippocampus proper, 
subiculum, dentate gyrus (DG), presubiculum, parasubiculum and entorhinal cortex. The 
hippocampus proper can be further sub-divided into 4 fields (CA1-CA4), with CA4 
considered to be part of the DG. Axons from the dentate granule cells, termed mossy 
fibres, spread out into the CA3 region (Blacksted et al., 1970), and form excitatory 
connections with both the proximal dendrites of CA3 principal cells and with inhibitory 
interneurons (Henze et al., 2000). SE is known to disrupt normal excitatory signalling 
from the mossy fibres, whilst also disturbing inhibitory interventions of the 
hippocampus. More specifically, SE stimulates excessive GABAergic signalling in the 
DG, resulting in γ-aminobutyric acid (GABA) release. The GABA receptors, once 
bound by GABA, internalise, effectively removing GABA inhibitory control from the 
hippocampus. This indirectly increases neuronal excitability, increasing the likelihood 
of a seizure (Sankar et al., 1997; Wasterlain et al., 1996; Walker et al., 2001).
Furthermore, enhanced excitatory glutamate release is observed from the mossy fibres, 
4following activation of the dentate granule cells, leading to elevated neuronal firing 
(Gutierrez et al., 2003).
The GABAergic and glutaminergic systems play a key role in epileptic seizure 
generation, and seizures are often attributed to an imbalance between the excitatory 
glutamate and the inhibitory GABA pathways (Tasker & Dudek., 1991). It has been 
shown that inhibition of the GABAergic pathways via GABAA receptor blockade, 
induces epileptiform activity (Collins et al., 1983), whilst pharmacological intervention 
to enhance GABAergic inhibition, are shown to prevent seizures in humans (Gale., 
1992). Conversely, the glutamate receptor agonist, Kainate, is known to induce seizure-
like characteristics and is routinely used in kainic acid (KA)-induced seizure models 
(reviewed in Fisher., 1989), whilst many ACDs act as glutamate receptor antagonists, 
such as felbamate, topiramate and Phenobarbital (Rogawski & Loscher., 2004a). It 
should be noted here, that throughout this thesis I will discuss findings from animal 
models, which whilst are not true seizures, do exhibit many of the characteristics. 
Therefore I will refer to such models as ‘seizures’, for brevity, throughout. 
1.1.3 Molecular changes associated with epileptic seizure
Epileptic seizures induced complex biochemical and pathophysiological changes 
within the brain. These changes can occur very quickly, and within the first few seconds 
of a seizure, neurotransmitter release is activated, specific ion channels are activated 
whilst others are deactivated, and receptor phosphorylation occurs. Following this, 
within minutes, receptor trafficking is initiated, with the trafficking of GABA and 
glutamate receptors shown to be responsible for key cellular adaptations. In the longer 
5time period of a few hours, neuropeptide expression in altered, with enhanced pro-
convulsant neuropeptide expression and decreased anti-convulsant neuropeptides 
observed, further enhancing neuronal excitability (Wasterlain & Chen., 2008).  
It has been shown that during the transition from a single seizure into SSSE, 
GABAA receptors translocate from the neuronal membrane, into the cytoplasm, 
reducing the overall number of receptors available at the synapse to bind to the 
inhibitory GABA (Naylor et al., 2005). In addition, it has been shown that the quantity 
of GABAA receptor γ2 and β2-3 subunits at the synaptic membrane also diminish 
following SE (Naylor & Wasterlain., 2005; Naylor et al., 2005). Furthermore, AMPA 
(alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-
D-aspartic acid) subunits move to the synaptic membrane resulting in neuronal 
hyperexcitability (Mazarati & Wasterlain, 1999; Wasterlain et al., 2002b). These 
systems are of great significance to SSSE, with NMDA receptor antagonists shown to 
abolish the maintenance phase of SSSE in rats (Mazarati & Wasterlain., 1999). 
Seizures have also been shown to stimulate the expression of a diverse range of 
genes, including immediate-early genes such as the transcription factors (TFs) c-fos and 
c-jun (Morgan & Curran., 1991; Kiessling & Gass., 1993), proteases such as the 
extracellular serine protease tPA (tissue-plasminogen activator) (Qian et al., 1993), the 
membrane trafficking protein synaptotagmin IV (Glisovic et al., 2007), and microRNAs, 
such as the CREB-regulated microRNA miR-132 (Nudelman et al., 2009). In addition, 
changes in ion channel expression have been observed in KA seizure models, including 
an up-regulation of both sodium channel Nav1.6 (Blumenfeld et al., 2009) and voltage-
dependent calcium channel, β2 subunit (CACNB2) expression (Gastaldi et al., 1998) 
6and a suppression of HCN2 (Hyperpolarization activated cyclic nucleotide-gated 
potassium channel 2) expression (Powell et al., 2008). Finally, certain ligand-gated 
receptors, such as the tachykinin receptor NK3R, have been shown to be elevated 
following KA-induced seizures (Roder et al., 1994).
The brain derived neurotrophic factor, BDNF, is also considered to play a key 
role in seizure and epileptogenesis, with high levels of BDNF, and its receptor, trkB 
found in brain areas associated with seizure susceptibility, such as the hippocampus. The 
view that BDNF is important in epileptogenesis has arisen from reports employing the 
kindling model. In this model, repeated, focal application of initially subconvulsive 
electrical stimuli is given, until eventually an intense focal and tonic–clonic seizure is 
generated. Expression of both BDNF and trkB are greatly up-regulated in kindling and 
other seizure models (Isackson et al., 1991; Mudo et al., 1996; Bengzon et al., 1993; 
Poulsen et al., 2002). Kokaia et al, reported a greater than 2x fold reduction in the rate 
of kindling development in BDNF heterozygous (+/-) mice (Kokaia et al.1995), whilst 
transgenic mice over-expressing BDNF have been shown to suffer more severe seizures 
in response to KA (Croll et al., 1999). Furthermore, conditional deletion of trkB, has 
been shown to prevent epileptogenesis (He et al., 2004). 
1.1.4 Neuropeptides in epilepsy
As aforementioned, the hippocampus is considered to be a key brain area in 
epilepsy, where numerous neuropeptides are expressed. These include the tachykinins 
Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), the cocaine and 
amphetamine-regulated transcript (CART), calcitonin gene related peptide (CGRP), 
7galanin and neuropeptide Y (NPY) (Sperk et al., 1990., Mathe, 1999; Schwarzer et al., 
1995; Freund et al., 1997; Gruber et al., 1994; Seress et al., 2004; Baraban., 2004). 
SSSE is associated with a change in expression of many of these neuropeptides, 
including a reduction of the inhibitory neuropeptides galanin (Mazarati et al., 1998), 
dynorphin (Mazarati et al., 1999), somatostatin (Sperk et al., 1986) and NPY (Gruber et 
al., 1994). Galanin is known to be a potent inhibitor of SSSE, with galanin over-
expressing mice exhibiting enhanced resistance to the development of SSSE (Mazarati 
et al., 2000). 
In addition, SSSE is associated with the increased expression of the 
proconvulsant tachykinins, SP (Liu et al., 1999; Liu et al., 2000) and NKB in the 
hippocampus (Sperk et al., 1990; Marksteiner et al., 1992; Chen et al., 2008). SP and 
NKA are encoded by the same gene, the tachykinin 1 gene (TAC1), also termed pre-
protachykinin A (PPT-A), with elevated TAC1 expression following KA-induced 
seizure, corresponding to enhanced expression of NKA in the rodent hippocampus 
following electoconvulsive stimulation (Stenfors et al., 1992). Furthermore, both SP and 
NKB have been shown to increase the frequency, and in some cases, the duration of 
epileptiform discharge in the entorhinal cortex (Maubech et al., 1998). The deregulation 
of inhibitory excitatory neuropeptide expression following an insult may impact upon 
the outcomes of the epilepsy condition, such as seizure duration and neuronal damage. 
1.1.5 Epileptogenesis
The term ‘Epileptogenesis’ refers to a phenomenon in which the brain undergoes 
molecular and cellular alterations following a brain-damaging insult (e.g., traumatic 
8brain injury or stroke). These modifications increase neuronal excitability and 
eventually lead to the occurrence of recurrent spontaneous seizures, i.e. epilepsy 
(Pitkanen et al., 2007). Cellular alterations include neurogenesis, neurodegeneration, 
axonal sprouting, dendritic remodelling, angiogenesis and acquired channelopathies 
(Pitkanen et al., 2009). How this process occurs is poorly understood, however 
alterations in gene expression and neuronal reorganization are two proposed factors in 
epileptogenesis. Seizures are known to induce dramatic alteration of gene expression 
profiles and these changes can bring about long-term structural and functional changes 
within the brain. A latent period exists between the insult and the development of the 
epilepsy condition proper, and such structural and functional changes are proposed to 
occur during this latent period. This latent period can differ depending on the initial 
insult, for example epilepsy (spontaneous seizures) take up to 1 month following an 
initial seizure or SE, whilst the latency period following traumatic brain injury can be up 
to several months (Pitkanen et al., 2007). 
It is known that during epileptogenesis, several cellular alterations occur
including neuogenesis and neurodegeneration. In animal models, it has been shown that 
neurogenesis can be activated in the DG for several weeks following SE, contributing to 
aberrant neuronal network reorganisation (Parent et al., 2007; Parent et al., 1997). 
Furthermore, in the epileptic rodent brain, migration of newly born neurons can be 
disturbed by seizures, resulting in their ectopic location in the hilus, aberrant 
connectivity, and as a consequence, enhanced excitability (Scharfman et al., 2000). In 
terms of structural alterations, there is a well-established reorganization of the axons of 
the dentate granule cells (Proper et al., 2000), the CA1 pyramidal neurons (Esclapez et 
9al., 1997) and the interneurons (Magloczky et al., 2000), in a process known as 
‘sprouting’. In fact the sprouting of glutamatergic granule cell axons or ‘mossy fibres’, 
is one of the most widely studied forms of axonal plasticity in epilepsy. In addition, 
there is evidence pointing towards the stimulation of angiogenesis, with the increased 
expression of angiogenic factors following SE observed (Hunsberger et al., 2005). 
1.1.6 Epigenetics and epileptogenesis
In addition to changes in gene expression and structural reorganization within 
the brain, there is now increasing evidence to support a role for epigenetic changes 
during epileptogenesis. The term ‘epigenetics’ refers to changes in a gene, which occur 
without affecting the DNA sequence, with chromatin modification being a prime 
example. Examples of modifications include DNA methylation, or changes to histone 
methylation or acetylation status. Histone modifications have been reported following 
both electroconvulsive seizures and KA-induced SE, at the promoters of numerous 
genes, including the TFs c-fos and CREB, BDNF and the glutamate receptor GluR2 
(Huang et al., 2002; Tsankova et al., 2004; Taniura et al., 2006). SE-induced H4 
acetylation of the BDNF P2 promoter was found to correlate with elevated BDNF 
mRNA expression (Tsankova et al., 2004), whilst deacetylation of histones at the GluR2 
promoter was found to induce reduced GluR2 expression (Sanchez et al., 2001; Jia et 
al., 2006). 
Support for the importance of epigenetic changes during epileptogenesis comes 
from the ACD valproic acid (VPA), which is a HDAC (histone deacetylase) inhibitor. 
KA-induced seizures have been shown to stimulate neurogenesis in the DG (Parent et 
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al., 2007; Parent et al., 1997) and VPA is known to potently block seizure-induced 
neurogenesis, through HDAC inhibition, modulating HDAC-dependent gene expression 
within the DG (Jessberger et al., 2007). Furthermore, the neuron restrictive silencing 
transcription factor (NRSF), also termed repressor element-1 silencing transcription 
factor (REST), which has a well documented role in coordinating epigenetic change, via
the recruitment of a battery of co-repressors and chromatin remodelling enzymes
(reviewed in Ooi & Wood., 2007), has been shown to be up-regulated in rodent models 
of SSSE (Palm et al., 1998; Spencer et al., 2006). In this thesis, the importance of such 
chromatin remodelling TFs will be explored, with regards to pro-convulsant gene 
expression regulation, and as potential targets for ACD action. Our principle hypothesis 
is that chromatin remodelling or epigenetics, is a fundamental mechanism underlying 
the progression from a single seizure, into the condition of spontaneous seizures, i.e. 
underlying epileptogenesis. 
1.1.7 Seizure Models
An important aspect in testing the theory that epigenetics and gene regulation 
have a key role to play in epileptogenesis, is the availability of appropriate models. To 
date, the majority of models employed in epilepsy research are in vivo animal models. 
These include the induction of SE via either electrical stimulation, such as the PPS 
model, or through chemoconvulsants, such as pilocarpine or KA administration. These 
models are believed to reflect some of the described molecular and cellular changes 
which occur during epileptogenesis. For example, PPS has been shown to activate the 
DG granule cells, invoking excessive glutamate release (Mazarati et al.,1998), whilst 
pilocarpine has been shown to activate the cholinergic muscarinic receptors, in turn 
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modulating GABAnergic inhibitory signalling  pathways (Kumar & Buckmaster., 2006). 
Whilst such models are excellent tools for studying gene expression changes during and 
post SE, it is often important to begin investigations using a cellular model so that we 
can address the biochemistry and cellular pathways in a more homogenous cell 
population where one can more easily control the challenge. 
There are two main types of cellular models one may wish to utilise, these being 
immortalised cell lines or primary cell cultures. Our group has previously employed the 
latter option, to reveal that isoforms of the TF NRSF are modulated in terms of sub-
cellular localisation in response to KA, in dissociated rat hippocampal cultures (Spencer 
et al., 2006). Such an approach has the benefits that one can experiment on regions that 
are critical in seizure progression, such as hippocampi, however the number of cells one 
can obtain from a specific tissue from a sacrificed animal, is often too few to perform 
certain experiments such as chromatin immunoprecipitation (ChIP). Furthermore the 
heterogeneity still does not allow for addressing cellular changes in a specific 
subpopulation of cells in the hippocampus and can present problems for certain 
biochemical and molecular techniques. Due to these reasons, this thesis will utilise 
immortalised cell lines throughout. 
Despite decades of experimental research into epilepsy and seizure, there is yet 
to be a single cell line deemed to be the seizure-model cell line. This is perhaps 
unsurprising given the complexity and heterogeneity of the cells affected within an 
epileptic brain. However, it was important to establish a useful cell line model for use 
throughout this thesis. Numerous neuronal cell lines were available for experimentation, 
including the rodent PC12 cell line, which are derived from rat adrenal medulla (Greene 
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& Tischler., 1976), and have previously been used by our group to explore the activity 
of the SP-encoding TAC1 gene promoter (Paterson et al, 1995). For this thesis, a human 
cell line was preferred, and two human neuroblastoma cell lines have been utilised: SH-
SY5Y and SK-N-AS. 
The human SH-SY5Y cell line is derived from the SK-N-SH cell line, first 
isolated in 1970, and have been shown to exhibit a number of neuronal features, 
including dopamine beta hydroxylase activity (Biedler et al., 1978), an enzyme linked to 
seizure susceptibility (Warter et al., 1975; Szot et al., 1999). This cell line has been 
shown to be responsive both to glutamate and NMDA (Sun et al., 1998; Jamsa et al., 
2006), suggesting that these cells may endogenously express glutamate receptors, and  
indeed Nair et al have shown that SH-SY5Y cells do express the NMDA receptor (Nair 
et al., 1996). Furthermore, recent findings have shown that this cell line is also 
responsive to KA stimulation (Cannarsa et al., 2008), indicating that this cell line may 
be a good cell model to investigate molecular changes in response to aberrant 
glutaminergic signalling, characteristic of seizure. In support of this, SH-SY5Y cells 
have been shown to express a number of neuronal genes implicated in epilepsy, 
including the BDNF receptor TrkB (Ehrhard et al., 1993), the Kv3 potassium channel 
(Friederich et al., 2002) and the cholinergic receptor nicotinic alpha 4 nAChR (Liu et 
al., 2006).
The second neuroblastoma cell line employed in this thesis, the SK-N-AS cell
line, was first isolated in 1981, and has received less attention than the SH-SY5Y cell 
line. Early publications revealed that SK-N-AS cells synthesis Insulin-like growth factor 
II (IGF-II) and express its receptor (El-Badry et al., 1989). IGF-II has been showed to be 
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expressed within the hippocampus, and is thought to have an important role in neural 
growth and differentiation (Dore et al., 1997). Interestingly, both IGF-I and IGF-II have 
been shown to be reduced in the hippocampus in both rodent kindling models 
(Kalynchuk et al., 2002), and following KA administration (Kar et al., 1997), suggesting 
that SK-N-AS cells may also be responsive to chemoconvulsant stresses, and therefore 
may be of use as a cell line model to explore molecular changes in response to pro-
convulsant challenges. Consistent with this, preliminary findings from our group have 
revealed that this cell line endogenously expresses the pro-convulsant neuropeptides SP 
and NKB, as well as the TF NRSF, which as discussed earlier are correlated with 
seizure. 
Throughout this thesis, the SH-SY5Y and SK-N-AS cell lines will be employed 
to explore molecular events relevant to seizure. Such cell lines are useful in initial 
experimentation, to build hypotheses and unlock questions, but it is important to stress 
that such models cannot reflect the true diversity nor the complexity of events which 
occur throughout the brain in response to seizure. As such, this thesis aims to open up 
lines of research for future in vivo experimentation. 
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1.2 The Tachykinins
1.2.1 The Tachykinin Family
The tachykinins are a group of peptides which function as excitatory 
neurotransmitters, sharing a common C-terminal amino acid sequence (Phe-X-Gly-Leu-
Met-NH2) (reviewed in Severini et al., 2002). They are widely distributed within the 
central nervous system (CNS) and the peripheral nervous system (PNS), with some 
recent findings in non-neuronal tissue (Pennefather et al., 2004). Since the early 
discovery of SP in the 1930’s (von Euler & Gaddum., 1931), a number of other 
tachykinin family members have been discovered, including NKA (Kangawa et al., 
1983; Nawa et al., 1984), NKB (Kanazawa et al., 1984; Kimura et al., 1984), 
neuropeptide K (NPK) (Tatemoto et al., 1985), neuropeptide γ (NPγ) (Kage et al., 1988) 
and most recently hemokinin-1 (HK-1) (Zhang et al., 2000). Tachykinins are 
predominately synthesised in the neurons of the CNS and the PNS and are stored in 
dense core vesicles (McCarthy & Lawson., 1989; Floor et al., 1982). The tachykinin 
family members are implicated in a wide range of processes and disorders such as 
neurotransmission (Otsuka & Yoshioka., 1993; Patacchini et al., 1998), pain (Duggan et 
al., 1987; Duggan et al., 1988; Cao et al., 1998), cognitive and psychiatric disorders 
(Kramer et al., 1998; Maubach et al., 1999), epilepsy (Liu et al, 1999; Wasterlain et al, 
2000), Parkinson’s disease (Barker., 1991; Chen et al, 2004), Huntington’s disease (HD) 
(Richfield et al., 2002),  pre-eclampsia (Page et al., 2000; Page et al., 2001; Page et al., 
2006) and breast cancer (Patel et al., 2005; Rao et al., 2004; Corcoran et al., 2008).
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Tachykinins interact with specific membrane bound G protein-coupled receptors 
(GPCRs), with three distinct tachykinin receptors discovered to date: NK1R, NK2R and 
NK3R (Gerard et al., 1991; Takeda et al., 1991; Gerard et al., 1990; Buell et al., 1992). 
These tachykinin receptors belong to the rhodopsin-like family of GPCRs, sharing a 
common structural motif consisting of bundle of seven transmembrane domains, three 
extracellular loops, three intracellular loops, an extracellular amino-terminus and a 
cytoplasmic carboxy-terminus. The tachykinins SP, NKA and NKB act as agonists on 
all three tachykinin receptors, whilst also exhibiting preferential binding to NK1R, 
NK2R and NK3R, respectively. (Mussap et al., 1993; Regoli et al., 1994; Maggi, 2000). 
The expression of these receptors, has been shown to match that of the high affinity 
tachykinins, with NK1R and NK3R observed in the CNS and peripheral tissue and
NK2R found in the peripheral tissue only (reviewed in Pennefather et al., 2004).
1.2.2 Neurokinin B (NKB)
NKB is encoded by the preprotachykinin-B (PPT-B) gene, also referred to as 
TAC3 (human) (Page et al., 2000) or TAC2 (rodent) (Chawla et al., 1997). The human 
TAC3 gene consists of seven exons, with exon 5 encoding the NKB peptide (Figure 
1.1a). Like the other tachykinins, NKB is proposed to act as an excitatory 
neurotransmitter, and has been shown to be expressed throughout the CNS (Lucas et al., 
1992; Moussaoui et al., 1992), and the PNS, with NKB and its endogenous high affinity 
receptor (NK3R) shown to be expressed in human airways and pulmonary veins and 
arteries. These findings suggest an addition role for NKB in lung pathophysiology 
(Pinto et al., 2004).  NKB mRNA has also been recorded in human lymphocytes, 
monocytes, neutrophils and eosinophils, suggesting NKB plays a role in the 
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pathophysiology of the inflammatory process (Klassert et al., 2008). Furthermore, NKB 
expression has been demonstrated in the placenta (Page et al., 2000) and the 
myometrium (Patak et al., 2003), and NKB is implicated in pre-eclampsia, with elevated 
NKB expression found in pre-eclamptic placenta (Page et al., 2006). In addition, recent 
findings have correlated mutations of both the NKB and NK3R genes, with 
hypogonadotropic hypogonadism, suggesting a key role for NKB in the control of 
reproduction (Topaloglu et al., 2009). NKB therefore, appears to have several important 
roles throughout the body, in addition to neurotransmission.
The related tachykinin, SP, has been shown to be of importance in epilepsy, with 
elevated levels of SP observed in rodent models of SSSE (Wasterlain et al., 2000). NKB 
has also been implicated in epilepsy, with elevated NKB immunoreactivity and mRNA 
levels observed in rat hippocampus following KA administration (Marksteiner et al., 
1992b). In support of this, NK3R, has been shown to exacerbate KA induced neuronal 
death in mice (Chen et al., 2008), and the NK3R agonist senktide, induces 
hyperlocomotor activity in rodents (Nordquist et al., 2008). Furthermore, SP and NKB 
have been shown to increase the frequency, and in some cases, the duration of 
epileptiform discharge in the entorhinal cortex (Maubach et al., 1998). Interestingly, 
NKB has recently been shown to be up-regulated in a rodent model of Parkinson’s 
disease, following administration of the dopamine mimic L-DOPA, whilst activation of 
the NK3R, evokes dopamine release (Zhang et al., 2008), indicating a role for NKB in 
the dopaminergic system. Subsequently, due to the importance of NKB in a multitude of 
conditions including epilepsy, pre-eclampsia and lung pathophysiology, it is of great 
importance to gain a greater understanding of the regulation of the NKB gene. 
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Figure 1.1 Schematic representation of the alternative splicing which results in the synthesis of 
different neuropeptide. (A) NKB is derived from the TAC3 gene, with exon 5 encoding the 
neuropeptide. (B) The human TAC1 gene encodes four neuropeptides: SP, NKA, NPK and NPγ. 
Chromosomal position of genes are given, as are the resulting peptide sequences, with the common 
sequence highlighted. 
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1.2.3 Regulation of NKB
The regulation of the NKB-encoding TAC3 gene is poorly understood, in 
comparison to that of the TAC1 gene. The only published findings are from Pal et al, 
who revealed that the rodent NKB gene (TAC2) is regulated by the GATA family of 
TFs, in non-neuronal cells. GATA-1 was shown to activate TAC2 transcription in 
erythroid cells, by replacing GATA-2 from a GATA motif located in intron 7 (Pal et al., 
2004). However, NKB regulation in human or indeed any neuronal cells has yet to be 
determined.
Potential candidates have arisen based on processes and systems which modify 
NKB expression. For example, NKB expression is found to be enhanced in the arcuate 
nucleus in post-menopausal women, i.e. those with low oestrogen, whilst oestrogen 
replacement suppresses NKB expression, suggesting that oestrogen represses NKB 
expression. This has been shown to be mediated by the oestrogen receptor (ERalpha) 
(Dellovade & Merchenthaler., 2004). The upstream stimulatory factor (USF) 1 (USF1), 
which has been correlated with seizures (Sirito et al., 1998), has also been shown to be 
activated by the ERalpha signalling pathway, inducing USF1 binding to the cathepsin D 
promoter (deGraffenried et al., 2004). Thus a case may be made for USF1 binding to the 
NKB promoter in a similar manner. Support for such a hypothesis comes from the fact I 
have located a putative E box motif, a DNA sequence to which USF and other basic-
Helix-Loop-Helix (bHLH) factors recognise and bind to, within the TAC3 proximal 
promoter (Figure 1.2). Furthermore, NKB has been shown to co-localise with arginine 
vasopressin (AVP), in AVP expressing neurons (Hatae et al., 2001). AVP is also 
regulated by USF factors binding to an E box within the AVP promoter (Coulson et al., 
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1999; Coulson et al., 2003) and I propose that USF may regulate the NKB promoter in a 
similar manner. 
Another TF, shown to regulate TAC1 expression, NRSF, has also been shown to 
regulate AVP expression (Quinn et al., 2002). Consequently, NRSF is a candidate 
regulator of NKB expression, due to its existing regulation of neuropeptides, and as 
NRSF has been shown to be up-regulated following seizure (Palm et al., 1998; Spencer 
et al., 2006), matching the changes observed for NKB (Sperk et al., 1990; Marksteiner 
et al., 1992b). Support for a role of NRSF in NKB regulation came from a recent 
bioinformatics search, which identified a putative NRSF recognition site (NRSE, or the 
neuron restrictive silencing element), upstream from the rodent TAC2 gene (Otto et al., 
2007). This site was however some 20kb upstream from the gene, and I have since 
identified an alternative putative NRSE much closer to the transcription start site (TSS), 
spanning +55 to +71 of the human TAC3 promoter (Figure 1.2). This putative NRSE 
was identified based on the NRSE consensus sequence (Figure 1.6a). Furthermore, NKB 
expression in striatal neurons has been shown to be distributed in association with µ-
opioid receptor localisation (Furuta & Kaneko., 2006), with the µ-opioid receptor also 
known to be regulated by NRSF (Formisano et al., 2007). In this thesis, the regulation of 
the human NKB gene will be explored, focusing on the potential regulatory roles of both 
USF and NRSF TFs in governing NKB promoter activity and endogenous NKB 
expression.  
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Figure 1.2 Sequence of the human NKB (TAC3) proximal promoter spanning -757 to + 181. Putative 
NRSE and E box motifs are highlighted in yellow and green respectively. The putative NRSE spans from 
+50 to +71, and the putative E box spans from +160 to +166. 
1.2.4 Substance P (SP)
Perhaps the most characterised tachykinin is SP, which is encoded by the TAC1 
gene. Like other tachykinins, SP is widely distributed throughout the CNS and the PNS 
and is predominantly synthesised within neurons and stored in dense secretory vesicles. 
Upon cellular excitation, SP is released and acts upon appropriate receptors, including 
its high affinity NK1R, to evoke a variety of responses (Maggi, 1993; Pennefather et al., 
2004). Due to its role in neuronal communication, SP is classically considered to be a 
21
neurotransmitter, but recent findings have implicated other roles for SP, including a role 
as an inflammatory molecule, analogous to a cytokine (Pascual et al, 1992; Luger & 
Lotti, 1998). SP is implicated in a wide range of disorders including Parkinson’s disease 
(Barker., 1991; Chen et al, 2004), HD (Richfield et al., 2002), pain (Duggan et al., 
1987; Duggan et al., 1988), cognitive and psychiatric disorders (Kramer et al., 1998; 
Maubach et al., 1999) and breast cancer (Patel et al., 2005; Rao et al., 2004; Corcoran et 
al., 2008).
SP is of particular interest to this thesis based upon its pro-convulsant role. Like 
NKB, SP is up-regulated in the hippocampus following PPS-induced SSSE (Liu et al,. 
1999; Wasterlain et al., 2000). In addition, studies have shown that hippocampal 
administration of SP can induce SSSE, at electrical stimulation below the normal SSSE-
inducing threshold (Liu et al., 1999). Furthermore, elevated SP expression in the 
hippocampal CA3, CA1 and DG regions have been implicated in neuronal damage 
following SSSE induced by either PPS or KA (Brene et al., 1992; Liu et al., 1999a; Liu 
et al., 1999b; Liu et al., 2000). The findings that NKA, an alternative peptide encoded 
by the TAC1 gene, is also up-regulated during KA treatment (Sperk et al., 1990), 
suggests that seizure has a direct affect upon the TAC1 gene, and that TAC1 regulation 
is of upmost importance in the early stages of SSSE. In support of this, TAC1 knockout 
mice show reduced seizure duration and severity in response to KA treatment (Liu et al, 
1999b). Finally, the SP peptide itself is shown to contribute to limbic seizure activity, as 
antagonists to NK1R, have been shown to prevent KA-induced SSSE (Zachrisson et al., 
1998). 
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1.2.5 Regulation of TAC1
Unlike NKB regulation, the regulation of the TAC1 gene is relatively well 
documented. The human TAC1 gene is 8kb long and consists of seven exons which give 
rise to four alternatively spliced mRNA transcripts, designated α, β, γ and δ (Nawa et al, 
1984; Carter & Krause, 1990). These transcripts differ in their exon combinations, for 
example αTAC1 lacks exon 6 whereas γTAC1 lacks exon 4. Four neuropeptides arise 
from these transcripts: SP, NKA, NKP and NPγ, with the SP precursor synthesised from 
all four isoforms (as summarised in Fig.1.2b) (Macdonald et al, 1988). Translation of 
mature TAC1 mRNA generates a large polypeptide which is transported to the Golgi 
apparatus, where it is cleaved and the active peptide is then packed into secretory 
granules destined for the nerve endings. 
Studies into the regulation of the TAC1 gene have predominantly focused upon 
the rat TAC1 proximal promoter sequence, although some studies has been undertaken 
exploring human TAC1 gene regulation (Mackenzie et al., 2000; Mackenzie & Quinn., 
2002; Greco et al., 2007; Murthy et al., 2008; Reddy et al., 2009). Early DNase 1 
footprinting studies revealed a number of cis-acting regulatory elements within the rat 
TAC1 proximal promoter, including a TATA box spanning -22 to -28 in relation to the 
TSS (Carter & Krause., 1990), initiator elements located -20 to +4 (Mendelson., 1995), 
an octamer-binding motif, Sp-1 motifs, activation protein 1/cAMP response element
(AP1/CRE) motifs, multiple E box sites and an unidentified but distinct factor 
(Fiskerstrand and Quinn, 1996;  Fiskerstrand et al., 1999;  Fiskerstrand et al., 2000;  
Fiskerstrand et al., 1997;  Mendelson and Quinn, 1995;  Paterson et al., 1995a;  
Paterson, et al., 1995b;  Paterson, et al., 1995c; Mendelson et al., 1998). A summary of 
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the known or proposed TF binding sites, within the rodent TAC1 proximal promoter, is 
given in Figure 1.3. Subsequently, sequence comparisons between TAC1 and AVP, 
revealed a domain with high sequence homology to the NRSE located within the 
proximal promoter, suggesting that NRSF maybe be a candidate regulator of TAC1 
(Quinn et al., 2002). In support of this, endogeneous levels of NRSF and its truncated 
isoform were reported to be elevated following KA-induced SE (Palm et al., 1998), 
consistent with an increase in TAC1 (Wasterlain et al., 2000). Our lab has recently 
shown that both NRSF and a truncated isoform can modulate TAC1 expression, as 
over-expression of these TFs led to both an increase in TAC1 promoter activity, and 
also an increase in endogenous TAC1 expression in dissociated rat hippocampal cultures 
(Spencer et al., 2006). Since these findings, a number of other groups in addition to our 
own, have shown that NRSF regulation of TAC1 is cell-specific, with both repression 
and activation of the TAC1 promoter or endogenous expression, governed by NRSF in a 
tissue-dependent manner (Greco et al., 2007; Howard et al., 2008; Reddy et al., 2009).
The USF family are also potential regulators of TAC1 expression, based upon 
the discovery of multiple E-box motifs within the rat TAC1 proximal promoter. The E 
box canonical sequence CANNTG is recognised by the bHLH family of proteins, to 
which the ubiquitously expressed USF belongs. One particular E-box motif, spanning 
nucleotides -67 to -47 (Paterson et al., 1995) was shown to be functional, regulating the 
response of the rat TAC1 promoter to nerve growth factor (NGF) stimulation in rat 
dorsal root ganglion (DRG) (Gerrard et al., 2005). Another cis-regulatory element
identified in the earlier studies, AP1/CRE, centered at -196, was also later shown to be 
functional, coordinating forskolin-induced TAC1 promoter activity, in a PKA-dependent 
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manner (Calin-Jageman et al., 2006). More recently, a role for NFκB in the regulation of 
human TAC1 has been proposed. In non-neuronal cells, NRSF has been shown to bind 
to TAC1 and suppress its activation. Following stimulation of mesenchymal stem cells 
(MSCs) with IL-1α, NRSF binding to TAC1 was found to decrease and suppression was
alleviated. NFκB was also found to bind to the human TAC1 proximal promoter, and 
this binding was also diminished following IL-1α stimulation. Subsequently, NFκB was 
proposed to work in synergy with NRSF to bring about TAC1 suppression in non-
neuronal cells (Greco et al., 2007). Furthermore, the chemokine Stromal-derived factor-
1 alpha (SDF-1α) has been shown to modulate TAC1 expression, through the activation 
of NFκB in non-tumorigenic human breast cells (Corcoran et al., 2008).
In this thesis, I will explore the regulation of the rat (and in part the human) 
TAC1 promoter further, by investigating a possible synergistic regulation of the TAC1 
promoter by the NRSF and USF TF families, akin to synergy proposed between NFkB 
and NRSF (Greco et al., 2007). 
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-865      CAGAGCTCCAAA
-850   GGTAAGCATCCAGCCTTTCTAGTCCCCCAACAAGGCTAAAGGGGAGAGAG
-800   GCACAATTATCCTCTTCCCACCCCTTCTGCCTTCAGGGTGTGCCTGGGAA
                   COMPLEX BINDING DOMAIN
-750   GAAGCTGTAGGGGAACAAAAGATGCCTTAGAATGGCTGATGGGTAAGTTC
-700   TACATGAGAAAGGAGGTTTAAATTCCTCTTTCCCCTAAATGTAAAACAAA
                                    Octamer
-650   CCTGCCTTCATCCTCTGAAGCGGGAGACCGGAAACACTTTTGCAGTGCTA
SP1/AP2
-600   GAGAAATGAGAATATTCTGACTGATTTGGTGGGGAGGGGGGTTGGGGGGG
-550   TGTGTTCCAGCCCTAGATATAACACCTCATAAACCTTAAGACACATAAAG
-500   TAGAAATGAAAGGAAAACCCCGCTTGCTTCATCCCTCTGAAGTGCTTGCT
                        
-450   GGTGTCTTAGTATTATTCACAAGGTTTTGCTGCTCAAGTTATTTGGCTGT
   
-400   CCTCAAAGCGCAATATTCCCTGATGCCTCTTGAGAGAAAAGTTCCCTAAG
-350   TCCGAAGCATGAGTCACTTCGCTCAGTTTTGATGAGTAATCTCAGGTGTC
AP1     AP1      E box
-300   ACTGAACCTTGTTCGGAAGAAGAGGGGAGGGGGGCGTCAGATTTGCAGAC
  SP1/AP2
-250   GGAAGAAAACAGGTCTCTCTGGATTGGATGGCGAGACCTCGACTTCCCTA
-200   AAATTGCGTCATTTCGAACCCAATTTGGTCCAGATGTTATGGACTCCGAC
AP1/CRE E box
-150   GGGTTACCGTCTCGGAAACTCTATCACGCAAGCAAAAGGCGAGGGGGCGG    
  
-100   CTAATTAAATATTGAGCAGAAAGTCGCGTGGGGAGAGTGTCACGTGGCTC
E box  
-50    TCCAGGCTCATCACGCCTGAGATAAATAAGGCGAAGCAGGAGCAGGGACT
          CRE         NRSE
+1     AGAGCGCACTCGGACCAGCTCCACTCCAGCACCGCGGCGGAGGAGAGCGA
+50    GGAGCGCCCAGCAAGTGCGCACCTGCGGAGCATCACCGGGTCC +92
  E box    E box
Figure 1.3 Sequence of the rat TAC1 proximal promoter region spanning -865 to +92. Cis-regulatory 
domains are highlighted as follows: Light green are E box motifs, pink is the NRSE, yellow is an AP1 
element, with overlapping CRE site underlined, whilst separate CRE elements are highlighted in black. 
Red indicates an AP2 site, with overlapping SP1 sites underlined, light blue represents the octamer site, 
and the grey indicates a complex binding domain, which can bind a number of single or double stranded 
binding proteins.  
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1.3 Gene regulation
1.3.1 Transcription
The exquisite control of gene expression can occur through multiple regulatory 
mechanisms including translation, post-translational modifications and degradation. One 
of the earliest and most efficient control points is at the level of transcription, the 
synthesis of RNA from a DNA template. The transcription process is coordinated by the 
enzyme RNA polymerase (Pol), with eukaryotes having three nuclear enzymes Pol I-III, 
of which Pol-II is vital to the transcription of mRNA. Pol-II alone, is incapable of 
specific initiation and transcription, instead it requires the activity of the general 
transcription factors (GTFs), denoted TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH, to 
assemble at the core promoter. Once assembled onto the core promoter, the GTFs form 
stable nucleoprotein complexes and recruits Pol-II, to form the pre-initiation complex 
(PIC). More specifically, the TATA-binding protein (TBP) in a complex with TAFs 
(TBP Associated Factors), collectively known as TFIID, first binds to the core promoter, 
which nucleates the formation of PIC (Pugh & Tjian, 1991). TFIIA and TFIIB 
subsequently bind to the TFIID complex, stabilising its interaction with the DNA. To 
this binds TFIIF, Pol-II, TFIIE and finally TFIIH, forming the basal transcription 
machinery. At this point, Pol-II and the GTFs are bound to the core promoter in an 
inactive state. The GTFs have a key role in the recognition of promoter sequences and to 
govern the response to regulatory factors, such as TFs. The basal transcription 
machinery consists of one final factor, known as Mediator. Mediator facilitates 
communication between regulatory proteins (i.e. TFs) and the transcriptional machinery, 
transducing regulatory information to Pol-II (Kelleher et al., 1990; Kim et al., 1994).
27
Once the PIC is established, a conformational change occurs in which 11-15bp 
of DNA surrounding the TSS are melted, and the template strand is positioned within 
the active site cleft of Pol-II (Wang et al., 1992). This melting step is mediated by the 
helicase activity of TFIIH (Tirode et al., 1999), which unwinds the DNA in an ATP-
dependent manner (Holstege et al., 1997). Initiation of transcription begins with the 
phosphorylation of Pol-II at serine-5 by TFIIH, releasing Pol-II from the PIC, followed 
by phosphorylation of serine-2, which enables Pol-II to begin RNA synthesis in the 
elongation phase. The resulting transcript, known as pre-mRNA, undergoes further 
processing, including removable of introns via splicing, and the addition of a 5’ cap 
(addition of modified guanine nucleotides to the 5’ end) and a 3’ poly-A-tail. 
Pol-II transcription can be governed by three distinct classes of DNA sequences. 
The first class includes DNA sequences within the core promoter with perhaps the best 
characterised core promoter elements being the TATA box (consensus TATAAA) 
located approximately -25 from the TSS, and a pyrimidine-rich sequence near the TSS 
known as the initiator element (Inr). As A-T rich sequences require less energy to 
denature into single strands, it is thought the TATA box facilitates strand separation. 
Both the TATA box and the Inr are recognised by the GTFs to initiate transcription. The 
remaining two classes are both cis-regulatory domains: the proximal-promoter elements 
and the distal-promoter elements (enhancers/repressors) (see figure 1.4). TFs bind to 
these cis-regulatory domains, and affect transcription either directly, whereby they may 
affect the GTFs, inhibiting/enhancing PIC assembly, or indirectly, through chromatin 
remodelling, which will be discussed later. Examples of these include the transcriptional 
activator cAMP response element binding protein (CREB), which has been shown to 
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interact directly with TFIID, recruiting the coactivators CREB-binding protein (CBP) 
and p300, which facilitate recruitment of Pol-II to the promoter (Nakajima et al., 1997; 
Vo & Goodman., 2001). 
Whilst the promoter region of many genes contains DNA sequences to which 
proteins can bind to, the mere presence of these DNA sequences, whilst necessary, is not 
sufficient for transcription factor binding. This is because DNA is packaged into 
chromatin, with DNA wrapped tightly around histone proteins. As histones affect 
protein-DNA interactions, and thus transcription, it is now widely accepted that 
chromatin has a significant role in coordinating transcriptional regulation of eukaryotic 
genes. 
Figure 1.4 Schematic diagram to illustrate RNA polymerase and GTFs recruitment to the core 
promoter for transcription initiation. The three classes of DNA sequences are given, the core promoter 
(TATA box), the proximal promoter and the distal promoter elements. A single TF is shown to illustrate 
how they may modulate transcription, via direct association with the basal transcription machinery. 
Mediator is shown, which transducers regulatory information to Pol-II.
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1.3.2 Chromatin
Approximately two metres of DNA is packaged within the nucleus of a cell, 
wrapped tightly around core histone proteins. The fundamental unit of chromatin is the 
nucleosome core particle which consists of 146bp of DNA wrapped 1.65 turns around a 
histone octomer, containing two central H3/H4 dimers, flanked by two H2A and H2B 
dimers (Arents et al., 1991). Histones are small proteins with protruding, charged, N-
terminal tails, which extend out from the nucleosome between turns of DNA. As more 
than 20% of the histone amino acid sequence is positively charged (lysine and arginine), 
strong interactions with the negatively charged DNA backbone can occur. Furthermore, 
with more than 14 contact points between histone and DNA, the nucleosome complex 
has a high degree of stability under physiological conditions. However, under low ionic 
strength buffer conditions, chromatin decondenses to resemble ‘beads on a string’ 
(Oudet et al., 1975). At this level of compaction, chromatin is often referred to as 11nm 
fibres. Chromatin can become more compact, through the linking of nucleosomes by 
‘linker’ histones, denoted 30nm fibres. It is believed that chromatin exists at an even 
greater level of compaction in vivo, and may exist as 80-100nm fibres (Belmont & 
Bruce., 1994). 
The highly compact nature of chromatin inhibits many processes which require 
access to the DNA, including DNA repair, replication and transcription. An increasing 
appreciation of the role of chromatin in transcription has developed, following the 
discovery that nucleosomes impede transcription in vitro (Knezetic and Luse, 1986), 
whilst deletion of histones or their basic tails enhances gene expression in vivo (Han & 
Grunstein, 1988; Han et al., 1988). The highly packaged nature of the DNA can prevent 
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TFs from recognising and binding to target DNA sequences, and can impair the 
formation of PIC and binding of TBP to core promoter regions (Imbalzano et al., 1994). 
In order to activate gene expression, this highly compact structure needs to be 
unwrapped, and conversely, if gene expression needs to be silenced, then this compact 
structure can be regenerated. Two major mechanisms have arisen to meet these 
demands: Chromatin remodelling and histone modifications.
1.3.3 Chromatin remodelling
As I have mentioned, the structure of chromatin presents quite a formidable 
barrier to transcription. To overcome this, both activators and repressors utilise 
chromatin-remodelling enzymes to catalyse the movement of nucleosomes, altering the 
availability of DNA sequences to the basal transcription machinery. Due to the strength 
of the interactions between the negatively charged DNA and the positively charged 
histones, chromatin-remodelling enzymes require energy derived from ATP hydrolysis 
to drive DNA away from the nuclesome (Narlikar et al., 2001). Consequently, 
chromatin-remodelling complexes contain a central ATPase, and can be separated into 
three family groups based upon this central ATPase: the SWI/SNF family, the ISWI 
family and the CHD1 family. It was thought that chromatin-remodelling enzymes were 
associated with transcriptional activation, facilitating access of Pol-II to the core 
promoter, however a number of chromatin-remodelling enzymes have been shown to 
repress transcription. One example is BRG1, a member of the SWI/SNF family, which 
is recruited by NRSF, stabilising NRSF binding to target DNA sequences, enhancing
repression of target genes (Ooi et al., 2006). 
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The consequence of chromatin remodelling include the unwrapping of DNA 
away from histone octomers, the formation of DNA loops, or the movement of 
nucleosomes to different translational positions, in a process known as ‘sliding’. All of 
these result in a change in the accessibility of DNA to TFs (reviewed in Li et al., 2007). 
It has recently emerged that histone displacement can also occur, in which H2A/H2B 
dimers can easily exchange in and out of nucleosomes, and indeed entire histone 
octomers can be displaced in a process known as ‘eviction’. Cooperation between TF 
binding, chromatin-remodelling complexes and actively transcribing Pol-II, can all 
mediate histone displacement (Adams and Workman, 1995; Bruno et al., 2003; Kireeva 
et al., 2002). Due to the fact that displaced histones can rebind to the same stretch of 
DNA, histone acceptors or chaperones (such as Asf1) are required to prevent this and 
are shown to be vital in histone eviction in vivo (reviewed in Li et al., 2007). 
Following chromatin remodelling, a nucleosome–free region becomes available 
for the formation and binding of the PIC. During transcription elongation, histone 
acetyltransferase (HAT) complexes associate with the elongation machinery to acetylate 
histones in front of Pol-II, facilitating in the disassembly of downstream nucleosomes, 
onto awaiting histone chaperones. This can lead to histone loss, with partial loss of 
nucleosomes recorded over the coding regions of actively transcribed genes in yeast 
(Lee et al., 2004), and in Drosophila (Wirbelauer et al., 2005). Following the passage of 
Pol-II, the displaced histones are replaced or reassembled. This is coordinated by the 
histone chaperone Spt6, which colocalises with the elongating Pol-II (Kaplan et al., 
2000). Spt6 interacts directly with displaced histones, enabling their assembly back 
behind the elongating Pol-II. Furthermore, histone H3 Lysine 36 (H3K36) is methylated 
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by the Pol-II bound Set2 methyltransferase, leading to a repressive environment behind 
the elongating Pol-II, preventing further PIC formation and subsequent transcription 
(summarised in Figure 1.5) (reviewed in Workman., 2006).   
Figure 1.5 Schematic diagram illustrating chromatin remodelling during transcription. Condensed 
chromatin is unravelled by the SWI/SNF chromatin remodelling complex, sliding nucleosomes to 
generate a nucleosome free region (NFR), to which the basal transcriptional machinery can bind. Pol-II 
binds and initiates transcription, entering the elongation phase. During elongation, HATs associate with 
Pol-II to acetylate downstream histones, thus facilitating in the de-condensation of future chromatin. 
Histones can be displaced, and reassembled behind the elongating Pol-II, mediated by the histone 
chaperone Spt6. Finally, histones assembled behind the elongating Pol-II are methylated by the Set2 
methyltransferase, resulting in a repressive environment behind Pol-II, preventing further PIC formation. 
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1.3.4 Histone modifications
Both the N-terminal tails and the globular domains of histones, are subject to a 
vast array of post-translational modifications, which include: methylation (of arginine 
(R) or lysine (K) residues); acetylation, ubiquitination, ADP-ribosylation, sumoylation, 
and serine/threonine phosphorylation (Reviewed in Kouzarides., 2007). To orchestrate 
these modifications, an array of enzymes has evolved which include HATs, HDACs, 
histone methyltransferases (HMTs), demethylases, ubiquitilases and serine/threonine 
kinases. Certain modifications are associated with active transcription, and are 
commonly referred to as euchromatin modifications, whilst modifications that are 
localised to inactive genes or regions, are often termed heterochromatin modifications (a
summary of such modifications is given in Table 1.1). Most of the histone modifications 
known to date are localised in distinct regions, which may be upstream of the promoter, 
at the core promoter or at the 5’ or 3’ end of the open reading frame (ORF). The correct 
localisation of such modifications is vital in coordinating its affect on transcription. For 
example, methylation of H3K36 usually occurs within the ORF, and is often referred to 
as a hallmark of elongation (Guenther et al., 2007), however methylation of H3K36 at 
the promoter leads to transcriptional repression (Strahl et al., 2002). A similar finding 
has been observed following methylation of H3K9 (Vakoc et al., 2005) (Table 1.1). 
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Modification Residues Modified Active or Repressive
Acetylation H3K56 ACTIVE
H4K16 ACTIVE
H3K9 ACTIVE
H3K4 ACTIVE
Methylation H3K4 ACTIVE
H3K4 ACTIVE
H3K79 REPRESSIVE
H3K9 REPRESSIVE/ ACTIVE
H3K27 REPRESSIVE
H3K36 REPRESSIVE / ACTIVE
H3K9 REPRESSIVE / ACTIVE
H4K20 REPRESSIVE
Table 1.1. Summary of histone modifications and their corresponding impact upon transcription. 
Modified from Li et al., 2007.
1.3.4.1 Histone acetylation
Acetylation is perhaps one of the most well characterised modifications of 
histones, and is almost invariably associated with transcriptional activation and gene 
expression (Pokholok et al., 2005). It is believed that the acetylation of lysine residues 
neutralises the net positive charge of the histone, reducing the strength of the 
electrostatic interactions between the histone and the negatively charged DNA. This 
results in a more relaxed chromatin configuration, enhancing the accessibility of the 
DNA to binding proteins. The enzymes responsible for histone acetylation are the 
HATs, which can be separated into three families: GNAT, MYST and CBP/p300 
(Sterner & Berger., 2000).  The majority of acetylation sites are found within the N-
terminal tails in a non-specific manner, although a number of more specific core histone 
lysines have since been found to be acetylated (see Table 1.1). This number has since 
risen to 18 histone acetylation sites following a genome wide study, with certain types 
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such as H3K9ac located at the TSS, and others such as H3K4ac, elevated in the 
promoter region (Wang et al., 2008).  
Histone acetylation can also be reversed by the HDAC complexes which are 
correlated with transcriptional repression. There are three main families of HDACs: the 
class I and class II HDACs and the class III NAD-dependent enzymes of the Sir family. 
These enzymes remove acetyl-groups from lysine residues, without much specificity, 
although the yeast enzyme Sir2, has been found to display some selectivity for H4K16ac
(Vaquero et al., 2006).
1.3.4.2 Histone methylation
In contrast to acetylation, methylation is a highly restricted modification, in 
terms of the specific residues targeted. The enzymes responsible for methylation, the 
HMTs, usually only modify a single lysine (or arginine) on a single histone, resulting in 
either transcriptional activation or repression (Bannister & Kouzarides., 2005). 
Methylation of lysine residues can be one of three forms (mono, di- or tri-methylation), 
whilst methylation of arginine can be either mono- or di-methylation. Methylation has 
been linked with both transcriptional activation and repression, depending upon which 
histone lysine sites are methylated (see Table 1.1) (reviewed in Kouzarides et al., 2007). 
Unlike acetylation, methylation has no impact on the net electrostatic charge between 
histone and DNA, instead its affects upon transcription are carried out by methylation 
providing a binding surface for effector proteins to bind to and perform defined tasks. 
For example, methylation of H3K9 acts as a binding site for the corepressor 
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heterochromatin protein-1 (HP1), which induces condensation of the chromatin 
structure, into a repressive heterochromatin form (Bannister et al., 2001). 
Methylation can be reversed by demethylase enzymes, with LSD1 being the first 
demethylase discovered (Shi et al., 2004). LSD1 can lead to transcriptional repression 
and activation, depending on which lysine the methyl group is removed. Removal of the 
methyl group from H3K4 has been shown to repress transcription (Shi et al., 2004), 
whilst demethylation of H3K9, in conjunction with the androgen receptor, leads to 
transcriptional activation (Metzger et al., 2005). Since then, a number of other 
demethylases have been discovered (reviewed in Kouzarides., 2007). 
Throughout this thesis, two TF families will be investigated, with regards to the 
regulation of pro-convulsant tachykinins and in response to ACD treatment. These being 
the NRSF and USF families, both of which have known roles in chromatin remodelling, 
and which form associations with many of the enzymes introduced here. 
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1.4 Neuron Restrictive Silencer Factor (NRSF)
NRSF (also termed REST), was discovered by two groups simultaneously in 
1995, as a protein which binds to the NRSE (also known as repressor element-1, RE1), 
in the rodent SCN2a (Chong et al., 1995) and SCG10 genes (Schoenherr & Anderson., 
1995). As the NRSE consensus sequence was found in multiple neuron-specific genes 
(including the M4 muscarinic acetylcholine receptor, CHRM4 (Wood et al., 1996); 
BDNF (Timmusk et al., 1999); Synaptosomal associated protein, Snap25 (Bruce et al., 
2004) and L1 cell adhesion molecule, L1CAM (Kallunki et al., 1997)), NRSF was 
initially thought to function as a silencer of neuronal genes in non-neuronal cells, and 
hence play a key role in neuronal differentiation. Since those early findings, NRSF has 
been shown to play a number of roles in gene regulation and chromatin remodelling, and 
is implicated in a range of disorders including cancer, HD and epilepsy. 
NRSF binds to the canonical 21bp NRSE site through eight C2H2 zinc fingers, 
with the consensus sequence being T(C/T)AG(A/C)(A/G)CCNN(A/G)G(A/C)(G/C)AG 
(Bruce et al., 2004; Wu and Xie., 2006) (Figure 1.6a). The use of genome wide 
bioinformatic assays and chromatin immunoprecipitation (ChIP) sequencing assays 
(ChIP-seq) have revealed a vast number of NRSEs throughout the genome, with 
estimates at 1892 in humans (Bruce et al., 2004). This has since been supported by the 
1946 in vivo NRSF binding sites observed in human (Johnson et al., 2007) and 893 
SACO (serial analysis of chromatin occupancy) identified NRSEs in a murine kidney 
cell line (Otto et al., 2007). The majority of these putative NRSEs are located within 
intergenic regions (40%), with 24% located within introns and 15% within promoter 
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regions (5kb upstream of TSS), consistent with other TFs, including CTCF and STAT1 
(Jothi et al., 2008).
These genome wide screenings have revealed which nucleotides of the NRSE 
are important for protein-DNA binding, with nucleotides 7-9 (ACC) and 12-17 
(GGACAG), shown to be critical for DNA binding, and residues 1-6 found to contribute 
to binding stability (Jothi et al., 2008). Over the past few years, the 21bp canonical 
sequence has been shown to be partitioned into two non-canonical half sequences, 
denoted the left half-site and the right half-site (Figure 1.6b) (Patel et al., 2007; Johnson 
et al., 2007; Jothi et al., 2008; Valouev et al., 2008). Interestingly, a recent study has 
revealed that neither the left nor the right half-site alone is an effective repressor, 
suggesting that whilst NRSF can bind to either half-site, half-site binding is not as 
strong or as functional as the canonical full site (Patel et al., 2007).  
Figure 1.6 The NRSF consensus sequence (NRSE) (A) the canonical 21bp sequence of the NRSE, and 
(B) the partitioned NRSE, split into two distinct halves, the left-half site and the right-half site. (Modified 
from Jothi et al., 2008). 
39
1.4.1 NRSF mediated gene regulation and chromatin remodelling
NRSF mediated gene regulation is coordinated through the recruitment of a 
battery of co-repressors and chromatin remodelling enzymes, at its two distinct domains;
the N- and the C-terminal domains. At the N-terminal domain, mSin3a binds to NRSF 
(Grimes et al., 2000) and recruits two class I HDACs (HDAC1 and HDAC2) (Huang et 
al., 1999). In addition, the class II HDACs HDAC4 and HDAC5, have also been shown 
to be recruited by the mSin3 complex, but this association is lost following HDAC 
phosphorylation by calcium/calmodulin-dependent protein kinase (CAMK) (Nakagawa 
et al., 2006). The C-terminal domain recruits CoREST (Andres et al., 1999), with 
CoREST able to recruit HDAC1 and HDAC2 (You et al., 2001). In addition, CoREST 
recruits the histone H3K4 demethylase LSD1 (Shi et al., 2004), BRG1 (a member of the 
SWI/SNF chromatin remodelling family) (Battaglioli et al., 2002; Ooi et al., 2006), G9a 
(Roopra et al., 2004), the NADH-binding corepressor CtBP (Garriga-Canut et al., 2006) 
and a methyl-CpG-binding protein, MeCP2 (Lunyak et al 2002; Ballas et al., 2005) 
(summarised in Figure 1.7). 
The formation of these complexes has a profound effect upon transcription. In 
the first instance, BRG1 facilitates and stabilises NRSF binding to the target NRSEs in 
vivo (Ooi et al., 2006). This function has been shown to require both the ATP-dependent 
chromatin remodelling activity of BRG1 (Ooi et al., 2006) and the bromodomain, which 
binds to acetylated H3K8 (Agalioti et al., 2002). It is thought that BRG1 induces 
chromatin remodelling to enable NRSF greater access to its target sequences. This 
SWI/SNF factor is shown to be critical in NRSF-mediated gene silencing, with knock-
40
down of BRG1 shown to induce derepression of NRSF target genes SCG10 and 
Synaptophysin (Watanabe et al., 2006).
Following NRSF recruitment to target NRSEs, the co-repressors can then start to 
invoke distinct changes. HDACs, as previously mentioned, remove acetyl groups from 
histones, resulting in a more condensed chromatin environment. Both the N- and C-
terminal domains have been shown to interact with HDAC1 and HDAC2, with either 
domains capable of deacetylating histone 3 (H3K9 and H3K14) (Bingham et al., 2006). 
Following deacetylation of histone 3, demethylation of H3K4 (a marker of activation) 
can occur, mediated by the histone demethylase LSD1 (Lee et al., 2005). Furthermore, 
H3K9, now free from an acetyl group, can be dimethylated by G9a (Roopra et al., 2004) 
becoming H3K9me2, a marker for repression (Li et al., 2007). This process has recently 
been shown to be orchestrated by Mediator, which as mentioned previously, is important 
in transducing regulatory signals to the basal transcription machinery. Ding et al, found 
that the MED12/ MED19/MED26 interface of Mediator, is key in linking NRSF with 
G9a, and thus plays a role in G9a-mediated H3K9 dimethylation (Ding et al., 2008; 
Ding et al., 2009). Intriguingly, a second group has shown that CDYL (chromodomain 
on Y-like), physically bridges NRSF and G9a, with disruption of this leading to 
oncogenic transformation (Mulligan et al., 2008). The process of dimethylation of 
H3K9, induces the subsequent recruitment of the HP1 (Belyaev et al., 2004; Roopra et 
al., 2004), which in turn mediates chromatin condensation. Overall, the process of 
deacetylation, demethylation and methylation generates a condensed heterochromatin 
environment, which suppresses transcription. 
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In addition to chromatin remodelling, NRSF has been shown to affect 
transcription more directly, affecting the basal transcription machinery. NRSF has been 
shown to bind to TBP, in turn inhibiting PIC formation (Murai et al., 2004). 
Furthermore, NRSF has been shown to interact with Pol-II bound small CTD 
phosphatases (SCPs), inhibiting the activity of Pol-II (Yeo et al., 2005). Thus NRSF has 
a profound impact upon gene regulation and transcription. 
Figure 1.7 NRSF and its cofactors. Schematic representation of the cofactors which form associations 
with NRSF. At the N-terminal domain, the mSin3 complex forms, which recruits HDACs. The C-terminal 
domain, recruits a multitude of cofactors, including CoREST, HDAC1, HDAC2, LSD1, G9a and BRG. 
Addition recruited cofactors are also indicated including MeCP2 and CtBP. 
1.4.2 Modulation of NRSF activity
NRSF is known to be expressed at a high level in non-neuronal cells, but at a 
much lower level in neuronal tissue. This differential expression requires specific 
control of NRSF regulation, and yet, despite extensive studies into NRSF-mediated gene 
regulation, there is little known regarding the regulation of NRSF expression itself. Both 
human and mouse NRSF genes contain three non-coding exons, in the 5’UTR, and three 
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coding regions. To date, studies have focused on the three non-coding exons (exons I, II 
and III). NRSF transcripts arise from one of the three non-coding exons, with the 
majority (80%) arising from exon I (Palm et al., 1998). It has been suggested that NRSF 
contains two (Kojima et al., 2001) or three (Koenigsberger et al., 2000) promoters, with 
none of these promoters exhibiting cell-specific properties. Therefore it is possible that 
the levels of endogenous NRSF are not fully governed by transcription per se, but 
perhaps are modulated at a post-transcriptional level (such as splicing, mRNA stability 
or post-translational modifications), in a cell-specific manner. 
One potential candidate TF for NRSF regulation is Sp1, based upon the presence 
of multiple GC boxes flanking exons I, II and III (Koenigsberger et al., 2000). However, 
the effect of over-expression or knock-down of Sp1 upon NRSF expression has yet to be 
clarified. In addition, Nichihara et al, have shown that NRSF expression is mediated by 
the Wnt-signalling pathway, with over-expression of Wnt1 or β-catenin resulting in 
enhanced NRSF expression in chick embryos (Nishihara et al., 2003). More recently, a 
role for both Oct4 and Nanog TFs in regulating NRSF expression have been proposed, 
with Oct4 and Nanog binding sites found 2kb upstream of NRSF exon I, and 
knockdown of either Oct4 or Nanog found to induce a reduction in NRSF expression in 
mouse embryonic stem cells (ESCs) (Loh et al,. 2006). Finally, a role in the repression 
of NRSF expression has been postulated for MeCP2. MeCP2 deficiency in the brain has 
been shown to reduce expression of the NRSF-regulated gene BDNF, and this is thought 
to be due to enhanced NRSF expression. In support of this, Abuhatzira et al, have shown 
that MeCP2 binds to the NRSF promoter, and that MeCP2 knockdown induces elevated 
NRSF expression in human and mouse brains (Abuhatzire et al., 2008). 
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The modulation of endogenous NRSF protein levels is also an important factor
which may affect the NRSF regulatory system. Recent reports have uncovered the 
process by which NRSF protein levels are maintained. Two groups have shown that 
NRSF is degraded by the ubiquitin system, with the E3 ligase responsible for 
orchestrating this degradation found to be the Skp1-Cul1-F-box protein complex 
containing the F-box protein β-TRCP (SCF β-TRCP) (Westbrook et al., 2008; 
Guardavaccaro et al., 2008). 
1.4.3 Truncated isoform sNRSF
Truncated isoforms of NRSF have been observed in both rat (Palm et al., 1998) 
and human tissue (Palm et al., 1999; Coulson et al., 2000), and have been implicated in 
both SE (Spencer et al., 2006) and neuroendocrine cancers, such as small cell lung 
cancer (SCLC) (Coulson et al., 2000). Palm et al, first revealed the presence of 
alternatively splice isoforms of NRSF in rats, with five isoforms discovered, denoted 
rREST1, rREST2, rREST3, rREST4 and rREST5 (Palm et al., 1998). I will continue to 
use these names for now, to distinguish between the rodent and human isoforms 
reported. rREST1-3 were found to arise from the addition of short sequences in rat exon 
IV (rREST1) and exon V (rREST2) and as a result of the loss of 8bp from exon VI 
(rREST3). Two other isoforms were discovered, which arise from the presence of an 
extra exon, designated exon N, between exons V and VI. This exon N, can be either 
16bp long or 28bp long, both encoding a premature stop codon, which results in the 
formation of the truncated isoforms rREST4 and rREST5 respectively. These latter two 
isoforms lack the entire C-terminal domain, have only 5 zinc fingers, and are shown to 
be less repressive that wild type rREST (Palm et al., 1998). The abundance of these 
44
isoforms is relatively low in brain tissue, with rREST4 accounting for only 1% of the 
total rREST transcripts (Palm et al., 1998). 
Palm et al, later discovered that rREST4 and rREST5 were conserved in mice, 
with two truncated isoforms isolated, arising from either a 16bp or 28bp exon N, 
matching that found in the rat. In humans, the presence of an extra exon (N) between 
exons V and VI, was also observed, which could be either a mere 4bp or 62bp in length. 
The 62bp insertion was found to have almost perfect homology to the rat and mouse 
exon N sequence, at its 3’ end, except for a single nucleotide difference (Palm et al., 
1999). Like the rodent isoforms, this 62bp insertion encodes for a premature stop codon, 
resulting in a truncated isoform. Since these findings, our group has also published on 
the presence of a truncated isoform of NRSF in human SCLC cells (Coulson et al., 
2000). Our group discovered a 50bp sequence insertion between exons V and VI, again 
designated exon N, encoding a premature stop codon, thus mirroring in part, that found 
in the rodent. The resulting truncated isoform is designated short NRSF or sNRSF. As 
with the rodent truncated isoforms rREST4 and rREST5, sNRSF has only five zinc 
fingers, and is missing the entire C-terminal domain (Coulson et al., 2000). As 
mentioned previously, the 3’ end of the 62bp sequence identified by Palm et al, had an 
almost perfect homology to the rodent exon N sequence, and the latter 50bp sequence, 
reported by Coulson et al, is contained within this 62bp sequence. The addition 12bp 
found by Palm et al, are a perfect match for the extra 12bp found in the rodent, which 
distinguishes between rREST4 and rREST5. This suggests that two truncated isoforms 
may occur in human tissue. 
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Whilst the role of full-length NRSF is well established, a role for the truncated 
isoform is poorly characterised. Based on the absence of the C-terminal domain, one 
may postulate that sNRSF may function differently to NRSF, and it has been suggested 
that the truncated isoform may act as an activator rather than a repressor (Lee et al., 
2000).  The early findings that NRSF isoforms are up-regulated following KA treatment
suggest a possible role in seizure (Palm et al., 1998), which was later confirmed by our 
group (Spencer et al., 2006). The rodent rREST4 was found to be up-regulated 
following 3hrs KA, which correlated with an increase in TAC1 mRNA expression, 
supporting the postulated role in transcriptional activation for the truncated isoform
(Spencer et al., 2006). Various other studies have suggested that truncated NRSF may 
exert a different regulatory role over NRSF targets, compared to full-length NRSF. For 
example, Magin et al, revealed that whilst NRSF represses the human synapsin I 
promoter, the truncated NRSF does not (Magin et al., 2002). Alternatively, the truncated 
isoform has been proposed to act as an antagonist of NRSF-mediated gene repression. 
NRSF repression of both the BDNF promoter and the cholinergic gene locus has been 
shown to be alleviated by the truncated isoform (Tabuchi et al., 2002; Shimojo & 
Hersh., 2004). In fact, rREST4 has been shown to inhibit NRSF binding to the 
cholinergic gene NRSE, leading to de-repression and activation of the cholinergic gene 
locus (Shimojo et al., 1999). Furthermore, whilst full-length NRSF has been shown to 
almost completely inhibit the induction of gene transcription following glucocorticoid 
stimulation in non-neuronal cells, the truncated isoform, in contrast, was found to 
stimulate gene transcription, shown to be mediated by the chromatin remodelling factor 
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hBrm (Abramovitz et al., 2007). Thus, the NRSF regulatory system may be impaired in 
conditions or disorders with elevated truncated isoform expression, such as SE or SCLC. 
Figure 1.8 The human truncated isoform sNRSF. The human truncated isoform of NRSF, sNRSF, 
consists of the N-terminus of full-length NRSF, and five zinc fingers. The chromatin remodelling complex 
hBrn has been shown to interact with this isoform in response to glucorticoid stimulation.
1.4.4 NRSF Localisation
The localisation of any protein is an important factor in determining its function, 
and this is particularly true when considering TFs which require nuclear localisation to 
function as regulators of gene expression. NRSF has been shown to exhibit a 
cytoplasmic localisation in untreated neurons (Zuccato et al., 2003; Spencer et al., 
2006), and is known to translocate into the nucleus following KA-induced SSSE 
treatment in rat hippocampi (Spencer et al., 2006). In contrast, the truncated isoform has 
been shown to be localised in the nucleus in rat (Spencer et al., 2006), mouse (Lee et al., 
2000b) and human (Magin et al., 2002), and was found to translocate in the opposite 
direction, into the cytoplasm, in KA-treated rat hippocampi (Spencer et al., 2006). Thus 
understanding the mechanisms which govern NRSF isoform localisation is an important 
step in elucidating their function. Two distinct proteins have been found to be important 
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in regulating the nuclear translocation of NRSF, these being Huntingtin (Zuccato et al., 
2003) and the REST/NRSF interacting Lin-11, Isl-1, Mec-3 (LIM) domain protein (or 
REST interacting LIM protein, denoted RILP) (Shimojo & Hersh, 2003). 
Huntingtin has been shown to interact with NRSF and sequester NRSF in the 
cytoplasm (Zuccato et al., 2003), whilst RILP has been shown to interact with NRSF, 
particularly the N-terminal domain common to both NRSF and sNRSF, and is thought 
to act as a nuclear receptor for these TFs. In support of this, both NRSF isoforms were 
found to traffic from the nucleus into the cytoplasm, following RILP knock down 
(Shimojo & Hersh, 2003). More recently, Shimojo has shown that the nuclear 
translocation of NRSF is modulated by a complex containing both Huntingtin and RILP, 
and a third ‘gluing’ protein, known as Dynactin p150GLUED, which brings together 
Huntingtin, RILP and NRSF (Shimojo., 2008). In this complex, only RILP and Dynactin 
p150GLUED interact with NRSF, whilst Huntingtin’s association with NRSF is indirect. 
Finally, a fourth protein, HAP-1 (Huntingtin-associated protein 1) was also found to also 
bind to this complex, but this interaction was found to prevent nuclear translocation, and 
is thus important in cytoplasmic sequestering of NRSF (Figure 1.9) (Shimojo., 2008). 
          
Figure 1.9. Cellular localisation of NRSF is modulated through a multi-protein complex incorporating 
RILP, Dynactin p150GLUED and huntingtin, resulting in NRSF locating within the nucleus. HAP-1 prevents 
this complex entering the nucleus, and thus sequesters REST in the cytoplasm.
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1.4.5 NRSF & Disease
As has been previously discussed, NRSF has the capability of regulating 
transcription of a multitude of genes, and as such, it  is perhaps unsurprising that 
aberrant NRSF expression has been correlated to a host of disorders including HD 
(Zuccato et al., 2003; Zuccato et al., 2007), epilepsy (Palm et al., 1998; Spencer et al.,
2006; Bassuk et al., 2008), Down’s syndrome (Bahn et al., 2002; Canzonetta et al., 
2008), X-linked mental retardation (Tahiliani et al., 2007), cognitive disfunction 
(Miyajima et al., 2009) and cancer. 
1.4.5.1 Cancer
NRSF has been implicated in a range of cancers which includes neuroblastomas 
(Palm et al., 1999; Lawinger et al., 2000; Fuller et al., 2005), SCLC (Coulson et al., 
2000) and colorectal cancers (Westbrook et al., 2005). Interestingly NRSF has been 
shown to have both tumour suppressor and oncogenic functions. NRSF knockdown has 
been shown to induce oncogenic transformation of immortalised primary human cells, 
via the de-repression of the proto-oncogene TrkC (Mulligan et al., 2008), indicating a 
potential tumour suppressor role. NRSF has also been identified as a tumour suppressor 
in epithelial tissue, with NRSF expression shown to be down-regulated due to an 
increase in SCF β-TRCP, resulting in oncogenic transformation (Westbrook et al., 2008). 
Furthermore, NRSF is proposed to have tumour suppressor properties with regards to 
breast cancer, through the repression of TAC1 (Greco et al., 2007). In support of this, 
NRSF expression is shown to be inversely proportional to tumour cell aggression 
(Reddy et al., 2009). 
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Conversely, NRSF has also been implicated as an oncogenic factor. NRSF has 
been shown to be markedly up-regulated in many medulloblastomas (Lawinger et al., 
2000; Watanabe et al 2004; Su et al., 2004), correlating with the observed repression of 
many NRSF-regulated genes, such as synapsin. This suggests that it is the NRSF 
repressor function that is important in tumourigenesis. In support of this, REST-VP16 
over-expression induces activation of NRSF-target gene expression and blocks of 
tumour generation (Lawinger et al., 2000). Abnormal expression of NRSF, in 
conjunction with Myc, in NS cells and neuronal progenitor cells, has also been shown to 
induce the formation of cerebellum-specific tumours, via the blockade of neuronal 
differentiation (Su et al., 2006), thus highlighting NRSFs propensity to be tumourigenic. 
1.4.5.2 Huntington’s Disease (HD)
HD is an incurable inherited disease, caused by a CAG-expansion in the gene 
encoding the huntingtin protein, resulting in a mutant protein. This disorder causes 
severe dysfunction of motor and cognitive processes, resulting from neuronal cell death. 
The length of the CAG-expansion has been directly correlated with the severity of the 
disease. NRSF has been implicated in HD due to the role of huntingtin in determining 
NRSF localisation, with huntingtin important in governing the cytoplasmic localisation 
of NRSF. The mutant huntingtin protein is unable to bind to NRSF due to the CAG-
expansion, resulting in its failure to sequester NRSF in the cytoplasm, leading to 
enhanced nuclear NRSF accumulation (Zuccato et al., 2003). This leads to elevated 
suppression of the neuronal survival factor, BDNF, contributing to neuronal death. 
NRSF therefore has an important role to play in HD, and Zuccato et al, have recently 
shown that NRSF binding to target gene NRSEs (including BDNF, Syn1, Chrm4, Drd3, 
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Penk1, Chrnb2) is up-regulated in a HD cell line model, resulting in an corresponding 
suppression of these genes (Zuccato et al., 2007).
1.4.5.3 Epilepsy
As mentioned at the beginning of this thesis, epilepsy is a commonly acquired, 
chronic neurological disorder, affecting more than 50 million people worldwide. The 
principle hypothesis of this thesis is that epilepsy arises following genome wide changes 
in chromatin structure and in turn gene expression profiles, following an initial insult, 
which increases the propensity of having future, spontaneous seizures. My hypothesis is 
that NRSF is a major factor in governing such changes, and throughout this thesis I aim 
to explore the roles of NRSF in relation to epilepsy, particularly its role in regulating 
pro-convulsant neuropeptide gene expression. The importance of NRSF in epilepsy has 
come to fruition in the past decade. In the late 1990’s, Palm et al revealed that NRSF 
and its truncated isoform, are markedly up-regulated following treatment with the 
chemo-convulsant KA (Palm et al., 1998). This has since been confirmed by our own 
group, with NRSF isoforms found to be dynamically up-regulated during both PPS and 
KA SSSE models (Spencer et al., 2006). Following these findings, a number of genes 
found to be of importance in seizure, including TAC1 and BDNF, have been shown to 
be regulated by NRSF (Quinn et al., 2002; Spencer et al., 2006; Greco et al., 2007; 
Howard et al., 2008; Reddy et al., 2009; Timmusk et al., 1999; Zuccato et al., 2003). 
These findings suggested a role of NRSF in governing gene expression in response to a 
seizure. Consistent with this, are the findings that 2-Deoxy-D-glucose (2DG) reduces 
the progression of epilepsy, through a NRSF-CtBP-dependent manner. The ketogenic 
diet is an anti-epileptic diet used to treat drug-resistant TLE. Carriga-Canut et al, 
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discovered that inhibition of glycolysis (the hallmark affect of the ketogenic diet), 
enables the NAD-sensitive compressor CtBP, to join NRSF at target NRSEs, inhibiting 
seizure-induced increases in BDNF and TrkB expression in vivo (Carriga-Canut et al. 
,2006). Thus suggesting that NRSF mediating gene regulation is a potentially a pro-
convulsant mechanism, causing abnormal gene expression. 
In addition to changes in expression, NRSF has been shown to translocate into 
the nucleus following KA-induced SSSE in rodents (Spencer et al., 2006), which may 
lead to aberrant gene expression, akin to that observed in HD. The importance of NRSF 
localisation in epilepsy has recently been substantiated, with a homozygous mutation in 
the human RILP gene having been shown to cause an autosomal-recessive progressive 
myoclonus epilepsy (PME)-ataxia syndrome (Bassuk et al., 2008). This mutation is 
located within the RILP protein binding domain, and was found to disrupt the RILP-
NRSF interaction, resulting in enhanced nuclear localisation of NRSF. This is consistent 
with the translocation of NRSF observed following KA treatment in rats (Spencer et al., 
2006), suggesting that NRSF localisation has an important role to play in SSSE. Thus 
there are multiple indicators implying that NRSF is a key factor in the progression of 
epilepsy, and this is an issue which will be explored further throughout this thesis. 
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1.5 Upstream Stimulatory factors (USFs)
A second class of TFs will be explored throughout this thesis, these being the 
upstream stimulatory factors USF1 and USF2. The USF genes are members of the 
eukaryotic evolutionary conserved bHLH leucine zipper TF family. They recognize and 
bind to the canonical E-box regulatory element (CANNTG, whereby N denotes any 
nucleotide) with high affinity, with E box motifs often located within 500bp of a target 
gene’s TSS (Rada-Iglesias et al, 2008). Whilst an association between the USF TFs and 
epilepsy has yet to be established, there are a number of reports that suggest USF may 
play a role in this disorder. Firstly, Sirito et al, observed that USF knockout mice were 
more prone to spontaneous seizures compared to wild types (Sirito et al., 1998), and 
later reports revealed that related bHLH factors Mash1, Id2 and Hes5 are modulated in 
in vivo rodent seizure models (Elliot et al., 2001). In addition, the USF TFs have been 
shown to regulate a host of neuronal genes, implicated in epilepsy including BDNF 
(Tabbuchi et al., 2002b), the GABAB receptor (Steiger et al., 2004) and the potassium-
chloride co-transporter KCC2 (Markkanen et al., 2008). Furthermore, our lab has 
previously shown a role for USF TFs in the regulation of the pro-convulsant SP-
encoding gene TAC1 (Paterson et al., 1995; Gerrard et al., 2005). Consequently a 
putative role for such TFs in mediating the progression of epilepsy can be proposed, and 
shall be explored in this thesis, in a manner similar to that for NRSF.
The USF proteins were first identified in human cells due to their involvement in 
the transcriptional regulation of the major late adenovius promoter (Ad2MLP) (Carthew 
et al, 1985; Sawadogo & Roeder, 1985). USF was found to elevate promoter activity 10-
20 fold, through binding to a -63 to -53 E-box site (similar to that in TAC1), suggesting 
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a potential role in transcriptional activation. The purification of USF from HeLa nuclei 
presented two similar proteins of 43 and 44kDa in size (Sawadago et al, 1988), which 
were later termed USF1 and USF2, respectively (Gregor et al, 1990; Sirito et al, 1992). 
They are ubiquitously expressed proteins, with elevated levels observed in the brain 
(Sirito et al, 1994), and specifically in the nuclei of neurons in the hippocampus, a 
critical brain region in epilepsy (Wasterlain et al., 1996). A role for USF1 and USF2 in 
neuronal development and embryogenesis has also been suggested, following the 
observation that USF1/USF2 compound mutant mice suffered embryonic lethality 
(Sirito et al, 1998). This has been recently supported following the observation of 
enhanced levels of USF1 and USF2 within the neural tissue and neural crest, during the 
progression into the neurula stage in Xenopus larvis development (Fujimi et al, 2008). 
USFs are known to form dimers via their HLH-leucine zipper domains, with 
heterodimers (USF1/USF2) more common than the respective homodimers (Sirtio et al, 
1992). Despite having similar DNA binding properties, USF dimers may modulate 
target gene expression, differentially, via the establishment of specific interactions with 
different TFs (Kirschbaum et al, 1992). For example, USF1 has been shown to interact 
with the Cha bHLH TF in vitro and in vivo, resulting in the inhibition of USF1 activity 
(Rodriguez et al, 2003). Furthermore, interactions between USF1 and general and cell-
specific TFs SP1, Pea3 and MTF1, respectively, has been shown to lead to cooperative 
transcriptional regulation of target genes (Andrews et al, 2001).  
As I have previously hypothesised, the progression of epilepsy, from an initial 
insult to spontaneous seizures, may arise due to global, long-term changes in gene 
expression patterns, perhaps via chromatin remodelling. USFs have been implicated in 
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chromatin remodelling through the recruitment of enzymes involved in acetylation and 
methylation of histones, and thus may play a role in such remodelling in response to a 
seizure. USF1 has been shown to mediate recruitment of PCAF, which acetylates 
histones H3 and H4 (Schiltz et al, 1999) and SET7/92 that methylates histone H3K4 
(West et al, 2004) a marker of active chromatin. Furthermore, it has been shown that 
regions enriched by USF1 or USF2 binding, are also significantly enriched with histone 
H3 acetylation (Rada-Iglesias et al, 2008), and that USF1 interacts preferentially with 
highly acetylated H4 histones (Vettese-Dadey et al, 1996). Taken together, USFs exhibit 
the capacity to mediate a change in the chromatin environment, from a repressive 
heterochromatin formation into the more open and active euchromatin environment, and 
hence promoting gene expression. The regulation of gene promoters by USF is thus a 
complex and dynamic process, incorporating multiple TFs, together with the recruitment 
of chromatin remodelling enzymes, enabling chromatin reorganisation, in turn 
modulating transcriptional regulation (Sha et al, 1995). 
1.5.1 The USF TFs in disease
The USF TFs have been shown to play important roles throughout the body, 
including mediating the immune response to factors such as viral invasion, and the 
skin’s melanin-production response to UV-radiation (reviewed in Corre & Galibert., 
2005). In addition USF has been shown to have a key function in coordinating cellular 
differentiation and proliferation, and subsequently is important in disorders 
characterised by aberrant cellular proliferation, i.e. cancers. More specifically, USF has 
been shown to have anti-proliferative roles, with USF shown to inhibit both c-Myc and 
Ras-induced transformation of primary rat cells (Aperlo et al., 1996; Luo & Sawadogo., 
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1996), and inhibits cellular proliferation in thyroid follicular cells (Jung et al., 2007). 
Consistent with a role in cellular proliferation, a number of USF-regulated genes have 
established roles in differentiation and proliferation, such as human telomerase reverse 
transcriptase (hTERT) (Goueli & Janknecht., 2003). This particular gene is of interest as 
hTERT expression is known to be up-regulated in more than 85% of tumour cells. USF 
has been shown to mediate hTERT promoter activity, with both USF1 and USF2 shown 
to inhibit hTERT promoter driven luciferase reporter gene activity, suggesting that USF 
TFs repress hTERT expression. Consistent with this, USF1 and USF2 expression was 
found to be repressed in tumour tissue, correlating with a marked increase in hTERT 
expression (Chang et al., 2005). This suppression was found to be controlled via direct 
binding of USF proteins to an E box located within the hTERT promoter. 
Given the importance of its role in the regulation of hTERT and in governing 
cellular proliferation, USF has also been shown to regulate the expression of a number 
of tumour suppressor genes, including p53 and APC (Jaiswal & Narayan., 2001; 
Reisman & Rotter., 1993). Thus a role in tumour suppression can be attributed to the 
USF TFs, which is consistent with the observed reduction in USF expression in tumour 
tissues (Chang et al., 2005). More recently, Chen et al, have shown a tumour suppressor 
role for USF2 in prostate cancer, with the over-expression of USF2 in three prostate 
cancer cell lines, causing a substantial inhibition in both anchorage-independent growth 
and invasion capability of these cells (Chen et al., 2006). Finally, the USF TFs have 
been shown to play an important role in lung cancers, particularly SCLCs (Coulson et 
al., 2003; Ocejo-Garcia et al., 2005), in which NRSF has also been demonstrated to play 
an important role (Coulson et al., 2000). 
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1.6 Anti-convulsant drugs (ACDs)
The primary intention of ACD treatment is to prevent epileptic seizures. ACDs 
exert their anti-convulsant activity through single or multiple targets, which include ion 
channels, neurotransmitter receptors and neurotransmitter metabolic enzymes (Rogawsi 
& Loscher., 2004a). The ultimate aim is to modulate neuronal firing and to inhibit the 
spread of abnormal firing to distant parts of the brain. Unfortunately, despite ongoing 
research and the emergence of new generation ACDs, approximately 50% of patients 
treated with modern ACDs continue to experience seizures (Pitkanen,, 2002). In 
addition to their roles in protection against seizure, ACDs have been shown to be 
beneficial in the treatment of migraine, neuropathetic pain, bipolar disorder (BD), 
anxiety, schizophrenia and alcohol dependence and withdrawal (Rogawsi & Loscher., 
2004b).  
To date, there are over 20 ACDs approved for use in the UK (British National 
Formulary, No.55, March 2008), each of which can be separated into groups based upon 
their mechanisms of action and which type of epilepsy the drug can be used for. For 
example, carbamazepine (CBZ), phenytoin (PHY) and lamotrigine (LMT) all are 
proposed to function by targeting voltage-gated sodium channels, such as the type II 
voltage-gated sodium channel SCN2a, and all three are approved for use in treating 
GTC and Partial seizures, based on this function (Rogawsi & Loscher., 2004a). These 
drugs have been shown to block high-frequency repetitive spike firing, which is 
hypothesised to occur during the spread of seizure activity, without affecting normal 
neuronal firing (Xie et al., 1995). Other drugs, such as Vigabatrin, work by enhancing 
synaptic inhibition by targeting GABAA receptors, enhancing inhibitory GABAergic 
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signalling (Hanaya et al., 2002). Alternatively, excitatory neurotransmitter systems can 
be impaired by blocking glutamate receptors NMDA or AMPA using Felamate or 
topiramate respectively (Yang et al., 2007; Gryder & Rogawski., 2003).
1.6.1 Voltage-Gated Sodium Channels
Sodium channels are important in the rising phase of neuronal action potentials. 
Following depolarisation, sodium channels undergo conformational changes, converting 
the channel from its resting ‘closed’ non-conductive state, to an ‘open’ conformation 
which enables Na+ flux. The channel is then rapidly repolarised, returning to its ‘closed’ 
state. ACDs such as CBZ, PHY and LMT bind only weakly to target sodium channels 
(e.g. SCN2a) at hyper-polarised membrane potentials, but are able to bind strongly
following depolarisation, markedly increasing their inhibitory properties, (Willow el al., 
1985; Xie et al., 1995; Remy el al., 2003). Interestingly, blockade of sodium channels 
by PHY and LMT has a slow onset, and when the drugs are bound, the interaction is 
tight and slow to unbind. An advantage of this slow onset is that it enables normal 
neuronal firing to continue. Furthermore, as binding is slow, and depolarisation and 
repolarisation is rapid, then binding of PHY and LMT can only bind if depolarisation is 
prolonged, which is characteristic of certain types of epilepsy, such as focal epilepsy. 
It has been shown that despite structural dissimilarities (see figure 1.10), CBZ, 
PHY and LMT all bind to a common recognition site on the inner pore of the SCN2a 
sodium channel (Kuo et al., 1998). Each drug contains a motif of two phenyl groups, 
which are proposed as being crucial to drug binding to the S5 and S6 transmembrane 
domain units. Furthermore, specific residues phenylalanine (F1764) and tyrosine 
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(Y1771) in the S6 domain have been shown to be important in PHY and LMT drug 
action (Ragsdale et al., 1996; Liu et al., 2003).
Fig 1.10 Structure of the three ACDs utilised in this thesis; CBZ, PHY and LMT. Modified from 
Rogawski & Loscher 2004a. 
1.6.3 Carbamazepine (CBZ)
CBZ (5H-dibenz[b,f]azepine-5-carboxamide) has been one of the most 
commonly prescribed ACDs since it was first used for the treatment of epilepsy in the 
mid-1960s (Ambrosio et al., 2002; LaRoche and Helmers, 2004). It has also been 
prescribed for the treatment of neuropathic pain and approved for use in the treatment of 
psychiatric disorders including mania (Ettinger & Argoff, 2007). CBZ is structurally 
distinct from other ACDs, being an iminodibenzyl derived, tricylic compound with a 
short amide side chain (Ambrosio et al, 2002). Despite this, CBZ is thought to function 
by targeting the same voltage-dependent, tetredoxin-resistant sodium channels as PHY
and lamotrigene (Kuo, 1998). By impairing the activity of these sodium channels, CBZ
reduces the frequency of repetitive action potentials, thus lowering neuronal firing 
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(Elliot, 1990). CBZ also functions by affecting both glutamate and GABA transmission 
and regulation. Glutamate is transported by excitatory amino acid transporters (EAAT), 
from the extracellular to the intracellular space, preventing extracellular accumulation of 
glutamate, and thus preventing enhanced neuronal firing. These transporters have been 
implicated in epilepsy, following the discovery that the dysfunction of EAAT3 induces 
seizure in rodents (Sepkuty et al, 2002). CBZ has been shown to enhance the activity of 
this glutamate transporter (Lee et al, 2005), indicating that it can function by targeting 
glutamate regulatory mechanisms. Furthermore, CBZ has been found to inhibit sodium 
channel mediated glutamate release in a dose dependent manner (Sitges et al, 2007). It is 
thus apparent that CBZ is capable of regulating key excitatory neurotransmitter 
pathways.
As well as regulating excitatory neurotransmitter pathways, CBZ also affects 
inhibitory neurotransmitter pathways. GABA is known to be degraded by multiple 
enzymes, including Succinic semialdehyde dehydrogenase (SSADH). This enzyme is 
implicated in epilepsy, with SSADH deficient mice exhibiting enhanced seizure activity 
and an epileptic phenotype (Cortez et al, 2004; Gupta et al, 2004). CBZ has been shown 
to physically interact with SSADH and decrease its activity (Sawaya et al, 1975), 
suggesting that CBZ could enhance the half-life of GABA. Consistent with this, GABA 
levels were found to be elevated in the hippocampus following CBZ treatment in rats 
(Yoshida et al., 2007). Taken together, CBZ clearly regulates both excitatory and 
inhibitory signalling pathways, generating an inhibitory neurotransmitter environment 
within the brain.  
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1.6.4 Phenytoin (PHY)
PHY (5,5-diphenylhydantoin), like CBZ has been used in the treatment of 
seizure for over fifty years, since it was approved for use by the FDA in 1953. Despite 
sharing a common binding target with CBZ and LMT, PHY is structurally quite distinct, 
containing a chemical structure which is traditionally viewed as a key structure for anti-
convulsant activities, known as the ureide structure (Figure 1.10). In addition to its use 
in the treatment of seizure, PHY has been used to treat both neuropathetic and 
trigeminal pain, as well as being routinely used in the treatment of the manic phase of 
BD (Rogawski & Loscher., 2004b). 
PHY has been shown to be effective in blocking the development of SSSE, if 
administered prior to PPS. However, PHY is shown to be less effective when given 
10mins after PPS (Chen & Wasterlain., 2006), which may be due to the slow-onset of 
PHY’s affects. In addition to sodium channel blockade, PHY has been show to reduced 
spontaneous release of glutamate, whilst enhancing spontaneous GABA release in rat 
entorhinal cortex (Cunningham et al., 2000a). Furthermore, Sitges et al revealed that 
PHY, like CBZ blocks sodium-channel mediated release of glutamate in the rat 
hippocampus (Sitges et al., 2007), indicating that PHY can modulated the release of 
both excitatory and inhibitory neuropeptides, shifting the balance towards neuronal 
inhibition.
1.6.5 Lamotrigine (LMT)
LMT is a member of the 2nd generation of ACDs, which targets the same sodium 
channels as CBZ and PHY (Kuo., 1998), but has a more simplistic structure containing 
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just two aromatic rings (Figure 1.10). Unlike CBZ and PHY, LMT has been shown to 
selectively inhibit late epileptiform after-discharges, without affecting initial action 
potential responses (Xie et al., 1995). Furthermore, LMT has also been shown to inhibit 
high voltage calcium channels (Stefani et al., 1996; Wang et al., 1996), which may 
explain why LMT is useful for the treatment of Absence seizures and Myoclonic 
seizures (Posner et al., 2005; Auvin., 2008), whilst PHY and CBZ are not. These high 
voltage calcium channels are known to be crucial for abnormal oscillatory behaviour 
underlying generalized absence seizures (Huguenard et al., 1996).
LMT has been shown to delay the development of kindling (McNamara et al
1995), and like PHY, LMT has also been shown to impair spontaneous glutamate 
release, whilst enhancing spontaneous GABA release in rat entorhinal cortex 
(Cunningham et al., 2000b). In addition, LMT (like CBZ) has been shown to up-
regulate BDNF expression in rat frontal cortex (Chang et al., 2009), indicating that LMT
promotes an inhibitory neuronal phenotype, whilst enhancing neuronal survival. 
Consistent with this, LMT has been shown to alleviate hippocampal damage in rats 
following PPS inducing SSSE (Halonen et al., 2001), as well as exhibiting 
neuroprotective properties in KA-induced SE models (Maj et al., 1998). Perhaps 
because of this, LMT has been noted to induce fewer side effects, on the basis of less 
patient withdrawal from treatment, compared to both CBZ (Brodie et al.,1995) and PHY
(Steiner et al., 1999).
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1.7 Cocaine
Cocaine is a psychostimulant drug which exerts its affects predominantly via 
dopamine transporter (DAT) blockade, preventing dopamine uptake and resulting in 
elevating dopamine concentrations in the synaptic cleft. This causes the well-
documented euphoric psychological effect. In addition, cocaine is known to inhibit other 
neurotransmitter transporters including SLC6A4 and norepinephrine (NET). An 
increasing appreciation of cocaine-induced seizures has arisen in the past 20 years, with 
cocaine-induced seizures documented in both humans and rodents, with short-term GTC 
seizures observed in humans (Lowenstein et al., 1987) and short seizures exhibiting 
clonic features observed in rodents (Hanson et al., 1999) (see Lason., 2001, for a 
review). Other reports have revealed that repeated subconvulsive doses of cocaine can 
induce kindling (Miller et al., 2000). One potential cause of this is cocaine’s effect on 
the dopaminergic system, which has become increasingly associated with epilepsy. 
Hyperactivity and spontaneous seizures have been reported in mice following the loss of 
D1 dopamine receptor expressing cells (Gantois et al., 2007), whilst D2 and D4 
dopamine receptor knock-out mice have been shown to be more susceptible to 
pharmacological induced seizures (Weinshenker & Szot., 2002). Furthermore, D3 
dopamine receptor agonists have been shown to exhibit pro-convulsant properties, 
which can be reversed using D3 dopamine receptor antagonists (Witkin et al., 1998).  In 
addition, a number of ACDs have been trialled to treat cocaine addiction, including CBZ 
(Brady et al., 2002; Lima et al., 2002; Campbell et al., 2003).
Another potential mechanism for cocaine-induced seizures could be the 
modulation of TFs such as NRSF, which I postulate to be an important TF in the 
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progression of epilepsy. Whilst the impact of cocaine upon the NRSF regulatory system 
has yet to be determined, NRSF has recently been shown to modulate the expression of 
CART. CART is a peptide shown to be up-regulated following cocaine treatment 
(Douglass et al., 1995) and is intriguingly found to be co-localised with the NRSF-
regulated SP in the rodent nucleus accumbens. In addition, cocaine treatment has also 
been shown to up-regulate the expression of the NRSF-regulated gene, BDNF (Zhang et 
al., 2002; Grimm et al., 2003; Filip et al., 2006). These findings suggest that cocaine 
may indeed affect the NRSF regulatory system, an issue I aim to clarify in chapter 8. 
Furthermore, an apparent overlap between the proconvulsant tachykinin 
signalling system and cocaine has become apparent in the past 5 years, with antagonism 
of NK1R, shown to reduce behavioural sensitization to cocaine in rats (Davidson et al. 
2004). Similarly, NK3R has been shown to coordinate cocaine’s psychostimulant 
affects. Notably NK3R antagonism has been found to block these psychostimulant 
properties in both rats and primates (Jocham et al., 2006), whilst the NK3R agonist, 
senktide, has been shown to potentiate cocaine-induced dopamine release (De Souza 
Silva et al., 2006). This overlap with the pro-convulsant signalling system may be 
another aspect of cocaine-induced seizures. 
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1.8 Aims & Objectives
The progression from an initial insult to recurrent, spontaneous seizures, or 
‘epilepsy’, involves dramatic cellular and molecular changes, including structural 
modifications of neuronal circuitry and gene expression profile changes. I postulate that 
the latter could be governed by long-term changes in chromatin structure, resulting in 
aberrant gene expression, leading to a hyper-excitable neuronal phenotype. A multitude 
of TFs have the capability to induce such chromatin remodelling, and in this thesis I will 
focus on two distinct TFs families, NRSF and USF. I aim to explore their relevance to 
epilepsy in terms of governing gene expression, and as a response to both pro and anti-
convulsant treatments. 
In the first instance I aim to explore the regulatory roles of these two TFs upon
two pro-convulsant neuropeptides, the tachykinin genes TAC3 and TAC1. With regards 
to TAC3, I aim to clone the NKB promoter region into a reporter gene construct, to test 
if these TFs modulate the NKB promoter activity. In addition, I aim to explore the effect 
of NRSF isoforms and the USF1 and USF2 on endogenous NKB expression. With 
regards to TAC1, I aim to further explore the already documented roles of NRSF and 
USF in the regulation of TAC1 (Quinn et al., 2002; Spencer et al., 2006; Greco et al., 
2007; Howard et al., 2008; Reddy et al., 2009; Paterson et al., 1995; Gerrard et al., 
2005), by exploring a potential synergistic regulation of TAC1 by these two TFs, akin to 
the documented NRSF and NFκB synergy (Greco et al., 2007). Our theory that a 
relationship between NRSF and USF-mediated regulation exists, is born out of the 
overlapping regulation of BDNF, AVP, and TAC1 (Timmusk et al., 1999; Tabuchi et 
al., 2002a; Coulson et al., 1999; Coulson et al., 2003).
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To gain a greater insight into the relevance of these TFs in epilepsy, I also sought 
to investigate how NRSF and USF respond to ACD treatment. Potential factors for ACD 
modulation include mRNA expression, cellular localisation and DNA binding ability. 
Each of these factors will be explored for the NRSF isoforms and the USF genes USF1 
and USF2, in response to three ACDs (CBZ, PHY and LMT), which share a common 
initial target (sodium channel), but can induce different downstream modifications. 
Furthermore, I aim to explore global gene expression changes following the over-
expression of both the full-length NRSF and a truncated version analogous to sNRSF, 
via microarray analysis. NRSF isoforms have been shown to be up-regulated following 
3hrs (Spencer et al., 2006) and 4hrs (Palm et al., 1998) KA administration in rats, 
representing an initial insult. By over-expressing these isoforms and exploring global 
gene expression changes, it is hoped one can unravel the more long term changes in 
gene expression which may lead to an enhanced susceptibility to future seizures, and 
hence gain a greater insight into the process of epileptogenesis. 
Finally, due to an increasing appreciation of the dopaminergic system in seizures 
and the increase in cocaine-induced seizure reports, I wish to explore the impact of 
cocaine treatment on both NRSF and USF. One hopes that by comparing how these TFs 
respond to cocaine to how they respond to both pro- and anti-convulsant chemical 
stimulation, underlying mechanisms or pathways which govern these TFs may be 
revealed, which may help in the generation of future anti-epileptic strategies. 
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials 
2.1.1 Plasmids and vectors
Plasmid Name Description Source
Reporter Gene Constructs
pNKB -757 +181 
luc
(pNKB-757)
pGL3basic luciferase reporter gene backbone 
containing a fragment of the human NKB 
proximal promoter spanning -757 to +181, cloned 
upstream of the luciferase reporter gene DNA.
See Chapter 3.
pNKB -289 +181 
luc
(pNKB-289)
pGL3basic luciferase reporter gene backbone 
containing a fragment of the human NKB 
proximal promoter spanning -289 to +181, cloned 
upstream of the luciferase reporter gene DNA.
See Chapter 3.
rTAC1 -865 +92 
luc
(-865 TAC1)
Recombinant adeno-associated virus 2 (rAAV2) 
plasmid backbone, containing a fragment of the 
rat TAC1 proximal promoter spanning -865 to 
+92 and the luciferase reporter gene DNA  in 
place of the AAV genome.
Harrison et 
al., 1999
rPPT-A -865 +92 
luc
(-60 TAC1)
As the rTAC1 -865 +92 luc but with a 10bp 
insertion at -60 position in the rat TAC1 promoter 
disrupting the -60 E Box motif.
Paterson et al., 
1995
NRSF expression constructs
REEX1 pCMV expression vector containing the full 
length human NRSF cDNA (4137bp) cloned into 
HindIII and BamHI sites of a pCMV vector.
Gift from Prof 
G Mandel.
HZ4 Contains 2kb of the human NRSF sequence, 
equivalent to the N-terminus domain, under the 
control of a CMV promoter (see figure 2.1)
Gift from Dr 
D.J.Anderson
67
bHLH plasmids
pN3 pSG5 expression vector containing full length 
USF1
Gift from Dr 
M.Sawadogo
pN4 pSG5 expression vector containing full length 
USF2
Gift from Dr 
M.Sawadogo
Control Vectors
pRL-TK-Renillin Reporter gene construct, containing renillin 
luciferase DNA driven by the TK promoter. Used 
as an internal control
Promega
Table 2.1: Plasmids used in the current study. The above table summarises the plasmids used in this 
study and a brief overview of what they contain. 
Figure 2.1. Schematic comparison of NRSF isoforms and the NRSF expression constructs employed.
REEX1contains the full-length human NRSF cDNA, whilst HZ4 contains 2kb of human NRSF cDNA, 
incorporating the N-terminal domain and the eight zinc fingers found in full-length NRSF, but lacks the 
C-terminal domain. HZ4 is employed as a tool to mirror sNRSF over-expression due to the shared 
absence of the entire C-terminal domain, however it should be noted that human sNRSF contains only 
five out of eight zinc fingers, thus HZ4 only an analogous representation of sNRSF. 
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2.1.2 Commonly used solutions and reagents 
2.1.2.1 Microbiology and Molecular Biology
Luria broth (LB) media
10.0g/l peptone, 5.0g/l yeast extract and 10.0g/l NaCl.
LB agar
10.0g/l peptone, 5.0g/l yeast extract and 12g/l agar. 
5x TBE buffer
54g Tris(hydroxymethyl)methylamine (Tris) (BDH), 27.5g  boric acid (VWR 
International), 20ml 0.5M Ethylenediamine Tetraacetic Acid (EDTA) (Sigma) and 
dH2O up to 1 litre.
6x agarose gel loading buffer    
Blue/Orange 6x loading dye (Promega)
DNA Ladders
Mass ruler (Fermentas), 100bp Ladder & 1Kb Ladder (both Promega)
ChIP fixation solution
20ml 1x PBS and 540µl 37% formaldehyde.
ChIP glycine stop-fix solution
2ml 10x Glycine (Active Motif), 2ml 10x PBS and 16ml dH2O.
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ChIP cell scraping solution
400µl 10x PBS, 3.6ml dH2O and 10µl of 100mM PMSF added just prior to use.
Protein extraction buffer 
50mM Tris-HCl pH 7.2, 150mM NaCl, 2mM EDTA, 1mM EGTA, 1% Triton x-
100, 1 tablet of protease inhibitor cocktail (PICt) (Roche) 100 µM PMSF was added 
fresh from stocks before use.
1x NuPAGE MOPS SDS running buffer
760ml dH2O and 40ml 20x NuPAGE MOPS SDS running buffer (Invitrogen).
20x NuPAGE MOPS SDS transfer buffer
500mM Bicine, 500mM Bis-Tris and 20.5mM EDTA to a volume of 125ml. 
1x NuPAGE MOPS SDS transfer buffer
749ml dH2O, 50ml 20x NuPAGE MOPS SDS transfer buffer, 200ml 100% 
molecular grade methanol (Sigma) and 1ml NuPAGE antioxidant. pH adjusted to pH7.2.
Triton-PBS
1% triton in PBS
Stripping buffer
100mM β-mercaptoethanol, 2% SDS and 62.5mM Tris-HCl pH 6.7
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2.1.3 Treatment solutions
2.1.3.1 Carbamazepine (CBZ)
CBZ (Sigma; Cat No: C4024) was dissolved in 100% molecular grade ethanol to 
make a 15mg/ml stock solution. This stock solution was diluted in complete media at a 
dilution of 1:300 or 1:1500, to make 50µg/ml or 10µg/ml, respectively. 
2.1.3.2 Phenytoin (PHY)
PHY (Sigma; Cat No: D4007) was dissolved in 100% biotechnology 
performance grade dimethyl sulfoxide (DMSO) (Sigma; Cat No: D2438) to make a 
20mg/ml stock solution. This stock solution was diluted in complete media at a dilution 
of 1:400 or 1:2000, to make 50µg/ml or 10µg/ml, respectively. 
2.1.3.3 Lamotrigine (LMT)
LMT (Sigma; Cat No: L3791) was dissolved in 75% biotechnology performance 
grade DMSO (Sigma; Cat No: D2438) in ddH2O to make a 5mg/ml stock solution. This 
stock solution was diluted in complete media at a dilution of 1:100 or 1:500, to make 
50µg/ml or 10µg/ml, respectively. 
2.1.3.4 Kainic Acid (KA)
KA (Sigma; Cat No: K0250) was dissolved in sterile ddH2O to make a 1mM 
stock solution. This stock solution was diluted in complete media at a dilution of 1:200 
or 1:1000, to make 50µM or 10µM, respectively. 
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2.1.3.5 Cocaine 
Cocaine (Sigma; Cat No: C5776) was dissolved in sterile ddH2O to make a 1mM 
stock. This stock solution was diluted 1:100 or 1:1000 in complete media, to make 
10µM or 1µM, respectively.
2.1.3.6 Vehicle Control C
Vehicle control for CBZ treatment (Control C) was 100% molecular grade 
ethanol diluted in complete media at a ratio of 1:300, making a final concentration of 
0.33% ethanol.
2.1.3.7 Vehicle Control P
Vehicle control for PHY treatment (Control P) was 100% biotechnology 
performance grade DMSO diluted in complete media at a ratio of 1:400, making a final 
concentration of 0.25% DMSO.
2.1.3.8 Vehicle Control L
Vehicle control for LMT treatment (Control L) was 75% biotechnology 
performance grade DMSO diluted in complete media at a ratio of 1:100, making a final 
concentration of 0.75% DMSO
2.1.3.9 Vehicle Control KA
Vehicle control for KA treatment was sterile ddH2O diluted in complete media at 
a ratio of 1:200.
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2.1.3.10 Vehicle Control Cocaine
Vehicle control for cocaine treatment was sterile ddH2O diluted in complete 
media at a ratio of 1:100.
2.1.4 Cell culture media 
2.1.4.1 Complete Media for human SK-N-AS neuroblastoma cell line
Dulbecco’s modified eagle’s media (DMEMs) (Sigma) supplemented with 10% 
Foetal bovine serum (FBS) (Perbio, Hyclone), 1% penicillin + streptomycin (Sigma), 
1% non essential amino acids (NEAA) (Autogen Bioclear) and 1% 200mM L-glutamine 
(Sigma). 
2.1.4.2 Serum Free Media for human SK-N-AS neuroblastoma cell line
DMEMs (Sigma) supplemented with 1% penicillin + streptomycin (Sigma), 1% 
NEAA (Autogen Bioclear) and 1% 200mM L-glutamine (Sigma). 
2.1.4.3 Complete Media for human SH-SY5Y neuroblastoma cell line
1:1 ratio of DMEMs (Sigma) and Hams F12 (Sigma) supplemented with 10% 
FBS (Perbio, Hyclone), 1% penicillin + streptomycin (Sigma), 1% NEAA (Autogen 
Bioclear) and 1% 200mM L-glutamine (Sigma). 
2.1.4.4 Serum Free Media for human SH-SY5Y neuroblastoma cell line
1:1 ratio of DMEMs (Sigma) and Hams F12 (Sigma) supplemented with 1% 
penicillin + streptomycin (Sigma), 1% NEAA (Autogen Bioclear) and 1% 200mM L-
glutamine (Sigma). 
73
2.2 Methods
2.2.1 General cloning methods
2.2.1.1 Polymerase Chain Reaction (PCR) primer design
Polymerase chain reaction (PCR) primers were designed using the online primer 
designer programmes Primer 3 (http://frodo.wi.mit.edu/) and NetPrimer 
(http://www.premierbiosoft.com/netprimer).  Primer 3 was employed to generate a list 
of potential PCR primers to amplify a sequence of interest, and Net Primer was utilised 
to bioinformatically test the primers; screening for appropriate melting temperatures, 
GC% content, potential dimerisation and hairpin formation, rejecting primers whenever 
necessary. In general, primers were designed to be between 18-25 bp nucleotides long, 
have a melting temperature of 50-65 °C and a GC content between 40-60%. BLASTN 
searches were used to confirm the total gene specificity of the primer sequences chosen.
2.2.1.2 Standard PCR      
PCR was employed to amplify specific DNA fragments for use in either 
molecular cloning applications, or to analyse mRNA expression of a specific gene. 
Standard PCR reactions were performed in a Px2 thermal cycler (Thermo Scientific). In 
general, for PCR reactions of DNA fragments used in molecular cloning, the proof 
reading polymerase enzyme Pfu DNA polymerase (Promega) was employed to amplify 
and proof read the DNA fragments. A 50µl Pfu PCR reaction included 10-100ng DNA 
template, 5µl Pfu reaction buffer with MgSO4, 0.5µl 20pmol forward and 0.5µl 20pmol 
reverse primers, 1µl 10mM dNTPs and 0.75µl (1.25 unit) Pfu DNA polymerase 
(Promega). For standard PCR reactions, GoTaq polymerase (Promega) was employed. 
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25µl GoTaq PCR reactions included 10-100ng DNA template, 4µl 25mM MgCl2, 5µl 
5x GoTaq reaction buffer (Promega), 0.5µl 20pmol forward and 0.5µl 20pmol reverse 
primers, 1µl 10mM dNTPs and 0.2µl (1 unit) GoTaq polymerase (Promega). Specific 
Primers used throughout are given in Table 2.2.
2.2.1.3 PCR purification
To purify single- or double-stranded DNA fragments from PCR reactions or 
DNA from other reactions such as enzymatic digestion reactions, the QIAquick PCR 
Purification Kit (Qiagen) was used following manufactures’ instructions. Briefly, 5x 
volumes of Buffer PB (Qiagen) to 1x volume of the PCR sample were mixed, applied 
into the QIAquick column and centrifuged for 1min at 13,000 rpm. The flow-through 
was discarded and the column was washed by adding 750µl PE buffer and centrifuged 
as before. Again, the flow-through was discarded and the column was re-centrifuged as 
before to completely remove residual Buffer PE. The column was then placed into a 
clean 1.5 ml eppendorf tube and the DNA was eluted using 30µl of Elution Buffer, 
incubated for 1min at room temperature (RT) and centrifuged as before.     
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Table 2.2.1 Primers used in RT-PCR and qPCR. *HCN2 primers from Stilitano et al., 2008. ** HCN3 
primers from Varghese et al., 2006. *** HDAC2 primers from Tateno et al., 2007.
DNA 
fragment
Forward (5’ – ‘3) Reverse (5’ – 3’)
Product 
Size (bp)
pNKB-757
(-757 to +181)
AAACGCGTCTCGTGAAACTCCAC
AACGA
AACTCGAGCATCCAGCATTCTCC
CACTT
954bp
pNKB-289 
(-289 to +181)
AAACGCGTCTTCTGAGGCGGCTA
TTGAG
AACTCGAGCATCCAGCATTCTCC
CACTT
358bp
Table 2.2 Primers used in molecular cloning, for amplification of the Human NKB proximal promoter. 
Gene (Species) Forward (5’ – ‘3) Reverse (5’ – 3’)
Product 
Size (bp)
Pol II (Human) GCACCACGTCCAATGACAT GTGCGGCTGCTTCCATAA 267bp
NRSF (Human) TATGCGTACTCATTCAGGTGAG TTTGAAGTTGCTTCTATCTGCTGT 166bp
sNRSF (Human) GGATACCATTTGGTAATATTTAC TTTGAAGTTGCTTCTATCTGCTGT 191bp
USF1 (Human) AACGTCAAGTACGTCTTCCGA CCGTGCTGGGGAAGTAAGTAT 232bp
USF2 (Human) AATTGATGGAACCAGAACACC AAGCAGGGCGTTCTCATTCTT 313bp
TAC1 (Human) ACTGTCCGTCGCAAAATCC TCCAAAGAACTGCTGAGGC 220bp
NKB (Human) TGCTGCTATTCACAGCCATC AGCAATCCCTCCAGAGATGA 174bp
HCN2 (Human)* CGTTACCAGGGCAAGATGTTTG GTTGTCCACGCTCAGCGAAT 393bp
HCN3 (Human)** CCTACAGCGACTTCCGGTTT GTGCCGTTTTGTAGACCTCAGC 351bp
SCN9a (Human) GAGGCCTGTTTCACAGATGG TGGGCCAAGATCTGAGTAG 401bp
CART (Human) CAGCAACGACGAGTTTCAGA TGGGGATGTATGGAGGAGAA 405bp
β-actin (Human) CATCCTCACCCTGAAGTACC ATAGCAACGTACATGGCTGG 219bp
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2.2.1.4 Analysis of DNA using Agarose Gel-Electrophoresis 
To analyse DNA fragments from PCR reactions or from restriction digests, 
agarose gel-electrophoresis was employed. 1-2% agarose gels were made by dissolving 
1-2% multi-purpose agarose (Bioline) in 0.5x TBE buffer, heated in a microwave until 
boiling. The resulting solution was supplemented with 5μl ethidium bromide (10mg/ml 
aqueous solution, Sigma E-5134) once cooled. Gels of 60ml or 100ml were cast in 
12x14cm or 20.5x10cm trays, respectively and the appropriate combs were inserted.  
Gels were left at RT until set and were then submerged in horizontal gel electrophoresis 
tanks (Hybaid turn and cast submarine gel system, Hybaid, or Savant HG 350 tank) 
containing 0.5x TBE buffer. All samples beside GoTaq PCR reaction samples were 
supplemented with 6x Blue/Orange loading buffer (Promega) and loaded into the wells. 
GoTaq PCR reactions contained loading dye in the GoTaq reaction buffer, and hence 
did not require addition loading buffer. The size of a PCR product or restriction digest 
fragments was determined by loading a DNA ladder (Mass ruler: Fermentas; 100bp 
Ladder: Promega; 1Kb Ladder: Promega). Gels were run for 1 hour at 100Volts 
(Hybaid). The electrophoretically separated DNA was then visualised using an 
Evenscan broadband dual wavelength transluminator in a MultiImageII Light Cabinet 
(both Alpha Innotech Corporation) at a wavelength of 302nm. Images were recorded 
with a CCD camera (Alpha Innotech Corporation) and stored electronically.
2.2.1.5 Recovery of DNA from agarose-gels 
DNA products from PCR reactions or restriction digests were run and separated 
using agarose gels. In cases where the DNA was required, the DNA had to be recovered 
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from the agarose gels. The QIAquick Gel Extraction Kit (Qiagen) was used to extract 
and purify the DNA out of the agarose gels, following manufacturers’ instructions. 
Briefly, the desired DNA band was excised from the gels, under UV translumination, 
using a clean blade and the resulting gel slices were weighed. To dissolve the agarose 
gel, 3x volumes of buffer QG was added to 1 volume of gel slice, and incubated for 
10mins at 50°C. 1x gel volume of 100% molecular grade isopropanol (Sigma) was 
added to each sample and vortexed to mix. This was then applied into a QIAquick spin 
column, placed within a 2ml collection tube and centrifuged for 1min at 13,000rpm 
using a bench top centrifuge. The flow-through was discarded and the column was 
washed by adding 750µl PE buffer and centrifuged as before. The flow-through was 
then discarded and the column was re-centrifuged as before to completely remove 
residual buffer PE. The column was then placed into a clean 1.5ml eppendorf tube and 
the DNA was eluted using 30µl Elution Buffer, incubated for 1 minute at RT and 
centrifuged as before.     
2.2.1.6 Generation of NKB promoter reporter gene constructs  
Two human NKB promoter reporter gene constructs were generated as follows:  
DNA fragments of the NKB proximal promoter region spanning either -757 to +181 
(pNKB-757) or -289 to +181 (pNKB-289), were PCR amplified from human genomic 
DNA (Promega), using the Pfu DNA polymerase enzyme (Promega). Primers used to 
amplify each DNA fragment (Table 2.2.2) were designed with flanking MluI (forward 
primer) and XhoI (reverse primer) restriction enzyme sites for directional cloning into 
the corresponding MluI and XhoI sites in pGL3basic (Promega) promoter-less luciferase 
reporter gene construct (upstream of the luciferase reporter gene). Furthermore, an 
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additional AA sequence was added 5’ of each primer to enhance cleavage efficiency. 
The PCR reaction conditions were as follows: denaturation at 95oC for 2mins, followed 
by 40 cycles of: 95oC for 30 seconds, 60oC for 30 seconds, 72oC for 1mins, followed by 
a final elongation step 72oC for 5mins. Resulting DNA was ran on an agarose gel 
(Section 2.2.1.4), gel extracted and purified (Section 2.2.1.5). 
The DNA fragments and the target pGL3basic vector were then subjected to 
restriction enzyme digestion, to generate the MluI and XhoI sticky ends required for 
ligation. Briefly, 8µl of DNA (PCR product or pGL3basic) was mixed with 1µl 10x 
reaction buffer D, 0.5µl MluI and 0.5µl XhoI (all Promega), and incubated overnight at 
37oC. The resulting cleaved DNA was purified using the Qiagen PCR purification 
protocol (See section 2.2.1.3) to remove enzymes. The purified NKB promoter 
fragments were then ligated into pGL3basic (Section 2.2.1.7).
2.2.1.7 Ligation
In order to ligate the NKB promoter DNA fragments into the pGL3basic vector, 
the amount of DNA required needed to be calculated, via the the following ligation 
calculation: The amount of insert required (ng) =
[(ng vector X insert size kb)/(vector size kb)] X insert:vector ratio = ng insert
In general, two different insert:vector molar ratios were used, either 1:1 or 3:1 
ratios. In the ligation reaction 1l (25ng) of vector and appropriate volume of insert 
were added to 1l 10x ligase buffer (NEB) and 1μl 200 units of T4 DNA ligase (NEB) 
in at total volume of 10μl, incubated at RT for 4 hours then at 4˚C overnight.
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2.2.1.8 Transformation of chemically competent E. Coli cells
Following ligation of the NKB promoter into the pGL3basic vector, the resulting 
plasmid was transformed into strains of chemically competent E. Coli DH5-α cells 
(Invitrogen), following manufacturers guidelines. Briefly, the ligation reaction (10µl) or 
10ng DNA (for transformation of other DNA) were added to 50μl of competent DH5-α 
cells and incubated on ice for 30mins. The cells were then subjected to ‘heat-shock’ in a 
water bath (at 42oC) for 45 seconds and then incubated on ice for 2mins. Following this, 
950µl of pre-warmed LB broth was added to the cells, and the culture incubated on a 
shaker (at 225rpm), at 37oC for 1 hour. Between 50-200µl of this culture was spread 
evenly onto LB agar plates supplemented with 100µg/ml ampicillin, and cultured 
overnight at 37˚C. 
2.2.1.9 Isolation of DNA constructs from bacteria
2.2.1.9.1 Mini-preparation of plasmid DNA
In order to test plasmids following molecular cloning manipulation, a small scale 
preparation of DNA (up to 20µg) was undertaken. To test colonies grown on LB agar 
plates, individual colonies were transferred to 5ml LB broth supplemented with 
100µg/ml ampicillin, and cultured overnight at 37oC, on a shaker (at 225rpm). DNA was 
isolated from the resulting bacterial culture using the QIAprep Spin Miniprep Kit 
(Qiagen), according to manufacturer’s guidelines. Briefly, the bacterial culture was 
pelleted following centrifugation at 4000rpm for 5-10mins, and resuspended in a 
resuspension buffer. The cells were lysed using a modified alkaline lysis buffer for 
5mins at RT, following which the lysis was neutralised and adjusted to high salt binding 
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conditions, using a neurtralisation buffer. The neutralised lysate was cleared by 
centrifugation (13,000rpm for 10mins) before being applied into a column containing a 
membrane that selectively absorbs DNA in high-salt conditions. The column was then 
washed with buffer PB to remove endonucleases and then salts were removed by a final 
wash with buffer PE (both Qiagen). The plasmid DNA was then eluted into a fresh 
1.5ml eppendorf using 50µl nuclease-free water. This plasmid DNA was next tested by 
either using restriction enzyme digestion assays (Section 2.2.1.11) or sent for DNA 
sequencing (2.2.1.12). 
2.2.1.9.2 Maxi-preparation of plasmid DNA
For large scale production and isolation of DNA (up to 500µg), the QIAGEN 
Plasmid Maxi Kit (Qiagen) was employed. As with mini-preparation (Section 2.2.1.9.1), 
a bacterial culture is required, however this was increased from a 5ml overnight culture, 
to a 100ml overnight culture. Briefly, the 100ml culture was pelleted by splitting the 
culture into two 50ml falcon tubes, and centrifuged for 15mins at 4500rpm at 4oC. The 
resulting pellet was resuspended in the provided resuspension buffer supplemented with 
RNase A, and the cells were lysed at RT for 5mins, using a modified alkaline lysis 
buffer. The lysis reaction was neutralised following the addition of a potassium acetate 
neutralisation buffer, incubated on ice for 20mins. The resulting cell lysate contained a 
mixture of plasmid DNA, bacterial protein, DNA and cell debris. This cellular debris 
was removed via centrifugation at 13,000 rpm for 45mins, the supernatant was passed 
through a QIAfilter Maxi Cartridge and the DNA was bound to an anion-exchange 
column under high salt and low pH conditions. Medium-salt washes were used to 
remove RNA, proteins etc, and the plasmid DNA was eluted with a high-salt wash. The 
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eluted DNA was then precipitated with 0.7 volumes 100% molecular grade isopropanol 
(Sigma) and centrifuged for 30mins at 13,000rpm. The resulting DNA pellet was 
washed with 70% molecular grade ethanol (Sigma) and re-centrifuged a further 10mins 
at 13,000rpm. The DNA was resuspended in 100µl nuclease-free water and transferred 
into a 1.5ml eppendorf for storage at -20oC.
2.2.1.10 Analytical restriction enzyme digests
To test DNA fragments and DNA plasmids used in molecular cloning, or to 
screen for positive colonies following a ligation and transformation reaction, restriction 
enzyme digestion was employed. Restriction enzyme digests were carried out in an 
appropriate 1x restriction enzyme buffer. All restriction digest reactions were 
undertaken for a minimum time of 3 hours, incubated at the appropriate temperature for 
the specific restriction enzyme. In general, multiple restriction enzymes could be used in 
a single reaction, if the enzymes used a common reaction buffer. In cases where the 
restriction enzymes required different reaction buffers, a double digest would occur. 
Two or more separate digestion reactions would be performed, beginning with the 
enzyme that functioned in the reaction buffer with the lowest salt concentration. The 
following reaction would utilise the enzyme that functioned in the reaction buffer with 
the next lowest salt concentration, and so on. Each digest would be adjusted to maintain 
the ratio of 1:10, reaction buffer:total volume. Resulting DNA fragments were 
visualized after gel electrophoresis in a UV light transilluminator (Section 2.2.1.4).
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2.2.1.11 Sequencing
DNA sequencing was performed by The Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland) using Applied Biosystems Big-Dye Ver3.1 
chemistry on an Applied Biosystems model 3730 automated capillary DNA sequencer.
2.2.1.12 Measurement of DNA/RNA concentration by spectrophotometry
DNA and RNA concentrations were determined using an UV spectrophotometer 
(Jenway Genova Life Science Analyser). The UV spectrophotometer was zeroed against 
100µl dH2O before 1:20 diluted DNA or RNA preparation was placed into a quartz 
cuvette and placed in the cell holder for the determination of concentration, using the 
following formulae: 
dsDNA concentration = OD260 value (at wavelength of 260 nm) x 50 x dilution factor
ssDNA concentration = OD260 value (at wavelength of 260 nm) x 33 x dilution factor
RNA concentration = OD260 value (at wavelength of 260 nm) x 40 x dilution factor 
where 1 OD at 260 nm equals 50ng/µl of dsDNA (double-stranded DNA), 33ng/µl of 
ssDNA (single-strandard DNA) and 40ng/µl of RNA, hence x50, x33and x40 
respectively.
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2.2.2 Cell Treatment & Transfection
2.2.2.1 Cell Culture 
2.2.2.1.1 Culture of SK-N-AS cells
Human neuroblastoma SK-N-AS cells were obtained from American Type 
Culture Collection (ATCC) and maintained as an adherent monolayer in DMEMs 
medium (Sigma) as described in section 2.1.4. SK-N-AS cells were cultured at 37oC, 
5% CO2, in T75 flasks and the culture media was routinely changed every other day. 
Cells were split when 70−80% confluent.  
2.2.2.1.2 Culture of SH-SY5Y cells
Human neuroblastoma SH-SY5Y cells were also obtained from ATCC and 
maintained as an adherent monolayer in a 1:1 ratio EMEMs: HAM’s F12 medium (both 
Sigma) as described in section 2.1.4. As with SK-N-AS cells, SH-SY5Y cells were 
cultured at 37oC, 5% CO2, in T75 flasks and the culture media was routinely changed 
every other day. Cells were split when 70−80% confluent.  
2.2.2.2 Cell Treatment 
SK-N-AS cells and SH-SY5Y cells were seeded into 24-wells plates (luciferase 
assays), 12-well plates containing sterile coverslips (immunofluorescence ), 6-well 
p l a t e s  (Endogenous gene expression assays) or T175flasks (Chromatin 
Immunoprecipitation (ChIP) assays), at a density of 0.5x105 cells/cm2, and cultured until 
70% confluency was achieved. Prior to drug or control treatment, media was removed 
and replaced with corresponding serum free media (serum starvation) and left overnight. 
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Cells were subsequently incubated in corresponding complete media supplement with 
either: KA (at 1µM or 5µM), CBZ (at 10µg/ml or 50µg/ml), PHY (at 10µg/ml or 
50µg/ml), LMT (at 10µg/ml or 50µg/ml), cocaine (at 1µM or 10µM), or corresponding 
vehicle controls (See section 2.1.3), for either 4hrs or 24hrs. Following treatment, the 
cells were immediately harvested, allowing no recovery period. Cells treated with these 
drugs were used in a range of assays, including transfections, endogenous gene 
expression assays, immunofluorescence and ChIP as described below. 
2.2.2.3 Delivery of luciferase constructs into neuroblastoma cell line
Reporter gene plasmids (Table 2.1) were delivered into human SK-N-AS 
neuroblastoma cells using ExGen 500 in vitro Transfection Reagent (Fermentas). To 
normalise for transfection efficiency a modified pMLuc-2 vector containing a minimal 
TK promoter followed by an optimized Firefly luciferase cDNA were transfected into 
the cells to act as an internal control. The internal control was delivered at a ratio of 1:50 
ration pMLuc-2: reporter gene construct.
2.2.2.4 ExGen 500 in vitro Transfection
ExGen 500 in vitro Transfection Reagent (Fermentas) was used to transfect 
human SK-N-AS neuroblastoma cells. ExGen 500 is a polyethylenimine cationic 
polymer which interacts with DNA to form small, stable, highly diffusible particles that 
settle on the cell surface. The DNA/ExGen 500 complex is then absorbed into the cell 
via endocytosis. The resulting endosomes are then ruptured within the cytoplasm before 
lysosomal degradation releases the DNA/ExGen 500 complex, allowing the DNA to be 
translocated into the nucleus. Following manufactures’ instructions, 1μg of reporter 
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constructs and 20ng of the internal control plasmid pmLuc-2 were diluted in 100μl of 
150mM NaCl, vortexed and brief centrifuged. 3.3μl of ExGen 500 was added per 1μg of 
DNA used. The solution was immediately vortexed for 10 seconds and incubated for 
10mins at RT. 100μl of the DNA/ExGen 500 mixture was added to each well, so that the 
resulting volume of the DNA/ExGen 500 mixture equalled 10% of the total volume of 
the culture medium. The plates were then centrifuged for 5mins at 280xg and finally 
incubated at 37°C for 48 hours in a humidified 5% CO2 incubator. 48 hours post-
transfection the cells were lysed to analyse transgene expression.  
2.2.2.5 Co-transfection experiments
To assess the potential regulation of the human NKB proximal promoter region 
or the rodent TAC1 promoter region, by particular TFs, constructs expressing full length 
NRSF (RE-EX1), a truncated version (HZ4), USF1 (pN3) and USF2 (pN4) proteins 
were transfected into cell lines simultaneously with the reporter constructs (Table 2.1). 
The constructs were co-transfected using ExGen 500 following the protocol described 
above (section 2.2.2.2). In co-transfection experiments the amount of plasmid DNA 
transfected into the cells was maintained constant. For this, per every 1μg of expression 
vectors co-transfected with reporter constructs, an equal amount of innocuous DNA 
(pGL3b) was transfected with the reporter gene constructs when basal levels of 
transcription were assessed (no expression construct present). 
2.2.2.6 Analysis of transgene expression by Reporter gene assay
Analysis of the amount of luciferase protein activity produced by the transfected 
plasmids was estimated using the Dual Luciferase Assay kit (Promega, Madison Cat. No 
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E1500) on extracts of transfected cells. Briefly, cell extracts were obtained as follows: 
culture medium was removed and wells were washed twice with PBS. 70µl of 1x 
passive lysis buffer per well was added and incubated for 15mins on a rocking platform. 
At the end of this period, 20µl supernatant containing the lysed cell extracts, were plated 
into a 96-well plate and transferred into the Glomax 96 microplate luminometer 
(Promega). 100µl Firefly luciferase reagent and 100µl Renillin luciferase reagent were 
automatically dispensed into each well to calculate luminescence intensity. The Renillin 
luciferase substrate solution was added to each sample to determine the protein 
production of the internal control (pmLuc-2) to normalise for transfection efficiency in 
case the number of cells or the efficiency of the transfection varied from well to well. 
The calculated luminescence was processed by the Glomax 96 software, and data 
transferred and analysed in Microsoft Excel.  
2.2.3 mRNA analysis
2.2.3.1 RNA extraction
To analyse gene expression in treated and untreated cells, SK-N-AS and SH-
SY5Y cells were plated out and cultured on sterile 6-well plates. Cells were grown until 
70% confluent, and treated as described in section 2.2.2.2. Treated or untreated cells 
were harvested and RNA extracted using TRIzol (Invitrogen), according to 
manufacturer’s guidelines. Briefly, 1ml TRIzol was added to each well and incubated 
for 5mins at RT to permit the complete dissociation of nucleoprotein complexes. The 
TRIzol was then transferred to 1.5ml eppendorfs, and 200l of choloform solution was 
added to separate RNA from DNA and protein, through phase separation. Samples were 
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mixed vigorously for 15 seconds and incubated for 2-3mins at RT. Samples were then 
centrifuged at 12,000x g for 15mins at 2-8°C. Following centrifugation the mixture 
separated into lower red, phenol-chloroform phase (an interphase) and a colourless 
upper aqueous phase. The RNA containing upper aqueous phase was transferred into 
fresh RNase-free 1.5ml eppendorf tubes and 500l 100% molecular grade isopropanol 
(Sigma) was added. The mixture was incubated for 10mins at RT and then centrifuged 
at 12,000x g for 10mins, at 2-8°C, to precipitate the RNA. The resulting RNA pellet was 
washed with 70% molecular grade ethanol, and re-centrifuged for 5mins at 7,500x g, at 
2-8°C. The RNA pellet was then left to air-dry for 5-10mins, allowing complete 
evaporation of any residual ethanol. To dissolve the RNA, the pellet was resuspended in 
50l of RNase free water and incubated for 10mins at 55-60°C.  The RNA samples were 
stored at -80˚C. RNA concentration was determined as described in section 2.2.1.13.
2.2.3.2 DNase digestion of total RNA extraction
In order to remove any, potentially contaminating, DNA from the harvested 
RNA, each RNA sample was digested with RQ1 RNase-free DNase (Promega). Briefly, 
1g of total RNA was digested with 1μl (1unit) RQ1 RNase-free DNase supplemented 
with 1μl RQ1 10x buffer (Promega), in a total 10μl reaction volume. The reaction was 
incubated at 37oC for 30mins. To stop the reaction, 1μl Stop-solution (Promega) was 
added, and the DNase enzyme was inactivated at 65oC for 10mins. 
2.2.3.3 Reverse Transcriptase PCR (RT-PCR)
For conversion of RNA to complementary DNA (cDNA), the Reverse 
Transcription System (Promega) was utilised, according to manufacturer’s guidelines. 
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Briefly, 1µg DNase treated RNA was used as a template in a 20µl reaction containing: 
1µg of oligo dT primers, 2µl x10 Reverse Transcriptase reaction buffer, 2µl 10mM 
dNTPs, 0.5µl RNAsin ribonuclease inhibitor, 4µl 25mM MgCl2, 0.75µl reverse 
transcriptase (all Promega) plus dH2O to take the volume up to 20µl. For first strand 
cDNA synthesis, the reverse transcription reaction was carried out at 42C for 15mins 
for annealing, followed by 95oC for 5mins to inactivate the reverse transcriptase. The 
resulting cDNA concentration was determined (as described in section 2.2.1.13), diluted 
to 10ng/µl, for use in RT-PCR and quantitative PCR (qPCR), and stored at -20oC.
2.2.3.4 PCR to analyse mRNA expression
To analyse mRNA expression of specific genes, PCR was employed. PCR 
reactions were performed in a Px2 thermal cycler (Thermo Scientific), using GoTaq 
polymerase (Promega). Primers used throughout are given in Table 2.2.1, and all were 
obtained from MWG Biotech (Germany), prepared as a 100μM stock and stored at -
20˚C.For each 25µl PCR reaction, 10ng cDNA template was used, in combination with: 
4µl 25mM MgCl2, 5µl GoTaq reaction buffer (Promega), 0.5µl 20pmol forward and 
0.5µl 20pmol reverse primers, 1µl 10mM dNTPs (Promega) and 0.2µl (1 unit) GoTaq 
polymerase (Promega). DNase-free and nuclease-free dH2O was used to make a total 
volume of 25µl. 
PCR thermal cycle conditions were adapted for each gene investigated, with the 
annealing temperature varying according to the melting temperature of the primer pairs 
used and the extension time adapted according to the size of the expected product, with 
1 minute extension time for each 1000bp employed as a guide. In general, the thermal 
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cycle conditions were as follows: initial denaturation: 95oC for 2mins for 1 cycle; 
followed by 40 cycles of denaturation: 95oC for 30 seconds, annealing 60-62oC for 30 
seconds and elongation: 72oC for 1min; and a final elongation step of 72OC for 2mins.
2.2.3.5 Quantitative PCR (qPCR)
For more accurate analysis of mRNA expression, quantitative PCR (qPCR) was 
employed. qPCR reactions were performed using the iQ SYBR Green supermix 
(BioRad) in a BioRad iQ5 thermal cycler. The SYBR green method works via the 
binding of the SYBR green I fluorescent dye to DNA, which becomes excited in the 
presence of dsDNA generating fluorescence. The levels of fluorescence are directly 
proportional to the copy number of amplicons produced, and hence the quantity of PCR 
product can be measured, according to levels of fluorescence. The specificity of qPCR 
products can be determined by subsequent melt curve analysis, from 55°C to 95°C with 
0.5°C increments. The content of unknown samples can be calculated from the amount 
of the target gene, normalised relative to the amount of the housekeeping gene RNA 
polymerase II (Pol-II), using the ‘Relative Quantification’ calculation of 2-∆∆CT (Livak & 
Schmittgen., 2001). This equation takes into account the cycle threshold (CT) (the cycle 
number when the levels of recorded fluorescence meet a predetermined threshold level) 
of a target gene versus a house keeping control gene, and derives the initial quantity of  
that gene, based on the assumption PCR amplification if perfectly exponential. 
Each 25µl qPCR reactions contained 10ng cDNA as template, 12.5l iQ SYBR 
Green master mix (containing iTaq hot-start DNA polymerase, SYBR Green I dye, 
optimized PCR buffer, 5mM MgCl2, dNTP mix including dUTP and fluoresein), 0.3µl 
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20pmol forward and 0.3µl 20pmol reverse primers and DNase-free and nuclease-free 
dH2O to bring the total volume to 25µl. qPCR thermal cycle conditions for all genes 
(except the truncated NRSF isoform sNRSF) were as follows: initial denaturation step: 
95°C for 3mins for 1 cycle (activates the iTaq DNA polymerase enzyme), followed by 
40 cycles of denaturation: 95°C for 30secs and annealing: 62°C for 30secs. For sNRSF, 
the conditions were modified to: 95°C for 3 min for 1 cycle; 40 cycles of denaturation: 
95°C for 30secs and annealing: 58°C for 45secs.Continuous fluorescence was detected 
using the iQ5 thermal cycler software.
2.2.3.6 Affymetrix Microarray Analysis
In order to analyse global changes in gene expression patterns, Affymetrix 
Microarray technology was utilised. A total of 10µg of RNA was processed using 
established Affymetrix protocols for the generation of biotin-labeled cRNA and the 
hybridization, staining, and scanning of arrays as outlined in the Affymetrix technical 
manuals (Van Gelder et al., 1990; Warrington et al., 2000). The processed RNA was 
hybridized to Human Genome U133 Plus 2.0 arrays from Affymetrix, Inc. (Santa Clara, 
CA), and scanned on an Affymetrix GeneChip® scanner 3000 at 2.5μm resolution, and 
image data was analysed using Affymetrix GCOS software. A more complete 
description of this process is available in Dobbin et al., 2005. 
Samples were compared pairwise to corresponding controls. The data generated 
for each comparison was filtered for (a) Fold-change smaller or equal to 0.5, or greater 
or equal to 2.0 representing a decrease of increase in expression respectively, (b) p-value 
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change smaller than 0.05 or greater than 0.95 (two-sided p-value) and (c) Gene detected 
as present (P) or moderately present (M) in at least one of the two samples. 
2.2.4 Protein Analysis
2.2.4.1 Protein Extraction from Cell Lysates
In order to extract protein from cell lysates, cell pellets were washed with 1xPBS 
and lysed in 1ml protein extraction buffer (See section 2.1.2.1) in a 1.5ml eppendorf 
tube, for 30mins on ice. The pellet was then passed through a syringe x10 times, and 
cellular debris was removed through centrifugation, at 13,000rpm, for 15mins at 4oC. 
The supernatant containing the protein extract was stored at -80˚C.
2.2.4.2 Determination of protein concentration
In order to perform western blotting, the concentration of protein in each extract 
was first determined using a BCA Protein Assay Kit (Pierce). This assay is based on the 
chemical reduction of Cu2+ ions to Cu+ ions by proteins under alkaline conditions. Each 
Cu+ ion then reacts with two bicinchoninic acid (BCA) molecules and generates a purple 
product. This purple product can be used to determine the protein concentration of the 
unknown sample, based on a comparison of the purple intensity against the intensities 
generated from a set of standards with known protein concentrations. In short, a set of 
standards with protein concentrations ranging from 2000μg/ml to 25μg/ml were made 
up.  25μl of each standard and sample were pipetted into a clear 96-well microplate, and 
200μl of working reagent (made up from reagents A and B at a 50:1 ratio) were added. 
The reaction was incubated for 30mins at 37˚C. The plate was then cooled to RT and 
read in a plate reader (Lucy-2 microplate luminometer, Anthos Labtec Instruments 
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GmbH) at a wavelength of 570nm. The protein concentration was quantified using 
Microsoft Excel.
2.2.4.3 Western Blotting
2.2.4.4.1 Denaturing SDS-PAGE
For protein separation, NuPAGE 4-12% gradient of 10% Bis-Tris SDS-PAGE 
precast gels were used together with the XCell SureLock Mini-Cell system (Invitrogen). 
The gels were submerged in the inner chamber with 200ml 1x NuPAGE MOPS SDS 
running buffer (Section 2.1.2.1) containing 500µl NuPAGE antioxidant (Invitrogen). 
The outer chamber was then filled with 600ml 1x NuPAGE MOPS SDS running buffer. 
20g of either SK-N-AS or SH-SY5Y cellular protein extracts were mixed with 
1x NuPAGE LDS sample buffer and 0.2x 1M DTT, and boiled for 10 minutes, before 
being loaded into the gel. For identification of molecular weight of the separated 
proteins SeeBlue Plus2 Prestained Standard 1x protein ladder (Invitrogen) was loaded. 
Samples and markers were separated at a constant voltage of 200V for 1 hour.
2.2.4.4.2 Electrophoretic transfer
Following gel electrophoresis, the gel apparatus was dismantled, and the gels 
were submerged in 1x NuPAGE transfer buffer (Section 2.1.1.2). To transfer proteins 
from the SDS-PAGE gels onto nitrocellulose membrane, the BioRad Mini-Protein II cell 
system was employed. Sponges, filter paper and nitrocellulose membrane 
(BioTrace®NT, Pall Life Sciences),were all also soaked in 1x NuPAGE transfer buffer, 
and a transfer sandwich was assembled in transfer cassettes, according to the 
manufacturer’s guidelines. The cassettes were inserted into the BioRad transfer 
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apparatus, together with a frozen cooling unit to ensure overheating did not occur, and 
transferred for 1hour at 60V. After transfer, the transfer apparatus was disassembled and 
the nitrocellulose membrane was stained for 1min in Ponceau-S solution (Sigma), and 
washed in water. Staining of the transferred protein on the nitrocellulose membrane 
served as a control for an efficient and even transfer.
2.2.4.4.3 Detection of protein
For the removal of non-specific binding, the nitrocellulose membrane was 
blocked in 5% dry semi-skimmed milk/ 0.1% Triton/PBS overnight at 4°C. The 
nitrocellulose membrane was incubated with primary antibodies in PBS-T plus 2% milk 
at a 1 in 1000 dilution, on a rocker for 1 hour at RT or overnight depending on the 
antibody. NRSF and sNRSF antibodies were a kind gift from Noel Buckley, King’s 
College London. The NRSF antibody was raised against the rat C-terminal sequence 
CYFLEEAAEEQE. The antibody against the truncated isoform, was raised against an 
alternative rat C-terminal epitope SGCDLAG (Belyaev et al., 2004). Both anti-sera were 
raised in rabbit. These antibodies have been widely used in ChIP assays, for detection of 
protein by Western and immunofluorescence and in gel-shift experiments (Wood et al, 
2003, Belyaev et.al., 2004 and Spencer et al., 2006).  
The USF1 antibody is a rabbit polyclonal antibody raised against an epitope in 
the C-terminus of the human USF1 protein (Santa Cruz, Biotechnology). The USF2 
antibody is a rabbit polyclonal antibody raised against an epitope in the N-terminus of 
the mouse USF2 protein (Santa Cruz, Biotechnology). Both antibodies have been used 
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in western blotting, immunofluorescence and ChIP (Park et al., 2008; Rada-Iglesias et 
al., 2008; Crusselle-Davis et al., 2006). 
After primary antibody incubation, the membrane was washed 3x for 10mins in 
0.1% Triton/PBS, and then incubated in horseradish peroxidase-conjugated secondary 
anti-rabbit IgG antibody (GE Healthcare) at RT for 1 hour (at 1 in 2000 dilution). This 
was followed by washing as before. Enhanced chemiluminescence (ECL) was employed 
to visualize the antibodies, via the ECL Plus Western Blotting Detection Reagent 
(Amersham Biosciences) and Hyperfilm ECL (Amersham Biosciences), following  
manufacturers guidelines. 
2.2.4.4.4 Stripping and re-probing of a Western Blot
Western blots can be stripped of signal and antibodies, and re-probed with a 
different antibody. The blot was submerged in stripping buffer (section 2.1.1.2) for 1 
hour with gently agitation. The blot was then washed x6 10mins in PBS. The re-probing 
followed the standard western protocol, starting with the blocking step.
2.2.4.4 Immunofluorescence 
Human SH-SY5Y cells plated glass coverslips were washed x3 in PBS and fixed 
in 4% paraformaldehyde (PFA) for 15mins at RT. The cells were washed as before, and 
permeabilised by incubation in 0.1% Triton/PBS for 10mins, RT. The cells were washed 
as before, and blocked for a minimum of 1hr with 2% BSA in PBS. For detection of 
NRSF, the truncated isoform, USF1 or USF2, the corresponding primary antibody was 
diluted 1 in 100m in 2% BSA in PBS, added to the coverslip, and incubated overnight at 
4oC. Cells were washed as before, and then incubated with Alexa Fluor 568 anti-rabbit 
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secondary antibody (Invitrogen), diluted at 1:200 in 2% BSA in PBS, for 1hr, RT . As a 
negative control, cells were stained with secondary antibody alone. Cells were washed 
in PBS as before, and coverslips were mounted onto slides in DAPI containing Vecta-
Shield (Vector Laboratories), and sealed with nail varnish. Staining of the proteins was 
viewed using two photon confocal zeiss LSM S10 microscopy and excitation at 
wavelength 568 (Alexa 568) and infra red (DAPI). 
Antibody Clonality Host Species Immunogen Source
anti-NRSF Polyclonal Rabbit CYFLEEAAEEQE
Gift from Prof.
N. Buckley
anti-REST4 Polyclonal Rabbit SGCDLAG
Gift from Prof.
N. Buckley
anti-USF1 Polyclonal Rabbit
Against C-terminus of 
human USF1
Santa Cruz 
Biotechnology
anti-USF2 Polyclonal Rabbit
Against N-terminus of 
mouse USF2
Santa Cruz 
Biotechnology
IgG Control Polyclonal mouse Against mouse IgG Active Motif
Table 2.3. Antibodies used for western blotting , immunofluorescence and ChIP. Antibodies 
used for exclusively in ChIP are highlighted with orange shading.
2.2.5 Chromatin Immunoprecipitation (ChIP)
2.2.5.1 Cell Fixation and Chromatin Isolation
Human SH-SY5Y cells or SK-N-AS cells were grown to 70-80% confluency in 
T175 culture flasks prior to treatment or harvest. When ready for harvest, cells were 
washed twice with 10x PBS, and DNA-protein interactions were cross-linked (fixed) 
with Fixation solution (See section 2.1), and incubated for 10mins at RT on a rocking 
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platform. Following fixation, the cells were briefly washed with chilled 10x PBS, before 
the cross-linked interactions were quenched, with the addition of 10mls Glycine Stop-
Fix solution (See section 2.1) and incubated on a rocking platform for 5mins. Cells were 
washed as before, and then scraped away from the culture plate, under 2mls cell-
scraping solution (See section 2.1), using a cell scraper. Cells were then transferred to 
15ml conical tubes and centrifuged for 10mins at 2,500 rpm at 4 °C, to pellet the cells. 
After discarding the supernatant, the cell pellet was re-suspended in 1ml ice-cold Lysis 
Buffer supplemented with 5µl PICt and 5µl PMSF (ensuring the DNA-protein 
interactions were preserved during chromatin purification and immunoprecipitation (IP))  
(Active Motif) and incubated for 30mins on ice. To disrupt the cells and release the 
nuclei, the cells were passed through a needle/syringe ~5-10 times. The resulting 
solution was transferred to a 1.5ml eppendorf tube and centrifuged for 10mins at 5,000 
rpm, at 4 °C to pellet the nuclei. The supernatant was carefully removed and discarded. 
The nuclei pellet was then resuspended in 1ml Shearing Buffer supplement with 5µl 
PICt (both Active Motif) and distributed equally into three 1.5ml eppendorf tubes.
2.2.5.2 Chromatin Sonication Shearing
Chromatin was sheared by sonication; specifically 20x 30seconds pulses at 50% 
power using a Microson sonicator (Misonix), with each of the triplicate 1.5ml 
eppendorfs maintained on ice, to prevent over-heating.  After each pulse, the sheared 
chromatin samples were allowed to cool on ice for 1min before being centrifuged at
15,000 rpm at 4 °C for 1min. After the required number of pulses (20), the sheared 
chromatin was centrifuged at 15,000 rpm at 4°C for 12mins. The resulting supernatants 
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from each 1.5nl eppendorf, containing the sheared chromatin, was pooled into a fresh 
tube and stored at -80oC.
2.2.5.3 Estimate shearing efficiency and Chromatin concentration
In order to determine the shearing efficiency of the sonication procedure, 50µl of 
sheared chromatin sample was transferred to a fresh 1.5ml eppendorf tube. To this, 
150µl dH2O, 8µl 5M NaCl and 1µl RNase was added to reverse cross-links and the 
sample mix was vortexed and incubated at 65oC for 4hrs. Following incubation, the 
tubes were briefly centrifuged and allowed to return to RT. 10µl of Proteinase K (Active 
Motif) was added and the mixture was incubated at 42oC for 1.5 hours. To Determine 
the DNA concentration, the DNA was phenol/chloroform extracted and precipitated by 
adding 200µl phenol/chloroform to the sample, vortexed and centrifuged for 5mins at 
13,000rpm. The DNA containing aqueous top layer was then transferred to a fresh 1.5ml 
eppendorf tube containing 20µl 3M Sodium Acetate (pH 5.2) and 500µl 100% ethanol. 
The sample was vortexed to mix completely and placed at -20oC for at least 1 hour. 
Following incubation, the sample was centrifuged at 13,000rpm for 10mins at 4°C. The 
supernatant was discarded carefully so not to disturb the pellet. The pellet was then 
washed with 500µl 70% ethanol, and re-centrifuged at 13,000rpm for 5mins at 4°C. 
After discarding the supernatant, the pellet was allowed to air-dry for 5-10mins at RT, 
and then the pellet was re-suspended in 50µl dH2O. The DNA concentration was 
determined as described in section 2.2.1.12. The shearing efficiency of the sonication 
was determined by running 10µl DNA sample out via agarose gel electrophoresis, with 
a smear ranging between 500bp and 1000bp considered ideal.
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2.2.5.4 Capture Chromatin on Magnetic Beads
To capture the chromatin on magnetic beads, 6.3μg of sheared chromatin was 
added to 25l protein G magnetic beads (Active Motif), 10μl ChIP Buffer 1 (Active 
Motif), 1μl PICt (Active Motif), 3μg of antibody (Table 2.3) and dH2O to a final volume 
of 100μl, in a 1.7ml siliconised microcentrifuge tube, per IP. These tubes the samples 
were incubated at 4°C overnight on a rotating wheel. 
2.2.5.5 Elute Chromatin, Reverse Cross-links and Treat with Proteinase K
Following the overnight IP, the samples were briefly centrifuged to collect any 
liquid remaining in the tubes cap. The samples were then transferred to a clean 1.7ml 
siliconised microcentrifuge tube to reduce background contamination. The beads were 
washed 3x with 800µl ChIP Buffer 1 (Active Motif), followed by 3x washes with 800µl 
ChIP Buffer 2 (Active Motif). Between each wash, the beads were pelleted using 
magnetic pull down and pulse spins, and the supernatant discarded, before the beads 
were re-supsended in the appropriate ChIP buffer. Following washing, the beads were 
re-suspended with 50µl Elution Buffer AM2 (Active Motif) and incubated for 15mins at 
RT on a rotator wheel, in order to elute the DNA-protein-antibody mix from the beads. 
To then reverse protein-DNA cross links, each sample was briefly spun and 50µl of the 
Reverse Cross Link Buffer (Active Motif) was added. The tubes were immediately 
placed in magnetic stand to allow beads to pellet to sides of tubes. The resulting 
chromatin containing supernatant was then transferred to fresh tube.
For ‘INPUT DNA’ 10µl of sheared chromatin was thawed and mixed with 88µl 
ChIP buffer 2 (Active Motif) and 2µl 5M NaCl. All samples (INPUT and 
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immunoprecipitated chromatin) were incubated at 65oC for 2.5 hours. The tubes were 
then allowed to return to RT before 2µl of Proteinase K (Active Motif) was added, and 
then incubated for 1 hour at 37oC.  Samples were again left to return to RT before 2µl 
Proteinase K Stop Solution (Active Motif) was added. DNA was then used for PCR 
analysis or stored at -20 °C. 
2.2.5.6 PCR screening
To screen immunoprecipitated DNA for protein binding to particular DNA 
fragments, PCR was employed as described in section 2.2.1.2. The standard PCR 
protocol using GoTaq polymerase was utilised. Changes to the standard PCR protocol 
include the use of 10µl immunoprecipitated chromatin sample or 1µl INPUT DNA, per 
PCR reaction. In general, cycle conditions were as follows: initial denaturation: 95oC for 
2mins for 1 cycle; followed by 36 cycles of denaturation: 95oC for 30 seconds, 
annealing 60-62oC for 30 seconds and elongation: 72oC for 1min; and a final elongation 
step of 72OC for 2mins.
Gene Forward (5’ – ‘3) Reverse (5’ – 3’) Spanning
NKB CTCTAAGCCCCAGCAGTGTCA CATCCAGCATTCTCCCACTT -247 to +181
PPTA GCTGGGATAAATACCGCAAG CCAACCCACACCTTCAAACCA -13 to +313
BDNF GAGATTTTTAAGCCTTTTCCTC CTTGCCAAGAGTCTATTCC +22 to +345
Scg10 GCATCCTATCAGTCAGCAA GGTATGAAACCCTGGCAAGT -1667 to -1406
L1CAM GCCCCTCTTTATCTTCTACCTCC CTGTCCCTGGTGCTGAAATC +232 to +439
CART CAGCAACGACGAGTTTCAGA CACGGCAGAGTAGATGTCCA +104 to +259
Table 2.4. PCR primers used in ChIP, to amplify region containing known or putative NRSEs. All 
primers are against human genomic DNA.
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2.2.6 Statistics
Results are presented as averages ± standard error of the mean (standard 
deviation/ Square route of n number) where appropriate. Comparisons were made as 
appropriate, such as treated Vs control, using the unpaired one-tailed t-test in Microsoft 
Excel. Significant differences are indicated using: * = p<0.05; ** = p<0.01 and *** = 
p<0.001. 
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CHAPTER 3: Regulation of Human NKB (TAC3) gene and its 
promoter by the transcription factors NRSF and USF
3.1 Introduction
NKB is a member of the tachykinin family and is encoded by the TAC3 gene in 
humans. NKB, similar to the TAC1 encoded SP, is pro-convulsant in rodent epilepsy 
models, with elevated NKB immunoreactivity and mRNA levels observed in the rat 
hippocampus following KA administration (Sperk et al., 1990; Marksteiner et al., 1992; 
Wasterlain et al., 2002; Chen et al., 2008). Furthermore, NKB peptide agonist 
administration has been shown to exacerbate KA induced neuronal death in mice (Chen 
et al., 2008). In addition to its role in seizure, aberrations of the NKB pathway have 
been implicated in a number of other defects, including pre-eclampsia (Page et al., 
2006) and in lung pathophysiology (Pinto et al., 2004). Consequently, a greater 
understanding of NKB regulation would be of importance to a number of fields. 
Candidate transcriptional regulators include the TFs NRSF and its truncated 
isoform sNRSF. Both the rodent NRSF and its truncated isoform (rREST4) are found to 
be dynamically regulated during models of SSSE (Palm et al., 1998), and are both up-
regulated following KA stimulation in rodent hippocampal cultures (Spencer et al., 
2006), thus matching the observed increase in NKB mRNA following similar treatments 
(Sperk et al., 1990; Marksteiner et al., 1992; Wasterlain et al., 2002). These zinc finger 
protein isoforms bind to a 21bp consensus sequence termed the NRSE (Schoenherr & 
Anderson,1995; Chong et al., 1995). Through binding to target NRSEs, NRSF isoforms 
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can control temporal and spatial plasticity of neuronal genes in a number of pathways, 
such as neurogenesis (Ballas et al., 2005; Arora et al., 2007). Our group has previously 
shown that NRSF isoforms regulate the pro-convulsant tachykinin gene TAC1 (Quinn et 
al., 2002; Spencer et al., 2006), and I propose that NRSF may play a similar regulatory 
role for NKB. In support of this, the rodent NKB encoding gene (TAC2) was recently 
proposed to be a potential NRSF target based on the presence of a putative NRSE. This 
NRSE was however identified over 20Kb upstream from the gene (Otto et al., 2007). I
have identified an alternative putative NRSE much closer to the TSS, spanning +50 to 
+71 of the human NKB gene (TAC3) promoter, based on the consensus sequence 
(T(C/T)AG(A/C)(A/G)CCNN(A/G)G(A/C)(G/C)AG) (Wu & Xie., 2006; Bruce et al., 
2006). Thus I set out to investigate the potential regulatory role of NRSF isoforms on 
NKB promoter activity and expression.
In addition to the putative NRSE identified in this study, I have also identified a 
single bHLH binding motif (the E box) in the human NKB proximal promoter region, 
spanning +160 to +166, based on the canonical sequence CANNTG (Sirito et al., 1992). 
This therefore suggests a potential role for bHLH factors in NKB regulation. One such 
member of the bHLH family of TFs is USF. USF proteins are ubiquitously expressed 
throughout the body, with particularly high levels of expression found within the brain 
(Sirito et al., 1994). USF proteins have been shown to regulate a number neuronal genes 
such as GABA receptors (Steiger et al., 2004), BDNF (Tabuchi et al., 2002) and KCC2 
(Markkanen et al., 2008), and our group has previously shown that USF modulates rat 
TAC1 promoter activity in PC12 cells (Paterson et al, 1995) and in cultured DRG 
neurons (Gerrard et al, 2005). Interestingly, USF has been shown to regulate a number 
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of genes targeted by NRSF, including BDNF (Chen et al, 2005, Tabbuchi et al, 2002) 
and the AVP promoter (Coulson et al, 1999; Quinn et al, 2002; Coulson et al., 2003). 
Subsequently, I postulate that USF may also play a regulatory role for NKB expression, 
and set out to explore such a mechanism in this chapter. 
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3.2 Aims
 Test the activity of the human NKB proximal promoter region in cultured human 
neuroblastoma cells. 
 To explore if the NRSF isoforms and the USF proteins regulate the NKB 
promoter and endogenous NKB gene expression
 To test if this can be modulated using clinically prescribed ACDs.
 To explore potential binding of NRSF and USF to the NKB proximal promoter 
region via ChIP.
 To explore changes in NKB gene expression following ACD treatment. 
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3.3 Methods
3.3.1 PCR amplification of NKB promoter and generation of pNKB reporter gene 
constructs.
The NKB proximal promoter regions spanning -757 to +181 (pNKB-757) and -
289 to +181 (pNKB-289) were amplified by PCR as described in methods section 
2.2.1.2, using the primers given in Table 2.2.2 and PCR reaction conditions given in 
Section 2.2.1.6. The amplified NKB promoter regions were cloned into the upstream of 
the Firefly luciferase reporter gene in the promoter-less pGL3basic (pGL3b) vector as 
described in section 2.2.1.6. The full length human NRSF expression construct 
(REEX1) used in co-transfection experiments was obtained as described in Chong et al., 
1995. A truncated expression construct containing 2kb of the human NRSF sequence, 
analogous to sNRSF (HZ4), was a kind gift from Dr D.J.Anderson. Constructs 
expressing full length USF1 (pN3) and USF2 (pN4), were a kind gift from 
Dr.M.Sawadogo. For full descriptions of reporter gene constructs and expression 
constructs used in transient transfection experiments please see Table 2.1.
3.3.2 Cell culture, treatment, transfections and luciferase assays
Human SK-N-AS cells and SH-SY5Y cells were cultured as outlined in methods 
section 2.2.2.1.1 and 2.2.2.1.2, respectively, treated as described in section 2.2.2.2 and 
transfected as described in methods section 2.2.4.2. Cells were then harvested and 
assayed using the Dual Luciferase Reporter Assay System as outlined in methods 
section 2.2.6
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3.3.3 mRNA expression analysis
The expression of NKB, together with the TFs NRSF, sNRSF, USF1 and USF2, 
and the house keeping gene Pol-II, was investigated using RT-PCR as described in 
methods section 2.2.3.4, using the PCR primers set out in Table 2.2.1. Thermal cycle 
conditions for all expect NKB, were as follows: initial denaturation: 95oC for 2mins for 
1 cycle; followed by 40 cycles of denaturation: 95oC for 30 seconds, annealing 62oC for 
30 seconds and elongation: 72oC for 1min; and a final elongation step of 72oC for 
2mins. For NKB the annealing temperature was adjusted to 64oC, with all other 
conditions remaining the same. 
3.3.4 Transcription factor binding study
To investigate potential TF binding interactions with the NKB proximal 
promoter region encompassing the putative NRSE and +160 E Box (see Fig 3.1), ChIP 
was employed as outlined in method section 2.2.5, using the antibodies given in Table
2.3 and the PCR primers given in Table 2.4.
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3.4 Results
3.4.1 Identification of a putative NRSE and E box site within the NKB proximal 
promoter
I have identified a putative NRSE spanning +50 to +71 of the human NKB 
(TAC3) gene (Figure 3.1a), based on the consensus sequence 
(T(C/T)AG(A/C)(A/G)CCNN(A/G)G(A/C)(G/C)AG) (Wu & Xie., 2006), incorporating 
the core sequence CAGCACC (Bruce et al., 2006). A sequence comparison between 
this putative NKB NRSE and that of three other well characterised NRSEs in the NRSF 
target genes SCN2a, SCG10 and Synapsin, revealed a high degree of homology (Figure 
3.1b). Furthermore, the putative NKB NRSE sequence exhibits high homology with the 
characterised NRSEs of the neuropeptides TAC1 (rat) and AVP (human) (Coulson et 
al., 1999; Quinn et al., 2002), especially in the 5’ of the consensus (Figure 3.1c).
In addition, I have identified a putative E Box motif spanning +160 to +166 
(Figure 3.1a), based on the canonical sequence (CANNTG) (Sirito et al., 1992), which 
USF1 and USF2 are known to bind to with high affinity (Rada-Iglesias et al, 2008).
3.4.2 Expression of NKB in neuroblastoma cell lines SK-N-AS and SH-SY5Y
RT-PCR revealed that the human neuroblastoma cell line SK-N-AS expressed 
NKB, together with the TFs NRSF, USF1 and USF2 (Figure 3.2a), but not the truncated 
sNRSF isoform. This cell line was chosen to investigate the activity of the NKB 
proximal promoter, via luciferase reporter gene assays, and to explore modulation of 
endogenous NKB expression. At a later date, RT-PCR revealed the presence of NKB in 
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another human neuroblastoma cell line, SH-SY5Y, together with NRSF, sNRSF, USF1 
and USF2 (Figure 3.2b). This second cell line was used in the ChIP assays. 
3.4.3 NKB proximal promoter supports luciferase reporter gene activity
The neuroblastoma cell line SK-N-AS was used to test the ability of the NKB 
proximal promoter to support reporter gene expression, due to the endogenous 
expression of NKB (Figure 3.2a). I cloned two fragments containing the NKB proximal 
promoter, spanning either -757 to +181 (pNKB-757) or -289 to +181 (pNKB-289) 
(highlighted in Figure 3.1a), into a promoter-less luciferase reported gene plasmid, 
pGL3 basic (pGL3b). Both NKB proximal promoter fragments drove significantly 
elevated levels of luciferase activity compared to the pGL3 basic backbone, with pNKB-
757 supporting a 20x fold increase (P = < 0.001) and pNKB-289 driving a 35x fold 
increase in luciferase activity (P = < 0.001) (n=9) (Figure 3.3).  Interestingly, the 
shorter NKB construct (pNKB-289) drove significantly more luciferase activity 
compared to the longer construct (pNKB-757), suggesting the presence of a repressor 
element within the fragment spanning -757 to -289 (P = < 0.001) (n=9) (Figure 3.3).  
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Figure 3.1. (A) The human NKB proximal promoter region spanning -757 to + 181, which was cloned 
into the pNKB-757 reporter gene construct. Highlighted in grey is the region spanning -289 to +181, 
cloned into the pNKB-289 reporter gene construct. The putative NRSE spanning +50 to +71 is 
highlighted in yellow, and the putative E Box spanning +160 to +166 is highlighted in green. (B)
Sequence comparison of the putative NKB NRSE against known NRSEs within the genes SCN2a, SCG10 
and Synapsin. (C) Comparison of putative NKB NRSE with NRSEs within t neuropeptide genes TAC1 
and AVP. 
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Figure 3.2. Expression profile of the human cell lines SK-N-AS and SH-SY5Y. (A) RT-PCR was 
employed to detect the presence of NRSF, NKB, USF1 and USF2 in human SK-N-AS cells. (B) The 
human SH-SY5Y also expressed NRSF, NKB, USF1 and USF2, as well as the truncated sNFSF isoform. 
Figure 3.3. Luciferase reporter gene activity driven by the NKB proximal promoter. Both the 
shorter (-289 to +181) (pNKB-289) and the long (-757 to +181) (pNKB-757) NKB proximal promoters 
drove high levels of luciferase reporter gene activity when compared to the promoter-less backbone vector 
pGL3b. pNKB-289 was found to enhance activity to an even greater extent than pNKB-757. Human SK-
N-AS cells were transfected with either pNKB-289 or pNKB-757 reporter gene constructs or pGL3b 
promoter-less backbone vector. Luciferase activity was measured and mean fold changes compared to 
pGL3b are given. Statistics were performed using T-test, with *** = P < 0.001 (compared to pGL3b) & 
+++ = P < 0.001  (pNKB-289 Vs. pNKB-757). S.E. are given as Y-axis error bars (n=3, performed in 
triplicate).
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3.4.4 NRSF isoforms activate the NKB promoter and induces its expression
The presence of a putative NRSE within the NKB promoter suggested a role for 
the TF NRSF in the regulation of the human NKB gene. To address this, I co-transfected 
human neuroblastoma SK-N-AS cells, with the NKB reporter gene constructs, in 
combination with plasmids over-expressing either full-length NRSF (REEX1) or a 
truncated version analogous to the truncated NRSF isoform, sNRSF (HZ4). The HZ4 
construct has been used by many groups including our own, to mimic the properties of 
sNRSF (Roopra et al., 2000; Garriga-Canut et al., 2006; Spencer et al., 2006). 
Luciferase activity was measured and over-expression of both REEX1 and HZ4, 
resulted in a significant increase in the activity of both the long pNKB-757 and the short 
pNKB-289 reporter gene constructs, compared to controls (reporter gene constructs 
alone) (P = < 0.001) (n=9) (Figure 3.4). The over-expression of both NRSF isoforms 
resulted in a 3x fold increase in the luciferase activity of the short pNKB-289 construct, 
compared to pNKB-289 alone control (P = < 0.001) (n=9) (Figure 3.4). Furthermore, 
the over-expression of REEX1 led to a 3.5x fold increase in reporter gene activity of the 
long pNKB-757 construct, compared to pNKB-757 alone control, which interestingly 
was found to be statistically higher than the 2x fold increase induced by the over-
expression of HZ4 (P = < 0.001) (n=9) (Figure 3.4).
To address whether the observed modulation of NKB promoter activity, was 
manifested in changes in endogenous NKB gene expression, I over-expressed the 
REEX1 and HZ4 expression constructs for 24hrs or 48hrs and measured expression of 
the NKB gene by RT-PCR. The over-expression of both NRSF isoforms induced an 
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increase in the expression of NKB mRNA, which was found to be significant at 48hrs 
for REEX1 (Figure 3.5a) and 24hrs for HZ4 (Figure 3.5b) (P = < 0.05) (n=3).
Figure 3.4. Regulation of human NKB promoter by NRSF isoforms in SK-N-AS cells. Over-expression 
of NRSF (REEX1) and the truncated variant (HZ4) significantly enhances the activity of both pNKB-757 
and pNKB-289 reporter gene constructs.  Human SK-N-AS cells were transfected with either the short 
pNKB-289+181 reporter gene construct or the long pNKB-757+181 reporter gene construct, together with 
either the full length NRSF (REEX1), a truncated version analogous to sNRSF (HZ4) or no expression 
construct (control). Luciferase activity was measured and mean fold changes compared to controls are 
given. Statistics were performed using Students T-test, with *** = P = < 0.001 (compared to control) and 
^^^ = P = <0.001 (comparing pNKB-289 vs. pNKB-757). S.E. are given as Y-axis error bars (n=3, 
performed in triplicate).
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Figure 3.5. Over expression of NRSF (REEX1) and the truncated varient (HZ4) enhances NKB mRNA 
expression. (A) The over-expression of full length NRSF (via the REEX1 expression construct) and (B) a 
truncated variant (via the HZ4 expression construct) led to the significant increase in NKB mRNA levels, 
following 48hrs (REEX1) and 24hrs (HZ4) over-expression. Changes in endogenous NKB mRNA levels 
following 0hrs (control), 24hrs and 48hrs REEX1 or HZ4 over-expression, where measured via RT-PCR, 
with band intensities normalized against Pol II, * = P = < 0.05. (n=3). 
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3.4.5 USF1 and USF2 repress the NKB promoter 
The presence of a putative E Box motif spanning +160 to +166 within the human 
NKB promoter suggested a possible role for the TFs USF1 and USF2 in the regulation 
of the NKB gene. To address this, I co-transfected human neuroblastoma SK-N-AS 
cells, with the NKB reporter gene constructs, in combination with plasmids over-
expressing either full-length USF1 (pN3) or full-length USF2 (pN3). Luciferase activity 
was measured and the over-expression of both USF1 and USF2 resulted in the 
significant repression of both the long (pNKB-757) and short (pNKB-289), compared to 
controls (P = < 0.001) (n=9) (Figure 3.6). The over-expression of USF1 resulted in an 
almost identical 40% reduction in luciferase activity driven by both the long and short 
NKB constructs. USF2 over-expression resulted in a similar 40% reduction in luciferase 
activity driven by the longer (pNKB-757) construct, whilst eliciting even greater 
repression of the short pNKB-289 construct, with a 60% reduction in luciferase activity 
compared to control (no expression construct) alone (P = 0.001) (n=9) (Figure 3.6).
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Figure 3.6. Regulation of human NKB promoter by USF proteins in SK-N-AS cells. Over-expression of 
both USF1 and USF2 significantly represses the activity of both pNKB-757 and pNKB-289 reporter gene 
constructs.  Human SK-N-AS cells were transfected with either the short pNKB-289+181 reporter gene 
construct or the long pNKB-757+181 reporter gene construct, together with either USF1 (pN3), USF2 
(pN4) or no expression construct (control). Luciferase activity was measured and mean fold changes 
compared to controls are given. Statistics were performed using Students T-test, with *** = P = < 0.001
(compared to control) and ^^^ = P = <0.001 (comparing pNKB-289 vs. pNKB-757). S.E. are given as Y-
axis error bars (n=3, performed in triplicate ).
3.4.6 Transcription factor binding to the NKB promoter revealed by ChIP 
To determine if the NRSF isoforms regulate NKB expression directly via 
binding to the NKB proximal promoter, I analysed binding of both NRSF and the 
truncated isoform sNRSF to the region encompassing the NKB promoter. Furthermore, 
as USF1 and USF2 repressed NKB promoter activity, I also analysed binding of both 
USFs to the same region. I used PCR to identify the region spanning -247 to +181 
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(which encompassed both the putative NRSE and the E Box motif) in the material 
enriched by the chromatin ChIP.    
In the human SK-N-AS cell line, there was no strong evidence for sNRSF 
binding to the NKB promoter, as indicated by comparison with the non-specific 
background (negative) control; IgG band (Figure 3.7a). This was as expected due to the 
absence of sNRSF in the SK-N-AS cell line, as determined by RT-PCR (Figure 3.2a). In 
contrast, the full-length isoform did appear to exhibit weak binding to the NKB 
promoter, when compared against the IgG negative control. In order to investigate 
sNRSF binding to the NKB promoter and to confirm the weak NRSF binding, I utilised 
a second human neuroblastoma cell line, SH-SY5Y, which expressed both NRSF and 
sNRSF isoforms, as well as NKB (Figure 3.2b). In human SH-SY5Y cells, both NRSF 
and sNRSF exhibited strong binding to the NKB promoter, when compared against the 
non-specific background control; IgG (Figure 3.7b).  Binding of NRSF and sNRSF to 
the NKB promoter was found to be specific, as neither NRSF nor sNRSF IPs gave rise 
to an amplification of the control GAPDH PCR product.
In addition, USF binding to the NKB promoter region was also observed in both 
SK-N-AS and SH-SY5Y cell lines. Interestingly, in the SK-N-AS cell line, USF1 was 
found to bind to the NKB promoter (based on stronger PCR band intensities compared 
to the IgG negative control), but USF2 was absent (Figure 3.7a). In direct contrast, 
USF2 was found to bind the NKB promoter in SH-SY5Y cells, but USF1 was absent 
(Figure 3.7b). 
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Figure 3.7. NRSF isoform and USF binding to the NKB proximal promoter. (A) ChIP analysis 
revealed that only USF1 exhibited strong binding to the NKB promoter in untreated human SK-N-AS 
cells, compared to IgG negative control. NRSF displays weak, if any binding to the NKB promoter, with 
no sNRSF or USF2 bindng obsereved. (B) In contrast, both NRSF and sNRSF were found to bind to the 
NKB promoter in untreated human SH-SY5Y cells compared to IgG negative control, as was USF2, but 
no USF1 binding was observed. Binding is shown to be specific to the NKB proximal promoter, as no 
binding is observed in the GAPDH PCR negative controls (n=1). 
3.4.7 The anticonvulsant CBZ impairs both NRSF isoform and USF regulation of 
the NKB promoter and represses NKB expression 
The data presented here indicates that both NRSF isoforms and the USF TFs are 
capable of regulating the pro-convulsant neuropeptide NKB promoter. I wished to 
explore whether ACD treatment could modulate NRSF and USF-mediated regulation of 
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NKB, as a potential novel mechanism of action for ACDs. Treatment of human SK-N-
AS cells with 50µg/ml CBZ, for 24hrs following transfection, resulted in no significant 
change in luciferase reporter gene activity, driven by neither the long (pNKB-757) nor 
the short (pNKB-289) NKB promoter (Figure 3.8). 24hrs 50µg/ml CBZ did however 
cause a marked impairment of both NRSF isoform and USF regulation of the NKB 
reporter gene constructs. The observed activation of both the long (pNKB-757) and 
short (pNKB-289) NKB reporter gene constructs following over-expression of either 
NRSF (REEX1) or the truncated construct (HZ4), was significantly reduced following 
24hrs 50µg/ml CBZ (P = < 0.001) (n=9) (Figure 3.8a and Figure 3.8b, respectively). 
The observed CBZ induced impairment, was greatest for the shorter pNKB-289 
construct, with CBZ inducing a 3x fold reduction in luciferase activity following either 
REEX1 or HZ4 over-expression, returning levels close to untreated control levels  (P = 
< 0.001) (n=9) (Figure 3.8b).
Treatment of SK-N-AS cells with CBZ also resulted in a significant impairment 
of USF regulation of the NKB reporter gene constructs. The observed repression of 
luciferase activity following both USF1 and USF2 over-expression was found to be 
abolished following 24hrs 50µg/ml CBZ treatment. USF1 and USF2 repression of the 
long pNKB-757 reporter gene construct was significantly modulated by CBZ treatment, 
with luciferase activity returning back to untreated control levels for USF2 and greater 
still, leading to enhanced luciferase activity with regards to USF1 (Figure 3.9a) (P = 
<0.001) (n=3). The luciferase activity driven by the shorter pNKB-289 construct was 
also returned to untreated control levels, following CBZ treatment (Figure 3.9b) (P = 
<0.001) (n=3).
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Figure 3.8. Effect of anticonvulsant drug treatment on the regulation of NKB promoter by NRSF 
isoforms. Anticonvulsant drug treatment of human SK-N-AS neuroblastoma cells resulted in a significant 
decrease in response of both the (A) pNKB-757 and (B) pNKB-289 reporter gene construct to the over-
expression of both full length NRSF (REEX1) and truncated isoform sNRSF (HZ4). Human SK-N-AS 
cells were transfected with either the pNKB-757 or the pNKB-289 reporter gene construct alone (control) 
or co-transfected with either the full length NRSF (REEX1) or the truncated isoform sNRSF(HZ4) 
expression constructs. Cells were either treated with vehicle alone (black bars) or treated with 50µg/ml 
CBZ for 24hrs following transfection (white bars). Luciferase activity was measured and mean fold 
changes compared to controls are given. Statistics were performed using Students T-test comparing
treated vs. untreated, with *** = P = < 0.001. S.E. are given as Y-axis error bars (n=3, performed in 
triplicate). 
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Figure 3.9. Effect of anticonvulsant drug treatment on the regulation of NKB promoter by USF. 
Anticonvulsant drug treatment of human SK-N-AS neuroblastoma cells resulted in a significant increase 
in response of both the (A) pNKB-757 and (B) pNKB-289 reporter gene construct to the over-expression 
of both USF1 and USF2. Human SK-N-AS cells were transfected with either the pNKB-757 or the 
pNKB-289 reporter gene construct alone (control) or co-transfected with either USF1 (pN3) or USF2 
(pN4) expression constructs. Cells were either treated with vehicle alone (black bars) or treated with 
50µg/ml CBZ for 24hrs following transfection (white bars). Luciferase activity was measured and mean 
fold changes compared to controls are given. Statistics were performed using Students T-test comparing 
treated vs. untreated, with *** = P = < 0.001. S.E. are given as Y-axis error bars (n=3, performed in 
triplicate).
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To determine the impact of CBZ induced impairment of NRSF and USF 
regulation of the NKB promoter, on NKB expression, RT-PCR was employed. 
Expression of the endogenous NKB gene was also found to be significantly repressed 
following 24hrs 10µg/ml CBZ treatment when compared to the housekeeping gene 
RNA polymerase II, (P = < 0.05) (n=3) (Figure 3.10), but not by 24hrs 50µg/ml CBZ. 
This data suggests that the anticonvulsant CBZ may function by repressing NKB 
expression, perhaps though the inhibition of NRSF and sNRSF regulation of the NKB 
promoter, indicating a novel mechanism of action for this anticonvulsant drug. 
Figure 3.10. CBZ treatment modulates NKB mRNA expression. SK-N-AS cells were treated with 
10µg/ml, 50µg/ml or vehicle alone (control) for 24hrs, and immediately processed for RNA extraction. 
Changes in endogenous NKB mRNA levels were measure via RT-PCR, with band intensities normalised 
against RNA polymerase II (Pol II), with averages given. Statistics were performed using Students T-test, 
with * = P = < 0.05. S.E. are given as Y-axis error bars (n=3).
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3.5 Discussion
NKB, like the related tachykinin SP, has been shown to be pro-convulsant in 
rodent epilepsy models, with elevated NKB immunoreactivity and mRNA levels 
observed in the rodent hippocampus following KA treatment (Sperk et al., 1990; 
Marksteiner et al., 1992; Wasterlain et al., 2002; Chen et al., 2007). We, and others, 
have shown that NRSF isoforms are one of the initial targets increased in rodent models 
of SSSE (Palm et al., 1998; Spencer et al., 2006), and our identification of a putative 
NRSE within the NKB proximal promoter suggested a potential regulatory role of 
NRSF isoforms in governing NKB expression. 
The data presented in this chapter indicates that NRSF isoforms are indeed 
capable of modulating NKB expression, with over-expression of both full length NRSF 
(through the REEX1 expression construct), and a truncated version (through the HZ4 
construct), resulting in the elevation of NKB mRNA in human neuroblastoma cells 
(Figure 3.5). Furthermore, NRSF isoforms positively regulated the NKB promoter, with 
both REEX1 and HZ4 over-expression resulting in significantly elevated luciferase 
activity of reporter gene constructs driven by both the long (pNKB-757) and short 
(pNKB-289) NKB promoter (Figure 3.4). Preliminary ChIP assays indicated that NRSF 
isoforms could bind to the region spanning the NKB promoter, most prominently 
observed in the human SH-SY5Y neuroblastoma cell line (Figure 3.7), which suggests 
that NRSF regulation of NKB may be through a direct mechanism. However, it should 
be stated that I have yet to prove that the NRSF isoforms act via, or binds directly to, the 
putative NRSE, merely that NRSF isoforms bind to the region encompassing that 
NRSE. To this aim, a cloning strategy was undertaken to remove the putative NRSE 
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from the NKB reporter gene constructs, and the resulting mutant construct would have 
been subjected to similar NRSF over-expression studies, as described in this chapter. 
Unfortunately, unavoidable cloning issues have delayed the generation of this mutant 
NKB construct, preventing this experiment being undertaken in time for this thesis, 
however work is continuing at present to generate these mutant constructs for future 
study.
A second set of TFs, the USF family, were also thought to be potential regulators 
of NKB expression, based on the identification of a putative E box motif (CANNTG), 
spanning +160 to +166 of the NKB promoter. In addition, USF proteins have been 
shown to be important in regulating a number of epilepsy associated genes including 
GABA receptors (Steiger et al., 2004) and BDNF (Tabuchi et al., 2002), and our group 
has shown that USFs are key regulators of the related SP encoding gene, TAC1. Thus I 
set out to explore a potential role of USF1 and USF2 in NKB regulation. 
Both USF1 and USF2 were found to repress or silence luciferase activity driven 
by both the long (pNKB-757) and short (pNKB-289) NKB reporter gene constructs, 
(Figure 3.6) suggesting a role for USF proteins in NKB promoter regulation. In support 
of this, as with the NRSF isoforms, preliminary ChIP assays indicated that both USF1 
and USF2 could bind to the NKB promoter region, encompassing the putative E box 
motif (Figure 3.7). This suggests that any USF regulation of NKB may function via 
direct binding to its promoter. However, as with the NRSF isoforms, I have not proved 
that neither USF1 nor USF2 binds specifically to the +160 E Box, only that they bind to 
the region encompassing that E box, and a cloning strategy to mutant the +160 E box 
within the NKB reporter gene constructs, would be required to demonstrate specific 
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binding. Furthermore, the affect of USF over-expression on NKB mRNA expression, 
has yet to be determined, and would be an important future experiment, together with 
the generation of the E box mutant, to better understand USF regulation of the human 
NKB gene. 
Interestingly, binding of USF1 and USF2 to the NKB promoter region, was 
found to be cell specific, with USF1 only, bound to the NKB promoter in SK-N-AS 
cells, and in contract, USF2 only, was found to bind to the same region in SH-SY5Y 
cells (Figure 3.7). Expression profiling indicated that USF1 and USF2 are expressed in 
both cell lines (Figure 3.2) and so differential expression of USF proteins between cell 
lines cannot explain the observed difference in binding. In general, USF1 is found to 
bind to virtually all E box sites to which USF2 is known to bind (Rada-Iglesias et al., 
2008), suggesting competition between USF1 and USF2 for binding sites may exist. It is 
therefore plausible that competition for binding at that locus between USF1 and USF2
prevents the binding of both TFs to the NKB promoter, resulting in only one bound at 
any one time. It would thus be of interest to repeat the ChIP assay at different time 
points in both cell lines, to determine whether this differential binding was solely cell 
specific, or whether temporal plasticity of USF binding at this region was taking place. 
Alternatively, it has been shown that USF1 and USF2 can bind to different proteins, and 
thus expression of these proteins may modulate USF binding to the NKB promoter 
locus, in a cell specific manner. For example, USF1 has been shown to form a complex 
with the bHLH TF Cha, with the resulting complex able to bind to E box DNA elements 
(Rodriquez et al., 2003). Therefore, it would be of interest to characterise the expression 
of such bHLH factors in both cell lines, to address the differential binding observed. 
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Finally, it is also known that many proteins target and bind to E box DNA elements, 
such as Mitf (Askan & Goding., 1998) and Myc (Fisher et al., 1993), and thus may 
compete with USF1 or USF2 for binding privileges, and thus monitoring both 
expression and binding of these TFs to the NKB promoter locus, in each cell line, would 
be of particular interest. 
The data presented in this chapter suggests an activator role for NRSF isoforms 
in NKB regulation, and a repressive regulatory role for USF proteins. Interestingly, this 
is in contrast to the classical roles of these TFs. NRSF is classically thought of as a 
repressor, after first being discovered as a repressor of neuronal genes in non-neuronal 
cells (Schoenherr & Anderson., 1995; Chong et al., 1995), and shown to repress a host 
of genes including SCN2a (Tapia-Ramirez et al., 1997), L1CAM (Kallunki et al., 1997) 
and Scg10 (Chen et al., 1998). In comparison, USF proteins are in general considered to 
act as activators, based on the recent findings showing an association between acetylated 
histone H3(H3ac) localisation and USF binding to target genes’ TSS (Rada-Iglesias et 
al., 2008). Furthermore, we and others have shown USF activates a range of genes 
including TAC1 (Quinn et al., 2002), hepatic lipase (Van Deursen et al., 2009) and 
follicle stimulating hormone (FSH) (Hermann et al., 2008). 
Despite NRSF and USF regulation of the human NKB being in contrast to the 
classical regulatory roles of these TFs, there are examples of both NRSF and USF 
performing these contradictory roles in other genes. We have previously shown that 
both NRSF isoforms activate the related tachykinin gene TAC1 in rodent hippocampus 
(Spencer et al., 2006), and this regulatory roles appears to be cell specific, with 
repression and activation of the TAC1 promoter and endogenous expression observed in 
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a tissue dependent manner (Quinn et al.,2002;Spencer et al., 2006; Greco et al., 2007; 
Howard et al., 2008; Reddy et al., 2009). The truncated isoform has also been shown to 
act as an activator of the TAC1 promoter in epilepsy (Spencer et al., 2006) and another 
neuropeptide; AVP (Coulson et al., 2000; Quinn et al., 2002). 
Interestingly, in all three neuropeptides shown to be activated by NRSF isoforms 
(TAC1, NKB and AVP), the location of the NRSEs are close to, or at the major TSS, 
whereas the majority of all other identified NRSF binding sites (Bruce et al., 2006) have 
NRSEs that are quite distant from TSS. This location may be important in governing 
NRSF regulation, with a closer proximity of the NRSE to the TSS, perhaps impairing 
NRSF recruitment of co-repressors, and thus pushing NRSF function from a repressor to 
an activator. In support of this, a study by Bessis et al, revealed that the location of the 
NRSE can confer whether the NRSE acts as an repressor or an activator. NRSEs located 
within 50bp of the TATA box of a synthetic promoter, were found to act as activator 
elements in neuronal cells, whilst those further upstream acted as repressor elements 
(Bessis et al., 1997).
The NKB putative NRSE is located +51 from the TSS and thus is close to the 
boundary indicated by Bessis et al, suggesting that the putative NKB NRSE could act as 
an activator element, which is consistent with the activator roles of NRSF isoforms 
observed here. In addition, the other genes shown to be activated by NRSF (TAC1 and 
AVP) have similar NRSE locations, with the rat TAC1 NRSE located at -21 to +4 
(Quinn et al., 2002) and the AVP NRSE -2 to +23 (Coulson et al., 1999). Thus the close 
proximity of these NRSEs to the TSS, may confer transcriptional activator roles
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Furthermore, when I compared the TAC1, AVP and NKB (putative) NRSEs 
(Figure 3.1) I found stronger conservation at the left hand side of the NRSE consensus 
sequence (nucleotides 2-10) (Appendix 5). Recently the classic 21bp canonical NRSE 
sequence has been shown to be a bipartite sequence, with a left half-site and a right half-
site. Interestingly, whilst NRSF can bind to either half-site, individually neither half-site 
is an effective repressor, with NRSF binding to both half-sites required for repression 
(Patel et al., 2007). The homology of the left hand side of the TAC1, AVP and 
(putative) NKB NRSEs, matches that of the left-half site, suggesting in all three cases 
NRSF binding occurs, but is unable to induce repression. This may indicate that a subset 
of NRSF target genes exist, which share a NRSE consensus sequence exhibiting 
stronger homology to the NRSE left-half site, and perhaps this subset is regulated 
differently to those genes with more complete NRSEs.
As highlighted earlier, USF1 and USF2 also play a regulatory role which is in 
contrast to their typically described activator roles. However, USF mediated suppression 
of gene expression has been previously documented, with USF1 and USF2 shown to 
repress the promoter activity of human telomerase reverse transcriptase (hTERT), 
through direct binding to its target E box (Chang et al., 2005). Furthermore, USF have 
been shown to recruit a host of histone modifying enzymes, including the H3K4-specific 
methyltransferase SET7/9 and the H3-specific HAT (West et al., 2004). Differential
recruitment of these histone modifying enzymes could therefore have a impact on USF 
regulatory function, and it would thus be important to clarify both the expression of 
these enzymes in our cell lines, and also determine whether or not these enzymes are 
bound to the NKB +160 E box, through ChIP assays. 
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Finally, consistent with a model in which NRSF modulated NKB expression is a 
mechanism that operates during epilepsy, the governed increase in NKB endogenous 
expression and promoter activity by the NRSF isoforms is inhibited by the action of the 
anticonvulsant CBZ. 24hrs 50μg/ml CBZ resulted in a reduction in luciferase activity 
driven by the NKB promoter following REEX1 or HZ4 over-expression (Figure 3.8). 
This concentration had limited impact on endogenous NKB mRNA expression, 
however, a lower concentration of 24hrs 10µg/ml, did lead to a significant reduction in 
NKB mRNA expression (Figure 3.10). This may in part, be due to the fact that NKB 
promoter repression induced by USF1 and USF2 over-expression is quenched following 
24hrs 50μg/ml CBZ (Figure 3.9), suggesting this concentration of CBZ not only disrupts 
NRSF activation of NKB, but also USF-mediated repression. The disruption of both 
regulatory mechanisms by 24hrs 50µg/ml CBZ may result in neither activation nor 
repression of endogenous NKB occurring, and thus no change in NKB expression. It 
would be of interest to explore the impact of 24hrs 10µg/ml CBZ on NRSF and USF-
mediated regulation of the NKB promoter, to better understand the repression of 
endogenous NKB expression following such treatment. 
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CHAPTER 4: Differential regulation of the rat TAC1 promoter by 
NRSF and sNRSF, in cooperation with USF family members
4.1 Introduction 
In the previous chapter, the regulation of the human NKB gene (TAC3) was in 
part, found to be coordinated by two distinct TF families, the NRSF isoforms and the 
USF proteins. In a number of instances, both NRSF and USF proteins have been shown 
to regulate the same gene. Examples include the regulation of AVP (in which USF
proteins have been shown to activate the AVP promoter, whilst NRSF over-expression 
silences the AVP promoter (Coulson et al., 1999; Coulson et al., 2003)), BDNF (with 
USF considered as a BDNF promoter activator (Tabuchi et al., 2002a), whilst NRSF 
represses the BDNF promoter, and the truncated isofrom activates the BDNF promoter 
(Tabuchi et al., 2002b)) and now NKB. Both TF families have been implicated in 
cartain diseases such as epilepsy (Palm et al., 1998; Sirito et al., 1998), SCLC (Coulson 
et al., 1999; Coulson et al., 2003) and breast cancer (Ismail et al., 1999; Patel et al., 
2005; Reddy et al., 2009).
In addition to NKB, AVP and BDNF, another NKB related tachykinin gene, 
TAC1, has also been shown by our own group, and others, to be regulated by both
NRSF and USF proteins. The TAC1 encoded gene SP, is implicated in a wide range of 
neurological disorders including epilepsy (Liu et al., 1999; Wasterlain et al., 2000), 
Parkinson’s disease (Barker., 1991; Chen et al., 2004), HD (Richfield et al., 2002), pain 
(Duggan et al., 1987; Duggan et al., 1988) and cognitive and psychiatric disorders 
(Kramer et al., 1998; Maubach et al., 1999).
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The NRSF binding sequence, the NRSE, has been identified in both the rat 
(Quinn et al., 2002) and the human (Greco et al.¸ 2007) TAC1 proximal promoter 
regions (near the TSS), and has been shown to regulate TAC1 promoter activity and 
expression. This regulatory role was found to be cell specific, with repression and 
activation of the TAC1 promoter and endogenous expression observed in a tissue 
dependent manner (Quinn et al.,2002;Spencer et al., 2006; Greco et al., 2007; Howard 
et al., 2008; Reddy et al., 2009). Similarly, USF has also been shown to modulate rat 
TAC1 promoter activity in PC12 cells (Paterson et al., 1995). This modulation is 
thought to occur through USF recognising and binding to a canonical E box at -60 
(CACGTG). Mutation of this E box has been shown to abolish the ability of a reporter 
gene construct spanning -865 to +92 of the rat TAC1 promoter, to support reporter gene 
expression in PC12 cells (Paterson et al., 1995). Additionally, this -60 E box has been 
shown to be important in coordinating the response of the TAC1 promoter to NGF 
stimulation (Gerrard et al., 2005).
Furthermore, both USF and NRSF are known to recruit chromatin remodelling 
enzymes, to bring about changes in chromatin structure such as histone methylation and 
acetylation. USF has been shown to recruit enzymes which can acetylate histones 
(PCAF) and methylate histone H3K4 (SET7/92) (West et al., 2004). Whereas NRSF has 
been shown to recruit a multitude of enzymes and cofactors including mSin3, HDAC1 
and HDAC2, CoREST, CtBP and G9a (reviewed in Ooi & Wood, 2007). 
Due to NRSF and USF having been shown to regulate a number of shared target 
genes (NKB, AVP, BDNF and TAC1), I was interested in exploring the possibility of an 
inherent mechanistic relationship existing between NRSF and USF in the regulation of 
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neuropeptides. I have focused on the rat TAC1 promoter based on the presence of a 
single NRSE, multiple USF binding sites, and the availability of reporter gene constructs 
with mutations in the key -60 E box site. The rat TAC1 promoter shares a good degree 
of homology with the human TAC1 promoter region, with the E box motifs located at -
60, -170 and -308 in the rat TAC1 promoter, perfectly conserved in the human
(Appendix 3). Furthermore, the characterised rat TAC1 NRSE is also well conserved in 
the human (65% homology), however this is not the same NRSE as that proposed and 
characterised by the Rameshwar group (Greco et al., 2007), and thus will be referred to 
as a putative human TAC1 NRSE. 
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4.2 Aims
 Test the activity of the rat TAC1 reporter gene construct spanning -865 to +92 
(-856 TAC), together with the mutant construct, containing a mutation at the -60 
E box (-60 TAC), in the TAC1 expressing SK-N-AS human neuroblastoma cell 
line.
 To determine the impact of NRSF isoform and USF protein over-expression on 
both reporter gene constructs.
 To explore the impact of over-expressing NRSF isoforms and USF proteins in 
combination with each other. 
 To determine TF binding to the human TAC1 promoter in human neuroblastoma 
cell lines (SK-N-AS and SH-SY5Y) using ChIP.  
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4.3 Methods
4.3.1 Cell culture, transfections and luciferase assays
Human SK-N-AS cells were employed for reporter gene assays based on the 
observed endogenous expression of TAC1 as revealed by RT-PCR (Figure 4.2). In 
addition, the sNRSF-expressing human SH-SY5Y neuroblastoma cell line was 
employed in ChIP assays to explore sNRSF binding to the human TAC1 promoter. SK-
N-AS and SH-SY5Y cells were cultured as outlined in methods section 2.2.2.1.1 and 
2.2.2.1.2, respectively, in sterile 24-well plates (reporter gene assays) or T75 flasks 
(ChIP assay). SK-N-AS cells were transfected as described in methods section 2.2.4.2, 
and harvested and assayed for luciferase reporter gene assays as outlined in methods 
section 2.2.6. Cells were harvested and processed for ChIP assays as described in 
section 2.2.5.
To explore the regulation of the TAC1 promoter by the TFs NRSF and USF, 
both alone and in combination, I opted to utilise the rat TAC1 promoter reporter gene 
construct -865 TAC1, which contains the rat TAC1 promoter region spanning -865 to 
+92. This promoter region contains both an NRSF binding site (the NRSE), and multiple 
USF binding motifs (E boxes), as shown in Figure 4.1. Furthermore, a second reporter 
gene construct containing a disruptive 10bp insertion in the -60 E box (-60 TAC) 
(Paterson et al., 1995) was utilised. This -60 E box has previously been shown to be 
important in USF regulation of the rat TAC1 promoter (Paterson et al., 1995; Gerrard et 
al., 2005), and I was interested in exploring a role of this E box in NRSF regulation of 
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the rat TAC1 promoter. Over-expression constructs employed are described in section 
2.1.1.
4.3.2 mRNA expression analysis
The expression of TAC1, together with the TFs NRSF, sNRSF, USF1 and USF2 
was investigated using PCR as described in methods section 2.2.3.4, using the PCR 
primers set out in Table 2.2.1. Thermal cycling conditions for all were as follows: initial 
denaturation: 95oC for 2mins for 1 cycle; followed by 40 cycles of denaturation: 95oC 
for 30 seconds, annealing 62oC for 30 seconds and elongation: 72oC for 1min; and a 
final elongation step of 72OC for 2mins. 
4.3.3 Transcription factor binding study
To investigate potential TF binding interactions with the human TAC1 proximal 
promoter region encompassing the characterised NRSE (Greco et al., 2007), the putative 
human TAC1 NRSE (based on homology to the rat TAC1 NRSE) (Appendix 2 & 3) and 
multiple E Box motifs, ChIP was employed as outlined in method section 2.2.5, using 
the antibodies given in Table 2.3 and the PCR primers given in Table 2.4.
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Figure 4.1 Sequence of the rat TAC1 promoter region spanning -865 to +92. The rat TAC1 promoter 
region (utilised in the -865 TAC1 reporter gene construct) contains multiple bHLH binding motifs (E box) 
highlighted in green, and a single NRSE, highlighted in yellow. 
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4.4 Results
4.4.1 Expression of TAC1, NRSF, USF1 and USF2 in human SK-N-AS 
neuroblastoma cells
The regulation of the TAC1 promoter will be determined by the TFs present in 
the cell. Consequently, it was important to use an appropriate cell line which expressed 
TAC1 endogenously. I was however limited in the number of clonal cell lines that 
express the endogenous TAC1 gene (Quinn et al., 2000). By screening a number of 
clonal cell lines in our lab by RT-PCR, I found that the human neuroblastoma cell line 
SK-N-AS, expressed TAC1 endogenously (Figure 4.2). I therefore used this cell line to 
investigate the effect of over-expression of the NRSF and USF TFs, on the activity of 
the TAC1 promoter. Furthermore, RT-PCR showed the presence of NRSF, USF1 and 
USF2 in SK-N-AS cells, but the truncated NRSF isoform, sNRSF, was non-detectable.
Figure 4.2 Expression profile of TFs in human SK-N-AS neuroblastoma cells. RT-PCR revealed that 
human SK-N-AS cells express full length NRSF, TAC1, USF1 and USF2, but not the truncated NRSF 
isoform sNRSF.
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4.4.2 The TAC1 proximal promoter contains a -60 E box motif, which acts as an 
enhancer in SK-N-AS cells. 
The rat TAC1 promoter spanning -865 +92 (-865 TAC1) contains a functional E 
box motif (5’-CAGCTG-3’) at -60 relative to the major TSS, known hereafter as the -60 
E box. This -60 E box has been shown be important in supporting TAC1 promoter 
activity in rat PC12 cells (Paterson et al., 1995) and is conserved in the human TAC1 
promoter. I validated that in human SK-N-AS neuroblastoma cells, the rat TAC1 (-865 
TAC1) promoter supported high levels of luciferase expression and that disruption of 
the -60 E box site via a 10bp insertion (as in the -60 TAC1 reporter gene construct) 
resulted in a significant 80% reduction in reporter gene activity (P = < 0.01) (n=18) 
(Figure 4.3), thus demonstrating that the -60 E box is a major determinant of TAC1 
promoter activity in SK-N-AS cells.
Figure 4.3 -60 E box site acts as an enhancer. Comparison of the -865 TAC1 and -60 TAC1 reporter 
gene constructs luciferase activity, reveals the -60 TAC mutant construct has significantly lower activity 
compared to -865 TAC1 construct, indicating that the -60 E box as an enhancer. Human SK-N-AS cells 
were transfected with either the -865 TAC or the -60 TAC1 reporter gene constructs and luciferase 
activity was measured, with mean fold changes compared to untreated -865 TAC1 given. Statistics were 
performed using T-test, with ** = P < 0.01. S.E. are given as Y-axis error bars (n=6, performed in 
triplicate).
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4.4.3 Modulation of TAC1 promoter by Upstream Stimulatory Factors (USF) 1 & 2
The role of USF1 and USF2 in the regulation of the TAC1 promoter was 
investigated by analysing the response of both the -865 TAC1 and -60 TAC1 mutant 
reporter gene constructs, to the over-expression of USF1 and USF2 in human SK-N-AS 
cells. Over-expression of USF1 or USF2, had no significant impact on -865 TAC1 
reporter gene activity, compared to untreated basal reporter gene levels (P > 0.05) 
(n=12) (Figure 4.4a). In contrast, the activity of the -60 TAC1 mutant, was significantly 
elevated 3-fold by both USF1 and USF2 (P = < 0.01) (n=12) over-expression (Figure 
4.4b). One is therefore left to assume that this increase in reporter gene expression is via 
one or more of the other E boxes in this promoter construct. However it should be noted
that the increase in -60 TAC1 mutant reporter gene activity with USF over-expression, 
reaches a similar level to the wild type (-865 TAC1) promoter alone (Figure 4.4b) (P > 
0.05) (n=12). This may indicate that USF1 and USF2 may stimulate activity of the 
TAC1 promoter via different E box sites, negating the loss of the -60 E box site, and 
returning the activity of the TAC1 promoter back to the wild type. 
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Figure 4.4. Regulation of rat TAC1 reporter gene activity by USF1 & USF2 in SK-N-AS cells. (A)
Over-expression of USF1 and USF2 expression constructs had no significant impact on the -865 TAC 
reporter gene construct activity. (B) In contrast both USF1 and USF2 led to significant increase in -60 
TAC reporter gene activity, elevating activity to the same level as the -865 TAC construct alone. Human 
SK-N-AS cells were transfected with -865 TAC reporter gene construct and the USF1 or truncated USF2 
expression constructs. Luciferase activity was measured and mean fold changes compared to basal are 
given. Statistics were performed using T-test, with ** = P < 0.01. S.E. are given as Y-axis error bars 
(n=4, performed in triplicate).
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4.4.4 Regulation of TAC1 promoter by the NRSF isoforms is independent of the -60 
E box. 
The over-expression of both the full length NRSF (REEX1), or a truncated 
variant (HZ4), resulted in increased reporter gene expression supported by the TAC1 
promoter in human SK-N-AS cells, similar to previous findings in rat hippocampal 
cultures (Spencer et al., 2006). NRSF was found to act as an activator of the -865 TAC 
promoter activity, with REEX1 over-expression resulting in a 2.5x-fold increase in 
promoter activity (Figure 4.5a) (P = < 0.01) (n=12). This increase was found to be 
independent of the -60 E box site, as disruption of this site (-60 TAC1 mutant) gave the 
same 2.5-fold increase in reporter gene construct activity compared to basal (Figure 
4.5b) (P = < 0.01) (n=12). Similarly over-expression of the HZ4 construct resulted in a 
significant 2x fold increase in -865 TAC1 reporter gene activity (Figure 4.5a) (P = < 
0.01) (n=12).  As with NRSF, this increase in reporter gene expression following HZ4 
over-expression was found to be independent of the -60 E box site (Figure 4.5b) (P = < 
0.01) (n=12). Furthermore, in our cell line model, although not conclusive, both NRSF 
variants, generate the same 2-2.5x fold increase in TAC1 activity, suggesting that 
potentially the shared N-terminal region of NRSF, common to both REEX1 and HZ4 is 
responsible for the regulation of TAC1.
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Figure 4.5. Regulation of TAC1 reporter gene activity by NRSF variants in SK-N-AS cells. Over-
expression of both full-length NRSF (REEX1) and a truncated construct analogous to sNRSF (HZ4) 
caused a significant increase in both (A) -865 TAC and (B) -60 TAC reporter gene construct activities. 
Human SK-N-AS cells were co-transfected with either the -865 TAC or -60 TAC reporter gene constructs 
and the full length NRSF (REEX1) or truncated sNRSF (HZ4) expression constructs. Luciferase activity 
was measured and mean fold changes compared to reporter gene construct alone are given. Statistics were 
performed using Students T-test, with ** = P < 0.01. S.E. are given as Y-axis error bars (n=4, performed 
in triplicate).
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4.4.5 NRSF variants are capable of enhanced activation of the TAC1 promoter in 
conjunction with USF, but via different mechanisms. 
The data presented in this chapter demonstrates that both USF and NRSF 
proteins are important in the regulation of the rat TAC1 promoter. Similarly, in chapter 
3, I demonstrate important regulatory roles for both USF and NRSF proteins in the 
regulation of the related tachykinin gene TAC3, and our group has also indicated a role 
for both of these TFs in the regulation of AVP (Coulson et al., 1999; Quinn et al., 2002; 
Coulson et al., 2003). As previously indicated in chapter 3, the position of the NRSE in 
all three neuropeptide genes is close to the TSS and that all three gene promoters contain 
E box motifs in close proximity to their NRSEs. Thus, I was interested in exploring the 
possibility of an inherent mechanistic relationship between NRSF and USF.
To investigate this, SK-N-AS cells were transfected with either REEX1 or HZ4 
plus either USF1 or USF2 expression constructs, together with the TAC1 reporter gene 
constructs. Co-expression of NRSF (REEX1) plus either USF1 or USF2, failed to have 
an impact on TAC1 regulation, when compared to REEX1 alone (Figure 4.6a) (P = 
>0.05) (n=12). In contrast co-expression of the truncated variant, (HZ4) plus USF1 
(3.6x fold compared to -865 TAC1 alone) and USF2 (3.3x fold compared to -865 TAC1 
alone)  led to a significant additive increase in -865 TAC1 promoter activity compared 
to single treatment with HZ4, USF1 or USF2, alone (1.9x fold, 1.4x fold and 1.3x fold 
compared to -865 TAC1 alone, respectively) (Figure 4.7a) (P = < 0.01) (n=12).  
To determine the potential mechanisms underlying the observed differences 
between the NRSF variants, I performed the same co-transfections with the (disrupted) -
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60 E box construct. In direct contrast to the impact upon the wild type -865 TAC1 
promoter, co-expression of NRSF (REEX1) plus USF1 or USF2, led to a significant 
increase in the reporter construct activity of the -60 TAC1 mutant (6.3x fold and 8.9x 
fold, compared to -60 TAC1 alone, respectively), when compared to treatment with 
either NRSF, USF1 or USF2 alone (2.7x fold,  3.1x fold and 3.2x fold, compared to -60 
TAC1 alone, respectively) (Figure 4.6b) (P = < 0.01) (n=12). Interestingly, the co-
expression of HZ4 plus USF1 or USF2 had no impact on the -60 TAC1 mutant promoter 
activity (Figure 4.7b) (P > 0.05) (n=12), indicating that the additive affect of HZ4 plus 
USF is dependent on the -60 E box site.
4.4.6 USF binding to the human TAC1 promoter is cell specific.
In chapter 3, USF binding to the human NKB promoter was found to differ 
between sNRSF expressing (SH-SY5Y) and non-expressing (SK-N-AS) cells. Based 
upon findings in this chapter indicating a cooperative regulatory role between NRSF 
variants and USF proteins, I was interested in characterising NRSF and USF binding to 
the endogenous TAC1 promoter in the human cell lines employed. In the sNRSF non-
expressing SK-N-AS cell line, ChIP assays revealed that both USF1 and USF2 were 
bound to the human TAC1 promoter locus, when compared against the non-specific 
background (negative) control; IgG (Figure 4.8a). In addition, NRSF was found to be 
bound to human TAC1 promoter locus, but as expected, sNRSF was not bound (Figure 
4.8a). Interestingly, in the sNRSF expressing cell line, SH-SY5Y, USF1 binding is lost, 
with only NRSF, sNRSF and USF2 found bound to the human TAC1 promoter locus 
(Figure 4.8b). This is consistent with the lack of USF1 binding observed at the human 
NKB promoter locus in SH-SY5Y cells, as described in Chapter 3.
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Figure 4.6. Additive regulation by NRSF & USF requires the disruption of the -60 E box. (A) 
Combined over-expression of NRSF (REEX1) together with either USF1 or USF2 had no impact on -865 
TAC reporter gene activity when compared to the affect of REEX1 alone. (B) In contrast, enhanced -60 
TAC reporter gene activity was observed following combined over-expression of  REEX1 with USF1 or 
USF2. Human SK-N-AS cells were co-transfected with (A) -865 TAC  or (B) -60 TAC reporter gene 
constructs, together with the NRSF (REEX1), USF1 or USF2 expression constructs, singularly and in 
cotransfection combination. Luciferase activity was measured and mean fold changes compared to basal 
are given. Statistics were performed using student’s T-test, with * = P < 0.05, ** = P < 0.01 (basal vs. 
single transfection) and ^^ = P < 0.01 (co-transfection vs. single transfection). S.E. are given as Y-axis 
error bars (n=4, performed in triplicate).
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Figure 4.7. Additive regulation by HZ4 & USF requires the -60 E box. (A) Combined over-expression 
of both the truncated construct HZ4 together with either USF1 or USF2 expression constructs resulted in a 
significant increase in -865 TAC reporter gene construct activity when compared to single transfection of 
HZ4 alone. (B) In contrast, combined over-expression of both HZ4 together with either USF1 or USF2 
expression constructs had no significant impact on the -60 TAC reporter, compared to the single 
transfection of HZ4 alone. Human SK-N-AS cells were co-transfected with (A) -865 TAC  or (B) -60 
TAC reporter gene construct, together with the truncated NRSF construct (HZ4), USF1 or USF2 
expression constructs, singularly and in co-transfection combination. Luciferase activity was measured 
and mean fold changes compared to basal are given. Statistics were performed using student’s T-test, with 
* = P < 0.05, ** = P < 0.01 (basal vs. single transfection) and ^^ = P < 0.01 (co-transfection vs. single 
transfection). S.E. are given as Y-axis error bars (n=4, performed in triplicate ). 
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Figure 4.8. NRSF and USF binding to the human TAC1 proximal promoter. (A) ChIP analysis 
revealed that NRSF, USF1 and USF2 show binding to the human TAC1 promoter in untreated human SK-
N-AS cells, compared to IgG negative control. The truncated isoform sNRSF was as expected, not found 
to bind.(B) In sNRSF expressing SH-SY5Y cells, NRSF, sNRSF and USF2 were found to bind to the 
human TAC1 promoter locus. In all cases, binding is shown to be specific to the human TAC1 proximal 
promoter, as no binding is observed in the GAPDH PCR negative controls (n=1). 
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4.5 Discussion
The TFs NRSF and USF have been shown by our lab and others to regulate a 
small set of common target genes including AVP (Coulson et al., 1999), BDNF 
(Tabuchi et al., 2002a) and NKB (chapter 3). In this chapter I have confirmed the role of 
both NRSF variants and USF proteins in the regulation of the TAC1 promoter, as shown 
by our group and others (Quinn et al.,2002;Spencer et al., 2006; Greco et al., 2007; 
Howard et al., 2008; Reddy et al., 2009; Paterson et al., 1995; Gerrard et al., 2005). Due 
to the close proximity of the NRSE to the TSS and to characterised or putative E box 
motifs, within the neuropeptides AVP, TAC3 and TAC1 promoters, I was interested in 
exploring a potential inherent mechanism existing between NRSF and USF in the 
regulation of such neuropeptide genes. In this chapter I show that the NRSF variants can 
differentially enhance TAC1 promoter activity in conjunction with USF proteins, 
dependent, in part, on the integrity of an E box motif at -60 relative to the major TSS.
The E box motif at -60 was found to act as an enhancer in human SK-N-AS 
cells. The rat promoter spanning -865 to +92 (-865 TAC1) supported high levels of 
luciferase activity, which was significantly reduced 5x fold, following the abolishment 
of the -60 E box (-60 TAC1). This is consistent with previous findings from our group 
in rat PC12 cells (Paterson et al., 1995). Interestingly, the over-expression of USF 
proteins failed to have an impact on the wild type rat TAC1 promoter (-865 TAC1), but 
did induce a 3x fold increase in luciferase supported by the mutant -60 TAC1 construct. 
Simplistically this indicates that USF1 and USF2 can modulate the activity of the TAC1 
promoter through other E box motifs within the proximal promoter, as the abolishment 
of the -60 E box could inhibit USF recognition and binding to this site. Interestingly, the 
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elevation in activity of the -60 construct failed to surpass the basal level of the wild type 
-865 TAC1 reporter gene construct. This suggests that whilst USF1 and USF2 are 
capable of modulating TAC1 promoter activity through different E box motifs, the -60 E 
box may still remain the most important element, as other E box motifs cannot drive 
expression higher than the basal wild type -865 TAC1 construct in response to USF. 
These findings indicate that the -60 E box cannot wholly account for any USF-mediated 
modulation of TAC1 promoter, and implies that other E boxes are also important in 
regulating the TAC1 promoter. 
Regulation of the rat TAC1 promoter by NRSF variants (alone) was found to be 
independent to the -60 E box motif, as both the -865 TAC1 and -60 TAC1 responded in 
the same way to full length (REEX1) over-expression, and to that of a truncated 
construct analogous to the truncated NRSF variant, sNRSF (HZ4). This is, in part, 
consistent with previous finding from our group, in that REEX1 over-expression drives 
elevated luciferase activity supported by the rat TAC1 promoter in cultured hippocampi 
(Spencer et al., 2006). However, in these hippocampal cultures, the HZ4 construct was 
found to drive x3 fold higher luciferase activity compared to REEX1 over-expression 
(Spencer et al., 2006), which is not seen here.
Over-expression of HZ4 together with either USF1 or USF2 was shown to drive 
luciferase activity supported by the wild type -865 TAC1 promoter, approximately 2x 
fold higher than compared to HZ4, USF1 or USF2 alone. This additive activity was 
found to be dependent on the -60 E box, as abolishment of this motif (in the -60 TAC1 
construct), led to no significant impact on luciferase activity when over-expressing HZ4 
with either USF constructs, compared to HZ4, USF1 or USF2 alone. In contrast, over-
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expression of full-length NRSF via the REEX1 construct, failed to drive enhanced 
luciferase activity of the wild type -865 TAC1 promoter, when in conjunction with 
USF1 or USF2, compared to REEX1, USF1 or USF2 alone. 
This is interesting as, in this chapter, I show that over-expression of HZ4, and 
not REEX1, has an additive impact on luciferase activity of the wild type -865 TAC1 
construct, when over-expressed in conjunction with USF1 or USF2. This could be of 
particular relevance to TAC1 regulation during seizure. NRSF isoforms are known to be 
up-regulated during seizure (Palm et al., 1998, Spencer et al., 2006), and whilst there are 
no publications regarding USF modulation during seizure, USF proteins are known to be 
expressed in the CNS (Corre & Galibert., 2005). Therefore it is plausible that seizure-
induced up-regulation of NRSF isoforms, induces enhanced TAC1 regulation, and when 
USF proteins are also present, TAC1 regulation is further enhanced by coordinated 
regulation between USF and truncated NRSF isoform (summarised in Figure 4.9). This 
is supportive of a hypothesis that it is the truncated NRSF isoform, which is of greatest 
importance in the regulation of TAC1 in KA seizure models (Spencer et al., 2006), as 
the full-length NRSF fails to regulate the wild-type TAC1 promoter in cooperation with 
the USF proteins, and so does not have the same degree of regulatory control over the 
TAC1 promoter, as the truncated isoform. 
Interestingly, in Chapter 6, I show that KA does induce elevated USF mRNA 
expression in human neuroblastoma cells, thus it would be of great interest to monitor 
USF expression during an in vivo rodent seizure model, to establish the affects of 
seizure on USF expression. Furthermore, it would be of interest to monitor endogenous 
TAC1 mRNA expression in response to both HZ4 and USF over-expression, singularly 
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and in combination, in cell lines and in vivo, to explore whether or not this cooperative 
regulation of the TAC1 promoter, has an effect on endogenous expression. 
Figure 4.9 Potential significance of USF and truncated NRSF cooperative regulation of TAC1. 
During KA-induced seizure, both full-length and truncated NRSF isoforms are up-regulated, which drives 
an increase in TAC1 expression (Spencer et al., 2006). USF proteins can additively regulate the wild-type 
rTAC1 promoter in cooperation with the truncated variant only, which is supportive of the theory that the 
truncated NRSF variant is of greater importance in seizure-induced TAC1 regulation.
Clues to how the truncated isoform and USF proteins could facilitate and 
enhance TAC1 promoter activity may come from studying the TF binding profile to the 
endogenous TAC1 promoter in humans. The human TAC1 promoter shares a degree of 
homology with the rat promoter, with the three E box motifs located at -60, -170 and -
308 in the rat, perfectly conserved in the human, with the closest E box within 34bp of a 
putative NRSE (based upon sequence alignment against the rat TAC1 NRSE) (See 
Appendix 2, 3 & 4), similar to the rat, whereby the rat -60 E box is within 33bp of the 
characterised NRSE (See Figure 4.1 & Appendix 4). In the human SK-N-AS cell line, 
the truncated isoform sNRSF is absent. In these (untreated) cells, the preliminary ChIP 
experiment, suggested that both USF1 and USF2 could bind to the human TAC1 
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promoter locus, as could full-length NRSF, whereas, as one might expect, sNRSF was 
not found to be bound to that region. Interestingly, in untreated sNRSF expressing cells 
(SH-SY5Y), sNRSF was found to bind to the human TAC1 promoter locus, at the 
expense of USF1, with USF1 no longer bound (but USF2 and NRSF remained bound). 
USF1 and USF2 predominantly form heterodimers (Corre & Galibert., 2005), 
and so one may expect to find both bound to the same DNA locus. In the SK-N-AS cell 
line, both USF1 and USF2 were found bound to the TAC1 promoter region. The 
presence of sNRSF, may in some way abolish USF1 binding to the human TAC1 
promoter locus, and this pattern in consistent with that observed in chapter 3 at the 
human NKB locus. This may suggest that sNRSF competes with USF1 for either 
binding privileges at the TAC1 and NKB promoter. The fact that abolishment of the -60 
E box in the rat TAC1 promoter, which is the closest E box to the rat NRSE, inhibits 
sNRSF and USF cooperative regulation, may be supportive of a model in which sNRSF 
and USF interact. The rat NRSE is within 50bp of the -60 E box, and this close 
proximity may lead to some interaction between sNRSF and USF. Disrupting this E box 
would prevent USF binding, preventing any possible interactions, and thus abolishing 
the cooperative regulation. Additional support for NRSF and USF interactions have 
come from unpublished findings from our group in which complexes bond to the rat 
TAC1 NRSE (NRSF/sNRSF) were found to be removed by homologous competitors in 
electophoretic mobility shift assays (EMSAs), as expected, but also by a -60 E box 
specific competitors (USFs) (Spencer et al., thesis). This suggested that proteins bound 
to the rat TAC1 NRSE could bind to, or interact with those which bind to the -60 E box 
(USF) (Spencer et al, thesis 2006). Subsequently, efforts were made to explore potential 
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interactions between the NRSF isoforms and USF1 and USF2, through Co-IP, but 
unfortunately the technique was not optimised in time for this thesis. This however 
remains an important experiment to perform, to fully support this interaction theory. 
NRSF was also found to work in cooperation with the USF TFs, but only when 
the -60 E box was disrupted. Over-expression of full-length NRSF (REEX1) in 
combination with USF had no impact on the wild type -865 TAC1 promoter, but did 
lead to an additive increase in luciferase activity supported by the disrupted -60 E box 
mutant -60 TAC1. This suggests that NRSF and USF have the capacity to cooperate to 
enhance TAC1 regulation, but requires USF to bind to an E box other than the -60 E 
box. USF over-expression failed to modulate the wild type -865 TAC1 construct, but did 
activate the -60 TAC1 construct, indicating that USF could function via different E box 
sites. Therefore, potential cooperation between NRSF and USF may exist. It would be 
thus of interest to address NRSF and USF interactions (via Co-IP), and characterise USF 
binding to other E box motifs, perhaps via the generation of multiple mutant constructs, 
one per E box, to elucidate the importance of each on TAC1 regulation.
The differences observed in this chapter, are often difficult to explain, but what 
is clear is that NRSF isoforms are capable of regulating the TAC1 promoter in 
conjunction with USF proteins, in a differential manner, and that this is, in part, 
dependent on the key -60 E box motif. 
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CHAPTER 5: NRSF isoforms are modulated by ACD treatment
5.1 Introduction
The importance of the NRSF TF family in regulating the pro-convulsant 
tachykinin genes TAC3 and TAC1 has been discussed in Chapters 3 and 4, respectively. 
NRSF has also been shown to regulate a host of neuronal genes with known or 
suggested roles in epilepsy (as further explored and discussed in Chapter 7), such as 
BDNF (Timmusk et al., 1999; Koyama & Ikegaya., 2005; Hara et al., 2009), and has 
also been implicated in the molecular mechanisms governing the anti-epileptic 
ketogenic diet (Garriga-Canut et al., 2006), in which NRSF mediated repression of 
BDNF, and its receptor TrkB, is enhanced following glycolytic inhibition. Due to these 
findings and the fact that NRSF isoforms are modulated in KA epilepsy models (Palm et 
al., 1999; Spencer et al., 2006), I sought to investigate whether or not NRSF isoforms 
were targets for ACD modulation. 
A recent study found that the ACD Valproic acid (VPA), a known HDAC 
inhibitor, can reduce the expression of full-length NRSF, whilst up-regulating both 
BDNF and TrkB (Kim et al., 2007), thus indicating a possible role of ACDs in 
modulating NRSF expression. Furthermore, both CBZ and LMT have been shown to 
up-regulate BDNF expression in the rat cortex (Chang et al¸2009), suggesting these 
ACDs can also target the NRSF regulatory system in a similar manner. In this study, I 
have opted to focus on CBZ, LMT and a third ACD, PHY. These three drugs are widely 
prescribed in the UK for the treatment of epilepsy, and share similar mechanisms of 
action as they are known to function via sodium channel blockade (Reviewed by 
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Rogawski & Loscher., 2004a), by binding to a common recognition site on the sodium 
channel (Kuo., 1998). Perhaps due to this common trait, all three drugs are found to be 
beneficial for the same type of epilepsies (GTC and Partial seizures) (Reviewed by 
Rogawski & Loscher., 2004a).
However, despite being used in the treatment of both GTC and partial seizures 
and sharing the same sodium channel target, these three ACDs each have different 
properties and can elicit different cellular responses. In the first instance, the three drugs 
have different structures, with PHY being a hydantoin molecule containing the ureide 
structure, which is traditionally viewed as a key structure for anti-convulsant activities. 
CBZ in contrast, is a tricyclic molecule, with a short amide side chain, missing the 
ureide structure, whilst LMT is the smallest compound containing just two aromatic 
rings (Kuo., 1998). Secondly, with regards to differential clinical uses, it is known that 
all three drugs have reported mood stabilising properties, but are used differently in the 
clinic, with CBZ and PHY routinely used in the treatment of the manic phase of BD, 
whereas, LMT is used to treat the depressed phase of BD (Reviewed by Rogawski & 
Loscher., 2004b). LMT has also been shown to be useful in the treatment of Absence 
seizures and Myoclonic seizures (Posner et al., 2005; Wheless et al., 2007; Auvin., 
2008), and this is perhaps due to LMT targeting high voltage calcium channels (Stefani 
et al., 1996; Wang et al., 1996), which are known to be crucial for abnormal oscillatory 
behaviour underlying generalized absence seizures (Huguenard et al., 1996).
It is therefore anticipated that by exploring these three different ACDs, and 
comparing the outcome of each drug treatment individually on the NRSF regulatory 
system, one may reveal the underlying molecular mechanisms of seizure generation and 
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progression and perhaps gain a greater understanding of how else these drugs elicit their 
anti-convulsant properties. Our lab has previously revealed that pro-convulsive (KA) 
treatment has a marked impact upon the expression and localisation of the NRSF 
isoforms in rat hippocampi, with elevated expression of both full-length and truncated 
NRSF observed following KA. Furthermore, KA also induced a switch in the cellular 
localisation of both isoforms, with NRSF translocating to the nucleus whilst the 
truncated isoform moved into the cytoplasm (Spencer et al., 2006). Here I aim to 
explore the impact of ACD treatment on both the expression levels and localisation of 
the NRSF isoforms, in human neuroblastoma cells. In addition, the impact of ACD 
treatment on NRSF binding to its 21bp recognition sequence, the NRSE, in a number of 
relevant NRSF regulated genes, will be explored to determine whether or not ACDs can 
impact upon NRSF function, in addition to modulating expression or localisation.
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5.2 Aims
 To test if pro-convulsant treatment (KA) modulates the mRNA expression of the 
NRSF isoforms in human neuroblastoma cells (SH-SY5Y).
 To explore the impact of ACD treatment on NRSF isoform mRNA expression in 
SH-SY5Y cells, using the clinically prescribed ACDs CBZ, PHY and LMT.
 To explore NRSF isoform localisation in human neuroblastoma cells.
 To determine if the ACDs affect NRSF isoform localisation.
 To determine NRSF binding to target NRSE-containing regions in SH-SY5Y 
cells via ChIP. 
 To explore the affects of ACD treatment on NRSF binding to regions containing 
target NRSEs.
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5.3 Methods
5.3.1 Cell culture and treatment
Human SH-SY5Y cells were used throughout as RT-PCR revealed they express 
both full-length NRSF and the truncated isoform sNRSF (see chapter 3, Figure 3.1). In 
addition, the TAC1 expressing SK-N-AS cell line was used in a single experiment to 
monitor ACD modulation of TAC1 expression. SH-SY5Y and SK-N-AS cells were 
cultured as outlined in methods section 2.2.2.1.1 and 2.2.2.1.2, respectively, and treated 
with KA, ACDs or vehicle controls as described in section 2.2.2.2. KA, ACDs and the 
corresponding vehicle controls were prepared as described in section 2.1.3. For mRNA 
analysis, cells were then harvested as detailed in methods section 2.2.3.1, 2.2.3.3 and 
measured as described in section 2.2.3.5. For immunofluorescence, cells were fixed and 
processed as described in methods section 2.2.4.5 and for ChIP assays, cells were fixed 
and protein/DNA interactions cross-linked as described in section 2.5.1.
5.3.2 mRNA expression analysis
The expression of the TFs NRSF and sNRSF, as well as the house keeping gene 
Pol II, was investigated using qPCR as described in methods section 2.2.3.5, using the 
PCR primers set out in Table 2.2.1. Thermal cycle conditions for NRSF and Pol II, were 
as follows: initial denaturation: 95oC for 3 minutes for 1 cycle; followed by 40 cycles of 
denaturation: 95oC for 30 seconds and annealing 62oC for 30 seconds; and a final 
elongation step of 72OC for 2 minutes. For sNRSF the annealing temperature was 
reduced to 58.5oC, with all other conditions remaining the same. Specificity of products 
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was determined by subsequent melt curve analysis from 55°C to 95°C increasing in 
0.5°C increments
5.3.3 Protein analysis
5.3.3.1 Western Blotting
The anti-NRSF (R2174) and anti-rREST4 (R3122) antibodies were used on 
protein extracted from untreated SH-SY5Y cells as described in section 2.2.4.1. Western 
blotting was performed as outlined in methods section 2.2.4.3. 
5.3.3.2 Immunofluorescence 
SH-SY5Y cells cultured on cover-slips as described in section 2.2.2.1.2, treated 
as in section 2.2.2.2, and harvested as described in section 2.2.4.4. Cover-slip mounted 
cells were probed with antibodies described in Table 2.3, and mounted and visualised as 
outlined in section 2.2.4.4.
5.3.4 TF binding study - ChIP
To investigate NRSF TF binding to regions encompassing characterised and 
putative NRSEs, ChIP was employed as outlined in method section 2.2.5, using the 
antibodies given in Table 2.3 and the PCR primers given in Table 2.4.
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5.4 Results
5.4.1 Modulation of NRSF isoform mRNA following KA treatment.
In order to test the impact on NRSF isoforms of ACD treatment, a cell line 
responsive to pro-convulsive stresses was required. In chapter 3, the human 
neuroblastoma cell line SH-SY5Y was shown to express both NRSF isoforms and so I 
sought to test if NRSF isoforms were modulated following KA treatment in these cells. 
SH-SY5Y cells were exposed to either 1µm or 5µM KA, or vehicle control, for either 
4hrs or 24hrs, before being processed for RNA extraction. NRSF and sNRSF mRNA 
levels were quantified via qPCR and standardised relative to Pol II.
Modulation of both NRSF isoforms’ mRNA expression levels were observed 
following KA treatment, with 24hrs 1µM KA and 5µM KA inducing a 2x-fold (P = < 
0.05) and 5x-fold increase (P = < 0.001) respectively, in full-length NRSF mRNA 
(Figure 5.1a) (n=3). qPCR also revealed that 24hrs 5µM KA induced a marked increase 
in the expression of the truncated isoform sNRSF, with a 3x-fold increase observed 
(Figure 5.1b) (P = < 0.001) (n=3). These observed elevations in NRSF isoform
expression levels are, in part, consistent with those observed in the rat in vivo models 
(Spencer et al., 2006).
160
Figure 5.1 Modulation of NRSF isoforms by KA. qPCR analysis of (A) NRSF and (B) sNRSF mRNA 
expression in response to KA treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 1µM or 5µM KA, or vehicle control, for 4hrs or 24hrs, before being processed for 
RNA extraction. mRNA expression of NRSF and the truncated isoform sNRSF, were analysed using 
qPCR, standardized against the house keeping gene Pol II, mean fold changes compared to vehicle 
controls are given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold 
changes against vehicle controls with: * = P = < 0.05; ** = P = < 0.01 & *** = P = < 0.001. (n=3).
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5.4.2 Modulation of NRSF & sNRSF mRNA following ACD treatment.
NRSF isoforms have previously been shown to be modulated during seizure 
conditions (Palm et al., 1998; Spencer et al., 2006), and both isoforms are found to be 
elevated here following KA treatment in SH-SY5Y cells. Due to the importance of 
NRSF variants in the regulation of the pro-convulsant tachykinins NKB and TAC1 (as 
discussed in Chapters 3 and 4 respectively), I was interested in exploring the effect of 
ACD treatment on NRSF and sNRSF mRNA expression. I opted to treat the SH-SY5Y 
cells with two 1st generation drugs, CBZ and PHY, and a new generation alternative 
LMT. CBZ, PHY and LMT, are all proposed to function via a similar mechanism of 
inhibiting voltage-gated sodium channels, but despite this, all three induce distinct 
patterns of modulation of NRSF isoform (mRNA) expression.
5.4.2.1 CBZ modulation of NRSF & sNRSF mRNA
CBZ treatment was found to induce a time-dependent change in full length 
NRSF mRNA expression, with 4hrs 10µg/ml CBZ inducing a 2x-fold increase in NRSF 
mRNA, and 4hrs 50µg/ml CBZ inducing a 4x-fold increase (Figure 5.2a) (P = < 0.01) 
(n=3), when compared to vehicle control (Control C). In contrast, the prolonged 
exposure led to a significant decrease in NRSF mRNA levels, with both 24hrs 10µg/ml 
(P = < 0.001) and 24hrs 50µg/ml (P = < 0.01) inducing approximately a 60% reduction 
in NRSF mRNA compared to vehicle control (Figure 5.2a) (n=3).
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Figure 5.2 Modulation of NRSF isoforms by CBZ. qPCR analysis of (A) NRSF and (B) sNRSF 
mRNA expression in response to CBZ treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y 
cells were treated with either 10µg/ml or 50µg/ml CBZ, or vehicle control, for 4hrs or 24hrs, before being 
processed for RNA extraction. mRNA expression of NRSF and the truncated isoform sNRSF, were 
analysed using qPCR, standardized against the house keeping gene Pol II. Mean fold changes compared to 
vehicle controls are given. Standard errors are given as y-axis error bars. Students t-test was used to 
compare fold changes against vehicle controls with: * = P = < 0.05; ** = P = < 0.01 & *** = P = < 
0.001.(n=3).
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CBZ treatment also led to a significant reduction in the mRNA expression of the 
NRSF truncated isoform, sNRSF. Following 4hrs CBZ, only the higher 50µg/ml 
concentration invoked a (30%) reduction in sNRSF mRNA (P = < 0.05), compared to 
vehicle control (Control C). Whereas with 24hrs treatment, both 10µg/ml and 50µg/ml 
CBZ resulted in a more significant 60% reduction in sNRSF mRNA levels (P = < 0.01) 
(n=3) (Figure 5.2b). It should also be noted that previous studies in our lab have 
revealed that CBZ and KA treatment (at the concentrations and durations tested here) 
have no affect on cell viability, with no change in cell death observed (as measured by 
Propidium Iodide staining) compared to untreated cells (unpublished data). CBZ 
treatment is therefore of particular interest in modulating the expression of NRSF 
isoforms, in a time-dependent and concentration-dependent manner. 
5.4.2.2 PHY modulation of NRSF & sNRSF mRNA
Despite sharing similar mechanistic actions with CBZ, PHY treatment had no 
impact on the full-length NRSF mRNA levels, with neither 4hrs nor 24hrs treatment 
having a significant impact (Figure 5.3a) (P = > 0.05) (n=3), when compared to vehicle 
control (Control P). In contrast, PHY treatment did lead to a significant decrease in the 
truncated sNRSF isoform mRNA levels, with both 4hrs and 24hrs 50µg/ml PHY (P = < 
0.01 & P = < 0.05, respectively) inducing approximately a 40-50% reduction in sNRSF 
mRNA (Figure 5.3b) (n=3).
5.4.2.3 LMT modulation of NRSF & sNRSF mRNA
LMT is one of the newer ACDs, which shares a number of commonalities with 
CBZ and PHY, in terms of use and mechanism of action, but is believed to have fewer 
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adverse reactions, based on lower withdrawal from clinical drugs trials of patients taking 
LMT, compared to those given CBZ (Brodie et al., 1995) or PHY (Steiner et al., 1999). 
In our SH-SY5Y neuroblastoma cell line, 4hrs LMT induces a significant 60% increase 
in full-length NRSF mRNA levels, compared to vehicle control (Control L), following 
both 10µg/ml LMT (P = < 0.001) and 50µg/ml LMT treatment (P = < 0.01) (Figure 
5.4a) (n=3). This increase following 4hrs LMT is similar to that observed following 4hrs 
CBZ, albeit not as impressive.
As aforementioned, the truncated isoform sNRSF was significantly reduced 
following both CBZ and PHY treatment. LMT treatment however had no significant 
impact on sNRSF mRNA levels, with the treatment conditions used here. 
5.4.2.4 CBZ modulates TAC1 mRNA
In chapter 4, the importance of NRSF variants on the regulation of the pro-
convulsant tachykinin gene TAC1, was discussed. Spencer et al, showed that NRSF 
isoforms are up-regulated following KA stimulation, and this increase coincided with an 
increase in TAC1 expression at the same time point. Due to the modulation of NRSF 
isoforms following CBZ treatment, shown in this chapter, I sought to explore the impact 
of CBZ treatment on endogenous TAC1 expression, in the TAC1 expressing SK-N-AS 
cell line (See Chapter 4). CBZ treatment was found to induce a significant reduction in 
TAC1 mRNA levels, following both 10µg/ml and 50µg/ml CBZ, at both 4hrs and 24hrs 
time points (Figure 5.5) (P = < 0.01) (n=3). 
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Figure 5.3 Modulation of NRSF isoforms by PHY. qPCR analysis of (A) NRSF and (B) sNRSF mRNA 
expression in response to PHY treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 10µg/ml or 50µg/ml PHY, or vehicle control, for 4hrs or 24hrs, before being processed 
for RNA extraction. mRNA expression of NRSF and the truncated isoform sNRSF, were analysed using 
qPCR, standardized against the house keeping gene Pol II, mean fold changes compared to vehicle 
controls are given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold 
changes against vehicle controls with: * = P = < 0.05; ** = P = < 0.01 & *** = P = < 0.001. (n=3).
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Figure 5.4 Modulation of NRSF isoforms by LMT. qPCR analysis of (A) NRSF and (B) sNRSF
mRNA expression in response to LMT  treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y 
cells were treated with either 10µg/ml or 50µg/ml LMT, or vehicle control, for 4hrs or 24hrs, before being
processed for RNA extraction. mRNA expression of NRSF and the truncated isoform sNRSF, were 
analysed using qPCR, standardized against Pol  II, mean fold changes compared to vehicle controls are 
given. Standard errors are given as y-axis error bars. Student’s t-test was used to compare fold changes 
against vehicle controls with: * = P = < 0.05; ** = P = < 0.01 & *** = P = < 0.001. (n=3).
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Figure 5.5 Modulation of TAC1 by CBZ. qPCR analysis of TAC1 mRNA expression in response to 
CBZ treatment in human SK-N-AS neuroblastoma cells. SK-N-AS cells were treated with either 10µg/ml 
or 50µg/ml CBZ, or vehicle control, for 4hrs or 24hrs, before being processed for RNA extraction. mRNA 
expression of TAC1was analysed using qPCR, standardised against the house keeping gene Pol II. Mean 
fold changes compared to vehicle controls are given. Standard errors are given as y-axis error bars. 
Students t-test was used to compare fold changes against vehicle controls with: ** = P = < 0.01.(n=3).
5.4.3 Modulation of NRSF & sNRSF localisation in human SH-SY5Y cells 
following ACD treatment.
5.4.3.1 Localisation of NRSF & sNRSF in human SH-SY5Y cells.
The localisation of a protein within the cell can play a key role in governing its 
function, and this is of particular relevance when regarding TFs. Previous work from our 
lab, and others, has shown that NRSF in predominantly localised within the cytoplasm 
in untreated neuronal cells (Zuccato et al., 2003; Spencer et al., 2006), whereas the 
truncated isoform is found to be nuclear (Magin et al., 2002; Spencer et al., 2006). The 
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localisation of NRSF isoforms in our SH-SY5Y cells was consistent with these previous 
findings (Figure 5.7). 
Antibodies previously used by our group to detect NRSF and the truncated 
isoform in the rodent (rREST4) (Spencer et al., 2006), were tested to determine if they 
detect the human NRSF isoforms, using SH-SY5Y protein extracts. The anti-NRSF 
(R2174) antibody detected a specific NRSF band at approximately 200kDa (Figure 5.7), 
which is consistent with findings from other groups (Ballas et al., 2005b; Zuccato et al., 
2003). The antibody raised to detect the truncated isoform (R3122), recognised a 
specific doublet at approximately 50kDa (Figure 5.6), consistent with other reports for 
the human isoform (Magin et al., 2002, Howard et al., 2008).
Using confocal microscopy and immunofluorescence, the localisation of NRSF 
in untreated human SH-SY5Y neuroblastoma cells was determined to be predominantly 
cytoplasmic, with some nuclear aggregations observed (Figure 5.7), consistent with 
previous findings in resting neurons (Zuccato et al., 2003; Spencer et al., 2006). In 
contrast, the truncated isoform was found to be predominantly nuclear, with strong 
overlay with the DAPI (Figure 5.7). Some cytoplasmic staining for the truncated 
isoform was also detected, matching previous observations by our group and others 
(Magin et al., 2002; Spencer et al., 2006).
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Figure 5.6 Western blotting of human SH-SY5Y cells extract with NRSF and sNRSF antibodies.
Human SH-SY5Y cell extract probed with the anti-NRSF antibody (R2174) and anti-sNRSF (R3122). 
Specific NRSF antibody binding is observed at 200kDa and a doublet is observed with the anti-sNRSF at 
50kDa. 
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Figure 5.7 Immunofluorescence staining of NRSF isoforms in human SH-SY5Y cells. Untreated 
Human SH-SY5Y cells were stained with the anti-NRSF antibody (R2174) and anti-sNRSF (R3122).Both 
primary antibodies were recognized with Alexa 568 secondary antibody. Overlay images stained with 
DAPI and Alex 568, are given in the corners. NRSF is shown to be predominantly cytoplasmic, whilst the 
truncated isoform exhibits a more defined nuclear localisation, with some cytoplasmic staining observed. 
(n=2).
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5.4.3.2 CBZ treatment and NRSF isoform localisation in SH-SY5Y cells.
It is known that KA treatment modulates the localisation of NRSF isoforms in 
rodent hippocampi (Spencer et al., 2006). Consequently, I was interested in exploring 
the role of each of the three ACDs used so far, if any, on NRSF isoform localisation in 
the human neuroblastoma SH-SY5Y cell line. NRSF localisation was found to be 
modulated by the vehicle control (Control C), with both 4hrs and 24hrs vehicle control 
cells, exhibiting a predominantly nuclear NRSF staining pattern, based on overlap with 
DAPI (Figure 5.8) (n=2). This nuclear staining pattern was also found following 4hrs 
and 24hrs 50µg/ml CBZ, indicating that CBZ treatment has no further affect upon 
NRSF localisation, compared to the vehicle control.
The vehicle control had little impact on the localisation of the truncated isoform, 
with well-defined nuclear staining plus some cytoplasmic staining, observed in (4hrs 
and 24hrs) vehicle control treated cells (Figure 5.9) (n=2), matching that observed in 
untreated cells (Figure 5.7) (n=2). The cytoplasmic staining of the truncated isoform 
was observed to be reduced following 24hrs 50µg/ml CBZ treatment, when compared to 
(24hrs) vehicle control treated cells (Figure 5.9) (n=2). However, this reduction has yet 
to be quantified explicitly, and so such reductions in staining are merely suggestive
rather than conclusive. In addition, overall staining of the truncated isoform was found 
to be reduced compared to Control C (Figure 5.9) (n=2), which whilst not quantitative, 
is suggestive of a reduction in sNRSF levels, which would be consistent with that 
observed of mRNA levels following the same treatment (Figure 5.2b) (n=2). Analysis of 
protein levels would thus be of future interest. 
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Figure 5.8 Immunofluorescence staining of NRSF in response to CBZ treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml CBZ or vehicle control 
(Control C). Cells were stained with the anti-NRSF antibody (R2174) and with Alexa 568 secondary 
antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. NRSF is shown to be 
nuclear based on overlay with DAPI, in Control C and CBZ treated cells. (n=2).
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Figure 5.9 Immunofluorescence staining of the truncated isoform sNRSF in response to CBZ 
treatment in human SH-SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml 
CBZ or vehicle control (Control C). Cells were stained with the anti-sNRSF antibody (R3122) and with 
Alexa 568 secondary antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. 
sNRSF shows distinct nuclear staining in both Control C and CBZ treated cells, with reduced cytoplasmic 
staining following CBZ treatment observed. (n=2).
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5.4.3.3 PHY and LMT treatment and NRSF isoform localisation in SH-SY5Y cells.
CBZ treatment was found to have a limited impact on the localisation of the 
NRSF isoforms, with only 24hrs 50µg/ml CBZ found to affect sNRSF localisation, with 
suggested reduced cytoplasmic staining. Both PHY and LMT had, in part, similarities to 
CBZ treatment in terms of modulating NRSF and sNRSF mRNA expression. Therefore 
I wanted to determine the impact of both of these ACDs on NRSF isoform localisation 
in human SH-SY5Y cells.
NRSF localisation in vehicle control (for PHY treatment) treated cells (Control 
P), was found to exhibit both a nuclear and cytoplasmic staining pattern (Figure 5.10) 
(n=2). The proportion of nuclear NRSF staining appeared greater in vehicle control 
(Control P) treated cells, , compared to untreated SH-SY5Y cells, however this is not 
quantified. Cells treated with 24hrs 50µg/ml PHY also exhibited nuclear NRSF 
localisation, with some cytoplasmic staining (Figure 5.10) (n=2), indicating that PHY, 
like CBZ, has no further impact upon NRSF localisation compared to its corresponding 
vehicle control. In contrast, the vehicle control (Control P) had no impact upon the 
staining pattern of the truncated isoform, compared to untreated SH-SY5Y cells, with 
the truncated isoform exhibiting a well-defined nuclear localisation, with some 
cytoplasmic staining also observed (Figure 5.11) (n=2). Similar to 24hrs 50µg/ml CBZ 
treatment, 24hrs 50µg/ml PHY treatment led to an apparent reduction in cytoplasmic 
staining of the truncated isoform, with virtually 100% nuclear staining, when compared 
against 24hrs vehicle controls (Control P) (Figure 5.11) (n=2). However, again this is 
not quantitative, and future analysis to measure the proportion of nuclear to cytoplasmic 
staining would be of interest.   
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Like CBZ and PHY, LMT treatment was found to have little impact upon NRSF 
localisation when compared to vehicle control treated cells, but did impact upon the 
cytoplasmic staining of the truncated isoform. NRSF localisation was found to be 
predominantly cytoplasmic with some nuclear aggregations observed, in (4hrs and 
24hrs) vehicle control (Control L) treated cells (Figure 5.12) (n=2), matching that 
observed in untreated cells. LMT had no impact on this localisation pattern, with both 
4hrs and 24hrs 50µg/ml LMT resulting in cytoplasmic NRSF localisation (Figure 5.12) 
(n=2). The truncated NRSF isoform was found to exhibit a well-defined nuclear 
localisation, with some cytoplasmic staining observed in vehicle control treated cells. 
24hrs 50µg/ml LMT treated was found to reduced the cytoplasmic staining of the 
truncated NRSF isoform, compared to (24hrs) vehicle controls (Control L) (Figure 5.12) 
(n=2), whilst 4hrs LMT had little impact. 
All three ACDs therefore had limited impact on the localisation of the NRSF 
isoforms, when compared to their corresponding vehicle controls. A general trend was 
observed, with the localisation of the full-length NRSF unaffected by the ACD 
treatment, whereas the cytoplasmic staining of the truncated isoform was reduced, 
following 24hrs treatment with CBZ, PHY or LMT, compared to vehicle control treated 
cells. 
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Figure 5.10 Immunofluorescence staining of NRSF in response to PHY treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml PHY or vehicle control 
(Control P). Cells were stained with the anti-NRSF antibody (R2174) and with Alexa 568 secondary 
antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. NRSF is shown to be 
nuclear, with some cytoplasmic and some nuclear aggregations in both Control P and PHY treated cells. 
(n=2).
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Figure 5.11 Immunofluorescence staining of the truncated isoform sNRSF in response to PHY 
treatment in human SH-SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml 
PHY or vehicle control (Control P). Cells were stained with the anti-sNRSF antibody (R3122) and with 
Alexa 568 secondary antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. 
sNRSF shows distinct nuclear staining in both Control P and PHY treated cells, with reduced cytoplasmic 
staining following 24hrs PHY treatment. (n=2).
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Figure 5.12 Immunofluorescence staining of NRSF in response to LMT treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml LMT or vehicle control 
(Control L). Cells were stained with the anti-NRSF antibody (R2174) and with Alexa 568 secondary 
antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. NRSF is shown to be 
non-nuclear, with cytoplasmic staining. (n=2).
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Figure 5.13 Immunofluorescence staining of the truncated isoform sNRSF in response to LMT 
treatment in human SH-SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml 
LMT or vehicle control (Control L). Cells were stained with the anti-sNRSF antibody (R3122) and with 
Alexa 568 secondary antibody. Overlay images stained with DAPI and Alex 568, are given in the corners. 
sNRSF shows distinct nuclear staining in both Control L and LMT treated cells, with reduced cytoplasmic 
staining following 24hrs LMT treatment compared to Control L. (n=2).
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5.4.3 Modulation of NRSF binding to target NRSE-containing regions in human 
SH-SY5Y cells by CBZ and PHY.
5.4.3.1 NRSF binding to target NRSE-containing regions in human SH-SY5Y cells.
An important aspect in NRSF mediated gene regulation is the ability of NRSF to 
recognise and bind to its 21bp consensus sequence, the NRSE. I was interested in 
exploring the possibility of ACD treatment affecting NRSF binding to target regions 
which contain the characterised NRSE of several neuronal genes. In the first instance, 
the binding of NRSF to a number of targets was explored to validate the ChIP assay. 
To screen NRSF binding to target NRSE-containing regions, I opted to 
investigate a number of NRSF targets, including the ‘classic’ target genes SCG10 
(Schoenharr & Anderson., 1995) and L1CAM (Kallunki et al., 1997), the neurotrophic 
factor BDNF (Timmusk et al., 1999), and the neuropeptides CART (Li et al., 2008), 
TAC1 (Greco et al., 2007) and TAC3/NKB (Chapter 3). Each of these genes has a well 
characterised NRSE, with the exception of NKB, which has a putative NRSE as 
discussed in Chapter 3. A preliminary ChIP assay indicated that NRSF was able to bind 
to the NRSE-containing region of all 6 target genes, when compared to IgG background 
(negative control), in the human neuroblastoma cell line. NRSF binding was shown to 
be specific to the NRSE-containing regions, as no binding was observed using the 
GAPDH negative control PCR primer set (Figure 5.14) (n=1). 
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Figure 5.14. ChIP assay of NRSF binding to NRSE-containing regions in human SH-SY5Y cells. 
ChIP analysis of NRSF binding to characterised NRSE-containing regions in the genes Scg10, L1CAM, 
CART, BDNF, TAC1 and NKB (as described in chapter 3).IgG was included as a non-specific binding 
control (background). NRSF was found to bind to all characterised and putative NRSE-containing regions 
in untreated SH-SY5Y cells. Binding is shown to be specific to the NRSE locus of each gene, as no 
binding is observed in the GAPDH PCR negative controls.
5.4.3.2 NRSF binding to target NRSE-containing regions is modulated by ACD 
treatment in human SH-SY5Y cells.
To explore ACD modulation of NRSF binding to target NRSE-containing 
regions, I opted to treat cells with two ACDs, which differentially modulated NRSF and 
sNRSF mRNA expression levels, following 24hrs treatment: CBZ and PHY. As earlier 
discussed, 24hrs 50µg/ml CBZ treatment resulted in a significant decrease in mRNA 
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expression of both full-length NRSF and the truncated isoform sNRSF, compared to 
vehicle controls (Figure 5.2), whereas in contrast 24hrs 50µg/ml PHY resulted in a 
significant decrease in sNRSF mRNA only. Both of these drugs had no impact on NRSF 
localisation following 24hrs 50µg/ml treatment, but both did induced reduced 
cytoplasmic staining of the truncated isoform. Interestingly, the two drugs modulated 
NRSF binding to target regions, differentially, in a target specific manner. 
Preliminary findings indicate that 24hrs 50µg/ml CBZ treatment led to increased 
NRSF binding to the SCG10, TAC1 and NKB (putative) NRSE-containing regions, 
compared to vehicle control (Control C) treated cells, (after standardising the NRSF 
pull-down PCR band intensity against the non-specific background control; IgG) (Figure 
5.15). Interestingly, NRSF binding to the TAC1 and  NKB promoter regions (which 
contain NRSEs) appears reduced in vehicle control treated cells, compared to untreated 
cells, whilst 50µg/ml CBZ enhances NRSF binding to these two regions, returning 
NRSF binding back to that observed in untreated cells (Figure 5.15). These findings 
suggest that the vehicle control has an impact on NRSF binding, however, it should be 
stressed that these are only preliminary findings, and replicate experiments are required
before conclusions can be drawn. NRSF binding to the NRSE-containing regions of 
L1CAM, BDNF and CART was not different in vehicle control treated or CBZ treated 
cells, compared to untreated cell, thus suggesting that the modulation of NRSF binding 
could be target specific. 
PHY treatment induced a different pattern of NRSF binding, compared to 
untreated and vehicle control treated cells. 24hrs 50µg/ml PHY resulted in a decrease in 
NRSF binding to the SCG10 NRSE-containing region when compared to both untreated 
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and vehicle control treated (Control P) cells (Figure 5.16). NRSF binding to the 
L1CAM, CART, TAC1 and NKB (putative) NRSE-containing regions was found to be 
reduced in vehicle control treated cells compared to untreated cells, whilst binding to the 
L1CAM and NKB (putative) NRSE-containing regions was restored back to untreated 
levels (Figure 5.16). In contrast 24hrs 50µg/ml PHY had no further impact upon the 
binding of NRSF to the CART and TAC1 NRSE-containing regions compared to 
vehicle controls. These findings may be supportive that ACDs can modulate NRSF 
binding to target regions, however as these findings are preliminary, repeated 
experimentation is required in the future. 
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Figure 5.15. Modulation of NRSF binding to target NRSE-containing regions following CBZ 
treatment in human SH-SY5Y cells. ChIP analysis of NRSF binding to characterised or putative NRSE-
containing regions in SH-SY5Y cells treated with either 24hrs 50µg/ml CBZ, vehicle control (Control C) 
or untreated. IgG was included as a non-specific binding control (background). NRSF binding to the 
Scg10, TAC1 and NKB NRSE-containing regions was found to be enhanced following CBZ treatment 
when compared to vehicle control. (n=1).
185
Figure 5.16. Modulation of NRSF binding to target NRSE-containing regions following PHY 
treatment in human SH-SY5Y cells. ChIP analysis of NRSF binding to characterised or putative NRSE-
containing regions in SH-SY5Y cells treated with either 24hrs 50µg/ml PHY, vehicle control (Control P) 
or untreated. IgG was included as a non-specific binding control (background). NRSF binding to the 
Scg10 NRSE-containing locus was found to be reduced following PHY treatment when compared to 
vehicle control, whilst binding to the region encompassing the L1CAM NRSE appears enhanced. (n=1).
186
5.5 Discussion
The TF NRSF and its truncated isoform, have been shown to be key regulators 
of a number of neuronal genes implicated in epilepsy, including BDNF (Timmusk et al., 
1999; Tabuchi et al., 2002; Hara et al., 2009), TAC1 (Quinn et al.,2002; Spencer et al.,
2006; Greco et al., 2007; Howard et al., 2008; Reddy et al., 2009; Chapter 4) and NKB 
(Chapter 3). In addition, both NRSF isoforms are known to be modulated in KA seizure 
models (Palm et al., 1999; Spencer et al., 2006), and NRSF has recently been shown to 
play a fundamental role in orchestrating the molecular response to the anti-epileptic 
ketogenic diet (Garrige-Canut et al., 2006). Due to the apparent importance of NRSF 
mediated gene regulation in epilepsy, I sought to investigate the impact of ACD 
treatment on NRSF isoform expression, localisation and DNA binding in a human 
neuroblastoma cell line. Previous reports have suggested that the ACDs CBZ and LMT 
can induce elevated expression of BDNF in the rat cortex (Chang et al¸2009), and I 
hypothesis this is due to the modulation of the NRSF regulatory system. Subsequently, 
the impact of these two ACDs, together with a third drug sharing a common sodium 
channel target, PHY (Kuo., 1998; Rogawski & Loscher., 2004a) upon NRSF isoform
expression and localisation was explored.
5.5.1 NRSF isoform expression
NRSF isoform expression has been shown to be modulated by the pro-
convulsant drug KA (Spencer et al., 2006). In order to test the impact of ACD treatment, 
a cell line expressing both NRSF isoforms, which also exhibited NRSF modulation 
following KA stimulation, was required as an appropriate model. RT-PCR screening 
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revealed that the human neuroblastoma cell line SH-SY5Y expressed both full-length 
NRSF and the truncated isoform sNRSF, endogenously (see Chapter 3, Figure 3.1). In 
addition, both NRSF isoforms were found to be modulated following KA stimulation, 
with 24hrs (1µM and 5µM) KA inducing a significant increase in both full-length NRSF 
(Figure 5.1a) and the truncated isoform sNRSF (Figure 5.1b). Consequently, the human 
SH-SY5Y cell line was deemed to be an appropriate cell line to test the response of the 
NRSF TFs to ACD treatment. 
Three ACDs were chosen for this study based upon their overlapping initial 
targets (sodium channel) and clinical uses, as previously discussed. Despite sharing the 
same initial target, each drug induced a different affect upon NRSF isoform expression. 
The1st generation ACD CBZ, was found to invoke differential modulation of both full-
length NRSF and the truncated isoform sNRSF, in an exposure duration and drug 
concentration dependent manner. The shorter 4hrs exposure was found to induce a 
significant increase in NRSF expression (Figure 5.2a), whilst leading to a reduction in 
the expression of the truncated isoform (Figure 5.2b), whereas the longer 24hrs 
exposure, led to the significant reduction in both NRSF isoforms (Figure 5.2). CBZ is 
therefore a powerful modulator of NRSF isoform expression. To see whether CBZ 
treatment could also modulate expression of the NRSF regulated tachykinin gene, 
TAC1, the TAC1-expressing neuroblastoma cell line, SK-N-AS, was treated with CBZ. 
At all concentrations and exposure durations tested, TAC1 expression was significantly 
reduced (Figure 5.5). Thus, CBZ invokes a reduction in a pro-convulsant neuropeptide, 
which would be consistent with its function as an anti-convulsant, with this data 
providing evidence for a new mechanism of action for this ACD. 
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An alternative 1st generation ACDs, PHY, was found to have no impact on 
NRSF expression in the SH-SY5Y cell line, but did modulate the expression of the 
truncated isoform, sNRSF, with sNRSF significantly reduced following both 4hrs and 
24hrs PHY treatment (Figure 5.3). Previous data published by our group, and others, 
and data presented in this thesis, implicates the truncated NRSF isoform as the more 
important NRSF isoform in epilepsy models. Our group has shown that the truncated 
isoform in more dynamically regulated in in vivo rodent seizure models, and drives 
activity of the rat TAC1 promoter to a greater extent than the full-length isoform
(Spencer et al., 2006), whilst in Chapter 4, only the over-expression of the HZ4 
construct (expressing a truncated NRSF variant), and not the full-length NRSF construct 
(REEX1) led to further activation of the wild-type rat TAC1 promoter in cooperation 
with the USF proteins. Furthermore, the truncated isoform has also been shown to 
antagonise NRSF repression of the BDNF promoter (Tabuchi et al., 2002), thus 
implicating it in the regulation of BDNF, a key epilepsy associated gene (Koyama & 
Ikegaya., 2005). Due to the apparent importance of the truncated isoform in seizure-
associated gene regulation, it is of particular interest that PHY treatment reduces the 
expression of the truncated isoform exclusively, without affecting the levels of full 
length NRSF. In addition, as PHY targets only the truncated isoform, this may be a 
useful drug in other conditions correlated with sNRSF over-expression, such as small 
cell lung cancer (Coulson et al., 2000). 
LMT is a member of the 2nd generation of ACDs, which works similarly to CBZ 
and PHY, in terms of targeting voltage gated sodium channels (Kuo., 1998), but has a 
more simplistic structure, and has reported fewer side effects due and lower patient 
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withdrawal from treatment, compared to both CBZ (Brodie et al.,1995) and PHY 
(Steiner et al., 1999).  LMT treatment was found to induce an increase in NRSF 
expression following 4hrs treatment, similar to CBZ, whilst having no impact following 
a more prolonged 24hrs treatment period (Figure 5.4a). This may suggest that LMT and 
CBZ work via a similar pathway, to modulate NRSF expression. The fact that both CBZ 
and LMT have previously been shown to modulate BDNF levels in the rat cortex 
(Chang et al., 2009) may be supportive of this theory. However, unlike the more 
prolonged 24hrs CBZ treatment, LMT treatment was not found to reduce NRSF 
expression. This may be due to differences in the stability or half life of LMT, within the 
cell, compared to CBZ. Certainly, the two drugs are known to be removed via different 
mechanisms, with CBZ removed through oxidation, governed by the cytochrome p450 
gene CYP3A4 (Perucca., 2006; Pearce et al.,2008), whereas LMT is removed via a 
glucuronide conjugation controlled by the enzyme glucuronyl transferase type 1A4 
(Magdalou et al., 1992; Perucca., 2006). Due to these different routes of elimination, it 
is plausible that LMT may modulate (reduce) NRSF levels at different time points or 
treatment durations not tested here, and the only way to address this would be to repeat 
the experiment with different time courses.
Interestingly, LMT had no impact on the expression of the truncated isoform 
sNRSF, at the time points/treatment duration tested here. Again, differences observed 
between the three drugs, or more specifically LMT versus CBZ and PHY, in terms of 
sNRSF modulation, may be due to differences in the half-life of these three drugs. As 
with CBZ, PHY is eliminated through oxidation, this time orchestrated by CYP2C9 and 
CYP2C19 (Perucca., 2006; Mosher et al., 2009). Perhaps the lack of sNRSF modulation 
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by LMT is due to its route of elimination, which may be quicker or longer than that of 
CBZ and PHY, and perhaps one is missing any sNRSF modulation induced by LMT at 
these 4hrs and 24hrs time points. As mentioned, one would have to repeat the treatment 
at different, perhaps shorter time points, to conclude if LMT does have an impact on 
sNRSF expression. 
5.5.2 NRSF isoform localisation
The localisation of a protein within the cell can play a key role in governing its 
function, and this is of particular relevance when regarding TFs. Previous work from our 
lab, and others, has shown that NRSF in predominantly localised within the cytoplasm 
in untreated neuronal cells (Zuccato et al., 2003; Spencer et al., 2006), whereas the 
truncated version is found to be nuclear (Spencer et al., 2006). The localisation of NRSF 
and its truncated isoform in SH-SY5Y cells was found to be consistent with these 
previous reports. The localisation of NRSF is known to be controlled by two distinct 
proteins: Huntingtin (Zuccato et al., 2003) and the RILP (Shimojo & Hersh, 2003). 
Huntingtin has been shown to sequester NRSF in the cytoplasm, with the mutant 
Huntingtin protein (the hallmark of HD) failing to sequester NRSF into the cytoplasm, 
leading to nuclear accumulation of NRSF (Zuccato et al., 2003). In contrast, RILP is 
known to govern the nuclear localisation of NRSF, with cytoplasmic localisation of 
NRSF found upon knock-down of RILP (Shimojo  Hersh., 2003). 
NRSF localisation is of particular interest when regarding seizure, as the 
localisation of the NRSF isoforms switches following pro-convulsant KA treatment 
(Spencer et al., 2006). More recently, a mutation in the RILP gene was found to cause 
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an autosomal-recessive PME-Ataxia syndrome (Bassuk et al., 2008). Taken together, 
the localisation of NRSF isoforms appears to be an important aspect in seizure. 
Subsequently, I sought to explore the potential affect of ACD treatment on the 
localisation of NRSF and sNRSF in human SH-SY5Y cells.
ACD treatment was found to have little impact upon the localisation of full-
length NRSF, following the treatments tested here. The ACDs did however all lead to an
apparent reduction in cytoplasmic staining of the truncated isoform, following 24hrs 
treatment, which may be supportive of the greater importance of the truncated isoform 
in seizure, as the ACDs only had an impact upon the truncated isoform’s sub-cellular 
distribution. However, it is important to state that this data is not quantitative, and whilst 
the staining patterns observed suggests a reduction in cytoplasmic staining of the 
truncated isoform occurs, a more accurate approach is required in future investigations. 
For example, one could analyse the protein levels of the truncated isoform in both 
cytoplasmic and nuclear extracts, via a western blot, to determine if the change in 
staining observed, is a true reflection on a change in protein levels in the cytoplasm. 
Interestingly, the vehicle controls for CBZ treatment and PHY treatment had a marked 
affect upon NRSF localisation, resulting in a more apparent nuclear localisation patterns 
compared to untreated cells. Therefore it is evident that the vehicle itself induces a shift 
in NRSF localisation, which may be masking any affect CBZ or PHY have. It would 
therefore be of interest to repeat the experiments with different vehicles, for example, 
CBZ could be prepared in propylene glycol instead of ethanol. 
The fact that NRSF localisation was unaffected by ACD treatment compared to 
vehicle controls, and that the localisation of the truncated isoform was only moderately 
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affected, may well be consistent with the roles of these drugs in restoring neuronal cells 
back from a hyper-excitable state, to a more normal state. The fact that these drugs do 
not affect the localisation of NRSF isoforms, is perhaps a good thing, after all, it is 
during seizures or indeed in HD, that abnormal NRSF localisation is found. 
It may be of interest to explore the role of these ACDs in modulating NRSF 
isoform localisation, following seizure conditions. For example, it would be particularly 
interesting to see if KA induced a change in NRSF isoform localisation within these 
cells, and if the ACD treatment could return the NRSF isoform localisation back to pre-
KA or pre-seizure like conditions. Data from such an experiment may support a theory 
that these drugs only affect NRSF localisation, when abnormal localisation is observed, 
restoring it back to a normal state.  
5.5.3 NRSF binding to target NRSE-containing regions
In addition to modulation of expression and localisation, the regulatory role of a 
TF can be affected by modulating its ability to recognise and bind to its recognition 
DNA motif. Previous studies have shown that NRSF binding its recognition motif, the 
NRSE, is modulated following ischemic insults, with NRSF binding to the µ-opioid 
receptor (MOR-1) gene promoter, enhanced following ischemia in the rat hippocampus 
(Formisano et al., 2007). Furthermore, in a mouse transgenic model of HD, NRSF 
binding to target NRSEs in the BDNF, SYN1, Chrm4, Drd3 and Chrmb2 genes, was 
found to be elevated in the HD mice compared to wild-type mice (Zuccato et al., 2007). 
To investigate whether ACD treatment may affect NRSF binding to target NRSE-
containing regions, a preliminary ChIP assay was undertaken to explore the impact of 
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24hrs CBZ and 24hrs PHY treatment on NRSF binding to the regions containing the 
characterised or putative NRSE, of the genes SCG10, L1CAM, BDNF, CART, TAC1 
and TAC3.
The preliminary findings suggested that both CBZ and PHY could affect NRSF
binding to NRSE-containing regions.. Whilst neither treatment affected NRSF binding 
to the regions encompassing the BDNF or CART NRSEs, they did differentially 
modulate binding to SCG10, L1CAM, TAC1 and TAC3 NRSE-containing regions. 
CBZ treated resulted in elevated NRSF binding to the SCG10, TAC1 and NKB NRSE-
containing regions compared to vehicle controls (Figure 5.15). Interestingly, NRSF 
binding to TAC1 and NKB promoter regions appeared reduced in vehicle control treated 
cells, when compared to untreated cells, suggesting that the vehicle control may be 
having an impact upon NRSF binding. . Similarly, the vehicle control for PHY treatment 
also induced a reduction in binding to regions encompassing the L1CAM, CART, TAC1 
and NKB NRSEs, whilst PHY treatment appeared to restore NRSF binding to the 
L1CAM and NKB NRSE-containing regions (compared to vehicle control) (Figure 
5.16). Whilst these findings are of interest, it should be stressed that they are preliminary 
findings, and it is therefore of particular interest to repeat these experiments in the future 
to gain a true reflection of any ACD-mediated modulation of NRSF binding to target 
regions. 
One common trend noted following these two preliminary investigations was the 
suggestive elevated NRSF binding to the NKB promoter, compared to vehicle controls. 
This is an intriguing finding, as I show in chapter 3 that NRSF is important in NKB 
regulation, acting as an activator in human neuroblastoma cells, and thus one may 
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expect an ACD to reduce NRSF binding to the NKB promoter, which may lead to 
reduced NKB expression. However, multiple TFs were found to be important in NKB 
regulation, including USF proteins and the truncated NRSF variant, and thus binding of 
these factors to the NKB promoter region needs to be explored to better understand the 
affects of ACD treatment on NKB regulation. 
Whilst these findings are preliminary, they do present interesting differences 
between the different ACDs which may be explained by their differential affects on the 
expression of full-length NRSF. Both CBZ and PHY led to a reduction in sNRSF 
mRNA expression, but only CBZ affected full-length NRSF expression, causing a 
reduction at the 24hrs time point tested here. Interestingly, despite a reduction in NRSF 
mRNA expression, NRSF binding to the regions containing the SCG10, TAC1 and 
NKB NRSEs, appeared to increase. One possible explanation for such differences could 
be due to the ratio of NRSF to sNRSF. It is predicted that the truncated isoform can 
bind, albeit weakly, to target NRSEs, and thus may compete or antagonise NRSF 
binding to target NRSEs (Tabuchi et al., 2002). Thus following PHY treatment, where 
NRSF expression is unaffected, but the truncated isoform is reduced; the ratio between 
the two isoforms is elevated in favour of full-length NRSF, which is in contrast to that 
observed following CBZ treatment, whereby both isoforms are reduced. Such 
differences in the ratio of NRSF:sNRSF, may help explain the observed differences in 
NRSE binding to target regions.
As stated earlier, binding of NRSF to the region encompassing the BDNF NRSE 
was unaffected by ACD treatment, in these preliminary experiments. Previous studies 
have also shown that NRSF binding to the BDNF NRSE is unaffected by the anti-
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epileptic ketogenic diet, more specifically by glycolytic inhibition (Garriga-Canut et al., 
2006). However, the ketogenic diet model did induce a marked change in chromatin 
structure around the BDNF promoter, indicated by an increase in H3K9 methylation 
(marker of closed, repressed chromatin) and a decrease in H3K9 acetylation (marker of 
open, active chromatin) (Garriga-Canut et al 2006). It would therefore be of interest to 
extend future investigations to explore whether pro-convulsant or ACD treatments, 
affect chromatin markers, in the human neuroblastoma cell model employed here. 
To summarise, ACD treatment targets and modulates the NRSF regulatory 
system, in a differential manner. Each drug elicited differential modulation of NRSF 
isoform mRNA expression at the concentrations and exposure durations tested here, 
whilst in general, maintaining and not disturbing NRSF isoform localisation. Finally, 
preliminary investigations suggest that ACD treatment may modulate NRSF binding to 
specific target regions. These findings provide new evidence for the function of these 
ACDs in modulating a distinct TF regulatory system, which is implicated in seizure 
progression and maintenance. 
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CHAPTER 6: USF1 and USF2 are modulated by ACD treatment
6.1 Introduction
In earlier chapters, a regulatory role for the USF TFs in governing both NKB 
(chapter 3) and TAC1 (chapter 4) expression was discussed . Both of these tachykinin 
genes are considered to be pro-convulsant (Marksteiner et al., 1992; Wasterlain et al., 
2002; Chen et al., 2008; Liu et al, 1999; Wasterlain et al, 2000) and as such are 
important in seizure. A number of bHLH factors have been shown to be modulated 
following seizure in vivo, including Mash1, Id2 and Hes5 (Elliot et al., 2001), which 
suggests that the USF TFs may also be modulated following seizure. In support of this, 
USF knockout mice are known to be prone to spontaneous seizures (Sirito et al., 1998), 
and the USF TFs are also known to regulate a host of neuronal genes implicated in 
epilepsy, including BDNF (Tabbuchi et al., 2002b), the GABAB receptor (Steiger et al., 
2004) and KCC2 (Markkanen et al., 2008). Despite these facts, the response of the USF 
family to seizure has not yet been explored. However, due to the proposed role of USFs 
in epilepsy, I sought to investigate whether USF expression, localisation and function 
(DNA binding) were affected by ACD treatment, as was tested in chapter 5 for the 
NRSF isoforms.
As discussed in chapter 5, the expression of the USF and NRSF-regulated gene 
BDNF has been shown to be up-regulated following VPA (Kim et al., 2007), CBZ and 
LMT (Chang et al¸2009) treatment, which may in part be due to the modulation of 
NRSF following such drug treatment (Kim et al., 2007; Chapter 5), but may also be due 
to these drugs modulating other TFs such as USF1 or USF2. Evidence to suggest that 
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ACDs may modulate USF1 or USF2 expression includes the observed down-regulation 
of the USF-regulated KCC2 gene, following VPA treatment in rat cortical neurons 
(Fukuchi et al., 2009). To determine if such drugs could modulate USF gene expression, 
the expression of both USF1 and USF2 was monitored following CBZ, PHY and LMT 
treatment. These three ACDs were employed in chapter 5 due to the fact that they can 
function via the same sodium channel blockade mechanisms, but can have different 
downstream targets, and different clinical use. 
By addressing USF modulation following ACD treatment, it is hoped that 
molecular mechanisms which play pivotal roles in seizure generation and progression, 
may be unearthed. Furthermore, our knowledge about the mechanisms by which ACD 
exert their effects may well be enhanced by screening for USF modulation here, to 
supplement the findings described in chapter 5. 
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6.2 Aims
 To test if pro-convulsant treatment (KA) modulates the mRNA expression of the 
USF TFs in human neuroblastoma cells (SH-SY5Y).
 To explore the impact of ACD treatment on USF1 and USF2 mRNA expression 
in SH-SY5Y cells, using the clinically prescribed ACDs CBZ, PHY and LMT.
 To explore USF1 and USF2 localisation in human SH-SY5Y neuroblastoma 
cells.
 To determine if the ACDs affect USF localisation in SH-SY5Y cells.
 To determine USF binding to neuropeptide promoter regions in SH-SY5Y cells 
using ChIP. 
 To explore the effects of ACD treatment on USF binding to target neuropeptide 
promoter regions.
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6.3 Methods
6.3.1 Cell culture and treatment
Human SH-SY5Y cells were used throughout as RT-PCR revealed they express 
both USF1 and USF2 (see chapter 3, Figure 3.1). SH-SY5Y cells were cultured as 
outlined in methods section 2.2.2.1.1 and treated with KA, ACDs or vehicle controls as 
described in section 2.2.2.2. KA, ACDs and the corresponding vehicle controls were 
prepared as described in section 2.1.3.For mRNA analysis, cells were then harvested as 
detailed in methods section 2.2.3.1, 2.2.3.3 and measured as described in section 2.2.3.5. 
For immunofluorescence, cells were fixed and processed as described in methods 
section 2.2.4.5 and for ChIP assays, cells were fixed and protein/DNA interactions 
cross-linked as described in section 2.5.1.
6.3.2 mRNA expression analysis
The expression of the TFs USF1 and USF2, as well as the house keeping gene 
Pol II, was investigated using qPCR as described in methods section 2.2.3.5, using the 
PCR primers set out in Table 2.2.1. Thermal cycling conditions for USF 1, USF2 and 
Pol II, were as follows: initial denaturation: 95oC for 3mins for 1 cycle; followed by 40 
cycles of denaturation: 95oC for 30 seconds and annealing 62oC for 30 seconds; and a 
final elongation step of 72oC for 2mins. Specificity of products was determined by 
subsequent melt curve analysis from 55°C to 95°C increasing in 0.5°C increments
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6.3.3 Protein analysis
6.3.3.1 Western blotting
To test the anti-USF1 and anti-USF2 antibodies, total protein was extracted from 
untreated SH-SY5Y cells as described in section 2.2.4.1. Western blotting was 
performed as outlined in methods section 2.2.4.3. 
6.3.3.2 Immunofluorescence 
SH-SY5Y cells cultured on cover-slips as described in section 2.2.2.1.2, treated 
as in section 2.2.2.2, and harvested as described in section 2.2.4.4. Cover-slip mounted 
cells were probed with antibodies described in Table 2.3, and mounted and visualised as 
outlined in section 2.2.4.4.
6.3.4 TF binding study – ChIP assay
To investigate USF2 TF binding to the human TAC1 and NKB promoter region, 
ChIP was employed as outlined in method section 2.2.5, using the antibodies given in 
Table 2.3 and the PCR primers given in Table 2.4. USF1 binding was not explored as 
conditions could not be optimised in time for completion of this thesis. 
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6.4 Results
6.4.1 Modulation of USF1 and USF2 mRNA following KA treatment.
To explore the impact of ACD treatment on the expression of the USF TFs, a 
cell-line model was required which was responsive to pro-convulsant challenge. In 
Chapter 5, the human SH-SY5Y cell line was found to respond to KA, with marked up-
regulation of the NRSF isoforms observed. The SH-SY5Y cell line was again used here 
due to this response to pro-convulsant stresses, but also as both USF1 and USF2 was 
found to be endogenously expressed (Figure 3.2). In addition, using the same cell line 
and treatment meant that comparisons between NRSF isoform and USF TF modulation 
could be made. To determine the response of USF1 and USF2 to pro-convulsant 
challenge, SH-SY5Y cells were treated with either 1µM or 5µM KA, or vehicle control, 
for either 4hrs or 24hrs, before being processed for RNA extraction. USF1 and USF2 
mRNA levels were quantified via qPCR and standardised relative to Pol II.
Differential modulation of both USF1 and USF2 mRNA expression was 
observed following KA treatment. USF1 modulation was found to be concentration and 
exposure-duration dependent , with 4hrs 1µM  KA inducing a marked 3x-fold increase 
(P = < 0.01), whilst 4hrs 5µM KA induced a less substantial 50% increase (P = < 
0.001) (Figure 6.1a) (n=3). With the more prolonged 24hrs KA treatment, only the 
higher 5µM KA concentration elicited a change in USF1 mRNA expression, with a 
significant 2x fold increase noted (P = < 0.01) (n=3) (Figure 6.1a). qPCR also revealed 
that 24hrs 5µM KA induced a 4x fold increase in the expression of USF2 (Figure 6.1b) 
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(P = < 0.05) (n=3). To my knowledge, these are the first findings that USF TFs are up-
regulated following KA treatment.
Figure 6.1 Modulation of the USF TFs by KA. qPCR analysis of (A) USF1 and (B) USF2 mRNA 
expression in response to KA treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 1µM or 5µM KA, or vehicle control, for 4hrs or 24hrs, before being processed for 
RNA extraction. mRNA expression of USF1 and USF2 were analysed using qPCR, standardized against 
the house keeping gene Pol II, mean fold changes compared to vehicle controls are given. Standard errors 
are given as y-axis error bars. Students t-test was used to compare fold changes against vehicle controls 
with: * = P = < 0.05; ** = P = < 0.01 & *** = P = < 0.001. (n=3). 
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6.4.2 Modulation of USF1 and USF2 expression following ACD treatment.
In chapters 3 and 4, the importance of the USF TFs in the regulation of the pro-
convulsant tachykinins NKB and TAC1 was highlighted, and USF proteins are known 
to regulate another epilepsy gene associated, BDNF (Tabbuchi et al., 2002b). In chapter 
5, the NRSF isoforms, also implicated in NKB, TAC1 and BDNF regulation, were 
found to be modulated by ACD treatment. I was thus interested in extending this 
analysis to the USF TFs, by exploring the effect of ACD treatment on USF1 and USF2 
mRNA expression. The three ACDs used in chapter 5, were again utilised here, those
being CBZ, PHY and LMT. As previously discussed, CBZ, PHY and LMT are proposed 
to function via a similar mechanism, but despite this, differential modulation of the USF 
TFs expression was observed.
6.4.2.1 CBZ modulation of USF1 & USF2 mRNA
CBZ treatment was found to induce a time-dependent  change in USF1 mRNA 
expression, with 4hrs 10µg/ml CBZ inducing a highly significant 75% reduction in 
USF1 mRNA, and 4hrs 50µg/ml CBZ inducing a 60-70% reduction (Figure 6.2a) (P = 
< 0.001) (n=3), when compared to vehicle control (Control C). In contrast, the more 
prolonged 24hrs exposure had no impact on USF1 mRNA levels (Figure 6.2) (P = > 
0.05) (n=3).CBZ treatment also led to a repression of USF2. 4hrs 10µg/ml and 50µg/ml 
CBZ treatment induced a significant 60% reduction in USF2 mRNA expression (P = < 
0.01) (n=3), whilst the more prolonged 24hrs 10µg/ml and 50µg/ml CBZ treatment led 
to a even more significant decrease (70-80%) (P = < 0.001) (n=3) (Figure 6.2b). 
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Figure 6.2 Modulation of the USF TFs by CBZ. qPCR analysis of (A) USF1 and (B) USF2 mRNA 
expression in response to CBZ treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 10µg/ml or 50µg/ml CBZ, or vehicle control (Control C), for 4hrs or 24hrs, before 
being processed for RNA extraction. mRNA expression of USF1 and USF2 were analysed using qPCR, 
standardized against the house keeping gene Pol II, mean fold changes compared to vehicle controls are 
given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold changes
against vehicle controls with: ** = P = < 0.01 & *** = P = < 0.001. (n=3).
205
6.4.2.2 PHY modulation of USF1 & USF2 mRNA
In chapter 5, PHY was found to differentially modulate NRSF isoform
expression, when compared to CBZ, despite sharing the same initial target (kuo et al., 
1998). Here, PHY is again found to elicit a different response to CBZ in terms of USF1 
and USF2 mRNA expression. PHY  modulation of USF1 was found to be concentration 
and exposure-duration dependent, with only 4hrs 10µg/ml PHY resulting in a significant 
2x fold increase in USF1 expression (P < 0.05) (n=3) (Figure 6.3a). PHY treatment had 
no significant impact upon USF2 expression (P = > 0.05) (n=3) (Figure 6.3b). 
6.4.2.3 LMT modulation of USF1 & USF2 mRNA
Previous reports have shown that both CBZ and LMT can modulate BDNF 
expression in the rat cortex (Chang et al¸2009), and in chapter 5 I proposed that this is 
due to similar affects of these drugs on the NRSF regulatory system. BDNF is also 
known to be regulated by USF proteins (Tabbuchi et al.,  2002b), and thus it was of 
interest to see if CBZ and LMT could affect the USF regulatory system, as an alternative 
explanation for this reported change in BDNF expression. Here, LMT was found to 
modulate USF1 and USF2 expression, in a manner similar to CBZ, mirroring the similar 
affect of LMT to CBZ treatment upon NRSF expression (see chapter 5). Both 4hrs 
10µg/ml and 50µg/ml LMT led to a highly significant 80% reduction in USF1 mRNA 
expression, when compared to vehicle controls (Control L) (Figure 6.4a) (P = < 0.001) 
(n=3), whilst the prolonged 24hrs LMT treatment had nil affect (P = > 0.05). This 
modulation was found to be mirrored with USF2 expression, with both 4hrs 10µg/ml 
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and 50µg/ml LMT inducing a highly significant 60% reduction in USF2 (Figure 6.4b) 
(P = < 0.001) (n=3), whilst 24hrs had no impact, compared to vehicle controls.
Figure 6.3 Modulation of the USF TFs by PHY. qPCR analysis of (A) USF1 and (B) USF2 mRNA 
expression in response to PHY treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 10µg/ml or 50µg/ml PHY, or vehicle control (Control P), for 4hrs or 24hrs, before 
being processed for RNA extraction. mRNA expression of USF1 and USF2 were analysed using qPCR, 
standardized against the house keeping gene Pol II, mean fold changes compared to vehicle controls are 
given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold changes 
against vehicle controls with: * = P = < 0.05. (n=3).
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Figure 6.4 Modulation of the USF TFs by LMT. qPCR analysis of (A) USF1 and (B) USF2 mRNA 
expression in response to LMT  treatment in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were 
treated with either 10µg/ml or 50µg/ml LMT, or vehicle control (Control L), for 4hrs or 24hrs, before 
being processed for RNA extraction. mRNA expression of USF1 and USF2 were analysed using qPCR, 
standardized against the house keeping gene Pol II, mean fold changes compared to vehicle controls are 
given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold changes 
against vehicle controls with: *** = P = < 0.001. (n=3).
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6.4.3 Modulation of USF1 & USF2 location in human SH-SY5Y cells following 
ACD treatment.
6.4.3.1 Localisation of USF1 & USF2 in human SH-SY5Y cells.
In chapter 5, ACD treatment was found to have limited impact upon the 
localisation of the NRSF isoforms. Due to the postulated roles of USF proteins in 
seizure, it was important to extend this investigation, to test whether or not the ACDs 
had an impact on USF localisation. To detect USF1 and USF2, I opted to use antibodies 
previously employed by collaborators, Park & Russo as they used these antibodies in 
western blotting (both in untreated neurons and following siRNA knockdown of USF 
proteins), and in immunofluorescence (Park & Russo., 2008). USF1 and USF2 proteins 
are 43kDa and 44kDa in size, respectively, and in SH-SY5Y cells, the USF2 antibody 
detects a band at approximately 40kDa (Figure 6.5). In addition, the USF2 antibody 
detected two further bands, over 50kDa in size, however only the lower ~40kDa band 
was detectable in other cell line extracts tested within the lab (including JAr cells, HaCat 
cells and HeLa cells). This USF2 antibody has been shown to be specific by other 
groups, as this specific band is markedly reduced following USF2 knockdown (Park & 
Russo., 2008). The additional bands observed in the western blot may well be splice 
variants such as USF2b (Viollet et al., 1996). 
Intriguingly, the USF1 antibody failed to detect a band at the appropriate 43kDa 
size, but did detect a band at approximately 52kDa, which was also detected by the 
USF2 antibody. These ~50kDa bands have previously been detected in western blots 
with other USF1 and USF2 antibodies, by other groups (West et al., 2004) suggesting 
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that they are not, non-specific binding, but perhaps detecting splice variants of the two 
USF proteins. Furthermore, the USF1 antibody detected a band at approximately 95kDa, 
which was also detected by West et al., in human K562 nuclear extracts (West et al., 
2004). Park & Russo, tested the specificity of the USF1 antibody employed here, via 
siRNA knockdown of USF1, noting a reduction in USF1 protein as detected by western 
blotting (Park & Russo., 2008).
Using confocal microscopy and immunofluorescence, the USF1 antibody was 
found to detect a nuclear protein in untreated SH-SY5Y cells (Figure 6.6), consistent 
with the published nuclear localisation of USF1 in cultured neurons (Park & Russo,. 
2008). This nuclear staining of USF1 was found in all untreated cells.USF2 was found 
to be predominantly cytoplasmic, with some nuclear staining, in untreated SH-SY5Y 
cells (Figure 6.6). These findings are supportive of those found by Park & Russo, who 
found USF2 to exhibit a more cytoplasmic distribution in cultured rat trigeminal ganglia 
(Park & Russo., 2008). Due to the consistencies with previous findings, I continued to 
use the USF1 and USF2 antibodies, to determine the impact ACD treatment had, if any, 
on USF protein localisation. 
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Figure 6.5 Western blotting of human SH-SY5Y cells extract with USF1 and USF2 antibodies.
Human SH-SY5Y cell extract probed with the anti-USF1 antibody and anti-USF2. The USF2 antibody 
detects a band at the expected 44kDa, as well as a higher band above 51kDa. This higher band is also 
detected by the USF1 antibody. 
211
Figure 6.6 Immunofluorescence staining of USF1 and USF2 in human SH-SY5Y cells. Untreated 
human SH-SY5Y cells were stained with the anti-USF1 or anti-USF2 antibodies. Both primary antibodies 
were recognized with Alexa 568 secondary antibody. Overlay images stained with DAPI and Alex 568, 
are given in the corners. USF1 is shown to be nuclear, whilst USF2 exhibits predominantly cytoplasmic 
staining. 
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6.4.3.2 CBZ, PHY and LMT has limited impact upon USF1 and USF2 localisation 
in human SH-SY5Y cells.
As aforementioned, USF1 was found to be predominantly nuclear in untreated 
cells. This nuclear staining was found in all cells, including those exposed to the ACDs, 
and to the corresponding vehicle controls. ACD treatment had thus little impact upon 
USF1 localisation. Both 50µg/ml CBZ and the vehicle control (Control C), elicited 
exclusive nuclear staining of USF1 at both 4hrs and 24hrs treatment time-points (Figure 
6.7), mirroring that observed in untreated cells (Figure 6.6). Similarly, USF1 staining 
was found to be fully nuclear following both 4hrs and 24hrs 50µg/ml PHY (Figure 6.8), 
which matched the distribution of both untreated cells (Figure 6.6) and vehicle control 
(Control P) treated cells (Figure 6.8). Finally, LMT treatment also had little impact upon 
USF1 localisation, with both vehicle control (Control L) and 50µg/ml LMT exhibiting 
fully nuclear USF1 localisation, at both 4hrs and 24hrs (Figure 6.9). Whilst USF1 
distribution between nucleus and cytoplasm remained constant following LMT 
treatment, 24hrs 50µg/ml LMT did induce a modest change, with distinct nuclear 
aggregations observed (Figure 6.9). 
The response of USF2 to both pro-convulsant and ACD treatment, in terms of 
mRNA expression, was found, in general, to mirror that of USF1. This consistency in 
the response of USF2 and USF1 to ACD treatment was also found to be the case with 
regards to modulation of USF2 localisation, with ACD treatment having little impact 
upon USF2 localisation in SH-SY5Y cells. USF2 was found to be distributed throughout 
the cell, with mostly cytoplasmic staining, and some nuclear (Figure 6.6). This 
predominantly cytoplasmic distribution of USF2 was also found in cells exposed to 
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either 4hrs vehicle control for CBZ treatment (Control C) or 4hrs 50µg/ml CBZ (Figure 
6.10). In contrast, the more prolonged 24hrs treatment with both Control C and 50µg/ml 
CBZ resulted in a more intense nuclear USF2 staining pattern compared to untreated 
cells, with some cytoplasmic staining remaining (Figure 6.10). Whilst this data is not 
quantitative, the stronger nuclear staining observed may indicate that the vehicle control 
can induce a shift in USF2 localisation, whilst CBZ has no noticeable additional impact. 
PHY and its vehicle control (Control P), evoked a similar response in USF2 
localisation to CBZ and Control C. Cells exposed to either 4hrs Control P or 4hrs 
50µg/ml PHY, exhibited predominantly cytoplasmic USF2 staining (Figure 6.11), 
matching that of untreated cells. In contrast, 24hrs exposure to Control P or 50µg/ml 
PHY induced a more nuclear USF2 distribution, with some cytoplasmic USF2 
remaining (Figure 6.11). This indicates that prolonged exposure to the vehicle results in 
a shift in USF2 sub-cellular distribution, which appears unaffected by the ACD PHY.
Intriguingly, the vehicle control for LMT, Control L, has a higher concentration 
of DMSO, compared to Control P, and induced the same shift in USF2 localisation, to a 
predominantly nuclear distribution, within 4hrs exposure (Figure 6.12). This 
predominantly nuclear pattern (with some cytoplasmic staining) was also exhibited at 
24hrs Control L, and following both 4hrs and 24hrs 50µg/ml LMT (Figure 6.12). Again, 
this reveals that the vehicle has a profound impact upon USF2 distribution, whilst the 
actual ACD, has no further effect. 
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Figure 6.7 Immunofluorescence staining of USF1 in response to CBZ treatment in human SH-SY5Y 
cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml CBZ  or vehicle control (Control 
C). Cells were stained with the anti-USF1 antibody and with Alexa 568 secondary antibody. Overlay 
images stained with DAPI and Alex 568, are given in the corners. USF1 is shown to be nuclear in Control 
C and CBZ treated cells. (n=2).
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Figure 6.8 Immunofluorescence staining of USF1 in response to PHY treatment in human SH-SY5Y 
cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml PHY or vehicle control (Control 
P). Cells were stained with the anti-USF1 antibody and with Alexa 568 secondary antibody. Overlay 
images stained with DAPI and Alex 568, are given in the corners. USF1 is shown to be nuclear in Control 
P and PHY treated cells. (n=2).
216
Figure 6.9 Immunofluorescence staining of USF1 in response to LMT treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml LMT or vehicle control 
(Control L). Cells were stained with the anti-USF1 antibody and with Alexa 568 secondary antibody. 
Overlay images stained with DAPI and Alex 568, are given in the corners. USF1 is shown to be nuclear in 
Control L and LMT treated cells. (n=2).
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Figure 6.10 Immunofluorescence staining of USF2 in response to CBZ treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml CBZ  or vehicle control 
(Control C). Cells were stained with the anti-USF2 antibody and with Alexa 568 secondary antibody. 
Overlay images stained with DAPI and Alex 568, are given in the corners. CBZ treatment elicits similar 
staining patterns to vehicle control (Control C), with 4hrs treatment inducing predominantly cytoplasmic 
staining, and 24hrs giving more nuclear staining patterns. (n=2).
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Figure 6.11 Immunofluorescence staining of USF2 in response to PHY treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml PHY or vehicle control 
(Control P). Cells were stained with the anti-USF2 antibody and with Alexa 568 secondary antibody. 
Overlay images stained with DAPI and Alex 568, are given in the corners. PHY treatment elicits similar 
staining patterns to vehicle control (Control P), with 4hrs treatment inducing predominantly cytoplasmic 
staining, and 24hrs giving more nuclear USF2 staining patterns. (n=2).
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Figure 6.12 Immunofluorescence staining of USF2 in response to LMT treatment in human SH-
SY5Y cells. Human SH-SY5Y cells were treated for 24hrs with either 50µg/ml LMT or vehicle control 
(Control L). Cells were stained with the anti-USF2 antibody and with Alexa 568 secondary antibody. 
Overlay images stained with DAPI and Alex 568, are given in the corners. LMT treatment induces similar 
staining patterns to vehicle control (Control L), with nuclear and cytoplasmic staining observed at both 
4hrs and 24hrs time-points. (n=2).
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6.4.3 Modulation of USF2 binding to TAC1 and NKB promoter regions in human 
SH-SY5Y cells by CBZ treatment.
ACD treatment has been shown to modulate USF1 and USF2 mRNA expression 
in human SH-SY5Y cells, but has little impact upon USF1 and USF2 localisation. This 
is analogous to the findings presented in Chapter 5, which revealed ACD treatment has a 
pronounced impact upon NRSF isoform mRNA expression, but limited impact upon 
NRSF isoform localisation. In addition, in chapter 5, ACD treatment was found to 
differentially modify NRSF binding to target regions, suggesting that these drugs can 
affect the function of NRSF in terms of recognising and binding to its DNA recognition 
motif, the NRSE. Here, I wished to explore whether or not a similar impact upon USF 
binding to its targets could be affected following ACD treatment. In previous chapters, 
USF2 has been shown to bind to the NKB and TAC1 promoter regions in the SH-SY5Y 
cells used here (chapters 3 and 4 respectively), and so I opted to explore USF2 binding. 
Unfortunately USF1 binding could not be explored in time for completion of this thesis, 
as experimental conditions could not be optimised in time. Furthermore, in chapter 3, 
the regulatory role of both USF proteins on the human NKB promoter was found to be 
abolished following CBZ. For these reasons I explored the impact of CBZ treatment 
upon USF2 binding to the human TAC1 and NKB promoter regions using a preliminary 
ChIP assay.
In a preliminary investigation, USF2 was found to bind to both the human TAC1 
and NKB promoter regions in untreated SH-SY5Y cells, based upon a stronger PCR 
signal observed from the chromatin enriched following USF2 pull-down, compared to 
the non-specific background negative control; IgG (Figure 6.13). The vehicle control 
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(Control C) was found to elevate USF2 binding to the TAC1 promoter region, following 
24hrs treatment, whilst USF2 binding to the NKB promoter region appears unchanged. 
24hrs 50g/ml CBZ treatment was found to completely abolish USF2 binding to the 
TAC1 locus, with no USF2 binding observed (Figure 6.13). Interestingly, the data also 
suggests that USF2 binding to the NKB promoter is reduced following CBZ treatment, 
when compared to vehicle control treated and untreated cells. However it is important to 
note that the IgG negative control band was also elevated in CBZ treated cells, and so 
one cannot conclude CBZ is affecting USF2 binding to the NKB promoter. Despite this, 
this preliminary experiment has suggested that CBZ treatment can impair USF2 binding 
to the promoter regions of the pro-convulsant neuropeptide encoding gene TAC1, which 
may be consistent with its role as an anti-convulsant.
Figure 6.13. Modulation of USF2 binding to neuropeptide promoter regions following CBZ 
treatment in human SH-SY5Y cells. ChIP analysis of USF2 binding to human TAC1 or NKB promoter 
in SH-SY5Y cells treated with either 24hrs 50µg/ml CBZ, vehicle control (Control C) or untreated. IgG 
was included as a non-specific binding control (background). USF2 binding to the TAC1 promoter region 
was found to be diminished following CBZ treatment when compared to vehicle control. Binding is 
shown to be specific to the TAC1 of NKB promoter locus, as no binding is observed in the GAPDH PCR 
negative controls. (n=1).
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6.5 Discussion
I have shown that the bHLH factors USF1 and USF2 regulate the pro-convulsant 
tachykinins NKB (chapter 3) and TAC1 (chapter 4), as have others (Paterson et al., 
1995; Gerrard et al., 2005), in addition to other neuronal genes implicated in epilepsy 
such as BDNF (Tabuchi et al., 2002b), GABAB receptors (Steiger et al., 2004) and 
KCC2 (Tornberg et al., 2005). Due to their regulation of such genes, I have postulated 
that the USF TFs are important in epilepsy, governing gene expression in response to 
seizure. In support of such a hypothesis, USF null-mice have been shown to be prone to 
spontaneous seizures (Sirito et al., 1998), and a number of other bHLH factors are 
known to be modulated during seizure (Elliot et al., 2001). 
As of yet, the response of USF1 and USF2 to seizure has yet to be clarified, but I 
have shown here, for the first time, that USF1 and USF2 expression is up-regulated 
following pro-convulsant challenge (KA) (Figure 6.1). This data suggests that the USF 
TFs are potentially modulated during seizure, and I propose that these TFs will respond 
to early changes brought about by seizure, in a similar manner shown by our lab, and 
others, of the NRSF isoforms (Palm et al., 1998; Spencer et al., 2006). Consistent with 
such a model in which USF gene expression is induced during seizure, are the findings 
that the p38 mitogen-activated protein kinase signalling pathway is pivotal in seizure. 
USF1 is shown to be p38 activated (Galibert et al., 2001), and p38 immunoreactivity has 
been shown to be elevated in the rat hippocampus following 3hrs KA (Park et al., 2008). 
Furthermore, transgenic mice with a single copy disruption of the p38 gene 
(p38alpha(+/-), are found to have reduced seizure susceptibility and mortality rates 
(Namiki et al., 2007). Taken together, a potential role for USF in epilepsy becomes 
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more apparent, bringing forward the need to quantify USF expression in in vivo rodent 
seizure models in the future. 
As USF1 and USF2 were found to be up-regulated during pro-convulsant (KA) 
challenge, similar to NRSF isoforms discussed in chapter 5, and the fact that the USF 
TFs regulate pro-convulsant neuropeptides, I sought to investigate the impact of ACD 
treatment upon USF expression, localisation and functional binding, akin to experiments 
undertaken in chapter 5. Interestingly the anti-convulsant treatment resulted in a number 
of parallels in the response of the USF TFs, compared to the NRSF isoforms, perhaps 
most notably being the lack of a response to ACD treatment in terms of TF localisation. 
Moreover, the response of USF mRNA expression to ACDs was found to be more 
consistent between CBZ and LMT treatment, compared to PHY, which mirrors that 
observed with the NRSF isoforms. 
6.5.1 USF gene expression
As mentioned in chapter 5, the three ACDs chosen here all share a similar initial 
target, the sodium channel,(Kuo et al., 1998). Interestingly, each of these drugs have 
different structures, with each having other initial targets (e.g. LMT also targets high 
voltage gated calcium channels (Wang et al.,1996)) and each has differential 
downstream targets. These differences and similarities are reflected in the response of 
the USF genes to each of these drugs. CBZ was found to induce an exposure duration-
dependent change in USF1 mRNA expression, with 4hrs treatment, but not 24hrs 
treatment, causing a highly significant reduction in USF1 mRNA (Figure 6.2a). USF2 
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also responded to CBZ with a marked reduction in USF2 mRNA expression observed at 
all concentrations and time-points tested (Figure 6.2b). 
Intriguingly, LMT treatment induced a similar trend to CBZ in USF1 and USF2 
modulation. As with CBZ treatment, LMT evoked  an exposure-dependent  modulation 
of USF1, with 4hrs, but not 24hrs LMT resulting in a significant reduction in USF1 
expression. USF2 responded in a similar manner, with 4hrs LMT only inducing a 
reduction in USF2 expression (Figure 6.4b). Thus, following 4hrs treatment, both CBZ 
and LMT induce a significant reduction in both USF1 and USF2 mRNA expression, 
whilst also causing a significant up-regulation of full-length NRSF following (see 
chapter 5). As these two drugs have recently been shown to modulate BDNF in the rat 
cortex (Chang et al., 2009), a gene regulated by both USF and NRSF TFs, it is plausible 
that CBZ and LMT are modulating a common pathway. 
One candidate pathway for modulation by CBZ and LMT is the p38 MAP kinase 
signalling pathway, which has been shown to be modulated by sodium channel blockade 
(a mechanism of action for both CBZ and LMT) via the drug Riluzole (Katoh-Semba et 
al., 2009). Riluzole was found to elevate p38 MAPK levels, which in turn elevated 
BDNF expression in rodent hippocampi (Katoh-Semba et al., 2009). Interestingly, 
blockade of  N-type voltage gate calcium channels, which is one of LMT’s mechanisms 
of action (Wang et al., 1996), reduces p38 production (Katoh-Semba et al., 2009). As 
stated earlier USF1 is activated by p38 (Galibert et al., 2001) and so blocking p38 
production, may in turn reduce USF1 expression, which would be consistent with our 
findings at 4hrs CBZ or LMT treatment. NRSF regulation may also be modulated by 
this pathway as p38 is found to be required for BDNF regulation (Katoh-Semba et al., 
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2009), a well established NRSF regulated gene (Timmusk et al., 1999). It is plausible 
that NRSF is inhibited by this pathway, which would mean that reduced p38, via N-type 
Ca2+ channel blockade, would elevate NRSF expression, and potentially lead to 
suppression of BDNF production. Supportive of this are the recent findings the NRSF-
mediated suppression of BDNF is activity dependent , changing in response to neuronal 
depolarisation (Hara et al., 2009). Consequently, an important future experiment would 
be to determine the role of the p38 MAPK signalling pathway on NRSF expression and 
function.  
PHY treatment has been found to elicit quite different effects upon USF gene 
expression following the treatment conditions tested here. PHY treatment was found to 
have no significant effect on USF2 mRNA expression, but did result in an increase in 
USF1 expression following 4hrs 10µg/ml PHY (Figure 6.3). Furthermore, unlike CBZ 
and LMT, PHY treatment had no impact on NRSF expression (see chapter 5, Figure 
5.3), but did repress sNRSF mRNA expression. This data implies that PHY may be 
modulating a separate signalling pathway to CBZ and LMT, inducing a different 
signalling cascade, and modulating different down-stream targets.   
6.5.2 USF protein localisation
Despite invoking a differential change in USF1 and USF2 expression compared 
to CBZ and LMT, PHY did generate similar data to these drugs in terms of USF 
localisation in response to ACD treatment. All three drugs had little impact upon USF1 
and USF2 localisation within the human neuroblastoma cells tested here, when 
compared to their corresponding vehicle controls. This is analogous to the lack of 
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response to these drugs from the NRSF isoforms. Interestingly, it was the vehicle 
controls which induced any observed change in USF localisation, with all three vehicle 
controls promoting a more nuclear localisation of USF2, compared to untreated cells. 
This USF2 nuclear localisation was also observed in cells exposed to the corresponding 
ACD treatment, indicating that the ACDs have no further impact upon USF2 
localisation, compared to their vehicle controls.  However, as stated in chapter 5, the 
immunoflourescence data is not quantitative, and so it would be of interest in future to 
measure USF2 protein levels in nuclear extracts in untreated and treated cells, to 
quantify the proposed changes in sub-cellular distribution. Furthermore, as proposed in 
chapter 5, it would be of interest to repeat the experiments with alternative vehicles for 
each ACD, to better derermine the impact of the ACDs on USF2 localisation.
As postulated in chapter 5, this lack of response of USF protein localisation, to 
ACD treatment (compared to vehicle controls) may be a result of these drugs 
maintaining a stable, normal neuronal phenotype, and in future, the more interesting 
experiment would be to stress the cells first with KA, monitor USF1 and USF2 
localisation, and determine if the ACDs could restore any KA-induced change observed. 
In addition, it would be of interest to explore USF localisation in response to seizure, in 
an in vivo rat model, similar to that published by our lab for NRSF (Spencer et al¸2006).
One note-worthy exception was found following 24hrs 50µg/ml LMT, with an increase 
in nuclear aggregations of USF1 found when compared to vehicle control (Control L) 
(Figure 6.9). These USF1 nuclear aggregations have previously been reported by other 
groups (Qyang et al., 1999) however their exact nature remains unclear. They may be 
promyelocytic leukemia (PML) nuclear bodies, which are known to accumulate TFs and 
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chromatin remodelling proteins such as CBP acetyltransferase and HDAC1 (Reviewed 
in Zimber et al., 2004). It would be important to determine what these nuclear 
aggregations are as this modulation is exclusive to LMT treatment, and as such may 
help determine the signal pathways LMT is targeting. 
6.5.3 USF binding
The ability of a TF to govern gene regulation will not only rely on its localisation 
and expression, but also its ability to recognise and bind to its DNA recognition 
sequence. The USF TFs recognise and bind to a canonical E box sequence CANNTG. In 
previous chapters, USF binding to both the human NKB (chapter 3) and TAC1 (chapter 
4) promoter regions was explored, with USF2, and not USF1, found to be bound to both 
promoter regions in SH-SY5Y cells. In contrast, in the SK-N-AS neuroblastoma cell 
line, USF1 was found bound to both promoter regions (Figure 3.7 and Figure 4.8). Due 
to the previously observed binding of USF2 only, to the TAC1 and NKB promoter 
regions, the effect of CBZ treatment on USF2 binding to these promoters was explored. 
In future, to determine the impact of such treatment on USF1 binding, one may opt to 
treat the SK-N-AS cell line, which exhibited USF1 binding to these promoter regions.
Previous reports have shown that the binding properties of the USF TFs, 
specifically USF1, to target E box motifs can be modulated by multiple signal 
transduction pathways and challenges, including the UV-stress induced p38 stress 
activate kinase pathway (Galibert et al., 2001), the phosphatidylinositol 3-kinase (PI3 
kinase) pathway (Nowak et al., 2005) and the protein kinase A and C pathways (Xiao et 
al., 2002). Previous reports have shown that such pathways can be modulated by ACD 
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treatment. VPA treatment has recently been shown to activate the PI3 kinase pathway
(Gurpur et al., 2009), whilst CBZ has been shown to enhance the activity of the 
glutamate transporter 3 via the same pathway (Lee et al., 2005). Due to these findings, I 
postulate that USF binding to target E box motifs could be modulated by ACD 
treatment. Indeed, in preliminary ChIP assays, CBZ treatment was found to reduce 
USF2 binding to the TAC1 promoter region, compared to vehicle controls and untreated 
cells (Figure 6.13), which supports the theory that ACDs can modulate USF2 binding to 
target regions. Such impairment of USF2 binding may be supportive of data presented in 
earlier chapters, whereby CBZ treatment was shown to significantly repress TAC1 
mRNA expression (Figure 5.5), with the USF TFs shown to be an activator of TAC1 
expression (Paterson et al., 1995). Thus CBZ not only reduces USF2 mRNA expression, 
but may also impair USF2 binding to the TAC1 promoter, leading, in part, to reduced 
TAC1 expression. This would be consistent with the role of an ACD to repress 
activation of a pro-convulsant neuropeptide, and to our knowledge, this is the first time 
this modulation has been reported. However, it should be stressed that these are only 
preliminary findings, that perhaps warrant further investigation in the future. 
Interestingly the decrease in USF2 binding to the TAC1 promoter region is in contrast to 
the elevated NRSF binding to the same regions, in the same CBZ treatment samples 
(Figure 5.15). This data, whilst preliminary, may indicate that a dynamic switch in TF 
recruitment to these pro-convulsant neuropeptide regions can occur under challenge, and 
may provide further support for the theory that NRSF isoforms and USF1 and USF2 
may be competing for binding privileges at these promoter loci. It would therefore be of 
interest to explore USF binding to these loci, in response to NRSF variant over-
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expression, and vice versa, to fully explore the relationship between USF and NRSF 
mediated regulation of these neuropeptide genes. Interestingly at the 24hrs time-point 
tested in ChIP assays, both USF2 and NRSF are found to be reduced following 50µg/ml 
CBZ treatment, and so it would be of interest to explore binding of these TFs following 
4hrs CBZ, as whilst USF2 mRNA expression is reduced, NRSF expression is enhanced. 
This would enable us to explore this proposed competition for binding privileges, much 
like the over-expression study I alluded to. 
To summarise, the data presented here suggests that USF1 and USF2 are 
modulated following pro-convulsant challenge in a human neuroblastoma cell line, and I 
postulate that these TFs are important factors bringing about dynamic changes in gene 
expression patterns, as an initial response to seizure. In addition, these findings indicate 
that ACD treatment targets and modulates the USF regulatory system. The drugs tested 
here modulated USF gene expression and possibly binding to target neuropeptide 
regulatory regions. These findings provide new evidence for the function of these ACDs 
in modulating distinct TF regulatory systems, which are implicated in seizure 
progression. The findings also support earlier discussions regarding an inherent 
relationship between the USF and NRSF regulatory systems, which appear to have an 
important role in the molecular mechanisms governing epilepsy. 
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CHAPTER 7: A distinct role for NRSF variants in modulation of 
epilepsy associated gene expression – revealed by microarray analysis
7.1 Introduction 
Altered expression of genes such as BDNF or the pro-convulsant neuropeptide 
SP is associated with early changes in rodent models of status epilepticus and may be a 
marker of a generalised cellular derangement that leads to immediate and longer-term 
changes in gene expression associated with epilepsy. As mentioned in previous chapters, 
NRSF isoforms are up-regulated in seizure (Palm et al¸1998; Spencer et al., 2006), and 
are known to regulate both BDNF (Timmusk et al., 1999; Tabuchi et al., 2002a) and the 
SP encoding gene TAC1 (Quinn et al., 2002; Spencer et al., 2006; Greco et al., 2007; 
Howard et al., 2008; Reddy et al., 2009). Furthermore, in chapter 3, NRSF variants were 
also found to regulate the expression of a second proconvulsant neuropeptide, NKB. 
Consistent with a model that NRSF isoforms are important in seizure, chapter 5 revealed 
that these isoforms were differentially modulated by ACD treatment, and recently a 
mutation in the gene encoding RILP, which governs NRSF localisation, has been 
correlated with epilepsy (Bassuk et al., 2008). 
It is well known that NRSF can alter chromatin structure and disturb epigenetic 
markers on many genes (reviewed in Ooi & Wood., 2007), including those encoding ion 
channels (Tapia-Ramirez et al., 1997; Kuwahara et al., 2003; Cheong et al., 2005) and 
neuropeptides (Quinn et al., 2002; Coulson et al., 1999., Coulson et al., 2000). This 
ability to alter epigenetic signatures on genes implicated in epilepsy could lead to long-
term changes in their gene expression profiles, which might change the threshold for 
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further seizures. The latter would be consistent with metabolic changes, induced by the 
glycolytic inhibitor 2-deoxy-D-glucose (2-DG), modulating seizure activity via, in part, 
modulation of NRSF function (Garriga-Canut et al., 2006). In addition, many patients 
suffering with epilepsy also experience cognitive disturbances likely to be indicative of 
the underlying brain dysfunction. Consistent with the importance of NRSF on 
expression of genes such as BDNF, our lab has recently demonstrated that variants in 
both BDNF and NRSF are important determinants of cognitive decline in the elderly 
(Miyajima et al., 2008). 
Whilst the function of NRSF is well established, the function of the truncated 
isoform sNRSF remains unclear. The truncated isoform has been shown to antagonise 
the action of full-length NRSF, inhibiting NRSF binding to the cholinergic gene NRSE 
(Shimojo et al., 1999) and inhibiting NRSF silencing of the BDNF promoter (Tabuchi et 
al., 2002). Furthermore, the truncated isoform has been shown to act as an activator 
rather than a repressor of some genes regulated by NRSF (Shimojo et al., 1999; Tabuchi 
et al., 2002; Spencer et al., 2006). The truncated isoform is therefore postulated to 
function differently to full-length NRSF. Indeed, in chapter 4, I eluded to functional 
differences between the two variants, based on the differential cooperation with the USF 
proteins in regulating the rat TAC1 promoter, and differential regulation of the human 
synapsin I promoter has also been reported (Magin et al., 2002). Our lab has previously 
suggested that the truncated NRSF isoform is perhaps more important than full-length 
NRSF, in modulating the pro-convulsant neuropeptide TAC1, due to the elevated 
response of the TAC1 promoter to the truncated isoform in rat hippocampi (Spencer et 
al., 2006) and in human SK-N-AS cells in cooperation with USF proteins (Chapter 4). 
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Due to the apparent importance of both NRSF isoforms in modulating gene 
expression following seizure, I sought to investigate the impact of over-expressing both 
full length and truncated NRSF variants on global gene expression profiles, through a 
Microarray analysis approach. Spencer et al., showed that NRSF isoforms are up-
regulated as an early response to seizure in rat hippocampi, and I was interested in 
whether this early response could induce medium to long-term changes in gene 
expression. Consequently, I have explored the impact of relatively long-term over-
expression of NRSF variants (24hrs and 48hrs over-expression), on global gene 
expression patterns via an Affymetrix microarray. In addition, Spencer et al., show that 
whilst the full length NRSF is expressed endogenously in control rat hippocampi, the 
truncated isoform is non-detectable, but is vastly up-regulated following 3hrs KA 
(Spencer et al., 2006). For my experiment, I wanted a cell line model which would be 
consistent with rat hippocampi in terms of NRSF expression, and opted to utilise the 
human SK-N-AS cell line, shown in chapter 3 to express NRSF endogenously, but not 
the truncated isoform (Figure 3.2). 
To perform in-depth analysis of the Affymetrix microarray dataset, the GeneGo 
software suite (http://www.genego.com) has been employed. The GeneGo suite 
incorporates the MetaCoreTM database (GeneGo Inc.) of documented protein-protein 
(gene-gene) associations and interactions, as well as a set of graphical and statistical 
tools to allow one to build networks and pathways based on known relationships 
between genes. MetaCoreTM is a manually curated database, compiling published 
interactions or associations between genes or proteins. MetaCoreTM provided a platform 
to identify differences between REEX1 and HZ4 over-expression, on gene expression 
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profiles and pathways. Furthermore, the GeneGo software suite provided a tool to 
generate an epilepsy disease network map, based on a manual collation of genes 
implicated in epilepsy. The microarray dataset was screened against this epilepsy 
network map, to uncover the impact of NRSF variant over-expression, on the expression 
of numerous genes with known or postulated associations with epilepsy. Finally, RT-
PCR was employed to validate changes in gene expression detected by the Microarray.
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7.2 Aims
 To explore global changes in gene expression following over-expression of full-
length NRSF via the REEX1 expression construct, and a truncated construct 
analogous to sNRSF (HZ4), in human SK-N-AS neuroblastoma cells. 
 To use GeneGo bioinformatic software to analyse the Microarray generated data, 
screening for similarities and differences between the REEX1 and HZ4 over-
expression.
 To use GeneGo bioinformatic software to analyse the Microarray generated data, 
screening for modulation of genes associated with epilepsy.
 Validate the dataset via RT-PCR.
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7.3 Methods
7.3.1 Cell culture, transfections and RNA extraction
Human SK-N-AS cells were cultured in 6-well plates as outlined in methods 
section 2.2.2.1.1 and transfected as described in methods section 2.2.4.2, delivering 
either the full-length NRSF expression construct REEX1, or the truncated variant, HZ4.
Following transfection, cells were harvested for RNA extraction as outlined in methods 
section 2.2.3.1, at 0hrs, 24hrs or 48hrs post transfection time points.  
7.3.2 Affymetrix Microarray Analysis
In order to analyse global changes in gene expression patterns, Affymetrix 
Microarray technology was utilised. A total of 10µg of RNA was processed as outlined 
in methods section 2.2.3.6, hybridized to Human Genome U133 Plus 2.0 arrays from 
Affymetrix, Inc. (Santa Clara, CA), and scanned on an Affymetrix GeneChip® scanner 
3000 at 2.5μm resolution. Image data was analysed using Affymetrix GCOS software, 
and imported into Microsoft Excel. Data was filtered as outlined in methods section 
2.2.3.6, through pairwise comparison of either 24hrs or 48hrs time points, REEX1 and 
HZ4 transfected samples, against corresponding 0hrs controls.
7.3.3 Bioinformatics – GeneGo MetaCoreTM analysis
Filtered data generated from the Affymetrix microarray analysis, was parsed into 
the online GeneGo data mining software suite (http://www.genego.com). The 
microarray dataset was screened against the manually curated MetaCore database, to 
provide in-depth analysis of the data, enabling us to extract functionally significance 
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from the dataset. In addition, one employed the GeneGo MapEditor Version 2.6.0 
(GeneGo Inc), to generate an ‘epilepsy network map’, incorporating genes implicated in 
epilepsy, discovered via manual screening of published findings. 
7.3.4 mRNA expression analysis – Validation of Microarray findings
In order to validate the dataset retrieved from the Affymetrix microarray, the 
expression of a small number of genes showing marked modulation, was carried out. 
The expression of the potassium channels HCN2 and HCN3, and the sodium channel 
SCN9a following REEX1 and HZ4 over-expression, was investigated using PCR as 
described in methods section 2.2.3.4, using the PCR primers set out in Table 2.2.1. 
Thermal cycle conditions for all, were as follows: initial denaturation: 95oC for 2mins 
for 1 cycle; followed by 40 cycles of denaturation: 95oC for 30 seconds, annealing 62oC 
for 30 seconds and elongation: 72oC for 1min; and a final elongation step of 72OC for 
2mins. 
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7.4 Results
7.4.1 Over-expression of REEX1 and HZ4 modulate differential changes in gene 
expression profiles
The regulatory function of NRSF has been well documented since its discovery 
over a decade ago (Chong et al., 1995; Schoenherr & Anderson., 1995), but that of its 
truncated isoform, sNRSF, has so far yet to be fully determined. The truncated NRSF 
isoform has been postulated to function by antagonizing the action of full-length NRSF 
or indeed act as an activator rather than a repressor of genes regulated by NRSF 
(Shimojo et al., 1999; Roopra et al., 2000; Tabuchi et al., 2002). In Chapter 4, I eluded 
to the fact that the truncated variant may function differently to the full-length isoform, 
due to the exclusive cooperation of the truncated variant with USF proteins to enhance 
the wild-type rat TAC1 promoter activity. Due to these potential functional differences 
between the two isoforms, I wished to explore global changes in gene-expression 
profiles, following over-expression of full-length NRSF via the REEX1 construct, and 
the over-expression of a truncated version, analogous to sNRSF:  HZ4.
Human SK-N-AS neuroblastoma cells were transfected with either REEX1 or 
HZ4, and harvested at 0hrs, 24hrs and 48hrs post transfection, with 0hrs considered to 
be a baseline time point (control). Harvested RNA was processed and analysed using an 
Affymetrix Microarray. The data generated from the microarray was parsed into the 
online computational platform MetaCoreTM for in-depth analysis. MetaCoreTM analysis 
revealed that the over-expression of full length NRSF (REEX1) and the over-expression 
of the truncated variant (HZ4), led to differential changes in gene expression profiles at 
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both 24hrs and 48hrs time points, when compared to the 0hrs baseline time point. For 
both 24hrs and 48hrs time points, MetaCoreTM revealed that the number of genes 
modulated (either increase or decrease in expression) uniquely by either REEX1 or HZ4 
over-expression, was greater than those which were modulated by both (Figure 7.1). At 
24hrs, 534 genes were exclusively modulated by HZ4 and 307 genes were exclusively 
modulated by REEX1, whereas only 165 genes were modulated by both constructs 
(Figure 7.1a). Similarly at 48hrs, 566 genes were uniquely modulated by REEX1, 381 
genes uniquely modulated by HZ4 and only 111 were found to be modulated by both  
(Figure 7.1b). (P = < 0.01) (n=3). These findings support a theory that the truncated 
variant regulates, either directly or indirectly, a distinctly different set of genes 
compared to full-length NRSF.
Figure 7.1. The number of genes modulated in response to the over expression of either REEX1 or 
HZ4. Venn diagram representing the number of genes found to be uniquely modulated following either 
24hrs or 48hrs over expression of full length NRSF (REEX1) or the truncated variant (HZ4), in human 
SK-N-AS neuroblastoma cells (P < 0.01) (n=3). Genes found to be modulated by both NRSF (REEX1) or 
the truncated variant (HZ4) are represented by the overlapping sections.
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Figure 7.2. Over-expression of REEX1 and HZ4 modulate different types of genes. Bar chart 
represents the number of genes found to be uniquely and significantly modulated following over-
expression of either 24hrs REEX1 (blue bar), 48hrs REEX1 (red bar), 24hrs HZ4 (green bar) or 48hrs 
HZ4 (purple bar), in human SK-N-AS neuroblastoma cells (P < 0.01) (n = 3). Gene descriptions or types 
where taken from MetaCoreTM.
MetaCoreTM provided the capability to probe the dataset to a greater extent, by 
subdividing the genes uniquely modulated by REEX1 or HZ4 over-expression 
(UNIQUE), into subgroups based on their function. These groupings included enzymes, 
adaptor proteins, transcription factors, receptors and channels, and transporters (Figure 
7.2) (P = < 0.01) (n=3). A general trend was observed in 7 out of 13 groups and 
specifically in the three most gene-abundant groups (Adaptors/Regulators, Generic 
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Proteins and the Generic enzyme groups), with a marked increase in the number of 
uniquely modulated genes in each group following prolonged REEX1 over-expression 
(48hrs vs 24hrs) observed. In contrast, the more prolonged over-expression of HZ4 
resulted in a decrease in the number of uniquely modulated genes (48hrs vs 24hrs), in 
the same 7 groups. This indicates therefore that the NRSF variants differentially 
modulate gene expression in a time dependent manner, and that duration of over-
expression plays a role in determining gene expression pathways.
7.4.2 REEX1 and HZ4 over-expression modulates differential expression of genes 
implicated in epilepsy.
In chapters 3 and 4, the importance of the NRSF variants in the regulation of the 
pro-convulsant neuropeptides NKB and TAC1, respectively, was revealed and in 
chapter 5, these NRSF isoforms were found to be modulated by both KA and ACD 
treatment. The importance of these NRSF isoforms in epilepsy has been shown by both 
our group and others, and had been discussed in detail in previous chapters. To test our 
theory that NRSF isoforms are central to gene expression changes observed in epilepsy, 
I set out to explore and screen the microarray dataset for modulation of genes associated 
with epilepsy, following either REEX1 or HZ4 over-expression, as NRSF isoforms are 
known to be up-regulated during seizure (Palm et al., 1998; Spencer et al., 2006). 
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Figure 7.3. Modulation of genes associated with epilepsy by REEX1 and HZ4. Human SK-NAS 
neuroblastoma cells were transfected with full length NRSF (RE-EX1) or the truncated isoform sNRSF 
(HZ4) for 24 and 48hrs. Global changes in gene expression patterns were recorded via Microarray. The 
fold changes of genes associated with epilepsy, are plotted on the cellular diagram via the coloured rulers, 
with red indicating enhanced expression, and blue indicating suppressed expression. The different 
treatments are number: (1) 24hrs RE-EX1, (2) 48hrs RE-EX1, (3) 24hrs HZ4 and (4) 48hrs HZ4. All fold 
changed are significant at P = < 0.05.
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I compiled a list of genes associated with epilepsy, through manually collating 
published associations, and supplementing this list with ‘proposed’ epilepsy associated 
genes, based on related genes having known associations with epilepsy. Using 
GeneGo’s online software suite, I generated an ‘epilepsy network map’, which gave a 
diagrammatic representation of the ‘epilepsy associated genes’, and enabled 
MetaCoreTM to overlay the microarray data onto this map (Figure 7.3). This approach  
revealed that a great number of genes associated with epilepsy were found to be 
modulated following either REEX1 or HZ4 over-expression, or in some cases by both. 
This data is provided in Tables 7.1-7.4, and is represented on the epilepsy network map 
(Figure 7.3), by coloured rulers next to each gene symbol, with red colouration 
indicating up-regulation and blue colouration indicating down-regulation. Genes 
encoding ion channels were found to one of the most abundant type of ‘epilepsy 
associated genes’ modulated, including calcium channels such as CACNB2 (Table 7.1) 
(P = < 0.001), potassium channels such as HCN2 (Table 7.1) (P = < 0.001) and HCN3 
(Table 7.3) (P = < 0.05), sodium channels such as SCN9a (Table 7.4) (P = < 0.001) 
and chloride channels such as CLCN2 (Table 7.3) (P = < 0.05) (all n=3). 
Other noteworthy findings include the elevated expression of glutamate 
receptors GRM8/mGluR8 (Table 7.1) (P = <0.01) and GRIN2D (Table 7.3) (P = 0.05), 
following 48hrs REEX1 and 24hrs HZ4 over-expression, respectively (n=3) and the 
down-regulation of GABA receptors GABBR1 and GABRE following 24hrs and 48hrs 
REEX1 respectively (Table 7.2) (P = < 0.05) (n=3). Furthermore, a number of genes 
known to be important in anti-epileptic drug action, metabolism and resistance were 
modulated. This includes cytochrome p450 genes, such as CYP3A5 (Table 7.1) (P = < 
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0.001) (n=3), which modulates carbamazepine pharmacokinetics (Seo et al., 2006), and 
CYP2C9 (Table 7.3) (P = < 0.01) (n=3), known to metabolise the anti-convulsant drug 
phenytoin (Tate et al., 2005; Mosher et al., 2009). The GABA transporter SLC6A1, a 
target for the anti-convulsant drug tiagabine (Meldrum & Chapman., 1999), was up-
regulated following both 24hrs REEX1 (Table 7.1) and 24hrs HZ4 (Table 7.3) (P = < 
0.05) (n=3), and finally the Levetiracetam anticonvulsant target SV2a (Kaminski et al.,
2008; Lynch et al., 2004), was found to be suppressed following 24hrs REEX1 over-
expression (Table 7.2) (P = < 0.01) (n=3).
Gene Description Relevance to Epilepsy  
(Reference)
Fold 
Chang
e
P value Exposur
e
Calcium Channels
CACNB2 Ca2+ channel, voltage-
dependent, β2 subunit
Elevated in KA seizure models 
(Gastaldi et al., 1998)
3.2 0.0001 48hrs
CACNA2D Ca2+ channel, voltage-
dependent, α2 / δ 
subunit 1
Target for ACDs Gabapentin 
(Gong et al., 2001) and 
pregabalin (Joshi et al., 2006) 
2.3 0.044 24hrs
Potassium Channels
KCNT2 K+ channel, subfamily 
T, member 2
Proposed 48.5 0.0007 24hrs
KCNE1/IS
K
K+ voltage-gated 
channel, Isk-related 
family, member 1
Mutation linked to QL 
syndrome (Splawski et al., 
2000) 
6.5 0.004 48hrs
KCNJ9/GI
RK3
K+ inwardly-rectifying 
channel, subfamily J, 
member 9
Ethosuximide inhibits GIRK 
channels (Kobayashi et al.,
2009)
4.0 0.047 24hrs
KCNQ1OT
1
KCNQ1 overlapping 
transcript 1
Proposed 3.2 0.002 24hrs
KCNJ2/IR
K1/Kir2.1
K+ inwardly-rectifying 
channel, subfamily J, 
member 2
Kir2.1 expressing cells are 
elevated in hippocampus 
following KA (Kang et al., 
2008)
2.5 0.03 48hrs
KCNK2 K+ channel, subfamily 
K, member 2
Proposed 2.5 0.0009 48hrs
GABA Transporters
SLC6A1 Solute carrier family 6, 
member 1
Target for the ACD tiagabine 
(Meldrum & Chapman., 1999)
12.0 0.029 24hrs
GABA receptors
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GABRA4 GABA A receptor, 
alpha 4
GABRA4 promoter activity 
elevated in seizure  (Roberts et 
al., 2005)
3.5 0.045 24hrs
Glutamate Receptors
GRM8/mGl
uR8
Glutamate receptor, 
metabotropic 8
mGluR8 agonist has 
anticonvulsive effects (Jiang et 
al., 2007)
2.3 0.0078 48hrs
Carbonic Anhydrase
CA9 Carbonic anhydrase IX Carbonic anhydrase inhibitors 
act as anticonvulsant agent s 
(Thiry et al., 2007)
2.0 0.029 24hrs
CA5BL Carbonic anhydrase
VB-like
Carbonic anhydrase inhibitors 
act as anticonvulsant agent s 
(Thiry et al., 2007)
2.0 0.033 48hrs
Drug Metabolising Enzymes
CYP3A5 cytochrome P450, 
family 3, subfamily A, 
polypeptide 5
Modulates CBZ 
pharmacokinetics (Seo et 
al.,2006)
12.0 0.001 48hrs
Other
NK1R / 
TACR1
Tackykinin-1 (TAC1) 
receptor
NK1 receptor antagonists 
reduces KA induced seizure 
activity (Zachrisson et al., 
1998)
21.11 0.0001 48hrs
NRSF / 
REST
Neuron restrictive 
silencing factor /RE1-
silencing transcription 
factor
Elevated in KA seizure models 
(Palm et al., 1998;   Spencer et 
al; 2006)
3.72 0.0001 24hrs
NTRkB BDNF/NT-3 growth 
factors receptor 
precursor
Elevated in SE models (Mudo 
et al., 1996; ) 
2.144 0.014 24hrs
CTBP2 C-terminal-binding 
protein 2
Implicated in molecular 
response of anti-epileptic 
Ketogenic diet (Garriga-Canut 
et al., 2006)
2.0 0.02 24hrs
Table 7.1. Genes associated with epilepsy up-regulated following REEX1 over-expression. The over-
expression of full-length NRSF, via the REEX1 expression construct, led to the significant increase in 
expression of genes listed, revealed by Affymetrix Microarray. Fold change, P values and over-expression 
duration are given. (n=3). 
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Gene Description Relevance to Epilepsy  
(Reference)
Fold 
Chang
e
P value Exposur
e
Calcium Channels
CACNA1C Ca2+ channel, voltage-
dependent, L type, 
alpha 1C subunit
Proposed 12.1 0.003 48hrs
Potassium Channels
HCN2 Hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 2
Reduced in KA seizure models 
(Powell et al., 2008)
14.9 0.0004 48hrs
KCNK13 K+ channel, subfamily 
K, member 13
Proposed 13.0 0.003 24hrs
KCNB2 K+ voltage-gated 
channel, Shab-related 
subfamily, member 2
Proposed 2.8 0.005 48hrs
KCNK17 K+ channel, subfamily 
K, member 17
Proposed 2.0 0.005 48hrs
GABA Receptors
GABBR1 GABA B receptor 1 Proposed 2.3 0.035 24hrs
GABRE GABA A receptor, 
epsilon
The ACD Stiripentol acts 
directly on GABA A receptor, 
with reduced potentiation 
when epsilon subunits present 
(Fisher., 2009)
2.0 0.047 48hrs
Synaptic Vesicle Proteins
SV2A synaptic vesicle 
glycoprotein 2A
ACD Levetiracetam target 
(Kaminski et al., 2008; Lynch 
et al., 2004)
2.1 0.008 24hrs
Other
GAL Galanin Anticonvulsant neuropeptide 
(Lerner et al., 2008)
2.3 0.0005 48hrs 
Table 7.2. Genes associated with epilepsy down-regulated following REEX1 over-expression. The 
over-expression of full-length NRSF, via the REEX1 expression construct, led to the significant decrease 
in expression of genes listed, revealed by Affymetrix Microarray. Fold change, P values and over-
expression duration are given. (n=3). 
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Gene Description Relevance to Epilepsy  
(Reference)
Fold 
Chang
e
P value Exposur
e
Calcium Channels
CACNA2D Ca2+ channel, voltage-
dependent, α2 / δ 
subunit 1
Target for ACDs Gabapentin 
(Gong et al., 2001) and 
pregabalin (Joshi et al., 2006)
16.0 0.0000
2
24hrs
CACNG6 Ca2+ channel, voltage-
dependent, gamma 
subunit 6
Proposed 2.8 0.001 24hrs
CACNB2 Ca2+ channel, voltage-
dependent, beta 2 
subunit
Elevated in KA seizure models 
(Gastaldi et al., 1998)
2.0 0.0001 48hrs
Potassium Channels
KCNJ9/GI
RK3
K+ inwardly-rectifying 
channel, subfamily J, 
member 9
Candidate gene for seizure 
susceptibility (Lohoff et 
al.,2005)
21.0 0.0003 24hrs
KCNQ4 K+ voltage-gated 
channel, KQT-like 
subfamily, member 4
Activated by ACD retigabine 
(Schroder et al., 2001)
13.0 0.001 48hrs
HCN3 Hyperpolarization 
activated cyclic 
nucleotide-gated K+
channel 3
Proposed: HCN gene family 
implicated in epilepsy (Mistrik
et al., 2005)
9.8 0.021 48hrs
KCNJ14/IR
K4
K+ inwardly-rectifying 
channel, subfamily J, 
member 14
Proposed 8.5 0.036 24hrs
KCNT2 K+ channel, subfamily 
T, member 2
Proposed 4.9 0.007 24hrs
KCNE1 K+ voltage-gated 
channel, Isk-related 
family, member 1
Mutation linked to QL 
syndrome (Splawski et al., 
2000)
4.3 0.004 48hrs
KCNMB4 K+ large conductance 
calcium-activated 
channel, subfamily M, 
beta member 4
variations infer susceptibility 
to sporadic epilepsy syndrome 
(Cavalleri et al., 2007)
3.0 0.004 48hrs
Chloride Channels
CLCN2 Chloride Channel 2 Susceptibility gene for 
childhood absence epilepsy 
(Everett et al., 2007) & 
idiopathic generalised seizure 
(Niemeyer et al., 2004)
2.0 0.0384 24hrs
GABA Transporters
SLC6A1 Solute carrier family 6, 
member 1
Target for the ACD tiagabine 
(Meldrum & Chapman., 1999)
13.0 0.033 24hrs
GABA receptors
GABRA5 GABA A receptor, 
alpha 5
Implicated in absence epilepsy 
(Lu et al., 2004)
2.6 0.022 24hrs
Glutamate Receptors
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GRIN2D Glutamate receptor, 
ionotropic, N-methyl 
D-aspartate 2D
Proposed 2.0 0.005 24hrs
Carbonic 
Anhydrase
CA5 Carbonic anhydrase 
VA
Carbonic anhydrase inhibitors 
act as anticonvulsant agent s 
(Thiry et al., 2007)
42.0 0.008 24hrs
Drug Metabolising Enzymes
CYP2C9 Cytochrome P450, 
family 2, subfamily C, 
polypeptide 9
Metabolises the ACD 
phenytoin (Tate et al., 2005; 
Mosher et al., 2009)
13.0 0.002 48hrs
Other 
ATP1A2 ATPase, Na+/K+ 
transporting, alpha 2 
polypeptide
ATP1A2 mutations noted in 
epilepsy (Gutierrez-Delicado 
et al., 2004; Gallanti et al., 
2008)
3.482 0.003 24hrs
NRSF/RES
T
Neuron restrictive 
silencing factor /RE1-
silencing transcription 
factor
Elevated in KA seizure models 
(Palm et al., 1998;   Spencer et 
al; 2006)
2.144 0.001 24hrs
NTRkB BDNF/NT-3 growth 
factors receptor 
precursor
Elevated in SE models (Mudo 
et al., 1996) 
5.657 0.041 24hrs
Table 7.3. Genes associated with epilepsy up-regulated following HZ4 over-expression. The over-
expression of the truncated variant, analogous to sNRSF, via the HZ4 expression construct, led to the 
significant increase in expression of genes listed, as revealed by Affymetrix Microarray. Fold change, P 
values and over-expression duration are given. (n=3). 
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Gene Description Relevance to Epilepsy  
(Reference)
Fold 
Chang
e
P value Exposur
e
Sodium Channels
SCN9A Na+ channel, voltage-
gated, type IX, alpha 
subunit
Proposed 10.6 0.0003 24hrs
Potassium Channels
KCNK12 K+ channel, subfamily 
K, member 12
Proposed 20 0.008 48hrs
KCNB2 K+ voltage-gated 
channel, Shab-related 
subfamily, member 2
Proposed 3 0.009 48hrs
KCNC3/Kv
3.3
K+ voltage-gated 
channel, Shaw-related 
subfamily, member 3
KV3 channel suppression 
causes seizures (Rudy et al.,
1999)
2.3 0.016 48hrs
KCNC4/Kv
3.4
K+ voltage-gated 
channel, Shaw-related 
subfamily, member 4
Kv3.4 modulated by 4-
aminopyridine in SE rats 
(Zahn et al., 2008).  
2 0.0078 48hrs
Other
LGI1 leucine-rich, glioma 
inactivated 1
LGI1 mutations associated 
with epilepsy (Berkovic et al., 
2004)
3.2 0.009 24hrs
EGR1 Early growth response 
protein 1
Differentially expressed in 
absence seizure  (Helbig et al., 
2008)
2.0 0.0001 48hrs
Table 7.4. Genes associated with epilepsy down-regulated following HZ4 over-expression. The over-
expression of the truncated variant, analogous to sNRSF, via the HZ4 expression construct, led to the 
significant decrease in expression of genes listed, as revealed by Affymetrix Microarray. Fold change, P 
values and over-expression duration are given. (n=3). 
7.4.2 RT-PCR validation of Microarray data – HCN2, HCN3 & SCN9a
The microarray data indicated that over-expression of the NRSF variants led to 
the modulation of numerous genes. It was important however to validate changes in 
gene expression following NRSF variant over-expression, revealed by the microarray 
dataset. To this end, the modulation of expression of three ion channels HCN2, HCN3 
and SCN9a was analysed via RT-PCR. The potassium channels HCN2 and HCN3 were 
analysed as they have both been previously identified as NRSF targets (Kuwahara et al., 
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2003; Sun et al., 2005; Johnson et al., 2007), and thus by validating changes in 
expression of these two genes, and comparing our data against previous publications, 
greater strength and confidence could be given to the microarray dataset. In addition, a 
gene with no published regulatory association with NRSF - SCN9a, was also screened. 
Two related genes, SCN2a (Tapia-Ramirez et al., 1997) and SCN8a (Drews et al., 2007) 
have previously been shown to be NRSF regulated, and thus SCN9a may also be 
regulated by NRSF variants. 
RT-PCR revealed a significant reduction in expression of the SCN9a gene in 
human SK-N-AS neuroblastoma cells, following 24hrs HZ4 over-expression compared 
to 0hr baseline time-points (Figure 7.4) (P = < 0.001) (n=3), when standardised against 
the house keeping gene RNA polymerase II (Pol-2). This is consistent with the change 
in SCN9a detected by the microarray. Similarly, the expression of the HCN2 gene was 
found to be significantly reduced following 48hrs over-expression of full length NRSF 
(REEX1), normalised against Pol-2 (Figure 7.5) (P = < 0.05) (n=3).  This is also 
consistent with the microarray dataset, and supports previously published reports that 
HCN2 is repressed by NRSF (Kuwahara et al., 2003), based on the presence of a 
putative NRSE (Johnson et al., 2007). Finally the microarray dataset indicated an 
increase in HCN3 expression following 48hrs HZ4 over-expression. This was validated 
by RT-PCR, with 48hrs HZ4 over-expression leading to an increase in HCN3 
expression, when compared to 0hrs baseline time-points, and standardised to Pol-2 
(Figure 7.6) (P = < 0.05) (n=3).
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Figure 7.4. Over-expression of HZ4 represses SCN9a. 24hrs over-expression of the truncated NRSF 
construct (HZ4), led to the significant reduction of SCN9a mRNA levels. (A) RT-PCR of SCN9a and Pol-
II following 0hrs and 24hrs HZ4 and (B) corresponding band intensities giving ratio of SCN9a to Pol-II.  
Human SK-NAS neuroblastoma cells were transfected with the HZ4 expression construct and were 
cultured for 0hrs or 24hrs before RNA extraction occurred. *** = P < 0.001. (n=3).
Figure 7.5. Over-expression of REEX1 represses HCN2. 48hrs over-expression of NRSF (REEX1), led 
to a significant reduction of HCN2 mRNA levels. Human SK-NAS neuroblastoma cells were transfected 
with the REEX1 expression construct and were cultured for 0hrs or 48hrs before RNA extraction 
occurred. (A) RT-PCR was used to detect endogenous levels of HCN2 and Pol-II, and (B) corresponding 
band intensities comparing HCN2 to Pol-II are given. * = P < 0.05. (n=3). 
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Figure 7.6. Over-expression of HZ4 elevates HCN3. 48hrs over-expression of the truncated variant 
construct (HZ4), led to the significant increase in HCN3 mRNA levels. (A) RT-PCR of HCN3 and Pol-II 
following 0hrs and 48hrs HZ4 and (B) corresponding band intensities giving ratio of HCN3 to Pol-II. 
Human SK-NAS neuroblastoma cells were transfected with the HZ4 expression construct and were 
cultured for 0hrs or 48hrs before RNA extraction occurred. * = P < 0.05. (n=3). 
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7.5 Discussion
One of the major hurdles standing in the way of epilepsy treatment and 
management, is to uncover the underlying molecular mechanisms and factors which can 
govern the cellular response to a stress or challenge, that can lead to a seizure, or which 
can modulate cellular response to future challenges. The NRSF TFs are an intriguing 
group, linked to epilepsy via their modulation during KA treatment (Palm et al., 1998; 
Spencer et al., 2006), and their regulatory roles over a set of genes implicated in 
epilepsy, including BDNF, TAC1 and NKB (Timmusk et al., 1999; Tabuchi et al.,
2002a; Quinn et al., 2002; Spencer et al., 2006; Greco et al., 2007; Howard et al., 2008; 
Reddy et al., 2009; Chapter 3). NRSF has a well established ability to modulate 
chromatin structure (Reviewed in Ooi & Wood., 2007), and is known to modulate 
activity dependent gene expression in neurons (Hara et al., 2009) suggesting that this 
molecule can respond quickly to challenges and has the ability to govern medium to 
long-term changes in gene expression profiles, in turn modifying the cellular phenotype. 
NRSF can be incorporated into many of the current hypotheses associated with epilepsy, 
including a role for adult neurogenesis in the subventricular zone (SVZ) (Gonzalez-
Martinez et al., 2007; Parent & Murphy., 2008) as NRSF is known to affect adult stem 
cell lineage (Reviewed by Ballas & Mandel., 2005).
The data presented in this chapter supports a role for NRSF variants modulating 
many genes which are associated with epilepsy and can therefore be positioned as an 
early step in the cascade of changes in the CNS that lead to epilepsy. Importantly I 
demonstrate that the different isoforms of NRSF can direct differential gene expression 
patterns, in a time dependent manner. For example, the more prolonged over-expression 
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of REEX1 (48hrs vs 24hrs), led to an increase in the number of genes uniquely 
modulated by REEX1 (Figure 7.1), with genes belonging to the ‘Adaptor/Regulator’ 
group, exhibiting the biggest change (Figure 7.2). Our group and others have shown that 
NRSF isoforms are differentially modulated in rodent models of SSSE (Palm et al., 
1998; Spencer et al., 2006), therefore the temporal control of these isoforms may have 
important consequences for the progression of epilepsy. Consistent with this model, are 
the findings that both full-length NRSF and its truncated isoform sNRSF are 
differentially modulated by the ACDs CBZ, PHY and LMT, as discussed in Chapter 5.
The over-expression of the NRSF variants was found to have a profound effect 
on global gene expression patterns, with over 1000 genes modulated at both 24hrs and 
48hrs time points, when compared to 0hrs baseline time point controls. It is reasonable 
to assume that these genes are not all regulated directly by the NRSF variants, but may 
also be modulated indirectly. However, the number of potential NRSF targets has been 
proposed to be more that 1000 genes based on the bioinformatic identification of some 
1,892 NRSEs in the human genome (Bruce et al., 2004), and more recently, the 
discovery of NRSF binding strongly to 1947 positions in the human genome, using a 
large-scale ChIP assay (ChIPSeq) (Johnson et al¸2007). An important investigation 
would be to compare our microarray data against the gene lists generated by such 
genome-wide studies, to determine how many of the genes modulated here, are potential 
direct NRSF targets, due to the presence of an NRSE or known NRSF binding to the 
locus of each gene promoter. This analysis is currently being undertaken in 
collaboration with bioinformatic groups. 
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The microarray dataset provided a multitude of gene expression changes which 
would be consistent with a model in which NRSF isoforms are up-regulated as an early 
response to seizure, with this change in NRSF isoform expression driving a change in 
expression of numerous genes, directly or indirectly, which have known associations 
with epilepsy. Genes within well-established epilepsy pathways are found to be 
modulated in the microarray dataset, consistent with changes one may expect following 
seizure. Members of the excitatory glutamate system, the glutamate receptors mGluR8 
and GRIN2D were found to be elevated in response to both REEX1 and HZ4 over-
expression, respectively (Table 7.1 & Table 7.3). Concurringly, repression of the 
inhibitory GABAnergic system was also observed, notably a reduction in expression of 
the GABA receptor genes GABBR1 and GABRE was found following REEX1 over-
expression (Table 7.2). Furthermore, the microarray indicated that over-expression of 
REEX1 resulted in the decreased expression of the anti-convulsant neuropeptide 
Galanin (Table 7.2), and the increased expression of the NK1R, the receptor for the pro-
convulsant neuropeptides SP and NKB. Taken together, such changes could lead to a 
hyper-excitable cellular phenotype, more prone to abnormal neuronal firing. 
In addition, changes in ion channel expression were observed, which are 
consistent with published modulation during or following seizure, such as the up-
regulation of the calcium channel CACNB2 following HZ4 over-expression (Table 7.3), 
which is consistent with previous reports of CACNB2 elevation following seizure 
(Gastaldi et al., 1998), and a repression of the potassium channel HCN2 following 
REEX1 over-expression, which is consistent with the observed reduction in HCN2 in 
KA seizure models (Powell et al., 2008). Finally, the NADH-binding co-repressor CtBP 
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was also found to be up-regulated by REEX1 over-expression (Table 7.1). This is of 
particular significance as the mechanisms underlying the anti-epileptic ketogenic diet 
have recently been eluded to, with NRSF and the NADH-binding co-repressor CtBP, 
shown to be of critical importance in coordinating a metabolic regulation of the neuronal 
genes BDNF and its receptor TrkB (Garriga-Canut et al., 2006), which was also found 
to be modulated by REEX1 in this study (Table 7.1).
Intriguingly, a number of genes known to be modulated by NRSF variants and
which are correlated with epilepsy, were notably absent from the dataset including
BDNF, TAC1, NKB and SCN2a.. These genes are covered by the Affymetrix 
microarray employed here, indeed the reported increase in BDNF expression following 
VPA treatment, was discovered employing the same U133 chip (Fukuchi et al., 2009).
Therefore the absence of these genes was of interest, and it became important to validate 
the microarray, to give confidence in the dataset. The modulation of three ion channels 
was validated via RT-PCR, these being SCN9a (Figure 7.4), HCN2 (Figure 7.5) and 
HCN3 (Figure 7.6). All three genes were found to be modulated consistent with that 
reported in the microarray, giving confidence in the dataset. Furthermore, the observed 
changes in HCN2 expression following REEX1 over-expression, supported previously 
published reports that HCN2 is repressed by NRSF (Kuwahara et al., 2003), based on 
the presence of a putative NRSE (Johnson et al., 2007), and gave further confidence in 
the microarray data. It is possible that the absence of BDNF, TAC1, NKB and SCN2a 
from the microarray dataset, is due to the lack of regulation of these genes by the NRSF 
variants at the given time points. Spencer et al., revealed that NRSF variant modulation 
of TAC1 is time dependent, with elevation of these isoforms and TAC1 mRNA found 
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after 3hrs KA treatment, but not at 24hrs KA treatment (Spencer et al., 2006). 
Furthermore, in Chapter 3, the observed increase in endogenous NKB expression 
following NRSF variant over-expression was found to be time-dependent (See chapter 
3, Figure 3.5). Therefore it is possible that the absence of these genes from the dataset is 
due to the time courses studied, and therefore it would be of particular interest to 
monitor the expression of these genes with different, perhaps shorter, time points. 
To summarise, I set out to explore the potential role of NRSF isoforms in 
modulating global changes in gene expression patterns, in a cell line model which was 
consistent, in part, with the underlying changes observed following seizure (i.e. elevated 
NRSF isoform expression, following seizure, with the truncated isoform absent in 
unstimulated cells). Our model is that NRSF isoforms respond to the initial insult or 
seizure, and this change in NRSF isoform expression can bring about more long-term 
changes in global gene expression profiles due to NRSF’s ability to modify chromatin 
structure. This could perhaps lead to a more sensitive or hyper-excitable cellular 
phenotype, more prone to abnormal neuronal firing. The microarray data gives support 
to such a model as dynamic differential modulation of global gene expression profiles 
were observed following over-expression of the NRSF variants. These changes in gene 
expression included a number of genes with known or proposed associations with 
epilepsy, and notable changes which are consistent with our model included the 
elevation of members of the excitatory glutamate system and the pro-convulsant 
receptor NK1R, as well as the repression of some members of the GABAnergic systems 
and the reduction of the anti-convulsant galanin. Taken together, I propose that NRSF is 
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key to understanding the molecular mechanisms underlying seizure progression, and as 
such warrants increased focus in epilepsy research.
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CHAPTER 8: Modulation of the NRSF and USF families following 
cocaine treatment
8.1 Introduction
Throughout this thesis, the role of two transcriptional regulatory systems has 
been explored with regards to epilepsy. More specifically, the roles of the NRSF and 
USF TFs in the regulation of two pro-convulsant neuropeptides (NKB and TAC1) have 
been investigated, as have the response of these TFs to ACD treatment. Furthermore, 
NRSF isoform over-expression was found to modulate the expression of a multitude of 
genes, with known or proposed functions in seizure generation and progression. The 
importance of these regulatory systems in this neurological disorder, have thus become 
increasingly more apparent throughout this thesis. 
It has been known for some time now that seizures can be induced through 
chemical means, such as KA administration which is routinely used in drug-induced 
seizure models. There is now an increasing body of evidence to suggest that cocaine 
administration can also induce seizures, with cocaine-induced seizures reported in both 
humans and rodents (Lowenstein et al., 1987; Hanson et al., 1999; Lason., 2001). 
Furthermore, cocaine’s affect on the dopaminergic system is well documented, and 
recent studies have shown that loss of certain dopamine receptors can induced 
spontaneous seizures (D1 receptor) (Gantois et al., 2007) and enhance susceptibility to 
pharmacological induced seizures (D2 and D4 receptors) (Weinshenker & Szot., 2002). 
Taken together, these reports suggest that cocaine can modulate pro-convulsant 
pathways. 
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To date, the effect of cocaine treatment on the NRSF regulatory system has yet 
to be clarified, despite a body of evidence pointing to a correlation. Firstly, cocaine is 
known to induce the expression of CART (Douglass et al., 1995), a transcript which has 
recently been shown to be repressed by NRSF, via direct binding to a NRSE within the 
CART promoter (Li et al., 2008). Interestingly CART has been shown to be expressed 
in the hippocampus, an area of the brain important in seizure (Wasterlain et al., 2002), 
and has been shown to co-localise with SP in rodent nuclear accumbens (Hubert & 
Kuhar., 2005), indicating an overlap with the NRSF regulatory system and CART 
expression. Cocaine is also known to modulate the expression of a second NRSF-
regulated gene; BDNF, with increased BDNF expression observed in the hippocampus 
(Filip et al., 2006), striatum (Zhang et al., 2002), amygdala and nucleus accumbens 
(Grimms et al., 2003), following cocaine treatment. Furthermore, cocaine has been 
shown to up-regulate the expression of the tachykinin receptor NK1R (Renthal et al., 
2007), a gene also found to be modulated following NRSF isoform over-expression 
(Chapter 7).  
These findings suggest a correlation between cocaine, NRSF and epilepsy. In 
this chapter, I set out to explore the impact of cocaine treatment on the NRSF regulatory 
system, in terms of both NRSF isoform expression, and NRSF binding ability, as a 
potential mechanism underlying cocaine-induced seizures. In addition, I explored the 
impact of cocaine treatment upon the pro-convulsant tachykinin NKB, and the USF 
regulatory system, to further explore the hypothesised association of cocaine and these 
TF systems, and how this could be correlated with epilepsy.
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8.2 Aims
 To clarify the affect of cocaine treatment on CART expression in human SH-
SY5Y neuroblastoma cells.
 To determine if any cocaine-mediated change in CART expression, arise due to 
cocaine modulation of NRSF isoform expression.
 To determine if cocaine modulates NRSF binding to the region encompassing 
the CART NRSE and other putative and determined NRSE-containing regions. 
 To explore any impact of cocaine treatment on the expression of the tachykinin 
NKB and the TFs USF1 and USF2
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8.3 Methods
8.3.1 Cell culture and treatment
Human SH-SY5Y cells were used throughout as the cell-line model, since RT-
PCR revealed they express both NRSF isoforms (see chapter 3, Figure 3.1), and as SH-
SY5Y are considered to be a dopaminergic neuroblastoma cell line (Biedler et al., 
1978). SH-SY5Y were cultured as outlined in methods section 2.2.2.1.1 and treated as 
described in section 2.2.2.2. For mRNA analysis, cells were then harvested as detailed in 
methods section 2.2.3.1, 2.2.3.3 and expression was analysed as described in section 
2.2.3.5. For ChIP assays, cells were fixed and protein/DNA interactions cross-linked as 
described in section 2.5.1.
8.3.2 mRNA expression analysis
8.3.2.1 RT-PCR
The expression of CART, NKB and the house-keeping gene β-actin, was 
investigated using RT-PCR as described in methods section 2.2.3.4, using the PCR 
primers set out in Table 2.2.1. Thermal cycle conditions for all were as follows: initial 
denaturation: 95oC for 2mins for 1 cycle; followed by 40 cycles of denaturation: 95oC 
for 30 seconds, annealing 64oC for 30 seconds and elongation: 72oC for 1min; and a 
final elongation step of 72oC for 2mins. 
8.3.2.2 Q-PCR
The expression of the NRSF, sNRSF, USF1, USF2 and the house-keeping gene 
Pol-II, was investigated using qPCR as described in methods section 2.2.3.5, using the 
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PCR primers set out in Table 2.2.1. CART was not analysed using qPCR as the product 
size was deemed too large for optimal qPCR conditions, whilst conditions for NKB 
could not be optimised in time, for qPCR.  Thermal cycle conditions for NRSF, USF1, 
USF2 and RNA polymerase II, were as follows: initial denaturation: 95oC for 3mins for 
1 cycle; followed by 40 cycles of denaturation: 95oC for 30 seconds and annealing 62oC 
for 30 seconds; and a final elongation step of 72OC for 2mins. For sNRSF the annealing 
temperature was reduced to 58.5oC, with all other conditions remaining the same. 
Specificity of products was determined by subsequent melt curve analysis from 55°C to 
95°C increasing in 0.5°C increments.
8.3.3 TF binding study – ChIP assay
To investigate the impact of cocaine treatment upon NRSF binding to target 
regions, ChIP was employed as outlined in method section 2.2.5, using the antibodies 
given in Table 2.3 and the PCR primers given in Table 2.4.
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8.4 Results
8.4.1 Cocaine up-regulates CART mRNA expression
CART was originally discovered as a transcript markedly up-regulated following 
cocaine treatment (Douglass et al., 1995). To determine if cocaine treatment affected the 
NRSF or USF TF family members, it was important to first establish an appropriate cell 
line model for experimental use. Human SH-SY5Y cells, which have been used in 
chapters 5 and 6 to explore the impact of ACD treatment upon the NRSF and USF 
families, were utilised due to their expression of both NRSF isoforms and USF1 and 
USF2. CART expression was observed in vehicle control treated SH-SY5Y cells, and 
CART mRNA was found to be significantly elevated following 4hrs cocaine treatment 
(at both 1µM and 10µM) compared to vehicle controls (P = < 0.05) (Figure 8.1) (n=5). 
The more prolonged 24hrs cocaine treatment had no impact on CART mRNA 
expression compared to vehicle controls. (P > 0.05) (Figure 8.1) (n=5). Thus cocaine 
induces CART mRNA expression in a time-dependent manner, in human SH-SY5Y 
cells.
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Figure 8.1 Modulation of CART mRNA expression following cocaine treatment. RT-PCR analysis of 
CART mRNA expression in response to cocaine treatment in human SH-SY5Y neuroblastoma cells. SH-
SY5Y cells were treated with either 1µM or 10µM cocaine, or vehicle control, for 4hrs or 24hrs, before 
being processed for RNA extraction. (A) Representative mRNA expression of CART. Changes to 
endogenous CART mRNA expression was analysed using RT-PCR, with band intensities normalised 
against the house keeping gene β-actin, and (B) mean fold changes compared to vehicle control given. 
Standard errors are given as y-axis error bars. Students t-test was used to compare fold changes against
vehicle controls with: * = P = < 0.05. (n=5). 
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8.4.2 NRSF isoform expression is modulated following cocaine treatment
Full-length NRSF has previously been shown to repress the expression of CART 
(Li et al., 2008), and whilst cocaine’s impact on CART is well documented, its impact 
on NRSF expression has yet to be determined. I reveal for the first time that cocaine 
treatment causes a marked reduction in the mRNA expression of both full length NRSF 
(Figure 8.2a) and the truncated isoform sNRSF (Figure 8.2b). 4hrs cocaine treatment 
(both 1µm and 10µM) caused a significant 50% reduction in NRSF mRNA expression 
compared to vehicle controls (P = < 0.001) (Figure 8.2a) (n=3), which is consistent with 
the observed elevation of CART expression, as one may expect. In addition 24hrs 1µM 
cocaine also caused a less significant decrease in NRSF expression (P = < 0.05) (Figure 
8.2a) (n=3). In addition, the truncated NRSF isoform (sNRSF) was also found to be 
reduced following cocaine treatment, in a duration and concentration dependent manner, 
with only 4hrs 10µM cocaine treatment invoking a significant ~30% reduction in 
sNRSF expression, compared to vehicle controls (P = < 0.05) (Figure 8.2b) (n=3).
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Figure 8.2 Modulation of NRSF isoforms following cocaine treatment. qPCR analysis of (A) NRSF 
and (B) sNRSF mRNA expression in response to cocaine treatment in human SH-SY5Y neuroblastoma 
cells. SH-SY5Y cells were treated with either 1µM or 10µM cocaine, or vehicle control, for 4hrs or 24hrs, 
before being processed for RNA extraction. mRNA expression of NRSF and the truncated isoform 
sNRSF, were analysed using qPCR, normalised against Pol-II, mean fold changes compared to vehicle 
controls are given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold 
changes against vehicle controls with: * = P = < 0.05 & *** = P = < 0.001. (n=3).  
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8.4.4 Cocaine may affect NRSF binding to target NRSE-containing regions
Li et al, showed that NRSF binds to a NRSE within the CART promoter region, 
repressing CART expression (Li et al., 2008). I have shown that 4hrs 1µM and 10µM 
cocaine treatment results in an increase in CART expression (Figure 8.1) and a 
corresponding decrease in NRSF mRNA expression (Figure 8.2). To determine if this 
reduction in NRSF could affect CART expression directly, I undertook preliminary 
investigations to explore the impact of 4hrs 10µM cocaine on NRSF binding to the 
CART promoter, using a ChIP assay. NRSF was shown to be capable of binding to the 
CART NRSE-containing promoter region in SH-SY5Y cells in chapter 5 (see Figure 
5.14). Here I show that NRSF is also bound to the CART promoter region in vehicle 
control treated SH-SY5Y cells, and that NRSF binding to this region may be reduced 
following 4hrs 10µM cocaine treatment, when normalised to the non-specific 
background (negative) control; IgG (Figure 8.3). However, as the IgG band is found to 
be particularly bold, it is possible that cocaine is affecting only the IgG background 
binding. Thus one cannot conclude NRSF binding to the CART promoter is affected by 
cocaine at present, and further investigations are required. Due to the proposed 
importance of cocaine in epilepsy, I explored the impact of cocaine on NRSF binding to 
the region containing the BDNF NRSE and the NKB and TAC1 promoter regions. In 
preliminary findings, 4hrs 10µM cocaine treatment was found to reduce NRSF binding 
to all three NRSE-containing regionss, compared to vehicle controls (Figure 8.3). This 
may be consistent with the fact that BDNF is up-regulated following cocaine treatment 
(Zhang et al., 2002; Grimm et al., 2003; Filip et al., 2006), as reduced binding would 
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inhibit NRSF mediated repression of BDNF expression, and hence BDNF expression 
would be induced. 
Figure 8.3. Modulation of NRSF binding to target NRSE-containing regions following 4hrs cocaine 
treatment in human SH-SY5Y cells. ChIP analysis of NRSF binding to characterised or putative NRSE-
containing regions in SH-SY5Y cells treated with either 4hrs 10µM cocaine or vehicle control. IgG was 
included as a control for non-specific background binding. NRSF binding to the NKB, TAC1and BDNF 
NRSE-containing regions was found to diminished following cocaine treatment when compared to vehicle 
control.(n=1).
8.4.5 Endogenous NKB expression is unaffected following cocaine treatment
The potential reduction of NRSF binding to both NKB and TAC1 promoter 
regions following cocaine treatment, may suggest the loss of NRSF-mediated activation 
of these two genes. Consequently I sought to explore the impact of cocaine treatment on 
the expression of these neuropeptides. As NKB (and not TAC1) was expressed in SH-
SY5Y cells, I focused on cocaine modulation of endogenous NKB expression. 
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Intriguingly neither 4hrs nor 24hrs (1µM or 10µM) cocaine treatment had any 
significant impact upon endogenous NKB expression when compared to vehicle 
controls (P = > 0.05) (Figure 8.4) (n=5). 
Figure 8.4 Modulation of NKB mRNA expression following cocaine treatment. Reverse transcriptase-
PCR (RT-PCR) analysis of NKB mRNA expression in response to cocaine treatment in human SH-SY5Y 
neuroblastoma cells. SH-SY5Y cells were treated with either 1µM or 10µM cocaine, or vehicle control, 
for 4hrs or 24hrs, before being processed for RNA extraction. (A) Representative mRNA expression of 
NKB. Changes to endogenous NKB mRNA expression was analysed using RT-PCR, with band intensities 
normalised against the house keeping gene B-Actin, and (B) mean fold changes compared to vehicle 
control given. Standard errors are given as y-axis error bars. Students t-test was used to compare fold 
changes against vehicle controls with: * = P = < 0.05. (n=5). 
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8.4.6 Cocaine represses USF1 and USF2 mRNA expression
The findings that cocaine treatment had no impact upon NKB expression, whilst 
abolishing NRSF binding to the putative NKB NRSE, were unexpected. The USF TFs 
were shown in chapter 3 to act as repressors of NKB proximal promoter activity, and 
thus I was interested in exploring the possibility that cocaine may modulate USF gene
expression. Human SH-SY5Y cells were treated with either 1µM or 10µM cocaine, or 
vehicle control, for either 4hrs or 24hrs. The response of both USF1 and USF2, to 
cocaine was found to be virtually identical. 4hrs cocaine treatment (both 1µM and 
10µM) induced a significant reduction in both USF1 (Figure 8.5a) and USF2 (Figure 
8.5b) mRNA expression (P = < 0.05) (n=3). Furthermore, 24hrs 10µM cocaine 
treatment also induced a reduction in both USF1 and USF2 (Figure 8.5a & Figure 8.5b, 
respectively) (P = < 0.05) (n=3). Therefore, cocaine treatment not only reduces the 
expression of the NKB-activator NRSF, but also the NKB-repressors USF1 and USF2, 
and this may explain why NKB is unaffected following cocaine treatment. 
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Figure 8.5 Modulation of USF1 and USF2 following cocaine treatment. Quantitative-PCR (qPCR) 
analysis of (A) USF1 and (B) USF2 mRNA expression in response to cocaine treatment in human SH-
SY5Y neuroblastoma cells. SH-SY5Y cells were treated with either 1µM or 10µM cocaine, or vehicle 
control, for 4hrs or 24hrs, before being processed for RNA extraction. mRNA expression of USF1 and 
USF2 was analysed using qPCR, normalised against the house keeping gene RNA polymerase II (Pol-2), 
mean fold changes compared to vehicle controls are given. Standard errors are given as y-axis error bars. 
Students t-test was used to compare fold changes against vehicle controls with: * = P = < 0.05, ** = P = 
< 0.01 & *** = P = < 0.001. (n=3).  
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8.5 Discussion
In the previous chapters, the NRSF isoforms and the USF family of TFs have 
been shown to govern the regulation of the NKB and SP encoding genes, TAC3 and 
TAC1, respectively. These TFs were later found to be modulated by ACD treatment, 
and their roles (specifically the NRSF isoforms) in modulating epilepsy-associated gene 
expression, was highlighted following their over-expression. This thesis has provided 
evidence supporting the hypothesis that these TFs are important in modulating gene 
expression in relation to seizure. To further explore such a hypothesis, I explored the 
response of these TFs to cocaine, a drug which has been reported to induce seizures 
(Lowenstein et al., 1987; Hanson et al., 1999; Lason., 2001), and is known to modulate 
the dopaminergic system, a system also implicated in seizures generation and 
progression (Gantois et al., 2007; Weinshenker & Szot., 2002; Witkin et al., 1998). 
Cocaine is known to induce the expression of the NRSF-regulated genes CART 
(Douglass et al., 1995; Li et al., 2008) and BDNF (Filip et al., 2006; Zhang et al., 2002; 
Grimms et al., 2003; Timmusk et al., 1998; Tabuchi et al,. 2002), however despite this, 
the effect of cocaine on NRSF has yet to be explored.  Here, I demonstate that cocaine 
treatment induces a significant repression of both full-length and truncated NRSF 
isoform expression (Figure 8.2). The observed repression of NRSF following cocaine 
treatment coincided, in part, with an observed increase in CART mRNA expression 
(Figure 8.1), which would be consistent with the findings that NRSF represses CART 
expression (Li et al., 2008), whilst cocaine increases CART expression (Douglass et al., 
1995). Furthermore, cocaine is known to induce BDNF expression, and our findings 
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suggest that this could be through cocaine’s repression of NRSF, which in turn would 
lead to de-repression of BDNF, although this has yet to be clarified.
How cocaine induces this observed reduction in NRSF expression, has yet to be 
determined. One potential mechanism could be through the up-regulation of the methyl-
CpG-binding protein MeCP2. Cassel et al, demonstrated that cocaine administration in 
rats led to a significant up-regulation of MeCP2 (Cassel et al., 2006) and interestingly, 
MeCP2 has been shown to bind to the NRSF promoter, and was proposed to function in 
NRSF repression based upon the observed up-regulation of  NRSF in MeCP2 knock-out 
mice (Abuhatzira et al., 2007). Therefore, cocaine may enhance MeCP2 expression, 
which could lead to repression of NRSF and in turn, enhanced expression of CART and 
BDNF. In support of this, MeCP2 deficiency has been correlated with decreased BDNF 
expression, due to enhanced repression of the BDNF promoter, resulting from elevated 
NRSF levels (Abuhatzira et al., 2007). It would therefore be of interest to explore the 
impact of cocaine upon MeCP2 binding to the NRSF promoter, to clarify if cocaine-
mediated MeCP2 repression of NRSF occurs.  
As aforementioned, NRSF is known to be up-regulated during seizure (Palm et 
al., 1998; Spencer et al., 2006), thus the cocaine-mediated reduction in NRSF 
expression, appears to be contradictory to a hypothesis suggesting cocaine-induced 
seizures operates via modulation of the NRSF regulatory system. However, we have 
previously postulated that it is the ratio between full-length NRSF and the truncated 
isoforms which is the key factor in governing seizure generation and progression 
(Spencer et al., 2006). Here I find that cocaine has a greater impact upon full-length 
NRSF expression compared to sNRSF expression, with a highly significant 60% 
274
reduction of NRSF observed compared to a 30% reduction in sNRSF (Figure 8.2). Thus 
cocaine treatment modulates the NRSF isoforms differentially, which would impact 
upon the NRSF isoform ratio, elevating the levels of the truncated isoform compared to 
full-length NRSF. This swing in the ratio towards the truncated isoform, is consistent, in 
part, with that observed in rodent seizure models (Spencer et al., 2006), suggesting that 
this may be an underlying mechanism orchestrating cocaine-induced seizures. 
The data presented here demonstrating that cocaine modulates NRSF expression, 
a TF with a well established role in chromatin remodelling (reviewed in Ooi & Wood., 
2007), may suggest such a role in epigenetics for cocaine. In support of this, cocaine has 
been shown to induce hyperacetylation of histones at the cFos, BDNF and Cdk5 
promoters, coinciding with elevated expression of these three genes (Kumar et al., 
2005). As a consequence, I was interested in exploring the impact of cocaine treatment 
upon NRSF binding to target NRSEs within the neuropeptides CART, NKB and TAC1, 
and the neurotrophic factor BDNF. 
One may expect that as cocaine induces CART expression (Figure 8.1), and 
NRSF represses CART, that cocaine would not only reduce NRSF expression (as seen 
in Figure 8.2), but may also impair NRSF binding to the CART NRSE, thus leading to 
de-repression. Unfortunately the preliminary ChIP assay presented here is inconclusive 
with regards to cocaine’s impact upon NRSF binding to the CART promoter, and further 
experimentation is required to provide an answer. (Figure 8.3). Interestingly, cocaine 
was found to reduce NRSF binding to the TAC1 and NKB promoter regions and the 
region encompassing the BDNF NRSE (Figure 8.3). This may well be a direct 
consequence of diminished NRSF expression following cocaine treatment, or it may be 
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due to an inhibition of a mechanism governing NRSF binding. Such a mechanism could 
be a common binding partner, which coordinates NRSF binding to such NRSEs. I have 
previously alluded to a shared regulatory role of NKB, TAC1 and BDNF between the 
NRSF and USF TFs, and I reveal here that cocaine reduces the expression of both USF1 
and USF2 in this cell line model (Figure 8.5). Perhaps USF proteins help to coordinate 
NRSF binding, and reduced expression of USF1 or USF2 may inhibit NRSF recruitment 
to target NRSEs. It would be of great interest therefore in future to characterise USF 
binding to these genes in response to cocaine treatment, particularly NKB, TAC1 and 
BDNF. Furthermore, as NRSF repression of CART was found to be HDAC dependent
(Li et al., 2008), it would be of interest to characterise HDAC recruitment to these target 
NRSEs to gain a greater understanding of how cocaine modulates the chromatin 
structure and in turn, expression of these genes. 
The data presented here, and by Li et al, indicates that CART expression is 
regulated by NRSF binding to the CART NRSE, and that cocaine treatment not only 
reduces NRSF expression, but also abolishes NRSF binding to the CART NRSE, with 
the net result that cocaine induces CART expression. The ChIP assay also suggested that 
cocaine reduces NRSF binding to the BDNF NRSE-containing region, which would be 
consistent with the reported elevated in BDNF following cocaine treatment (Zhang et 
al., 2002; Grimm et al., 2003; Filip et al., 2006), as like CART, BDNF is repressed by 
NRSF (Timmusk et al., 1999). NRSF binding to the TAC1 and NKB promoter region
was also found to be abolished following cocaine treatment in preliminary findings, and 
thus I wished to explore the impact of cocaine on the expression of these neuropeptides. 
As the cell line utilised only expressed NKB, I focused on endogenous NKB expression, 
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however in future, the experiment should be repeated in the TAC1-expressing SK-N-AS 
cell line, to gain data on cocaine’s affect on TAC1 expression. 
Intriguingly, endogenous NKB expression was found to be unaffected by the 
cocaine treatment employed here (Figure 8.4).A plausible reason for this is the observed 
down-regulation of USF 1 and USF2 expression (Figure 8.5). In chapter 3, I revealed
that USF repressed the activity of the NKB promoter, suggesting that USF repressed 
NKB expression. With the cocaine-induced reduction of both NRSF isoform and USF1 
and USF2 expression, both the NKB-activator and repressor are reduced, and so the 
ratio between the two is maintained to some degree, resulting in limited change in NKB 
expression. This is similar to the observations that CBZ treatment impaired both NRSF 
and USF regulation of the NKB promoter, resulting in only a limited change in NKD 
expression (see chapter 3). This provides further support for a shared regulatory role of 
NKB for both NRSF and USF TF families, as discussed in chapter 3.
Throughout this thesis, I have discussed the apparent importance of both the 
NRSF and the USF regulatory systems in governing gene expression, with regards to 
seizure. The relationship between cocaine and seizures has become increasingly 
apparent, and the data presented in this chapter suggests that cocaine-induced seizures 
may arise due to cocaine’s affect upon these two TF systems.  More work is required in 
this field to unravel the underlying molecular mechanisms at work which initiate and 
propagate seizures, and perhaps comparing the affects of cocaine administration with 
more classical pro-convulsant (i.e. KA) or even anti-convulsant treatment, may help to 
reveal the fundamental mechanisms, and may hopefully present new therapeutic targets 
for anti-epileptic treatment. 
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CHAPTER 9: NRSF and USF TFs regulate pro-convulsant 
neuropeptides and are modulated by ACD treatment.
The underlying aim of this thesis was to explore and gain a greater understanding 
of the molecular changes which may be relevant to the progression of epilepsy. It is 
generally accepted that the epilepsy condition can arise from an initial insult, such as a
brain trauma, and can result, over time, in recurrent spontaneous seizures. The phrase 
‘over time’ is especially relevant, with a well documented latent period existing between 
the initial insult and the epilepsy condition proper. It is believed that during this latent 
period, major changes occur in the brain, at both the cellular (e.g. neuronal circuitry 
reorganisation) and molecular level (e.g. gene expression changes), in a process known 
as epileptogenesis. This thesis was focused on molecular changes relevant to 
epileptogenesis, particularly that of neuropeptide gene regulation. In addition to 
immediate changes in gene expression, the process of chromatin remodelling is a strong
candidate for orchestrating molecular changes during epileptogenesis. Chromatin 
remodelling not only induces widespread changes in gene expression (i.e. multiple genes 
affected) but can induce medium to long-term changes in gene expression patterns, which 
would affect the long-term phenotype of the cell. 
Support for the importance of chromatin remodelling or epigenetic changes, in 
epileptogenesis has arrived from multiple sources. Firstly, one of most affective ACDs 
prescribed, VPA, is an inhibitor of HDAC activity. This HDAC inhibitor activity 
suggests that VPA prevents the repression of certain genes, which in turn implies that 
HDAC-mediated gene repression is a key factor in seizure generation and progression. In 
addition to this, a number of groups have shown that histone modifications occur 
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following SE, affecting the expression of certain genes. These include histone H4 
acetylation of the BDNF promoter, inducing elevated BDNF mRNA expression 
(Tsankova et al., 2004) and histone deactylation at the glutamate receptor (GluR2) 
promoter, repressing GluR2 expression (Sanchez et al., 2001; Jia et al., 2006).
Furthermore, TFs such as NRSF, which have well-documented roles in coordinating 
epigenetic modifications, are found up-regulated during SE (Palm et al., 1998; Spencer et 
al., 2006). 
Throughout this thesis I have focused on two distinct TF families; NRSF and 
USF. Our group has previously postulated that NRSF is a key TF in epileptogenesis 
based on the fact that it is modulated early during seizure (thus representing an initial 
target) (Spencer et al., 2006) and because NRSF can govern epigenetic changes, thus can 
bring about long-term changes in chromatin structure, and in turn long term changes in 
gene expression (Ooi & Wood., 2007). This ability confers to the epileptogenesis model, 
with molecular changes occurring over time (latent period), in response to an initial 
insult, which would modify long-term changes in gene expression. In support of this, a 
number of NRSF-regulated genes are found to be modulated during seizure, including 
BDNF (Koyama & Ikegaya., 2005), TAC1 (Palm et al., 1998; Spencer et al., 2006), 
Snap25, SCG10 and µ-opioid receptor (Becker et al., 2002). In addition, USF also has 
the capacity to induce epigenetic changes, and has been correlated with seizure, with 
USF1 null mice exhibiting increased susceptibility to spontaneous seizures (Sirito et al., 
1998). As with NRSF, a number of USF-regulated genes are modulated during seizure 
including BDNF and TAC1, as well as KCC2 (Markkanen et al., 2008) and the GABAB
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receptor (Steiger et al., 2004), suggesting that USF may also govern epigenetic changes 
in response to an initial insult, and thus may be of significance to epileptogenesis. 
9.1 Modulation of Neuropeptide expression
Following a seizure, the expression of multiple neuropeptides is altered, with 
enhanced expression of pro-convulsant neuropeptides SP and NKB (Liu et al., 1999; Liu 
et al., 2000; Marksteiner et al., 1992; Sperk et al., 1990) and reduced expression of anti-
convulsant neuropeptides galanin, dynorphin, somatostatin and NPY observed (Mazarati 
et al., 1998; Mazarati et al., 1999; Sperk et al., 1986; Sperk et al., 1992). This enhanced 
ratio of pro-convulsant to anti-convulsant neuropeptide expression, leads to a 
hyperexcitable neuronal phenotype, with a greater propensity to seizure. In this thesis, I 
have investigated the mechanisms governing the regulation of the NKB encoding gene, 
TAC3, in a human neuroblastoma cell line and have further explored those governing the 
SP-encoding gene TAC1. 
I have presented data that indicates that both NRSF and USF TF families have a 
role in governing the regulation of TAC3. Firstly, I identified a putative NRSE within the 
TAC3 proximal promoter regions, spanning +50 to +71, in relation to the TSS. Both 
NRSF and the truncated isoform sNRSF were found to bind to the region encompassing 
this putative NRSE in preliminary ChIP assays, both acted as activators of NKB 
promoter activity and both were found to differentially enhance endogenous NKB 
expression, in a human neuroblastoma cell line. These findings support the theory that 
both NRSF and its truncated isoform can act as pro-convulsant TFs, with both TFs found 
to activate the promoter of the pro-convulsant tachykinins NKB and SP (Spencer et al., 
2006). Intriguingly, NRSF was found to act as an activator of NKB expression, mirroring 
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its activator roles of two other neuropeptide genes; TAC1 and AVP (Quinn et al., 2002; 
Spencer et al., 2006), but is perhaps contradictory to its more established role as a 
transcription repressor. It is possible that NRSF regulates NKB indirectly, by repressing 
another factor important in NKB regulation. However the presence of the putative NRSE 
within the NKB proximal promoter region, together with the preliminary observations 
that NRSF could bind to the region encompassing the putative NRSE, suggests that 
NRSF-mediated regulation of NKB is direct. The question therefore remains, why does 
NRSF activate NKB expression?
One potential explanation may be due to the location of the putative NKB NRSE. 
As discussed in chapter 3, Bessis et al, revealed that the location of the NRSE can confer 
whether the NRSE acts as an activator element or a repressor element in neuronal cells. 
NRSEs located within 50bp of the TATA box of a synthetic promoter, were found to act 
as activator elements, whilst those further upstream acted as repressor elements, in 
neuronal cells (Bessis et al., 1997). The putative NKB NRSE is located +51 from the 
TSS and so is close to this boundary indicated by Bessis et al, suggesting that the NKB 
putative NRSE could acts as an activator element. This would be consistent therefore 
with the activation of NKB by NRSF presented here. In addition, other genes shown to 
be activated by NRSF, have similar NRSE locations, with the rat TAC1 NRSE at -21 to 
+4 (Quinn et al., 2002) and the AVP NRSE -2 to +23 (Coulson et al., 1999). Thus the 
close proximity of these NRSEs to the TSS, may confer transcriptional activator roles, 
consistent with the early findings of Bessis et al.
An alternative explanation may come from the sequence of the putative NKB 
NRSE. The putative NKB NRSE shares greater homology to the NRSEs of TAC1 (rat) 
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and AVP (human), both of which have been shown to be activated by NRSF (Quinn et 
al., 2002; Spencer et al., 2006; Howard et al., 2008; Coulson et al., 2000), than to the 
classical 21bp canonical sequence (see chapter 3, Figure 3.1 and Appendix 5). Recently 
the classic 21bp canonical NRSE sequence has been shown to be a bipartite sequence, 
with a left half-site and a right half-site. Interestingly, whilst NRSF can bind to either 
half-site, individually neither half-site is an effective repressor, with NRSF binding to 
both half-sites required for repression (Patel et al., 2007). Through sequence 
comparisons, I have revealed that the NKB NRSE shares a great degree of homology to 
the left-half site (sequence: CAGCACC), exclusively, with little conservation between 
the right-half site and the NKB (putative) NRSE. This is also seen in the TAC1 
sequences (both rat and human) and the AVP sequence (Figure 3.1 and Appendix 5). It is 
thus plausible that NRSF can recognise and bind to these neuropeptide NRSEs, but as 
they lack a strong homology to the right-half site, perhaps the binding is not sufficient to 
induce repression. Intriguingly, I have also shown that the putative NKB NRSE has not 
one, but two left-half site NRSE sequences, with a second match to the left-half site 
sequence CAGCACC, discovered within our putative NKB NRSE region (Appendix 5). 
This is not found in the TAC1 nor the AVP NRSE region, indicating that this is exclusive 
to the NKB promoter. This doublet may confer different binding properties of NRSF to 
the NKB putative NRSE, which would be interesting to study further in the future. 
In addition to NRSF mediated regulation of NKB, this thesis has also indicated
that the USF TFs can also regulate the NKB promoter, repressing NKB proximal 
promoter activity. A putative E box site was identified, spanning +160 to +166, and 
USF1 and USF2 were found to bind to the region encompassing this E box in 
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preliminary ChIP assays, in a cell specific manner. In sNRSF expressing cells (SH-
SY5Y) USF2 and not USF1 was found bound to the NKB proximal promoter, whilst in 
cells which do not express sNRSF (SK-N-AS), USF1 and not USF2 were found bound. 
This may indicate competition between the USF1 and USF2 for occupancy of the E box 
site, which may be influenced by the presence of sNRSF. 
As well as investigating the regulation of the NKB-encoding TAC3 gene, I 
sought to further explore the regulation of the SP-encoding TAC1 gene. Previous studies 
have revealed that USF can regulate a number of NRSF-regulated genes, including 
BDNF (Tabuchi et al., 2002), AVP (Coulson et al,. 2003), TAC1 (Paterson et al., 1995; 
Gerrard et al., 2005) and now NKB. NRSF mediated regulation of human TAC1 has 
been shown to operate in synergy with NFκB (Greco et al., 2007), and due to the close 
proximity of the NRSE to a single or multiple E box motifs in the TAC1, AVP and 
TAC3 promoter regions, I sought to explore a potential synergistic regulatory mechanism 
between NRSF isoforms and the USF TFs, by utilising the well-characterised rat TAC1 
promoter reporter gene constructs. 
The experiments undertaken (and presented in chapter 4) suggest that NRSF and 
USF can work together, driving enhanced rat TAC1 reporter gene activity, compared to 
when over-expressed individually. The truncated NRSF variant construct (HZ4) was 
found to activate the rat TAC1 promoter, consistent with previous reports (Spencer et al., 
2006). This activation was further enhanced when the USF TFs were co-over-expressed 
with HZ4, suggesting that truncated NRSF can work in synergy with USF1 or USF2 to 
activate the TAC1 promoter. Interestingly this was found to be dependent on the E box 
located at -60 in relation to the TSS, as when this was mutated, this synergistic up-
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regulation of the rat TAC1 promoter activity was abolished. This E box site is the closest 
to the rat TAC1 NRSE, suggesting that this close proximity is important in sNRSF-USF 
synergy. Moreover, it suggests that USF binding to this E box is necessary for this 
sNRSF-USF synergy, as the mutation should prevent USF binding at that site. In support 
of this, in cells not expressing sNRSF (SK-N-AS), both USF1 and USF2 were found 
bound to the human TAC1 proximal promoter, whilst in sNRSF-expressing cells (SH-
SY5Y), USF1 was displaced and sNRSF was found bound. This suggests that sNRSF 
and USF2 (in this case) interact, displacing USF1 from the TAC1 promoter region. 
However these findings are of a preliminary nature, and repeated investigations are 
required in the future to better understand the mechanism operating. Furthermore, I have 
yet to explore an interaction between these TFs, but this would be an interesting future 
study.  
Whilst these findings were obtained in a human neuroblastoma cell line, and not a 
more complex in vivo model, they do provide support for the potential importance of the 
USF TFs in epileptogenesis. The date indicates that the USF TFs have the capability to 
modulate the expression of two pro-convulsant neuropeptides, and whilst USF 
modulation during seizure has yet to be clarified, other bHLH factors are known to be 
modulated in response to seizure, including Mash1, Id2 and Hes5 (Elliot et al., 2001). 
Furthermore, I have shown that both USF1 and USF2 are up-regulated in response to KA 
in the SH-SY5Y cell line (chapter 6). If the USF TFs were also up-regulated in response 
to seizure in an in vivo model, this may have a significant impact on the expression of a 
multitude of genes including BDNF, TAC1 and TAC3. Subsequently, I hypothesise that 
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the modulation of the USF TFs and target genes, in an in vivo SE model is an important 
future experiment, which may reveal new aspects to SE and epileptogenesis. 
9.2 NRSF and USF are targets of ACD treatment
Throughout this thesis, I have proposed that the NRSF and USF TF families are 
important in epileptogenesis, responding to an initial insult (such as KA stimulation) and 
governing long term changes in gene expression, particularly governing regulation of 
pro-convulsant neuropeptides-encoding genes (TAC3 and TAC1). If these TFs were truly 
important in governing such changes in response to a seizure, then perhaps these TFs 
would be targeted by ACDs. In this thesis I have shown that both NRSF isoforms, as well 
as USF1 and USF2 are differentially modulated by ACD treatment, in terms of their 
mRNA expression and ability to bind to target DNA sequences in a human 
neuroblastoma cell line model. 
The first indication that ACDs could target and modulate the NRSF and USF 
regulatory systems, came in chapter 3, where CBZ treatment was found to abolish both 
NRSF and USF mediated regulation of NKB proximal promoter activity. CBZ was found 
to impair both NRSF variant-mediated activation of the NKB promoter, and USF-
mediated repression. This resulted in a modest repression of endogenous NKB mRNA 
expression, indicating that CBZ could reduce the expression of this pro-convulsant 
neuropeptide. Following on from this, I presented data showing CBZ could also reduced 
the expression of the second pro-convulsant neuropeptide, the SP-encoding TAC1 gene, 
in TAC1-expressing SK-N-AS cells. These findings indicate that CBZ may invoke its 
anti-convulsant properties through the repression of pro-convulsant neuropeptides, and 
that the CBZ target, the type II sodium channel, is a potential member of the pathway 
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which governs both TAC1 and TAC3 gene regulation. Thus modulation of this pathway
may have a downstream impact upon pro-convulsant neuropeptide expression, which is 
of interest for future study. 
The expression of the NRSF and USF TFs were found to be differentially 
modulated following treatment with three different ACDs. The three ACDs chosen, share 
a common initial target, the type II sodium channel, but have been shown to induce 
different downstream effects (Rogawski & Loscher., 2004a), and this held true in terms 
of modulating these TFs. CBZ was found to repress both USF1 and USF2, as well as the 
truncated sNRSF isoform, which considering the importance of these factors in TAC1 
regulation, is consistent with the repression of TAC1 expression. NRSF however was 
modulated in a treatment duration-dependent manner, with NRSF up-regulated following 
4hrs CBZ, whilst down-regulated following 24hrs treatment. PHY had less of an effect 
on the TFs, at the duration and concentrations tested, with nil effect on the expression of 
NRSF and USF2. PHY did however cause a reduction in sNRSF and an increase in 
USF1, which may explain why PHY had little effect on TAC1 expression (Appendix 1), 
as the reduction of sNRSF, whilst may reduced TAC1 expression, was balanced by an 
increase in USF1 expression, which may enhance TAC1 expression. LMT was the only 
drug not to repress sNRSF expression, but did induce an increase in NRSF, whilst 
invoking a decrease in both USF1 and USF2 expression. Thus each drug induced a 
different response in terms of NRSF and USF TF expression. This is the first time such 
ACDs have been shown to modulate the expression of these TFs and could be seen as an 
important step in further elucidating how these drugs elicit their anti-convulsant 
properties or a step to delineate specific mechanisms of such drugs. 
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Consistent with this differential affect upon the NRSF and USF regulatory 
systems, the ACDs invoked different affects on both NRSF and USF (USF2 in this case) 
binding to target DNA sequences, albeit in preliminary investigations. CBZ treatment 
was found to enhance NRSF binding to the Scg10, TAC1 and NKB (putative) NRSEs 
compared to vehicle controls, whilst PHY reduced NRSF binding to the Scg10 and 
TAC1 NRSE, and elevated NRSF binding to the L1CAM and NKB (putative) NRSEs, 
compared to vehicle controls. These findings again represent a possible mechanism of 
action for these ACDs, suggesting that these ACDs could modulate NRSF binding to 
target DNA sequences, which may have significant impacts upon the regulation of target 
genes.  CBZ treatment was also found to reduce USF2 binding to both the TAC1 and 
NKB proximal promoters, perhaps helping to explain CBZ mediated repression of TAC1 
mRNA expression, and CBZ induced impairment of USF regulation of the NKB 
promoter. 
Whilst these ACDs had little impact upon the localisation of the NRSF isoforms
nor the USF proteins, they did induce significant changes to the endogenous expression 
of these TFs, thus revealing a novel mechanism of action for these ACDs. Furthermore, 
as these ACDs target and modulate both the NRSF and USF regulatory systems, the 
potential importance of these TFs in seizure and epileptogenesis becomes more plausible. 
9.3 Is NRSF important in epileptogenesis?
The thesis so far alludes to the importance of the NRSF and USF TF families in 
seizure and epileptogenesis, and I have previously stated that a potential mechanism at 
work during epileptogenesis is chromatin remodelling, to bring about long term changes 
in gene expression. I have therefore further analysed the function of NRSF, a well-
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established coordinator of chromatin remodelling. The findings that NRSF isoforms can 
regulate pro-convulsant neuropeptide gene expression, and are potential targets for ACD 
action, strongly suggests that NRSF is of significance in epileptogenesis. This theory was 
further strengthen in chapter 7, whereby the modulation of NRSF isoforms, mirroring, in 
part that which occurs in response to KA-induced SSSE (Spencer et al., 2006), induced 
widespread changes in gene expression, modulating a host of neuronal genes with known 
association with epilepsy. Whilst these findings were obtained from a neuroblastoma cell 
line, and not a true SE model, they do provide support for the theory that NRSF is of 
particular importance in governing gene expression changes in response to an initial 
seizure, which could coordinate long term changes in gene expression profiles. It would 
therefore be of significant interest to take this work forward and experiment in a more 
appropriate in vivo model. 
The use of a microarray revealed that a host of genes were modulated following 
over-expression of both full-length NRSF and a truncated version lacking the C-terminal 
repressor domain, analogous to sNRSF. This included ion channels (calcium channels, 
potassium channels, sodium channels and chloride channels), GABA transporters and 
receptors, glutamate receptors, drug metabolising enzymes, neuropeptide receptors and 
neurotrophic factors. RT-PCR was used to validate the microarray findings. This dataset 
indicates that the modulation of the NRSF isoforms has a dramatic effect on neuronal 
gene expression, altering the expression of a vast number of genes, which would have a 
significant impact upon neuronal phenotype. The change in ion channel expression alone 
may have a severe impact upon the electrical potential of the neurons, affecting their 
ability to fire. This may provide an explanation (or future experimentation) as to why 
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neurons become more susceptible to future seizures or abnormal firing, following an 
initial insult. Perhaps most importantly, are the findings that the different NRSF isoforms 
induce different gene expression patterns, in a temporal manner. Our group has 
previously proposed that the truncated isoform is important in seizure, and have 
postulated that it is the ratio between the two isoforms that is key in SSSE (Spencer et 
al., 2006). These findings support such a notion, and highlight the requirement to further 
explore the impact of this truncated isoform on the NRSF regulatory system. It is perhaps 
important to note that I have yet to explore the impact of USF over-expression in such a 
manner, and this is perhaps another importance experiment to help uncover the possible 
mechanisms at work during epileptogenesis. Furthermore, it is important to stress that 
these experiments were carried out in human neuroblastoma cell lines, and whilst they 
may provide the basis of new theories regarding the role of these TFs in epileptogenesis, 
they are in no way conclusive, and should be explored further in in vivo seizure models. 
9.4 Cocaine modulates NRSF & USF
Due to an increasing appreciation of the role of the dopaminergic system in 
seizure, I sought to explore the impact of cocaine, a known modulator of the 
dopaminergic system, upon the NRSF and USF regulatory systems. Cocaine treatment 
was found to repress the expression of NRSF and, to a less significant extent, sNRSF, 
which corresponded, in part to an elevation in CART mRNA expression. This elevation 
in CART expression is thought to occur through the direct reduction of NRSF binding to 
the CART NRSE, leading to de-repression, however the preliminary ChIP assays failed 
to provide sufficient evidence to support this claim. Cocaine was found to also impair 
NRSF binding to the TAC1, NKB and BDNF NRSEs. This impairment however did not 
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affect the endogenous expression of NKB, presumably due to the repression of both 
USF1 and USF2 mRNA expression, supporting the earlier claims in chapter 3, that the 
USF TFs repress NKB expression. These findings reveal that cocaine modulate both the 
NRSF and USF regulatory systems, and perhaps controversially suggests that cocaine 
may elicit anti-convulsant properties, as its affect upon these TFs is in keeping to that 
elicited by the three ACDs tested. 
9.5 Relevance to epilepsy
This thesis set out to explore the regulatory systems which may be relevant to 
epilepsy, and has provided support for the theory that both NRSF and USF TF families
play a fundamental role in governing gene expression changes associated with 
epileptogenesis. Both TFs are shown here to be of importance in the regulation of two 
pro-convulsant neuropeptide encoding genes, TAC3 and TAC1, with NRSF and USF 
shown to cooperatively regulate the latter, in the cell line model employed here. I have 
proposed that these TFs fit the model of epileptogenesis, as both TF families are induced 
following an initial insult (such as KA-induced seizure), and are capable of orchestrating
changes in gene expression of a plethora of neuronal genes. After a prolonged latent 
period, such changes in gene expression patterns, could have a dramatic impact upon
neuronal phenotype, making the neurons more prone to future abnormal firing and hence
manifesting in seizures. 
In support of the potential importance of these distinct TFs in epileptogenesis, 
ACD treatment is shown to modulate the expression of these TFs in neuroblastoma cells. 
These findings represent a novel mechanism of action for the three ACDs tested here, 
and highlight the fact that these drugs work through multiple targets. Furthermore, the 
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importance of NRSF isoforms in governing changes in gene expression, with relevance
to epilepsy, was highlighted through the use of microarray technology. Elevated 
expression of NRSF variants, a known response to SSSE (Spencer et al., 2006) is shown 
to modulate the expression of a multitude of genes with known associations with 
epilepsy. This suggests that NRSF may have an important role in governing gene 
expression responses in relation to epilepsy and epileptogenesis, however this needs to be 
explored further in an in vivo SE model. Finally, I have shown that cocaine, which has 
been linked with inducing seizures (Lowenstein et al., 1987; Hanson et al., 1999; Lason., 
2001), also modulates both the NRSF and USF regulatory systems, further strengthening 
the theory that these TFs are of particular importance in orchestrating molecular changes 
in response to an initial insult or seizure.
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Appendix Section
Appendix 1
Figure A1. Phenytoin treatment has nil affect on TAC1 expression. qPCR analysis of TAC1 mRNA 
expression in response to PHY treatment in human SK-N-AS neuroblastoma cells. TAC1-expressing SK-
N-AS cells were treated with either 10µg/ml or 50µg/ml PHY, or vehicle control (Control P), for 4hrs or 
24hrs, before being processed for RNA extraction. mRNA expression of TAC1 was analysed using qPCR, 
standardised against the house-keeping gene Pol-II, with mean fold changes compared to vehicle controls 
given. Standard errors are given as y-axis error bars. Students t-test was performed. No significant 
changes compared to vehicle controls were observed. 
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Figure A2. (A) Human TAC1 proximal promoter spanning –850 to +134. Putative TF binding sites are 
highlighted. E box motifs based on the canonical sequence CANNTG are highlighted in green. A putative 
SP1 binding site based on the consensus sequence (G/T)(G/A)GGCG(G/T)(G/A)(G/A)(C/T) is 
highlighted in red. Putative AP1 binding sites based on sequence TGA(G/C)TCA are highlighted in light 
blue. The NFκB binding motif is highlighted in pink, and underlined to distinguish overlapping sequences 
(Greco et al., 2007). Two predicted NRSEs are highlighted in yellow. NRSE (A) is a putative NRSE 
based upon alignment with the characterised rat TAC1 NRSE, whilst NRSE (B) is the predicted NRSE 
from Greco et al., 2007. (B) Alignment of Rat and human TAC1 promoter regions, focused on the 
characterised rat NRSE aligned against human. This alignment revealed the putative NRSE (A)
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Figure A.3 Sequence alignment between rat and human TAC1 promoter regions. The human TAC1 
promoter region was aligned against the rat TAC1 promoter region, and the rat region spanning -325 to 
+98 is given. The alignment reveals that the rat TAC1 NRSE (highlighted yellow) aligns well with the 
human TAC1 sequence, with a resulting putative human TAC1 NRSE exhibiting 65% homology to the 
characterised rat TAC1 NRSE (17/26). In contrast the previously characterised human TAC1 NRSE, 
proposed by Greco et al (2007) (highlighted in light blue), is poorly conserved in the rat. The rodent E 
box motifs located at -60, -170 and -308 are perfectly (100%) conserved in the human TAC1 sequence. 
However the E boxes at +61 and +69 are poorly conserved, with only 50% homology and 33% homology 
between the rat and human sequences, respectively. The E box motifs are highlighted in green. 
328
Appendix 4
Rat TAC1:
E box motifs:
+61 to +67 (115bp)  to -54
-60 to -54 (104bp) to -164
-170 to -164 (132bp) to -302
-308 to -302
NRSE: -21 to +4
Distance between NRSE and E boxes: 
-170 E box and NRSE = 143bp
-60 E box and NRSE = 33bp
+60 E box and NRSE = 57bp
Human TAC1:
E box motifs:
-38 to -32 (106bp) to -144
-150 to -144 (132bp) to -282
-288 to -282
NRSE (A): +2 to +28
Distance between NRSE (A) and E boxes: 
-38 E box and NRSE = 34bp
-150 E box and NRSE = 146bp
Table A1. Comparison of E box motifs and putative NRSEs in rat and human TAC1 proximal 
promoter regions. Table gives the positions of previously characterised or putative E box motifs and 
NRSE within the rat and human TAC1 proximal promoter regions, with positions given corresponding to 
TSS. Distances between E box motifs are given in red, whilst distances between the (characterised or 
putative) NRSE and stated E box, is given in blue. Similarities between the rat and human TAC1 
promoter regions are highlighted in bold.
Appendix 5
Figure A4. Comparison of neuropeptide NRSEs to consensus reveals homology to the left-half site. 
Sequence comparison of the NRSEs in NKB (human, putative), TAC1 (rat, characterised; human, 
putative; human; characterised) and AVP (human, characterised), reveals strong homology between the 
neuropeptide NRSEs and the left-half site of the consensus NRSE (CAGCACC). Furthermore, the 
alignment reveals that the NKB sequence has two matches to the left-half site, with the second highlighted 
in black bold, and underlined. Homology between the neuropeptide sequence and the consensus sequence 
is highlighted in red, whilst homology between the neuropeptide sequences is highlighted in blue. 
